Abstract is: Tumor progression is the third and last phase in tumor development. This phase is characterised by increased growth speed and invasiveness of the tumor cells. As a result of the progression, phenotypical changes occur and the tumor becomes more aggressive and acquires greater malignant potential. Together with the progression, more and more aneuploidy occurs. This may be evident as nuclear polymorphism.
| P646 | Freebase ID | /m/0h64jlv |
| P6366 | Microsoft Academic ID | 2779256057 |
| P10283 | OpenAlex ID | C2779256057 |
| Q33273694 | "Dedifferentiation" in bone and soft-tissue tumors. A histological indicator of tumor progression |
| Q44757461 | "Stromatogenesis" and tumor progression |
| Q42127126 | "Suppressor genes; restraint of growth or of tumor progression"? |
| Q35777779 | "The involvement of Fc receptors in tumor progression". |
| Q48136709 | 'Go or grow': the key to the emergence of invasion in tumour progression? |
| Q30561836 | (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. |
| Q68754898 | 16th annual UCLA symposium. Abstracts: Tumor progression and metastasis |
| Q34531044 | 17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo |
| Q46775794 | 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma |
| Q69944064 | 18th annual UCLA symposium. Abstracts: Genetic mechanisms in carcinogenesis and tumor progression |
| Q34530928 | 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. |
| Q40059340 | 2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo |
| Q28506975 | 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice |
| Q45153549 | 24-hour oscillation of mouse methionine aminopeptidase2, a regulator of tumor progression, is regulated by clock gene proteins |
| Q43684384 | 25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression |
| Q30470306 | 3-D photoacoustic and pulse echo imaging of prostate tumor progression in the mouse window chamber |
| Q114100828 | 3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases |
| Q37606733 | 4-Methylumbelliferone Suppresses Hyaluronan Synthesis and Tumor Progression in SCID Mice Intra-abdominally Inoculated With Pancreatic Cancer Cells |
| Q63884133 | 438 Function and Regulation of G-protein-coupled Receptor Kinase 2 (GRK2) in Tumor Progression of Stratified Epithelia |
| Q43200018 | 4th international conference on tumor progression and therapeutic resistance: meeting report |
| Q53514075 | 5-Fluoruracil blocked giant cell tumor progression by suppressing osteoclastogenesis through NF-kappaB signals and blocking angiogenesis. |
| Q39183756 | 8-(Tosylamino)quinoline inhibits tumour progression through targeting phosphoinositide-3-kinase/Akt pathway. |
| Q28242012 | 90K (Mac-2 BP) and galectins in tumor progression and metastasis |
| Q104495546 | METTL14 Overexpression Promotes Osteosarcoma Cell Apoptosis and Slows Tumor Progression via Caspase 3 Activation |
| Q112280633 | PRRX1 Is a Novel Prognostic Biomarker and Facilitates Tumor Progression Through Epithelial-Mesenchymal Transition in Uveal Melanoma |
| Q41601109 | A -1573T>C SNP within the human TRAIL promoter determines TRAIL expression and HCC tumor progression |
| Q83899710 | A 3-D model of tumor progression based on complex automata driven by particle dynamics |
| Q92812580 | A Bayesian network model of lymphatic tumor progression for personalized elective CTV definition in head and neck cancers |
| Q92988209 | A Brief Review about the Role of Nanomaterials, Mineral-Organic Nanoparticles, and Extra-Bone Calcification in Promoting Carcinogenesis and Tumor Progression |
| Q90972985 | A Brownian dynamics tumor progression simulator with application to glioblastoma |
| Q90031676 | A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone |
| Q100302887 | A Complex and Evolutive Character: Two Face Aspects of ECM in Tumor Progression |
| Q92876956 | A Correlative Study of N-Cadherin Expression with Different Grades of Oral Squamous Cell Carcinoma Projecting as a Marker of Epithelial to Mesenchymal Transition in Tumor Progression |
| Q39181160 | A Disintegrin And Metalloproteinase 12 produced by tumour cells accelerates osteosarcoma tumour progression and associated osteolysis |
| Q97095172 | A Genetic Analysis of Tumor Progression in Drosophila Identifies the Cohesin Complex as a Suppressor of Individual and Collective Cell Invasion |
| Q50002410 | A Ketogenic Formula Prevents Tumor Progression and Cancer Cachexia by Attenuating Systemic Inflammation in Colon 26 Tumor-Bearing Mice. |
| Q44501371 | A Kunitz-type FXa inhibitor affects tumor progression, hypercoagulable state and triggers apoptosis |
| Q90981237 | A Localized Chimeric Hydrogel Therapy Combats Tumor Progression through Alteration of Sphingolipid Metabolism |
| Q35600821 | A MEK-independent role for CRAF in mitosis and tumor progression. |
| Q35999443 | A Meta-Analysis of Retinoblastoma Copy Numbers Refines the List of Possible Driver Genes Involved in Tumor Progression |
| Q40095340 | A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies |
| Q40163609 | A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17. |
| Q91315265 | A Nude Mouse Model of Orthotopic Liver Transplantation of Human Hepatocellular Carcinoma HCCLM3 Cell Xenografts and the Use of Imaging to Evaluate Tumor Progression |
| Q38934824 | A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis |
| Q114029366 | A PDE Model of Breast Tumor Progression in MMTV-PyMT Mice |
| Q50945164 | A Phase II safety and effect on time to tumor progression study of intratumoral light infusion technology using talaporfin sodium in patients with metastatic colorectal cancer. |
| Q38764893 | A Positive TGF-β/c-KIT Feedback Loop Drives Tumor Progression in Advanced Primary Liver Cancer |
| Q97412239 | A Potential Mechanism of Tumor Progression during Systemic Infections Via the Hepatocyte Growth Factor (HGF)/c-Met Signaling Pathway |
| Q59296874 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy |
| Q93081525 | A Radiogenomic Approach for Decoding Molecular Mechanisms Underlying Tumor Progression in Prostate Cancer |
| Q30998378 | A SAGE (serial analysis of gene expression) view of breast tumor progression. |
| Q101556047 | A Single-Center Retrospective Analysis of Periprocedural Variables Affecting Local Tumor Progression after Radiofrequency Ablation of Colorectal Cancer Liver Metastases |
| Q92147693 | A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression |
| Q112293223 | A Tumor Progression Related 7-Gene Signature Indicates Prognosis and Tumor Immune Characteristics of Gastric Cancer |
| Q41460209 | A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer |
| Q51896211 | A bayesian random-effects markov model for tumor progression in women with a family history of breast cancer. |
| Q36412780 | A bioreactor model of mouse tumor progression |
| Q39388529 | A clinically relevant bi-cellular murine mammary tumor model as a useful tool for evaluating the effect of retinoic acid signaling on tumor progression |
| Q36357411 | A critical role for Rac1 in tumor progression of human colorectal adenocarcinoma cells |
| Q40350326 | A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. |
| Q83629871 | A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma |
| Q98188137 | A dedifferentiated intracranial solitary fibrous tumor with osteosarcoma components: rapid tumor progression and lethal clinical course |
| Q71195255 | A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients |
| Q54216177 | A disintegrin and metalloprotease (ADAM)10 is highly expressed in hepatocellular carcinoma and is associated with tumour progression. |
| Q24794490 | A fly's eye view of tumor progression and metastasis |
| Q38429925 | A framework for the role of acute inflammation in tumor progression |
| Q35190545 | A functional in vivo screen for regulators of tumor progression identifies HOXB2 as a regulator of tumor growth in breast cancer |
| Q41931719 | A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression |
| Q36524341 | A growth-constrained environment drives tumor progression invivo |
| Q112096621 | A hidden Markov model for lymphatic tumor progression in the head and neck |
| Q92618200 | A high expression of MTERF3 correlates with tumor progression and predicts poor outcomes in patients with brain glioma |
| Q52881780 | A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. |
| Q40525129 | A joint frailty-copula model between tumour progression and death for meta-analysis |
| Q48033963 | A joint model for the dependence between clustered times to tumour progression and deaths: A meta-analysis of chemotherapy in head and neck cancer |
| Q94562094 | A lab-on-a-disc platform enables serial monitoring of individual CTCs associated with tumor progression during EGFR-targeted therapy for patients with NSCLC |
| Q47646877 | A link between RelB expression and tumor progression in laryngeal cancer |
| Q67555866 | A major solid undifferentiated carcinoma pattern correlates with tumour progression in locally advanced prostatic carcinoma |
| Q35620283 | A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression |
| Q90334126 | A methoxylated quercetin glycoside harnesses HCC tumor progression in a TP53/miR-15/miR-16 dependent manner |
| Q37688549 | A microRNA/Runx1/Runx2 network regulates prostate tumor progression from onset to adenocarcinoma in TRAMP mice |
| Q70991069 | A microassay for measuring cytosine DNA methyltransferase activity during tumor progression |
| Q34943133 | A minority of carcinoma cells producing acidic fibroblast growth factor induces a community effect for tumor progression |
| Q24314451 | A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression |
| Q46772699 | A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice |
| Q92355631 | A multi-labeled tree dissimilarity measure for comparing "clonal trees" of tumor progression |
| Q37396281 | A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease |
| Q34480657 | A multivariate analysis of factors determining tumor progression in childhood low-grade glioma: a population-based cohort study (CCLG CNS9702) |
| Q35076746 | A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease |
| Q34073272 | A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression |
| Q58779445 | A new drug combination significantly reduces kidney tumor progression in kidney mouse model |
| Q55469672 | A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. |
| Q41009556 | A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs |
| Q37317542 | A new role of the Rac-GAP β2-chimaerin in cell adhesion reveals opposite functions in breast cancer initiation and tumor progression |
| Q47643448 | A nonimmune function of T cells in promoting lung tumor progression |
| Q38964866 | A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer |
| Q39418475 | A novel DNA intercalator, 8-methoxy pyrimido[4',5':4,5]thieno (2,3-b)quinoline-4(3H)-one induces apoptosis in cancer cells, inhibits the tumor progression and enhances lifespan in mice with tumor |
| Q120491617 | A novel FGFR1 inhibitor CYY292 suppresses tumor progression, invasion, and metastasis of glioblastoma by inhibiting the Akt/GSK3β/snail signaling axis |
| Q34462001 | A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression |
| Q91517155 | A novel function of anaphase promoting complex subunit 10 in tumor progression in non-small cell lung cancer |
| Q40248551 | A novel functional polymorphism in the transforming growth factor-beta2 gene promoter and tumor progression in breast cancer |
| Q91243808 | A novel nomogram to predict the local tumor progression after microwave ablation in patients with early-stage hepatocellular carcinoma: A tool in prediction of successful ablation |
| Q91516328 | A novel protein encoded by circFNDC3B inhibits tumor progression and EMT through regulating Snail in colon cancer |
| Q38728459 | A novel signaling role for miR-451 in esophageal tumor microenvironment and its contribution to tumor progression. |
| Q35703737 | A novel strategy for designing specific gelatinase A inhibitors: potential use to control tumor progression |
| Q53473486 | A novel strategy for the investigation of clonality in precancerous disease states and early stages of tumor progression. |
| Q53248251 | A pathway-based approach for identifying biomarkers of tumor progression to trastuzumab-resistant breast cancer. |
| Q39030703 | A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression |
| Q73947549 | A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo |
| Q40896192 | A perspective on tumour progression |
| Q92639496 | A pipeline to create predictive functional networks: application to the tumor progression of hepatocellular carcinoma |
| Q38344626 | A pivotal role of cyclic AMP-responsive element binding protein in tumor progression |
| Q39302674 | A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients |
| Q36612020 | A positive role for PEA3 in HER2-mediated breast tumour progression |
| Q47949037 | A predictive model for distinguishing radiation necrosis from tumour progression after gamma knife radiosurgery based on radiomic features from MR images |
| Q36893250 | A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation |
| Q24298889 | A putative role for psoriasin in breast tumor progression |
| Q45027671 | A reductionist metastasis-on-a-chip platform for in vitro tumor progression modeling and drug screening |
| Q47927636 | A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. |
| Q42814013 | A role for ADAM12 in breast tumor progression and stromal cell apoptosis. |
| Q37195262 | A role for CCL2 in both tumor progression and immunosurveillance |
| Q39001313 | A role for pre-mNK cells in tumor progression. |
| Q36530335 | A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis |
| Q36603992 | A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge |
| Q30986760 | A simplicial complex-based approach to unmixing tumor progression data |
| Q36491378 | A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts. |
| Q45163826 | A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer |
| Q43229354 | A stiff blow from the stroma: collagen crosslinking drives tumor progression. |
| Q112694004 | A stromal Integrated Stress Response activates perivascular cancer-associated fibroblasts to drive angiogenesis and tumour progression |
| Q74625035 | A strong candidate gene for the Papg1 locus on mouse chromosome 4 affecting lung tumor progression |
| Q34710725 | A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma |
| Q37152082 | A surprising link between the energetics of ovariectomy-induced weight gain and mammary tumor progression in obese rats |
| Q53470650 | A switch from stromal to tumor cell expression of stromelysin-1 mRNA associated with the conversion of squamous to spindle carcinomas during mouse skin tumor progression. |
| Q87886229 | A sympathetic role for the pancreas in tumor progression? |
| Q27304351 | A synthetic modular approach for modeling the role of the 3D microenvironment in tumor progression |
| Q37112264 | A tense situation: forcing tumour progression |
| Q35131244 | A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis |
| Q37351983 | A traitor in our midst: mesenchymal stem cells contribute to tumor progression and metastasis |
| Q40744489 | A tricistronic retroviral vector expressing natural antiangiogenic factors inhibits angiogenesis in vitro, but is not able to block tumor progression in vivo |
| Q40680058 | A truncated isoform of the protein phosphatase 2A B56gamma regulatory subunit may promote genetic instability and cause tumor progression |
| Q31065517 | A tumor progression model for hepatocellular carcinoma: bioinformatic analysis of genomic data. |
| Q34773218 | A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers |
| Q35655551 | A versatile mathematical work-flow to explore how Cancer Stem Cell fate influences tumor progression |
| Q91998432 | A β-1,3/1,6-glucan from Durvillaea Antarctica inhibits tumor progression in vivo as an immune stimulator |
| Q43606385 | A-kinase anchoring proteins 10 expression in relation to 2073A/G polymorphism and tumor progression in patients with colorectal cancer |
| Q45785393 | AB055. Overexpression of CENPH is associated with tumor progression and prognosis of clear cell renal cell carcinoma. |
| Q46633170 | AB202. Overexpression of centromere protein H is associated with tumor progression and prognosis of clear cell renal cell carcinoma. |
| Q104686988 | ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models |
| Q40145085 | ADAM-17 expression in breast cancer correlates with variables of tumor progression. |
| Q53628066 | ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression. |
| Q35560725 | ADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression |
| Q91009979 | ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance |
| Q33346972 | ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression |
| Q37641594 | ADAMTS6 suppresses tumor progression via the ERK signaling pathway and serves as a prognostic marker in human breast cancer |
| Q87877692 | AEG-1 is associated with tumor progression in nonmuscle-invasive bladder cancer |
| Q33755044 | AF1q Mediates Tumor Progression in Colorectal Cancer by Regulating AKT Signaling |
| Q112645441 | AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer |
| Q41721700 | AHNAK as a Prognosis Factor Suppresses the Tumor Progression in Glioma |
| Q36021172 | AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis |
| Q98199027 | AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer |
| Q92675223 | ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression |
| Q64244423 | ALDH2 Repression Promotes Lung Tumor Progression via Accumulated Acetaldehyde and DNA Damage |
| Q91823842 | ALK7 Erects a Suppressive Barrier to Tumor Progression and Metastasis |
| Q104795251 | AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma |
| Q38764024 | AMPK β1 reduces tumor progression and improves survival in p53 null mice. |
| Q36847561 | ANP32B deficiency impairs proliferation and suppresses tumor progression by regulating AKT phosphorylation |
| Q90636802 | AOC1 Contributes to Tumor Progression by Promoting the AKT and EMT Pathways in Gastric Cancer |
| Q34774624 | AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. |
| Q58786032 | AP-2α expression in papillary thyroid carcinoma predicts tumor progression and poor prognosis |
| Q54343901 | APC gene deletions in gastric adenocarcinomas in a Chinese population: a correlation with tumour progression. |
| Q42594428 | APC loss-induced intestinal tumorigenesis in Drosophila: Roles of Ras in Wnt signaling activation and tumor progression |
| Q33418752 | APRIL is overexpressed in cancer: link with tumor progression |
| Q91037971 | ARHGAP17 suppresses tumor progression and up-regulates P21 and P27 expression via inhibiting PI3K/AKT signaling pathway in cervical cancer |
| Q49570752 | ARHGEF39 promotes tumor progression via activation of Rac1/P38 MAPK/ATF2 signaling and predicts poor prognosis in non-small cell lung cancer patients. |
| Q35096069 | ARK5 expression in colorectal cancer and its implications for tumor progression |
| Q96351865 | ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma |
| Q90288533 | ASO Author Reflections: mLST8 is a Prognostic Biomarker and Involved in Tumor Progression in Hepatocellular Carcinoma |
| Q35995147 | AT-rich sequence binding protein 1: Contribution to tumor progression and metastasis of human ovarian carcinoma |
| Q37982628 | ATAD3, a vital membrane bound mitochondrial ATPase involved in tumor progression |
| Q45831220 | ATCT-29INVESTIGATING THE EFFECT OF REIRRADIATION OR SYSTEMIC THERAPY IN PATIENTS WITH GBM AFTER TUMOR PROGRESSION: A SECONDARY ANALYSIS OF THE NRG ONCOLOGY/RTOG 0525. |
| Q65514403 | ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression |
| Q101466226 | ATOH8 overexpression inhibits the tumor progression and monocyte chemotaxis in hepatocellular carcinoma |
| Q24548843 | AZU-1: a candidate breast tumor suppressor and biomarker for tumor progression |
| Q91335775 | Aberrant CD137 ligand expression induced by GATA6 overexpression promotes tumor progression in cutaneous T-cell lymphoma |
| Q51255146 | Aberrant CpG Island Shore Region Methylation of CAV1 Is Associated with Tumor Progression and Poor Prognosis in Gastric Cardia Adenocarcinoma. |
| Q34540200 | Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer |
| Q90355083 | Aberrant KIF20A Expression Is Associated with Adverse Clinical Outcome and Promotes Tumor Progression in Prostate Cancer |
| Q92234221 | Aberrant accumulation of Dickkopf 4 promotes tumor progression via forming the immune suppressive microenvironment in gastrointestinal stromal tumor |
| Q80621765 | Aberrant activation of gamma-catenin promotes genomic instability and oncogenic effects during tumor progression |
| Q72331249 | Aberrant expression of gap junction proteins (connexins) is associated with tumor progression during multistage mouse skin carcinogenesis in vivo |
| Q38423631 | Aberrant expression of human ortholog of mammalian enabled (hMena) in human colorectal carcinomas: implications for its role in tumor progression. |
| Q99551741 | Aberrant expression of miR-4728 in patients with non-small cell lung cancer and its regulatory effects on tumor progression in tumor cells |
| Q36547766 | Aberrant gene silencing in tumor progression: implications for control of cancer |
| Q38894513 | Aberrant hypomethylation-mediated CD147 overexpression promotes aggressive tumor progression in human prostate cancer. |
| Q38296844 | Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. |
| Q38321663 | Aberrant methylation and loss expression of RKIP is associated with tumor progression and poor prognosis in gastric cardia adenocarcinoma |
| Q39156426 | Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression |
| Q37579010 | Aberrant methylation of DACT1 and DACT2 are associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma |
| Q36264201 | Aberrant methylation of H-cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma |
| Q94567071 | Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer |
| Q39539189 | Aberrant overexpression of membrane-associated mucin contributes to tumor progression in adult T-cell leukemia/lymphoma cells |
| Q38235794 | Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression |
| Q90826295 | Aberration of Nrf2‑Bach1 pathway in colorectal carcinoma; role in carcinogenesis and tumor progression |
| Q36962800 | Ablation of Neuropilin 1 from glioma-associated microglia and macrophages slows tumor progression |
| Q50126424 | Ablation of colorectal liver metastasis: Interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. |
| Q34602106 | Ablation of tumor progression locus 2 promotes a type 2 Th cell response in Ovalbumin-immunized mice. |
| Q85933014 | Ablative margin states by magnetic resonance imaging with ferucarbotran in radiofrequency ablation for hepatocellular carcinoma can predict local tumor progression |
| Q73168348 | Abnormal c-myc oncogene DNA methylation in human bladder cancer: possible role in tumor progression |
| Q39384831 | Abnormal expression of FOSB correlates with tumor progression and poor survival in patients with gastric cancer |
| Q34493542 | Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer |
| Q57298253 | Abnormal gametogenesis induced by p53 deficiency promotes tumor progression and drug resistance |
| Q36928327 | Abnormal patterns of DNA methylation in human neoplasia: potential consequences for tumor progression |
| Q54341980 | Abnormalities of the Wnt/β-catenin signalling pathway induce tumour progression in sporadic desmoid tumours: correlation between β-catenin widespread nuclear expression and VEGF overexpression. |
| Q35034285 | Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts |
| Q59530538 | Absence of histological signs of tumor progression in recurrences of completely resected meningiomas |
| Q113433535 | Abstract 1447: Suppressive effect of PLAG on tumor progression and its synergistic therapeutic effect with ICI therapy through adenosine clearance |
| Q115383414 | Abstract 180: Defining the metastasome in colorectal cancer: Novel hypotheses on tumor progression, metastasis evolution and therapy by whole genome sequencing |
| Q60029769 | Abstract 2182: Reconstructing evolutionary models of tumor progression from single-cell heterogeneity data |
| Q62570665 | Abstract 3404: Identifying genes involved in retinoic-acid-mediated breast tumor progression by total-genome-knockdown screen |
| Q61917652 | Abstract 4189: Characterization of tumor progression and chemoresponse in a novel transgenic mouse model of neuroblastoma (TH-MYCN) using magnetic resonance imaging |
| Q56455726 | Abstract 437: Mena at the nexus of chemotaxis and haptotaxis during tumor progression |
| Q59522377 | Abstract 461: Inhibition of HMGB1 delays tumor progression, reduces MDSC-mediated immune suppression, and diminishes MDSC-macrophage cross-talk interaction |
| Q62710736 | Abstract 5332: Snail transcription factor contributes to prostate cancer tumor progression via reactive oxygen species and Rac1 activation |
| Q115028438 | Abstract 6065: ASF1B potentiates stem cell traits and tumor progression in hepatocellular carcinoma via histone H3.3-dependent transcriptional reprogramming |
| Q57451401 | Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies |
| Q57570639 | Abstract CT333: Elypse-7: A randomized, placebo-controlled, Phase 2a evaluating the impact of IL-7 immunotherapy on CD4 count, risks of severe haematological toxicity and tumor progression in metastatic breast cancer patients |
| Q113433540 | Abstract LB-460: Effects of folic acid supplementation on mammary tumor progression |
| Q47936254 | Acacia ferruginea inhibits tumor progression by regulating inflammatory mediators-(TNF-a, iNOS, COX-2, IL-1β, IL-6, IFN-γ, IL-2, GM-CSF) and pro-angiogenic growth factor- VEGF. |
| Q60548866 | Accelerated Tumor Progression in Mice Lacking the ATP Receptor P2X7 |
| Q33818411 | Accessing key steps of human tumor progression in vivo by using an avian embryo model |
| Q34276850 | Accumulation of driver and passenger mutations during tumor progression |
| Q45977663 | Accumulation of nuclear p53 and tumor progression in bladder cancer. |
| Q41886417 | Accumulation of p53 is associated with tumour progression in cutaneous lesions of renal allograft recipients |
| Q53520569 | Acetic acid, a potent agent of tumor progression in the multistage mouse skin model for chemical carcinogenesis. |
| Q37747326 | Acidified bile acids enhance tumor progression and telomerase activity of gastric cancer in mice dependent on c-Myc expression |
| Q92648113 | Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer |
| Q98281113 | Acquired ATRX Loss and ALT Phenotype Through Tumor Recurrences in a Case of Pleomorphic Xanthoastrocytoma Suggest Their Possible Roles in Tumor Progression |
| Q40566013 | Acquisition of HP phenotype and alterations in the activity of catalase of in vitro transformed cells of different origin in the dynamics of in vivo tumor progression |
| Q39615527 | Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-Myc expression and B16-F0 tumor progression |
| Q83293278 | Actinomyces infection mimicking tumor-progression in rectal cancer under neoadjuvant therapy |
| Q49246137 | Activated CD8+ T cell extracellular vesicles prevent tumour progression by targeting of lesional mesenchymal cells. |
| Q50060949 | Activated STAT3 may participate in tumor progression through increasing CD133/survivin expression in early stage of colon cancer. |
| Q44175989 | Activated but not resting regulatory T cells accumulated in tumor microenvironment and correlated with tumor progression in patients with colorectal cancer |
| Q36302820 | Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling. |
| Q28646235 | Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma |
| Q42735941 | Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion |
| Q42026021 | Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin |
| Q51033061 | Activated neu induces rapid tumor progression. |
| Q37645070 | Activated platelets inhibit hepatocellular carcinoma cell differentiation and promote tumor progression via platelet-tumor cell binding |
| Q42484543 | Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression |
| Q33967736 | Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression |
| Q38705689 | Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression |
| Q47104680 | Activation of adrenergic receptor β2 promotes tumor progression and epithelial mesenchymal transition in tongue squamous cell carcinoma |
| Q26998742 | Activation of blood coagulation in cancer: implications for tumour progression |
| Q101043341 | Activation of dopaminergic VTA inputs to the mPFC ameliorates chronic stress-induced breast tumor progression |
| Q36417732 | Activation of iCaspase-9 in neovessels inhibits oral tumor progression |
| Q37190486 | Activation of mesenchymal stem cells by macrophages promotes tumor progression through immune suppressive effects |
| Q34539323 | Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression |
| Q45121992 | Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers |
| Q48839946 | Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. |
| Q24303389 | Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis |
| Q58859870 | Active antitumor immunotherapy, with or without B7-mediated costimulation, increases tumor progression in an immunogenic murine T cell lymphoma model |
| Q49018681 | Activin pathway enhances colorectal cancer stem cell self-renew and tumor progression. |
| Q39238942 | Activin-β(c) reduces reproductive tumour progression and abolishes cancer-associated cachexia in inhibin-deficient mice |
| Q40522524 | Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression |
| Q92422527 | Acute vs. Chronic vs. Cyclic Hypoxia: Their Differential Dynamics, Molecular Mechanisms, and Effects on Tumor Progression |
| Q34192789 | Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression |
| Q49565693 | Addendum: A regulated PNUTS mRNA to lncRNA splice switch mediates EMT and tumour progression. |
| Q44636550 | Adding interferon-α to octreotide slows tumour progression compared with octreotide alone but evidence is lacking for improved survival in people with disseminated midgut carcinoid tumours |
| Q79357712 | Adenocarcinoma in inflammatory colorectal disease. Histological features pertinent to local tumour progression |
| Q51228172 | Adenosquamous carcinoma in the biliary tract: association of the proliferative ability of the squamous component with its proportion and tumor progression. |
| Q40410447 | Adherens junction proteins in tumour progression |
| Q43681297 | Adhesion molecules alpha, beta and gamma-catenin as prognostic factors of tumour progression in upper urinary tract urothelial tumours: the role of AKT-P/GSK-3beta/beta-catenin pathway |
| Q33743676 | Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment |
| Q60673350 | Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment |
| Q36357889 | Adipocyte-derived endotrophin promotes malignant tumor progression |
| Q47888215 | Adipocyte-derived fibroblasts promote tumor progression and contribute to the desmoplastic reaction in breast cancer |
| Q113926673 | Adipocytes contribute to tumor progression and invasion of peritoneal metastasis by interacting with gastric cancer cells as cancer associated fibroblasts |
| Q96022732 | Adipocytes promote tumor progression and induce PD-L1 expression via TNF-α/IL-6 signaling |
| Q91175374 | Adipose tissue-derived stromal cells are sources of cancer-associated fibroblasts and enhance tumor progression by dense collagen matrix |
| Q34545862 | Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial |
| Q36292850 | Adjuvant gamma knife stereotactic radiosurgery at the time of tumor progression potentially improves survival for patients with glioblastoma multiforme |
| Q81803423 | Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo |
| Q43878225 | Adrenal carcinoma tumor progression and penultimate cell surface oligosaccharides. |
| Q54531501 | Adrenocortical cancer in Carney complex: a paradigm of endocrine tumor progression or an association of genetic predisposing factors? |
| Q82758745 | Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas |
| Q36651770 | Adrenomedullin: a tumor progression factor via angiogenic control |
| Q46515504 | Advanced multimodal nanoparticles delay tumor progression with clinical radiation therapy |
| Q26830932 | Advancement of relationship between metabolic alteration in cancer-associated fibroblasts and tumor progression in lung cancer |
| Q48191483 | Afatinib treatment of a squamous lung cancer after tumor progression of nivolumab. |
| Q39216446 | Age and space irradiation modulate tumor progression: implications for carcinogenesis risk |
| Q98568686 | Age-induced accumulation of methylmalonic acid promotes tumour progression |
| Q34507732 | Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression |
| Q55066509 | Akt-Girdin signaling in cancer-associated fibroblasts contributes to tumor progression. |
| Q34118999 | Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression |
| Q35151491 | Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer |
| Q49905204 | Aldolase A overexpression is associated with poor prognosis and promotes tumor progression by the epithelial-mesenchymal transition in colon cancer. |
| Q38701846 | Aldolase B Overexpression is Associated with Poor Prognosis and Promotes Tumor Progression by Epithelial-Mesenchymal Transition in Colorectal Adenocarcinoma |
| Q112761674 | All-trans retinoic acid and protein kinase C α/β1 inhibitor combined treatment targets cancer stem cells and impairs breast tumor progression |
| Q60637109 | Allele loss in human gastric carcinomas - relation to tumor progression and differentiation |
| Q43490603 | Allele percentage of the BRAF V600E mutation in papillary thyroid carcinomas and corresponding lymph node metastases: no evidence for a role in tumor progression |
| Q53473417 | Allelic loss at 1p is associated with tumor progression of meningiomas. |
| Q53405630 | Allelic loss in human intrahepatic cholangiocarcinoma: correlation between chromosome 8p22 and tumor progression. |
| Q47814647 | Allelic loss of chromosome 10q23 is associated with tumor progression in breast carcinomas |
| Q43839577 | Allelic loss of chromosome 3p24 correlates with tumor progression rather than with retinoic acid receptor beta2 expression in breast carcinoma |
| Q73042471 | Allelic loss on chromosome 1 is associated with tumor progression of cervical carcinoma |
| Q42860747 | Allelic loss on chromosome 10q in human lung cancer: association with tumour progression and metastatic phenotype |
| Q73939089 | Allelotype analysis of chemically induced squamous cell carcinomas in F(1) hybrids of two inbred mouse strains with different susceptibility to tumor progression |
| Q68159719 | Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer |
| Q77973089 | Allelotype of posterior uveal melanoma: implications for a bifurcated tumor progression pathway |
| Q92811815 | Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2+/- Mice |
| Q30930184 | Alpha shape theory for 3D visualization and volumetric measurement of brain tumor progression using magnetic resonance images |
| Q71694393 | Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice |
| Q74184512 | Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis |
| Q71056059 | Alpha-1-antichymotrypsin expression in lung adenocarcinoma and its possible association with tumor progression |
| Q57636678 | Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression |
| Q53376528 | Alteration of apoptotic regulatory molecules expression during carcinogenesis and tumor progression of renal cell carcinoma. |
| Q40809520 | Alteration of liver glycopatterns during cirrhosis and tumor progression induced by HBV. |
| Q72391386 | Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumor progression |
| Q44109886 | Alteration of the DNA damage response in colorectal tumor progression |
| Q38335254 | Alteration of the MDM2-p73-P14ARF pathway related to tumour progression during urinary bladder carcinogenesis |
| Q53363638 | Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. |
| Q41366659 | Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents |
| Q42496604 | Alterations in expression of basement membrane proteins during tumour progression in oral mucosa. |
| Q53377712 | Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. |
| Q73212017 | Alterations in hepatic p53 gene methylation patterns during tumor progression with folate/methyl deficiency in the rat |
| Q70949261 | Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage- and natural killer cell-resistant tumor variants |
| Q35154879 | Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis |
| Q35831746 | Alterations in the expression of uvomorulin and Na+,K(+)-adenosine triphosphatase during mouse skin tumor progression |
| Q40360938 | Alterations of choline phospholipid metabolism in ovarian tumor progression |
| Q74095006 | Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival |
| Q41652802 | Alterations of the p53 tumor suppressor gene during mouse skin tumor progression |
| Q58766803 | Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer |
| Q40582975 | Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma |
| Q40494207 | Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression |
| Q102974375 | Altered expression of microRNA-92b-3p predicts survival outcomes of patients with prostate cancer and functions as an oncogene in tumor progression |
| Q28218458 | Altered expression of the catenin p120 in human cancer: implications for tumor progression |
| Q74211742 | Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen |
| Q31811713 | Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma |
| Q47435187 | Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression. |
| Q42223817 | Altered p53 regulation of miR-148b and p55PIK contributes to tumor progression in colorectal cancer |
| Q45848130 | Altered purinergic signaling in CD73-deficient mice inhibits tumor progression |
| Q40172033 | Alternative production of Bcl-2 and Bax by tumor cells determines the rates of in vivo tumor progression: suggested mechanisms |
| Q37222930 | Alternative splicing and tumor progression |
| Q36135737 | Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer |
| Q92083803 | Amentoflavone Effectively Blocked the Tumor Progression of Glioblastoma via Suppression of ERK/NF- κ B Signaling Pathway |
| Q52716646 | Amentoflavone Inhibits ERK-modulated Tumor Progression in Hepatocellular Carcinoma In Vitro. |
| Q34332537 | Amplification and rearrangement of the Kirsten ras oncogene in virus-transformed BALB/c 3T3 cells during malignant tumor progression |
| Q74420011 | Amplification of 3q26 approximately qter correlates with tumor progression in head and neck squamous cell carcinomas |
| Q77540513 | Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice |
| Q72425331 | Amplification of chromosome subregion 12p11.2-p12.1 in a metastasis of an i(12p)-negative seminoma: relationship to tumor progression? |
| Q81419915 | Amplifications of the epidermal growth factor receptor gene (egfr) are common in phyllodes tumors of the breast and are associated with tumor progression |
| Q34810377 | An Ad5[E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice |
| Q92507408 | An Allosteric PRC2 Inhibitor Targeting EED Suppresses Tumor Progression by Modulating the Immune Response |
| Q51024540 | An Engineered Breast Cancer Model on a Chip to Replicate ECM-Activation In Vitro during Tumor Progression. |
| Q46017879 | An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. |
| Q98733140 | An IL6-Adenosine Positive Feedback Loop between CD73+ γδTregs and CAFs Promotes Tumor Progression in Human Breast Cancer |
| Q64040914 | An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors |
| Q97518942 | An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells |
| Q40838336 | An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. |
| Q39974503 | An emerging role for class I bHLH E2-2 proteins in EMT regulation and tumor progression |
| Q37952002 | An emerging role for the nuclear localization of maspin in the suppression of tumor progression and metastasis |
| Q67681056 | An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site |
| Q36710986 | An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression |
| Q47939014 | An error cascade mechanism for tumour progression |
| Q38729053 | An experimental model for oncogene activation during tumor progression in vivo |
| Q34980384 | An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models. |
| Q87977673 | An immunosuppressive pathway for tumor progression |
| Q37593566 | An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition |
| Q41628374 | An in vitro fibroblast model system to study myc-driven tumour progression |
| Q43666537 | An in vitro model for tumor progression in murine lymphoid cells |
| Q33201368 | An in vivo functional genetic screen reveals a role for the TRK-T3 oncogene in tumor progression |
| Q39656299 | An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells |
| Q34664017 | An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression |
| Q37381244 | An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression |
| Q120351282 | An invasive zone in human liver cancer identified by Stereo-seq promotes hepatocyte–tumor cell crosstalk, local immunosuppression and tumor progression |
| Q92869845 | An octopus-mimic PEGylated peptide as a specific integrin αvβ3 inhibitor for preventing tumor progression |
| Q47350526 | Analysis of Autoantibodies Related to Tumor Progression in Sera from Patients with High-grade Non-muscle-invasive Bladder Cancer |
| Q46177328 | Analysis of MYB oncogene in transformed adenoid cystic carcinomas reveals distinct pathways of tumor progression |
| Q53391786 | Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. |
| Q112639016 | Analysis of Non-Relapsed and Relapsed Adult Type Granulosa Cell Tumors Suggests Stable Transcriptomes during Tumor Progression |
| Q53388751 | Analysis of chromosome aberrations in cell lines derived from laryngeal cancer in relation to tumor progression. |
| Q93210757 | Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia |
| Q42601298 | Analysis of colorectal tumor progression by microdissection and comparative genomic hybridization |
| Q38975942 | Analysis of gene expression for studying tumor progression: the case of glucocorticoid administration |
| Q37384583 | Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage lambda transgene target |
| Q36909853 | Analysis of integrin signaling in genetically engineered mouse models of mammary tumor progression |
| Q92984431 | Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression |
| Q61696750 | Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis |
| Q83158936 | Analysis of patients with rapid aggressive tumor progression of hepatocellular carcinoma after percutaneous radiofrequency ablation |
| Q36207128 | Analysis of the Fibrinogen and Neutrophil-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and Prognosis |
| Q54527387 | Analysis of the K-ras/B-raf/Erk signal cascade, p53 and CMAP as markers for tumor progression in colorectal cancer patients. |
| Q33338282 | Analysis of the effects of exposure to acute hypoxia on oxidative lesions and tumour progression in a transgenic mouse breast cancer model |
| Q44013234 | Analysis of the layering pattern of the apparent diffusion coefficient (ADC) for differentiation of radiation necrosis from tumour progression. |
| Q84483770 | Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation |
| Q81616918 | Analysis of the saliva proteome from patients with head and neck squamous cell carcinoma reveals differences in abundance levels of proteins associated with tumour progression and metastasis |
| Q40353923 | Analysis of tumor progression by transcriptional profiling of mouse MK16 cell lines transformed with human papillomavirus type 16 E6 and E7 oncogenes and activated H-ras |
| Q53437094 | Analysis of two inbred strains of mice derived from the SENCAR stock with different susceptibility to skin tumor progression. |
| Q35836387 | Androgen receptor status is highly conserved during tumor progression of breast cancer |
| Q44308852 | Androgen receptors and growth fraction in metastatic prostate cancer as predictors of time to tumour progression after hormonal therapy |
| Q52679378 | Angiogenesis and Oxidative Stress in Metastatic Tumor Progression: Pathogenesis and Novel Therapeutic Approach of Colon Cancer. |
| Q53403140 | Angiogenesis and tumor progression in melanoma |
| Q39949956 | Angiogenesis and tumor progression in neuroendocrine digestive tumors |
| Q67900089 | Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma |
| Q37658309 | Angiogenesis and tumour progression: migration-stimulating factor as a novel target for clinical intervention |
| Q45818662 | Angiogenesis during tumor progression in human malignant melanoma |
| Q77942741 | Angiogenesis during tumor progression in the oral cavity is related to reduced apoptosis and high tumor cell proliferation |
| Q36262349 | Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets |
| Q46154925 | Angiogenic acceleration of Neu induced mammary tumor progression and metastasis |
| Q80531125 | Angiogenic switch during tumor progression of carcinoma ex-pleomorphic adenoma |
| Q39650526 | Angiotensin II induces tumor progression and fibrosis in intrahepatic cholangiocarcinoma through an interaction with hepatic stellate cells |
| Q79886995 | Animal model of drug-resistant tumor progression |
| Q40183872 | Animal models for tumor progression (short review). |
| Q97692578 | Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma |
| Q35448499 | Annexin A2 promotes glioma cell invasion and tumor progression |
| Q47144091 | Annexin A4 fucosylation enhances its interaction with the NF-kB p50 and promotes tumor progression of ovarian clear cell carcinoma |
| Q44824913 | Annexin-I overexpression is associated with tumour progression and independently predicts inferior disease-specific and metastasis-free survival in urinary bladder urothelial carcinoma |
| Q53338165 | Anti-Hsp20 antibody concentrations inversely correlated with tumor progression in ovarian cancer. |
| Q45906954 | Anti-IL-6 and PD-L1 antibody combination therapy reduces tumor progression in murine models of pancreatic cancer. |
| Q71804124 | Anti-interleukin 4 antibody and indomethacin synergistic effect on B16 melanoma tumor progression |
| Q35641618 | Antiangiogenic therapy and tumor progression |
| Q40511146 | Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option |
| Q36950772 | Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma |
| Q80502367 | Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism |
| Q104752059 | Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression |
| Q68700565 | Antigen dynamics in melanocytic and nevocytic melanoma oncogenesis: anti-ganglioside and anti-ras p21 antibodies as markers of tumor progression |
| Q40647179 | Antigen presentation, aberrant glycosylation and tumor progression |
| Q69354694 | Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas |
| Q67911798 | Antigens associated with tumor progression in melanocytic neoplasia |
| Q28075316 | Antioxidant Activity during Tumor Progression: A Necessity for the Survival of Cancer Cells? |
| Q38934623 | Antiphospholipid antibodies promote tissue factor-dependent angiogenic switch and tumor progression |
| Q70866450 | Antisense inhibition of parathyroid hormone-related peptide gene expression reduces malignant pituitary tumor progression and metastases in the rat |
| Q96231197 | Apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer via the Akt/β-catenin pathway |
| Q92861943 | Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer |
| Q92517872 | Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo |
| Q91243698 | Apoptosis induction and ERK/NF-κB inactivation are associated with magnolol-inhibited tumor progression in hepatocellular carcinoma in vivo |
| Q40711655 | Apoptosis inhibitor as a suppressor of tumor progression: expression of Bcl-2 eliminates selective advantages for p53-deficient cells in the tumor |
| Q34017838 | Apoptosis inhibitor-5 overexpression is associated with tumor progression and poor prognosis in patients with cervical cancer |
| Q38464336 | Apoptosis, proliferation, and angiogenesis in oral tissues. Possible relevance to tumour progression |
| Q57937792 | Apoptosis: a potential role for cytosolic transglutaminase and its importance in tumour progression |
| Q37148060 | Apoptotic pathways in tumor progression and therapy |
| Q42818525 | Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy |
| Q39405331 | Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression |
| Q53877554 | Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy. |
| Q83131270 | Aquaporin 3 protein expression in transitional cell carcinoma: a potential marker with regard to tumour progression and prognosis? |
| Q33966952 | Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells |
| Q40410455 | Are CD44 variant isoforms involved in human tumour progression? |
| Q38831902 | Areca nut alkaloids induce irreparable DNA damage and senescence in fibroblasts and may create a favourable environment for tumour progression |
| Q37706985 | Arg-Leu-Tyr-Glu tetrapeptide inhibits tumor progression by suppressing angiogenesis and vascular permeability via VEGF receptor-2 antagonism |
| Q54307578 | Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma. |
| Q54384524 | Argyrophilic nucleolar organizer regions in the evaluation of tumour progression in the oral mucosa: correlation with tissue pathology. |
| Q43288585 | Arterial enhancement of hepatocellular carcinoma before radiofrequency ablation as a predictor of postablation local tumor progression |
| Q94599796 | Aryl Hydrocarbon Receptor-Dependent inductions of omega-3 and omega-6 polyunsaturated fatty acid metabolism act inversely on tumor progression |
| Q42819875 | Ascorbic acid recycling in Nb2 lymphoma cells: implications for tumor progression |
| Q98233875 | Aspects of tumor progression |
| Q46171141 | Aspergillus terreus brain abscess mimicking tumor progression in a patient with treated glioblastoma multiforme |
| Q53379075 | Assembling a tumor progression model. |
| Q74121068 | Assessing genetic markers of tumour progression in the context of intratumour heterogeneity |
| Q33302948 | Assessing tumor progression factors by somatic gene transfer into a mouse model: Bcl-xL promotes islet tumor cell invasion |
| Q85928827 | Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases |
| Q38093519 | Assessment of audit methodologies for bias evaluation of tumor progression in oncology clinical trials |
| Q38432389 | Assessment of methylation events during colorectal tumor progression by absolute quantitative analysis of methylated alleles |
| Q35594463 | Associated changes of lipid peroxidation and transforming growth factor beta1 levels in human colon cancer during tumour progression. |
| Q42319246 | Association Between Tumor Progression Endpoints and Overall Survival in Patients with Advanced Neuroendocrine Tumors |
| Q90480978 | Association between interleukin-36γ and tumor progression in non-small cell lung cancer |
| Q41350041 | Association between sialyl Lewis(a) expression and tumor progression in melanoma |
| Q54936006 | Association between smoking and tumor progression in Japanese women with adenocarcinoma of the lung. |
| Q55516375 | Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression. |
| Q90288480 | Association of DCBLD2 upregulation with tumor progression and poor survival in colorectal cancer |
| Q54530929 | Association of E1AF mRNA expression with tumor progression and matrilysin in human rectal cancer. |
| Q91014968 | Association of HER2 gene amplification and tumor progression in early gastric cancer |
| Q37241707 | Association of MICA-TM and MICB C1_2_A microsatellite polymorphisms with tumor progression in patients with colorectal cancer |
| Q93000889 | Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study |
| Q77678930 | Association of N-acetyllactosamine with tumor progression in human breast cancer: a study using a 16 kDa chick embryo lectin |
| Q35870683 | Association of OPN overexpression with tumor stage, differentiation, metastasis and tumor progression in human laryngeal squamous cell carcinoma. |
| Q43453672 | Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. |
| Q78144382 | Association of cyclin D1 expression with factors correlated with tumor progression in human hepatocellular carcinoma |
| Q42774837 | Association of decreased expression of the macrophage scavenger receptor MARCO with tumor progression and poor prognosis in human hepatocellular carcinoma |
| Q54762268 | Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. |
| Q111898188 | Association of intra-procedural use of tumor feeding vessel tracking software with local tumor progression in hepatocellular carcinoma patients treated with hepatic arterial embolization |
| Q28279207 | Association of matrilysin-2 (MMP-26) expression with tumor progression and activation of MMP-9 in esophageal squamous cell carcinoma |
| Q43890214 | Association of p53/p21 expression and cigarette smoking with tumor progression and poor prognosis in non-small cell lung cancer patients |
| Q50111622 | Association of reduced cell adhesion regulator messenger RNA expression with tumor progression in human hepatocellular carcinoma. |
| Q96126533 | Association of sirtuin-1 and vascular endothelial growth factor expression with tumor progression and poor prognosis in liposarcoma |
| Q44282039 | Association of trypsin expression with tumour progression and matrilysin expression in human colorectal cancer. |
| Q36116036 | Association of tumour vasculature with tumour progression and overall survival of patients with non-early gastric carcinomas |
| Q24676501 | Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration |
| Q36007486 | Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy |
| Q46731684 | Attenuated phosphorylation of heat shock protein 27 correlates with tumor progression in patients with hepatocellular carcinoma |
| Q42489640 | Attenuation and loss of hormonal modulation of KGF (FGF-7)/KGF receptor expression and mitogenesis during mammary tumor progression |
| Q37626943 | Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model |
| Q54946576 | Attenuation of TGFBR2 expression and tumour progression in prostate cancer involve diverse hypoxia-regulated pathways. |
| Q40775264 | Attenuation of catalase activity in the malignant phenotype plays a functional role in an in vitro model for tumor progression |
| Q54583855 | Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. |
| Q91717387 | Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect |
| Q92577211 | Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality |
| Q91969185 | Author Correction: ATF4 couples MYC-dependent translational activity to bioenergetic demands during tumour progression |
| Q58734492 | Author Correction: Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression |
| Q61795873 | Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103 dendritic cell differentiation |
| Q96131229 | Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression |
| Q92002570 | Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface |
| Q52715970 | Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro. |
| Q39686133 | Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression |
| Q97537812 | Autocrine INSL5 promotes tumor progression and glycolysis via activation of STAT5 signaling |
| Q41966417 | Autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor in human gliomas with tumor progression |
| Q73984644 | Autocrine motility factor receptor expression associates with tumor progression in thymoma |
| Q38512661 | Autocrine production of TGF-alpha and TGF-beta during tumour progression of rat oral keratinocytes |
| Q73292294 | Autologous T cells control B-chronic lymphocytic leukemia tumor progression in human-->mouse radiation chimera |
| Q87114124 | Autologous Tumor Cell Lysate-Loaded Dendritic Cell Vaccine Inhibited Tumor Progression in an Orthotopic Murine Model for Hepatocellular Carcinoma |
| Q95429471 | Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma |
| Q89831514 | Autophagic Degradation of NBR1 Restricts Metastatic Outgrowth during Mammary Tumor Progression |
| Q57463739 | Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer |
| Q35812219 | Autophagy suppresses tumor progression by limiting chromosomal instability |
| Q28078649 | Autophagy-Dependent Secretion: Contribution to Tumor Progression |
| Q93111881 | Autophagy-related 7 modulates tumor progression in triple-negative breast cancer |
| Q54509748 | Autopsy case of primary myelofibrosis in which myeloid sarcoma was the initial manifestation of tumor progression. |
| Q88957751 | Autotaxin exacerbates tumor progression by enhancing MEK1 and overriding the function of miR-489-3p |
| Q40693170 | B cells promote tumor progression in a mouse model of HPV-mediated cervical cancer. |
| Q34755398 | B cells promote tumor progression via STAT3 regulated-angiogenesis |
| Q87331525 | B-1 cells and concomitant immunity in Ehrlich tumour progression |
| Q53321121 | B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis. |
| Q34059352 | B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression |
| Q104469322 | B3GNT3 overexpression promotes tumor progression and inhibits infiltration of CD8+ T cells in pancreatic cancer |
| Q80890589 | B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression |
| Q37140050 | B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma |
| Q36464312 | B7-H3 in combination with regulatory T cell is associated with tumor progression in primary human non-small cell lung cancer |
| Q54254305 | B7-H3 is related to tumor progression in ovarian cancer. |
| Q33703916 | B7-H3 overexpression in pancreatic cancer promotes tumor progression |
| Q35867721 | B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells |
| Q38887419 | B7-H3 silencing inhibits tumor progression of mantle cell lymphoma and enhances chemosensitivity |
| Q53238384 | B7-H3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression. |
| Q35543730 | B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma |
| Q34501651 | B7-H4 expression is correlated with tumor progression and clinical outcome in urothelial cell carcinoma |
| Q38294434 | BAG-1 is up-regulated in colorectal tumour progression and promotes colorectal tumour cell survival through increased NF-kappaB activity |
| Q77639445 | BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability |
| Q29617585 | BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis |
| Q54108340 | BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. |
| Q41935764 | BCCIP suppresses tumor initiation but is required for tumor progression |
| Q48122093 | BCL-XL overexpression promotes tumor progression-associated properties. |
| Q100945779 | BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity |
| Q34155610 | BCL2 expression in CD105 positive neoangiogenic cells and tumor progression in angioimmunoblastic T-cell lymphoma |
| Q35063960 | BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells |
| Q52894492 | BCL9-2 promotes early stages of intestinal tumor progression. |
| Q100945825 | BET degrader inhibits tumor progression and stem-like cell growth via Wnt/β-catenin signaling repression in glioma cells |
| Q34972203 | BI 5700, a Selective Chemical Inhibitor of IκB Kinase 2, Specifically Suppresses Epithelial-Mesenchymal Transition and Metastasis in Mouse Models of Tumor Progression |
| Q94352500 | BI-08MICROVESICLES CAN DISTINGUISH BETWEEN TUMOR PROGRESSION AND TREATMENT EFFECT/PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS TREATED WITH RADIATION AND TEMOZOLOMIDE |
| Q40504792 | BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas. |
| Q47687266 | BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer. |
| Q57292305 | BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation |
| Q64104423 | BRCAness in prostate cancer |
| Q91825095 | BRD4 promotes tumor progression and NF-κB/CCL2-dependent tumor-associated macrophage recruitment in GIST |
| Q55119106 | BRD7 inhibits the Warburg effect and tumor progression through inactivation of HIF1α/LDHA axis in breast cancer. |
| Q98284269 | BTB domain-containing 7 predicts low recurrence and suppresses tumor progression by deactivating Notch1 signaling in breast cancer |
| Q42832626 | Bacterial lacZ gene as a highly sensitive marker to detect micrometastasis formation during tumor progression |
| Q50094993 | Baicalein inhibits tumor progression by inhibiting tumor cell growth and tumor angiogenesis. |
| Q34472216 | Basic fibroblast growth factor in an animal model of spontaneous mammary tumor progression |
| Q91081690 | Bcl-2 and c-Myc expression in oral dysplasia and oral squamous cell carcinoma: An immunohistochemical study to assess tumor progression |
| Q43637083 | Bcl-2 expression in F-MuLV-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression |
| Q37414190 | Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation |
| Q40416273 | Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. |
| Q74576173 | Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis |
| Q39662432 | Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer |
| Q46454350 | Behavioral stress and tumor progression. |
| Q84225868 | Behaviour of breast cancer molecular subtypes through tumour progression |
| Q36076526 | Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression |
| Q90128673 | Beneficial effect of fluoxetine on anti-tumor progression on hepatocellular carcinoma and non-small cell lung cancer bearing animal model |
| Q43272859 | Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. |
| Q37043566 | Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer. |
| Q53246377 | Benzo[a]pyrene-7,8-diol-9,10-epoxide inhibits gap junction intercellular communication via phosphorylation of tumor progression locus 2 in WB-F344 rat liver epithelial cells. |
| Q39004445 | Benzyl isothiocyanate suppresses high-fat diet-stimulated mammary tumor progression via the alteration of tumor microenvironments in obesity-resistant BALB/c mice |
| Q68179327 | Beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia |
| Q78209167 | Beta-microseminoprotein in gastric carcinoids: a marker of tumour progression |
| Q48149239 | Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia? |
| Q91929524 | Beyond Angiogenesis: Exploiting Angiocrine Factors to Restrict Tumor Progression and Metastasis |
| Q36950965 | Beyond foreign-body-induced carcinogenesis: impact of reactive oxygen species derived from inflammatory cells in tumorigenic conversion and tumor progression. |
| Q28822348 | Bi-directional signaling: extracellular matrix and integrin regulation of breast tumor progression |
| Q53527168 | Bicluster and pathway enrichment analysis related to tumor progression of hepatocellular carcinoma. |
| Q49583955 | Bidirectional alteration of Cav-1 expression is associated with mitogenic conversion of its function in gastric tumor progression. |
| Q34992097 | Bilateral internuclear ophthalmoplegia associated with pediatric brain tumor progression: a case series and review of the literature |
| Q103810542 | Bile Acid Tethered Docetaxel-based Nanomicelles Mitigate Tumor Progression through Epigenetic Changes |
| Q37518877 | Biliary Phospholipids Sustain Enterocyte Proliferation and Intestinal Tumor Progression via Nuclear Receptor Lrh1 in mice |
| Q28199283 | Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression |
| Q38297488 | Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression. |
| Q53512825 | Biochemical analysis of metastasis-related Ax actin in B16 mouse melanoma cells after chemical reversional modulation and of tumor progression-related A' actin in the ontogeny of human malignant melanoma. |
| Q79837035 | Bioenergetic status and hypoxia in Lewis lung carcinoma assessed by 31P NMR spectroscopy: correlation with tumor progression |
| Q69025402 | Biological changes in serum antiproteases as related to tumor progression |
| Q37065281 | Biological modulation by lectins and their ligands in tumor progression and metastasis |
| Q36331266 | Biological responses to TGF-β in the mammary epithelium show a complex dependency on Smad3 gene dosage with important implications for tumor progression |
| Q28085247 | Biology of MET: a double life between normal tissue repair and tumor progression |
| Q40927587 | Biology of gastric cancer: gastritis-metaplasia-dysplasia sequence, role of H Pylori, and molecular correlates of tumor progression. |
| Q39765325 | Biology of tumor progression in human melanocytes. |
| Q39662175 | Bioluminescence imaging correlates with tumor progression in an orthotopic mouse model of lung cancer |
| Q37194276 | Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models |
| Q86896742 | Biomarker discordance during tumor progression |
| Q38779205 | Biophysical modeling of brain tumor progression: From unconditionally stable explicit time integration to an inverse problem with parabolic PDE constraints for model calibration. |
| Q38821342 | Bisdemethoxycurcumin (BDMC) Alters Gene Expression-associated Cell Cycle, Cell Migration and Invasion and Tumor Progression in Human Lung Cancer NCI-H460 Cells |
| Q37277241 | Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer |
| Q64095664 | Bladder cancer cells interact with vascular endothelial cells triggering EGFR signals to promote tumor progression |
| Q73093199 | Blockers of adrenergic neurons and receptors, tumor progression and effects of rotational stress in mice |
| Q100761273 | Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis/thromboembolism |
| Q33723733 | Blocking fatty acid synthase inhibits tumor progression of human osteosarcoma by regulating the human epidermal growth factor receptor 2/phosphoinositide 3-kinase/protein kinase B signaling pathway in xenograft models |
| Q68685714 | Blood group isoantigen expression during tumour progression of cervical neoplasia |
| Q73928505 | Blood level of B and CD4+ lymphocytes measured before induction of an experimental tumor in rats predicts tumor progression and survival |
| Q47739304 | Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma |
| Q43164811 | Bone marrow microenvironment and tumor progression. |
| Q41866817 | Bone marrow-derived CD13(+) cells sustain tumor progression: A potential non-malignant target for anticancer therapy |
| Q39853302 | Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression |
| Q87830815 | Both cancerous miR-21 and stromal miR-21 in urothelial carcinoma are related to tumour progression |
| Q40364723 | Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression |
| Q44250197 | Brain metastases after stereotactic radiosurgery using the Leksell gamma knife: can FDG PET help to differentiate radionecrosis from tumour progression? |
| Q92858828 | Breast Cancer Cell-Derived Soluble CD44 Promotes Tumor Progression by Triggering Macrophage IL1β Production |
| Q36545058 | Breast cancer associated a2 isoform vacuolar ATPase immunomodulates neutrophils: potential role in tumor progression |
| Q40365774 | Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression |
| Q57468211 | Breast cancer cells-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells |
| Q41726194 | Breast cancer metastasis-associated genes: role in tumour progression to the metastatic state. |
| Q90678549 | Breast cancer-derived exosomes: Tumor progression and therapeutic agents |
| Q93359927 | Breast cancer-released exosomes trigger cancer-associated cachexia to promote tumor progression |
| Q83457870 | Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib |
| Q37461714 | Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker |
| Q98498721 | Bromodomain and Extraterminal (BET) protein inhibition suppresses tumor progression and inhibits HGF-MET signaling through targeting cancer-associated fibroblasts in colorectal cancer |
| Q35952249 | Bromodomain and extraterminal inhibition blocks tumor progression and promotes differentiation in neuroblastoma |
| Q52602387 | Building Bonds: Cancer Stem Cells Depend on Their Progeny to Drive Tumor Progression. |
| Q46466051 | Bulbophyllum sterile petroleum ether fraction induces apoptosis in vitro and ameliorates tumor progression in vivo |
| Q50114136 | C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis. |
| Q64249721 | C-X-C Motif Chemokine Ligand 14 is a Unique Multifunctional Regulator of Tumor Progression |
| Q39559590 | C-heterochromatin variation and transposition in tumor progression |
| Q87635685 | C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma |
| Q36587856 | C14orf166 overexpression correlates with tumor progression and poor prognosis of breast cancer |
| Q112292866 | C1GALT1, Negatively Regulated by miR-181d-5p, Promotes Tumor Progression via Upregulating RAC1 in Lung Adenocarcinoma |
| Q64971079 | CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target. |
| Q28277511 | CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis |
| Q24320341 | CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis |
| Q34691397 | CARMA3 is crucial for EGFR-Induced activation of NF-κB and tumor progression |
| Q38946743 | CAS (CSE1L) signaling pathway in tumor progression and its potential as a biomarker and target for targeted therapy |
| Q37745865 | CBX6 overexpression contributes to tumor progression and is predictive of a poor prognosis in hepatocellular carcinoma |
| Q64063427 | CCL2/CCR2 Axis Promotes the Progression of Salivary Adenoid Cystic Carcinoma via Recruiting and Reprogramming the Tumor-Associated Macrophages |
| Q83966053 | CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma |
| Q36751581 | CCR7 mediates inflammation-associated tumor progression |
| Q47322834 | CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression |
| Q83300098 | CD105/Ki67 coexpression correlates with tumor progression and poor prognosis in epithelial ovarian cancer |
| Q60390373 | CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumour progression |
| Q92895834 | CD109: a multifunctional GPI-anchored protein with key roles in tumor progression and physiological homeostasis |
| Q45925171 | CD146 expression and its close relationship to tumor progression in systemic malignancies besides gall bladder carcinomas. |
| Q91341072 | CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker |
| Q90577133 | CD148 Serves as a Prognostic Marker of Gastric Cancer and Hinders Tumor Progression by Dephosphorylating EGFR |
| Q89529781 | CD155: A Multi-Functional Molecule in Tumor Progression |
| Q47651304 | CD155T/TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. |
| Q90326236 | CD164 promotes tumor progression and predicts the poor prognosis of bladder cancer |
| Q47677316 | CD215+ Myeloid Cells Respond to Interleukin 15 Stimulation and Promote Tumor Progression |
| Q79366352 | CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression |
| Q55190969 | CD300A promotes tumor progression by PECAM1, ADCY7 and AKT pathway in acute myeloid leukemia. |
| Q70948322 | CD34 expression in endothelial cells of small hepatocellular carcinoma: its correlation with tumour progression and angiographic findings |
| Q47126472 | CD4+ and Perivascular Foxp3+ T Cells in Glioma Correlate with Angiogenesis and Tumor Progression |
| Q38746207 | CD40 Expression in Human Esophageal Squamous Cell Carcinoma Is Associated with Tumor Progression and Lymph Node Metastasis |
| Q26851466 | CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis |
| Q40385492 | CD44 and its role in tumour progression and metastasis |
| Q53368700 | CD44 expression during tumor progression of follicular lymphoma. |
| Q57070165 | CD44 is overexpressed and correlated with tumor progression in gallbladder cancer |
| Q47949611 | CD44 isoform-cytoskeleton interaction in oncogenic signaling and tumor progression |
| Q40384365 | CD44 splice variants: expression during lymphocyte activation and tumor progression. |
| Q34362792 | CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression |
| Q58697956 | CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression |
| Q73986234 | CD44V6 in gastric carcinoma: a marker of tumor progression |
| Q74128156 | CD44v6 is not relevant in colorectal tumour progression |
| Q33615788 | CD45RA-Foxp3high but not CD45RA+Foxp3low suppressive T regulatory cells increased in the peripheral circulation of patients with head and neck squamous cell carcinoma and correlated with tumor progression. |
| Q59798518 | CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer |
| Q36414257 | CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models |
| Q33618348 | CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis |
| Q58110105 | CD90 determined two subpopulations of glioma-associated mesenchymal stem cells with different roles in tumour progression |
| Q94546926 | CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma |
| Q64063243 | CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer |
| Q64112562 | CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer |
| Q46053838 | CEACAM1 as a central modulator of metabolism, tumor progression, angiogenesis and immunity |
| Q44464353 | CEACAM5 has different expression patterns in gastric non-neoplastic and neoplastic lesions and cytoplasmic staining is a marker for evaluation of tumor progression in gastric adenocarcinoma |
| Q39314424 | CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer |
| Q38711185 | CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer |
| Q64085173 | CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer |
| Q39142597 | CHD1L promotes tumor progression and predicts survival in colorectal carcinoma. |
| Q57292487 | CHI3L1 promotes tumor progression by activating TGF-β signaling pathway in hepatocellular carcinoma |
| Q112645376 | CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression |
| Q43203188 | CIITA methylation and decreased levels of HLA-DR in tumour progression |
| Q100961820 | CILP2 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer in The Cancer Genome Atlas (TCGA) study |
| Q38763359 | CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. |
| Q91965786 | CKS2 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in epithelial ovarian cancer |
| Q91890919 | CLDN6 promotes tumor progression through the YAP1-snail1 axis in gastric cancer |
| Q38313479 | COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer |
| Q112286310 | COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas |
| Q39079666 | COUP-TFII in pancreatic adenocarcinoma: clinical implication for patient survival and tumor progression |
| Q36715145 | COX-2 modulates mammary tumor progression in response to collagen density. |
| Q50209286 | COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression. |
| Q112298820 | CREBBP/EP300 mutations promoted tumor progression in diffuse large B-cell lymphoma through altering tumor-associated macrophage polarization via FBXW7-NOTCH-CCL2/CSF1 axis |
| Q94352802 | CS-02SHP2 PROMOTES TUMOR PROGRESSION IN GBM VIA RAS ACTIVATION |
| Q101410017 | CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model |
| Q94149020 | CSIG-08. DYNAMICS OF GLIOMA GROWTH: SELF-ORGANIZATION GUIDES THE PATTERNING OF THE EXTRACELLULAR MATRIX AND REGULATES TUMOR PROGRESSION |
| Q98510238 | CTLA-4 immunotherapy exposes differences in immune response along with different tumor progression in colorectal cancer |
| Q100962224 | CUEDC1 inhibits epithelial-mesenchymal transition via the TβRI/Smad signaling pathway and suppresses tumor progression in non-small cell lung cancer |
| Q97687268 | CUX1-Transcriptional Master Regulator of Tumor Progression in Pancreatic Neuroendocrine Tumors |
| Q38743011 | CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer |
| Q92776216 | CXCL11 promotes tumor progression by the biased use of the chemokine receptors CXCR3 and CXCR7 |
| Q48795538 | CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. |
| Q36502915 | CXCL12/CXCR4 display an inverse mRNA expression profile in gastric carcinoma that correlates with tumor progression |
| Q34406206 | CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression |
| Q47115830 | CXCL8 derived from tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression by promoting migration and invasion of cancer cells |
| Q37429985 | CXCL9: evidence and contradictions for its role in tumor progression |
| Q39010600 | CXCR3 deficiency enhances tumor progression by promoting macrophage M2 polarization in a murine breast cancer model. |
| Q38133181 | CXCR3, a double-edged sword in tumor progression and angiogenesis |
| Q40493003 | CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells |
| Q38017150 | CXCR6: the role of environment in tumor progression. Challenges for therapy. |
| Q34209313 | CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma |
| Q46109594 | CYR61 downregulation correlates with tumor progression by promoting MMP-7 expression in human gastric carcinoma |
| Q37092692 | Cables1 is a tumor suppressor gene that regulates intestinal tumor progression in Apc(Min) mice |
| Q98190026 | CacyBP/SIP promotes tumor progression by regulating apoptosis and arresting the cell cycle in osteosarcoma |
| Q28262569 | Cadherin switch in tumor progression |
| Q37333596 | Cadherins and cancer: how does cadherin dysfunction promote tumor progression? |
| Q33743242 | Cadherins and catenins: role in signal transduction and tumor progression |
| Q34502753 | Cadherins and the tumour progression: is it all in a switch? |
| Q52862120 | Cadmium, arsenic, selenium and iron- Implications for tumor progression in breast cancer. |
| Q100519390 | Calcium-Binding Protein S100P Promotes Tumor Progression but Enhances Chemosensitivity in Breast Cancer |
| Q47360459 | Calpain-2 inhibitor treatment preferentially reduces tumor progression for human colon cancer cells expressing highest levels of this enzyme |
| Q114662847 | Can interruption of innate immune recognition-mediated emergency myelopoiesis impede tumor progression? |
| Q88348372 | Can tumor coverage evaluated 24 h post-radiofrequency ablation predict local tumor progression of liver metastases? |
| Q98615074 | Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression |
| Q36264065 | Cancer cell immune escape and tumor progression by exploitation of anti-inflammatory and pro-inflammatory responses |
| Q91064437 | Cancer cell plasticity: Impact on tumor progression and therapy response |
| Q40819588 | Cancer cell societies and tumor progression |
| Q38237431 | Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression |
| Q39035750 | Cancer cells exploit eIF4E2-directed synthesis of hypoxia response proteins to drive tumor progression |
| Q37315780 | Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle |
| Q98626256 | Cancer regeneration: Polyploid cells are the key drivers of tumor progression |
| Q38054321 | Cancer stem cell dynamics in tumor progression and metastasis: is the microenvironment to blame? |
| Q55122201 | Cancer stem cells as key drivers of tumour progression. |
| Q37663275 | Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis |
| Q47659283 | Cancer stem cells as the engine of unstable tumor progression. |
| Q36769448 | Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance |
| Q114873497 | Cancer stem cell–immune cell crosstalk in tumour progression |
| Q101405259 | Cancer type‑SLCO1B3 promotes epithelial‑mesenchymal transition resulting in the tumour progression of non‑small cell lung cancer |
| Q38881343 | Cancer-associated fibroblast-derived CXCL12 causes tumor progression in adenocarcinoma of the esophagogastric junction |
| Q64100273 | Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance |
| Q38425655 | Cancer-associated mesenchymal stem cells aggravate tumor progression |
| Q74609348 | Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression |
| Q36844475 | Cancer-associated stromal fibroblasts promote pancreatic tumor progression |
| Q35820674 | Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy |
| Q44656536 | Cancer: Bad blood promotes tumour progression |
| Q90868561 | Cancer‑associated adipocytes exhibit distinct phenotypes and facilitate tumor progression in pancreatic cancer |
| Q88024328 | Candidate gene DNA methylation associations with breast cancer characteristics and tumor progression |
| Q34593813 | Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. |
| Q28307549 | Capn4 mRNA level is correlated with tumour progression and clinical outcome in clear cell renal cell carcinoma |
| Q95309335 | Caprin1 targeted by circular circ_0000885 in the tumor progression of osteosarcoma |
| Q99611381 | Caprin1 targeted by circular circ_0000885 in the tumor progression of osteosarcoma |
| Q39502690 | Carbidopa abrogates L-dopa decarboxylase coactivation of the androgen receptor and delays prostate tumor progression |
| Q57815591 | Carbonic anhydrase IX enhances tumor cell proliferation and tumor progression in osteosarcoma |
| Q53594611 | Carbonic anhydrase IX expression is associated with tumor progression and a poor prognosis of lung adenocarcinoma. |
| Q37671272 | Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression |
| Q44750583 | Carcinogen-specific targeting of chromosome 12 for loss of heterozygosity in mouse lung adenocarcinomas: implications for chromosome instability and tumor progression |
| Q73931741 | Carcinoma-associated expression of core 2 beta-1,6-N-acetylglucosaminyltransferase gene in human colorectal cancer: role of O-glycans in tumor progression |
| Q37621644 | Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. |
| Q40923257 | Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium |
| Q46944520 | Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium |
| Q39295187 | Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes |
| Q28281154 | Cas and NEDD9 Contribute to Tumor Progression through Dynamic Regulation of the Cytoskeleton |
| Q51038972 | Catastrophic shifts and lethal thresholds in a propagating front model of unstable tumor progression. |
| Q91584198 | Catecholamines can mediate stress-related effects on tumor progression |
| Q41730404 | Cathepsin B and human tumor progression |
| Q74306162 | Cathepsin B expression and its correlation with tumor-associated laminin and tumor progression in gastric cancer |
| Q35833961 | Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival |
| Q74625032 | Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis |
| Q93139029 | Cationic polysaccharide spermine-pullulan drives tumor associated macrophage towards M1 phenotype to inhibit tumor progression |
| Q38746081 | Caudatin targets TNFAIP1/NF-κB and cytochrome c/caspase signaling to suppress tumor progression in human uterine cancer |
| Q38891711 | Causes and consequences of nuclear envelope alterations in tumour progression |
| Q37174457 | Caveolin-1 in tumor progression: the good, the bad and the ugly. |
| Q35727558 | Caveolin-1 is Associated with Tumor Progression and Confers a Multi-Modality Resistance Phenotype in Pancreatic Cancer |
| Q83217843 | Caveolin-1 overexpression correlates with tumour progression markers in pancreatic ductal adenocarcinoma |
| Q40440532 | Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice |
| Q38862698 | Cavin-2 in oral cancer: A potential predictor for tumor progression |
| Q34068211 | Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression |
| Q98574275 | Cdkn2a loss in a model of neurofibroma demonstrates stepwise tumor progression to atypical neurofibroma and MPNST |
| Q53476263 | Cell adhesion and tumor progression in mouse skin carcinogenesis: increased synthesis and organization of fibronectin is associated with the undifferentiated spindle phenotype. |
| Q37766448 | Cell adhesion: implication in tumor progression. |
| Q38814138 | Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma |
| Q24802934 | Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion |
| Q54503668 | Cell cycle and viral and immunologic profiles of head and neck squamous cell carcinoma as predictable variables of tumor progression. |
| Q37441239 | Cell fusion as a hidden force in tumor progression |
| Q38067160 | Cell fusion in myeloma marrow microenvironment: role in tumor progression. |
| Q34217897 | Cell fusion in tumor progression: the isolation of cell fusion products by physical methods |
| Q26992092 | Cell lineage specification in tumor progression and metastasis |
| Q71145664 | Cell membrane fluidity and adriamycin retention in a tumor progression model of AKR lymphoma |
| Q28317881 | Cell proliferation in colorectal tumor progression: an immunohistochemical approach to intermediate biomarkers |
| Q38105883 | Cell trafficking of endothelial progenitor cells in tumor progression |
| Q74172572 | Cell transforming genes and tumor progression: in vivo unified secondary phenotypic cell changes |
| Q93377454 | Cell-adhesion molecules and their soluble forms: Promising predictors of "tumor progression" and relapse in leukemia |
| Q36767326 | Cell-heritable stages of tumor progression in transgenic mice harboring the bovine papillomavirus type 1 genome |
| Q92074855 | Cell-in-Cell Phenomenon and Its Relationship With Tumor Microenvironment and Tumor Progression: A Review |
| Q92404090 | Cell-to-cell variation of chromosomal number in the adult testicular germ cell tumors: a comparison of chromosomal instability among histological components and its putative role in tumor progression |
| Q40837434 | Cellular and molecular changes during mouse skin tumor progression |
| Q42525189 | Cellular autophagic capacity changes during azaserine-induced tumour progression in the rat pancreas. Up-regulation in all premalignant stages and down-regulation with loss of cycloheximide sensitivity of segregation along with malignant transformat |
| Q30544875 | Cellular capsules as a tool for multicellular spheroid production and for investigating the mechanics of tumor progression in vitro |
| Q57801673 | Cellular origin, tumour progression and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells |
| Q37545268 | Cellular therapy to control tumor progression |
| Q37502782 | Ceramide targets xIAP and cIAP1 to sensitize metastatic colon and breast cancer cells to apoptosis induction to suppress tumor progression |
| Q38655747 | Cervical cancer cell-derived angiopoietins promote tumor progression |
| Q39246158 | Cetuximab alleviates neuropathic pain despite tumour progression |
| Q38111920 | Change in HER2 status during breast tumor progression |
| Q44979232 | Change in the role of the spleen from protective to harmful following tumor progression in AKR lymphoma |
| Q36464895 | Changes in intrinsic subtype of breast cancer during tumor progression in the same patient |
| Q42439078 | Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix. |
| Q53663179 | Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression? |
| Q70760192 | Changes in spleen morphology and lymphoid cell activity during tumor progression |
| Q92082798 | Changes in steroid hormone profile and tumour progression after genistein treatment of canine inflammatory mammary cancer xenotransplanted mice |
| Q44030649 | Changes in superoxide anion production and phagocytosis by circulating neutrophils during tumor progression in a rat model. |
| Q48090087 | Changes in the microvascular structure of mucosal squamous cell carcinoma of the esophagus and their significance in tumor progression |
| Q67525775 | Changes on distribution of CD4+/CD45RA- and CD8+/CD11- cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression |
| Q35125897 | Changing neighbours, changing behaviour: cell adhesion molecule-mediated signalling during tumour progression |
| Q112645220 | Chaperone-Mediated Autophagy Ablation in Pericytes Reveals New Glioblastoma Prognostic Markers and Efficient Treatment Against Tumor Progression |
| Q37624980 | Chapter 3: The shifting balance between CLU forms during tumor progression |
| Q92425197 | Characterisation of DNA methylation changes in EBF3 and TBC1D16 associated with tumour progression and metastasis in multiple cancer types |
| Q39473678 | Characteristics of cultured human melanocytes from different stages of tumor progression |
| Q53438138 | Characteristics of cultured human melanocytes isolated from different stages of tumor progression. |
| Q74754997 | Characteristics of tumors in lymph vessels play an important role in the tumor progression of invasive ductal carcinoma of the breast: a prospective study |
| Q73352878 | Characterization of early pulmonary hyperproliferation and tumor progression and their inhibition by black tea in a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis model with A/J mice |
| Q39398718 | Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics |
| Q37565083 | Characterization of metastatic tumor antigen 1 and its interaction with hepatitis B virus X protein in NF-κB signaling and tumor progression in a woodchuck hepatocellular carcinoma model |
| Q36649864 | Characterization of the expression of the pro-metastatic Mena(INV) isoform during breast tumor progression |
| Q41495212 | Characterization of tumor progression from threshold tumor inocula: evidence for natural resistance |
| Q34539840 | Characterization of tumor progression in engineered tissue using infrared spectroscopic imaging |
| Q92562602 | Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set |
| Q36578596 | Chemical mapping of tumor progression by FT-IR imaging: towards molecular histopathology. |
| Q72236390 | Chemically induced sarcomas in Sprague-Dawley rats: dose effects on autoantibody levels and tumor progression |
| Q73470781 | Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome |
| Q88764234 | Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer |
| Q37327023 | Chemokines in neuroectodermal tumour progression and metastasis |
| Q36164084 | Chemokines in tumor progression and metastasis |
| Q86814803 | Chemokines in tumor progression and metastasis |
| Q40443319 | Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma |
| Q92890634 | Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics |
| Q104694487 | Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer |
| Q53116773 | Chitosan oligosaccharide suppresses tumor progression in a mouse model of colitis-associated colorectal cancer through AMPK activation and suppression of NF-κB and mTOR signaling. |
| Q123253651 | Chloride Intracellular Channel Proteins (CLICs) and Malignant Tumor Progression: A Focus on the Preventive Role of CLIC2 in Invasion and Metastasis |
| Q71044351 | Chlorpromazine-induced hypothermia: effect on tumour progression and survival in mice |
| Q38722410 | Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression |
| Q28282754 | Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression |
| Q36713861 | Chondroitin sulfate proteoglycans in tumor progression |
| Q34654497 | Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression |
| Q55466552 | Chromosomal alterations in oligodendroglial tumours over multiple surgeries: is tumour progression associated with change in 1p/19q status? |
| Q38622118 | Chromosomal and molecular clues to tumor progression |
| Q53474173 | Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. |
| Q37936227 | Chromosomal evolution and tumor progression in a myxoid liposarcoma |
| Q51904634 | Chromosomal high-polysomies predict tumour progression in T1 transitional cell carcinoma of the bladder. |
| Q73714048 | Chromosomal imbalance in esophageal squamous cell carcinoma: 3q gain correlates with tumor progression but not prognostic significance |
| Q34274005 | Chromosomal imbalances in gastric cancer. Correlation with histologic subtypes and tumor progression |
| Q82316014 | Chromosome 8p deletions and 8q gains are associated with tumor progression and poor prognosis in prostate cancer |
| Q50710190 | Chromosome 9p deletions are an independent predictor of tumor progression following nephrectomy in patients with localized clear cell renal cell carcinoma. |
| Q40160795 | Chromosome Changes (Trisomies #15 and 17) Associated With Tumor Progression in Leukemias Induced by Radiation Leukemia Virus2 |
| Q39818978 | Chromosome abnormalities, gene amplification, and tumor progression |
| Q35853642 | Chromosome alterations in rat mammary tumor progression |
| Q52652794 | Chromosome-wide gene dosage rebalance may benefit tumor progression. |
| Q38799429 | Chronic Inflammation and Cancer: Paradigm on Tumor Progression, Metastasis and Therapeutic Intervention |
| Q33788519 | Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer |
| Q34657500 | Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. |
| Q81600259 | Chronic restraint stress impairs T-cell immunity and promotes tumor progression in mice |
| Q38841752 | Cinnamic aldehyde suppresses hypoxia-induced angiogenesis via inhibition of hypoxia-inducible factor-1α expression during tumor progression |
| Q39885745 | Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8+ T cells. |
| Q91257573 | Circ-ASH2L promotes tumor progression by sponging miR-34a to regulate Notch1 in pancreatic ductal adenocarcinoma |
| Q112710168 | CircCDK14 Promotes Tumor Progression and Resists Ferroptosis in Glioma by Regulating PDGFRA |
| Q90630518 | CircRNA fibroblast growth factor receptor 3 promotes tumor progression in non-small cell lung cancer by regulating Galectin-1-AKT/ERK1/2 signaling |
| Q91451411 | CircRNA-ENO1 promoted glycolysis and tumor progression in lung adenocarcinoma through upregulating its host gene ENO1 |
| Q90217349 | CircVRK1 regulates tumor progression and radioresistance in esophageal squamous cell carcinoma by regulating miR-624-3p/PTEN/PI3K/AKT signaling pathway |
| Q99632287 | Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis |
| Q36727437 | Circadian Clock in a Mouse Colon Tumor Regulates Intracellular Iron Levels to Promote Tumor Progression |
| Q91504848 | Circadian clock gene Per2 downregulation in non‑small cell lung cancer is associated with tumour progression and metastasis |
| Q41330602 | Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery |
| Q92142980 | Circular RNA 0016788 displays as a biomarker for tumor progression and poor prognosis in surgical hepatocellular carcinoma patients |
| Q92150488 | Circular RNA ABCB10 promotes tumor progression and correlates with pejorative prognosis in clear cell renal cell carcinoma |
| Q90777718 | Circular RNA FOXP1 promotes tumor progression and Warburg effect in gallbladder cancer by regulating PKLR expression |
| Q94544779 | Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma |
| Q112717977 | Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX |
| Q37111059 | Circulating Levels of M30 and M65 Molecules in Transitional Cell Carcinoma of the Bladder and Their Relation to Tumor Progression |
| Q42513574 | Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer |
| Q37502188 | Circulating endothelial cells as biomarkers for angiogenesis in tumor progression |
| Q81609310 | Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas |
| Q77948386 | Circulating macrophage colony stimulating factor as a marker of tumour progression |
| Q84232903 | Circulating miRNAs are correlated with tumor progression in prostate cancer |
| Q53588092 | Circulating nucleic acids in plasma/serum and tumor progression: are apoptotic bodies involved? An experimental study in a rat cancer model. |
| Q60048099 | Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy |
| Q36089989 | Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models |
| Q64276040 | Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression |
| Q43644524 | Claudin-7 expression and its association with tumor progression in systemic malignancies |
| Q44531271 | Claudin-7 expression and its association with tumor progression in systemic malignancies--reply |
| Q28566627 | Claudin-7 regulates EpCAM-mediated functions in tumor progression |
| Q112725465 | Cleavage and Polyadenylation Specific Factor 1 Promotes Tumor Progression via Alternative Polyadenylation and Splicing in Hepatocellular Carcinoma |
| Q36974284 | Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme. |
| Q51095228 | Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma. |
| Q112297691 | Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma |
| Q73412960 | Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas") |
| Q86046915 | Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib |
| Q33547823 | Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response |
| Q31144835 | Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. |
| Q88707023 | Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: A preliminary report |
| Q93230600 | Clinical prediction model for tumor progression in Barrett's esophagus |
| Q64941197 | Clinical significance of bromodomain-containing protein 7 and its association with tumor progression in prostate cancer. |
| Q60912783 | Clinical significance of miR-195 in hepatocellular carcinoma and its biological function in tumor progression |
| Q39084939 | Clinical significance of stanniocalcin 2 expression as a predictor of tumor progression in gastric cancer |
| Q71081223 | Clinical usefulness of the study of serum carcinoembryonic antigen (CEA) for the determination of the degree of tumor progression, prognosis and monitoring of surgical treatment of neoplasms of the large intestine |
| Q46167485 | Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. |
| Q36196750 | Clinicopathological significance of SPC18 in colorectal cancer: SPC18 participates in tumor progression |
| Q80532937 | Clinicopathological significance of WT1 expression in ovarian cancer: a possible accelerator of tumor progression in serous adenocarcinoma |
| Q37028962 | Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions |
| Q53347895 | Clonal diversity in tumor progression. |
| Q42802559 | Clonal diversity of the Kirsten-ras oncogene during tumor progression in athymic nude mice: mechanisms of amplification and rearrangement |
| Q36643787 | Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma |
| Q42828505 | Clonal dominance of select subsets of viral Kirsten ras(+)-transformed 3T3 cells during tumor progression. |
| Q84126873 | Clonal evolution and tumor progression in 2 human colorectal adenoma-derived cell-lines invitro - the involvement of chromosome-1 abnormalities |
| Q34233614 | Clonal expansion of p53 mutant cells is associated with brain tumour progression |
| Q70771441 | Clonality: more than just a tumor-progression model |
| Q46939655 | Cloning of novel mammary tumor progression and metastasis genes |
| Q36301071 | Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. |
| Q38695580 | Clusterin and neuropilin-2 as potential biomarkers of tumor progression in benzo[a]pyrene-transformed 16HBE cells xenografted nude mouse model |
| Q50881520 | Co-expression of AQP3 and AQP5 in esophageal squamous cell carcinoma correlates with aggressive tumor progression and poor prognosis. |
| Q34657188 | Co-expression of fatty acid synthase and caveolin-1 in pancreatic ductal adenocarcinoma: implications for tumor progression and clinical outcome |
| Q42500958 | Co-expression of ras p21 and epidermal growth factor receptor during various stages of tumour progression in oral mucosa |
| Q40827270 | Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins |
| Q36564043 | Co-opted integrin signaling in ErbB2-induced mammary tumor progression |
| Q91239470 | Co-targeting CK2α and YBX1 suppresses tumor progression by coordinated inhibition of the PI3K/AKT signaling pathway |
| Q99562037 | Codelivery of BV6 and anti-IL6 siRNA by hyaluronate-conjugated PEG-chitosan-lactate nanoparticles inhibits tumor progression |
| Q53099025 | Coil-assisted RFA of poorly visible liver tumors: effectiveness and risk factors of local tumor progression. |
| Q39277670 | Collaborative and Defensive Fibroblasts in Tumor Progression and Therapy Resistance |
| Q35951999 | Collagen VI ablation retards brain tumor progression due to deficits in assembly of the vascular basal lamina |
| Q37692855 | Collagen as a double-edged sword in tumor progression |
| Q39042485 | Collagen signaling enhances tumor progression after anti-VEGF therapy in a murine model of pancreatic ductal adenocarcinoma. |
| Q41484689 | Colon carcinoma cells switch their response to transforming growth factor beta 1 with tumor progression |
| Q38652361 | Colorectal cancer: an update on the effects of lycopene on tumor progression and cell proliferation |
| Q55411157 | Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. |
| Q73225788 | Colorectal carcinomas. Possible mechanisms of local tumor progression |
| Q38869367 | Combination Efficacy of Astragalus membranaceus and Curcuma wenyujin at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein. |
| Q51740036 | Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma. |
| Q35013115 | Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma |
| Q47369374 | Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors |
| Q64969945 | Combination of radiofrequency ablation and transcatheter arterial chemoembolization to treat hepatocellular carcinoma: measurement of distance from needle tip to nodule for assessment of local tumor progression. |
| Q47547096 | Combinatorial Effect of Abiraterone Acetate and NVP-BEZ235 on Prostate Tumor Progression in Rats. |
| Q34420371 | Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1alpha |
| Q40291730 | Combined cDNA array comparative genomic hybridization and serial analysis of gene expression analysis of breast tumor progression |
| Q37535484 | Combined microRNA-340 and ROCK1 mRNA profiling predicts tumor progression and prognosis in pediatric osteosarcoma |
| Q51109324 | Combined therapies of antithrombotics and antioxidants delay in silico brain tumour progression. |
| Q42635833 | Comment on "Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma". |
| Q48376145 | Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus 18FDG PET/CT in differentiating brain tumor progression from radiation injury. |
| Q73085523 | Comments on Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression, Oliver et al., Eur J Cancer, 32A, No. 3, pp. 396-397, 1996 |
| Q99710314 | Common sense and tumor treatment. A case of pilomatrical carcinoma in a 21-year-old patient with surprisingly rapid tumor progression |
| Q57809694 | Comparing the effects of different cell death programs in tumor progression and immunotherapy |
| Q46956664 | Comparison of diagnostic accuracy of (18)F-FDG PET, (123)I-IMT- and (99m)Tc-MIBI SPECT: evaluation of tumour progression in irradiated low grade astrocytomas |
| Q60656312 | Comparison of peptide cancer signatures identified by mass spectrometry in serum of patients with head and neck, lung and colorectal cancers: Association with tumor progression |
| Q35103504 | Comparison of proton magnetic resonance spectroscopy with fluorine-18 2-fluoro-deoxyglucose positron emission tomography for assessment of brain tumor progression |
| Q79925712 | Competing risks analysis of predictors of delisting owing to tumor progression in liver transplant candidates with hepatocellular carcinoma |
| Q26801339 | Complement and macrophage crosstalk during process of angiogenesis in tumor progression |
| Q37699277 | Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis |
| Q41808886 | Complex Regulation of the Pericellular Proteolytic Microenvironment during Tumor Progression and Wound Repair: Functional Interactions between the Serine Protease and Matrix Metalloproteinase Cascades |
| Q63884058 | Complex engagement of DNA damage response pathways in human cancer and in lung tumor progression |
| Q41117062 | Complex roles of matrix metalloproteinases in tumor progression. |
| Q47755246 | Components of the Hepatocellular Carcinoma Microenvironment and Their Role in Tumor Progression. |
| Q37641583 | Comprehensive N-glycan profiles of hepatocellular carcinoma reveal association of fucosylation with tumor progression and regulation of FUT8 by microRNAs |
| Q64244656 | Comprehensive characterization of the mutational landscape in multiple myeloma cell lines reveals potential drivers and pathways associated with tumor progression and drug resistance |
| Q112294103 | Comprehensive evaluation of microRNA-10b in digestive system cancers reveals prognostic implication and signaling pathways associated with tumor progression |
| Q39295059 | Comprehensive modulation of tumor progression and regression with periodic fasting and refeeding circles via boosting IGFBP-3 loops and NK responses |
| Q92830669 | Comprehensive transcriptomic analysis of papillary thyroid cancer: potential biomarkers associated with tumor progression |
| Q89498294 | Compression-induced dedifferentiation of adipocytes promotes tumor progression |
| Q90035345 | Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity |
| Q100512247 | Concepts of extracellular matrix remodelling in tumour progression and metastasis |
| Q43847405 | Concomitant microRNA-31 downregulation and radixin upregulation predicts advanced tumor progression and unfavorable prognosis in patients with gliomas |
| Q97687564 | Conditional Gene Targeting Reveals Cell Type-Specific Roles of the Lysosomal Protease Cathepsin L in Mammary Tumor Progression |
| Q37063904 | Conditional ablation of TGF-β signaling inhibits tumor progression and invasion in an induced mouse bladder cancer model |
| Q85653733 | Conditional expression of fascin increases tumor progression in a mouse model of intestinal cancer |
| Q77811241 | Connective tissue growth factor gene expression alters tumor progression in esophageal cancer |
| Q40400855 | Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. |
| Q42466584 | Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations |
| Q81573729 | Conservation of gene expression signatures between zebrafish and human liver tumors and tumor progression |
| Q53528699 | Constancy of genomic instability in tumor progression. |
| Q44260429 | Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. |
| Q64256027 | Constitutive activation of EGFR is associated with tumor progression and plays a prominent role in malignant phenotype of chondrosarcoma |
| Q73270642 | Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression |
| Q33414651 | Constructing tumor progression pathways and biomarker discovery with fuzzy kernel kmeans and DNA methylation data |
| Q54538320 | Consumption of high-fat diet induces tumor progression and epithelial-mesenchymal transition of colorectal cancer in a mouse xenograft model. |
| Q38909863 | Contextual niche signals towards colorectal tumor progression by mesenchymal stem cell in the mouse xenograft model. |
| Q37376481 | Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience |
| Q46617197 | Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression |
| Q36545146 | Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications |
| Q91323056 | Contrasting the impact of cytotoxic and cytostatic drug therapies on tumour progression |
| Q38801368 | Contribution of in vitro comparison of colorectal carcinoma cells from primary and metastatic lesions to elucidation of mechanisms of tumor progression and response to anticancer therapy |
| Q36752265 | Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways |
| Q41121047 | Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis |
| Q80798802 | Control of cyclosporine A-induced tumor progression using 15-deoxyspergualin for rat cardiac transplantation |
| Q40986604 | Control of tumor progression by maintenance of apoptosis |
| Q39008690 | Controlling Tumor Progression with Cyclophosphamide, Vincristine, and Dacarbazine Treatment Improves Survival in Patients with Metastatic and Unresectable Malignant Pheochromocytomas/Paragangliomas |
| Q38821542 | Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3. |
| Q41105704 | Cooperation between matrix metalloproteinases and the plasminogen activator-plasmin system in tumor progression |
| Q39499423 | Cooperation between multiple oncogenes in rodent embryo fibroblasts: an experimental model of tumor progression? |
| Q54407757 | Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression. |
| Q54422162 | Copy-number increase of AURKA in gastric cancers in a Chinese population: a correlation with tumor progression. |
| Q57518423 | Copy–Number Alterations for Tumor Progression Inference |
| Q112286750 | Core genes involved in the regulation of acute lung injury and their association with COVID-19 and tumor progression: A bioinformatics and experimental study |
| Q42364640 | Correction for Gabai et al., "Heat Shock Transcription Factor Hsf1 Is Involved in Tumor Progression via Regulation of Hypoxia-Inducible Factor 1 and RNA-Binding Protein HuR". |
| Q93086417 | Correction for Jailkhani et al., Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix |
| Q92750629 | Correction for: Mitochondrial fission regulator 2 (MTFR2) promotes growth, migration, invasion and tumour progression in breast cancer cells |
| Q88062823 | Correction to: A predictive model for distinguishing radiation necrosis from tumour progression after gamma knife radiosurgery based on radiomic features from MR images |
| Q91215975 | Correction to: Crosstalk between cancer cells and endothelial cells: implications for tumor progression and intervention |
| Q58743521 | Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling |
| Q58799552 | Correction to: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma |
| Q90310361 | Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer |
| Q55496804 | Correction to: Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer. |
| Q92643947 | Correction: Acidity promotes tumour progression by altering macrophage phenotype in prostate cancer |
| Q46207844 | Correction: Elevated Snail Expression Mediates Tumor Progression in Areca Quid Chewing-Associated Oral Squamous Cell Carcinoma via Reactive Oxygen Species |
| Q43227322 | Correction: EpCAM knockdown alters microRNA expression in retinoblastoma--functional implication of EpCAM regulated miRNA in tumor progression |
| Q42705182 | Correction: Expression of MYSM1 is associated with tumor progression in colorectal cancer |
| Q94581774 | Correction: High LINC01605 expression predicts poor prognosis and promotes tumor progression via upregulation of MMP9 in bladder cancer |
| Q45793370 | Correction: Liberati, S., et al. Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression. Cells 2014, 3, 112–128. |
| Q46005024 | Correction: Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression. |
| Q90789915 | Correction: PO-194 Novel potential targets for hakai oncogene during tumour progression |
| Q43094041 | Correction: Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells |
| Q45939013 | Correction: Reduced expression of AMPK-ß1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer. |
| Q42550114 | Correction: Sustained Endothelial Expression of HoxA5 In Vivo Impairs Pathological Angiogenesis And Tumor Progression |
| Q96022021 | Correction: Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation |
| Q45889595 | Correction: Up-Regulation of Hepatoma-Derived Growth Factor Facilities Tumor Progression in Malignant Melanoma |
| Q34682218 | Correction: grhl2 determines the epithelial phenotype of breast cancers and promotes tumor progression |
| Q45761807 | Correlation between DNA ploidy patterns and tumor progression, prognosis, and tumor infiltrating lymphocytes in human esophageal cancer |
| Q73071764 | Correlation between DNA ploidy, proliferation marker Ki-67 and early tumor progression in renal cell carcinoma. A prospective study |
| Q42156988 | Correlation between MTA2 overexpression and tumour progression in esophageal squamous cell carcinoma |
| Q81661355 | Correlation between RhoA overexpression and tumour progression in esophageal squamous cell carcinoma |
| Q40902578 | Correlation between growth control, neoplastic potential and endogenous connexin43 expression in HeLa cell lines: implications for tumor progression |
| Q92645971 | Correlation between overexpression of connective tissue growth factor, tumor progression, and clinical prognosis in endometrial cancer patients |
| Q73254713 | Correlation of CD44S expression in renal clear cell carcinomas with subsequent tumor progression or recurrence |
| Q28240885 | Correlation of inhibitor of differentiation 1 expression to tumor progression, poor differentiation and aggressive behaviors in cervical carcinoma |
| Q44470850 | Correlation of loss of heterozygosity at 11 p with tumour progression and survival in non‐small cell lung cancer |
| Q53204525 | Correlation of miR-494 expression with tumor progression and patient survival in pancreatic cancer. |
| Q72657653 | Correspondence re: B. Fernandes et al., beta 1-6 branched oligosaccharides as a marker of tumor progression in human breast and colon neoplasia. Cancer Res., 51: 718-723, 1991 |
| Q99726594 | Corrigendum to "Advanced multimodal nanoparticles delay tumor progression withclinical radiation therapy" [Journal of Controlled Release 238 (2016) 103-133] |
| Q92031483 | Corrigendum to "Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo" [Biomed. Pharmacother. 116 (2019) 109032] |
| Q89396783 | Corrigendum to "CXCL1-Mediated Interaction of Cancer Cells with Tumor-Associated Macrophages and Cancer-Associated Fibroblasts Promotes Tumor Progression in Human Bladder Cancer" [Neoplasia 18 (2016) 636-646] |
| Q91169997 | Corrigendum to "New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy" |
| Q42335444 | Corrigendum to: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma |
| Q55278978 | Corrigendum: Fucosylated Antigens in Cancer: An Alliance Toward Tumor Progression, Metastasis, and Resistance to Chemotherapy. |
| Q46860577 | Cortactin is associated with tumour progression and poor prognosis in prostate cancer and SIRT2 other than HADC6 may work as facilitator in situ |
| Q79297664 | Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome |
| Q115213087 | Corticotroph tumor progression after bilateral adrenalectomy (Nelson’s syndrome): systematic review and expert consensus recommendations |
| Q100731570 | Corticotroph tumor progression during long-term therapy with osilodrostat in a patient with persistent Cushing's disease |
| Q40085257 | Critical role of ADAM15 in tumor progression: targeting multiple factors for metastasis promotion |
| Q39885104 | Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model |
| Q37066559 | Cross-talk between Dopachrome Tautomerase and Caveolin-1 Is Melanoma Cell Phenotype-specific and Potentially Involved in Tumor Progression. |
| Q91375588 | Cross-talk between lung cancer and bones results in neutrophils that promote tumor progression |
| Q39038455 | Crosstalk between Hippo signalling and miRNAs in tumour progression |
| Q35730252 | Crosstalk between angiogenesis and lymphangiogenesis in tumor progression |
| Q89366287 | Crosstalk between cancer cells and endothelial cells: implications for tumor progression and intervention |
| Q34973811 | Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. |
| Q30501621 | Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression |
| Q34692268 | Cryptochrome 1 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer |
| Q34303357 | Cten mRNA expression is correlated with tumor progression in thymoma |
| Q34192387 | Cten mRNA expression was correlated with tumor progression in lung cancers |
| Q37343015 | Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. |
| Q40779943 | Current Research of the Roles of IL-35 in Tumor Progression |
| Q32068700 | Current data on metalloproteinases, obligatory partners of tumor progression |
| Q99636999 | Current mechanisms in obesity and tumor progression |
| Q77429606 | Cutaneous melanoma: patient surveillance and tumor progression |
| Q38471118 | Cyclin D1 protein overexpression is related to tumor differentiation, but not to tumor progression or proliferative activity, in transitional cell carcinoma of the bladder |
| Q53347926 | Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. |
| Q61809294 | Cyclin G2 Inhibits the Warburg Effect and Tumour Progression by Suppressing LDHA Phosphorylation in Glioma |
| Q92890036 | Cyclin-dependent kinase subunit 2 overexpression promotes tumor progression and predicts poor prognosis in uterine leiomyosarcoma |
| Q28268021 | Cyclin-dependent kinases 4 and 6 control tumor progression and direct glucose oxidation in the pentose cycle |
| Q40789590 | Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis |
| Q44818581 | Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma |
| Q86533493 | Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice |
| Q36925833 | Cyclooxygenases, prostanoids, and tumor progression |
| Q26827307 | Cysteine cathepsins: their role in tumor progression and recent trends in the development of imaging probes |
| Q44713996 | Cytochemical markers and DNA content of neuroendocrine cells in carcinoma of the prostate gland during tumour progression |
| Q44495774 | Cytogenetic changes during tumor progression towards invasion, metastasis and immune escape in the Eb/ESb model system |
| Q37927074 | Cytogenetics of tumor progression |
| Q34413756 | Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis |
| Q46391100 | Cytokeratin 20 as a marker of tumor progression or dissemination in patients with colorectal cancer |
| Q77813764 | Cytokeratin expression patterns as an indicator of tumour progression in oesophageal squamous cell carcinoma |
| Q38598868 | Cytokine Signaling in Tumor Progression |
| Q36999339 | Cytokine patterns in brain tumour progression |
| Q46190037 | Cytokine signalling by gp130 regulates gastric mucosal healing after ulceration and, indirectly, antral tumour progression. |
| Q77801646 | Cytolytic activities of IL-2 activated NK cells from MMTV/v-Ha-ras transgenic oncomice during tumor progression |
| Q42214727 | Cytoplasmic suppression of tumor progression in reconstituted cells |
| Q36355177 | Cytoplasmic/nuclear shuttling and tumor progression |
| Q68027655 | Cytoskeletal and junctional heterogeneity in mammary tumor cells and their possible significance in tumor progression |
| Q33685488 | Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression |
| Q92304992 | DC-AL GAN: Pseudoprogression and true tumor progression of glioblastoma multiform image classification based on DCGAN and AlexNet |
| Q59058784 | DCC constrains tumour progression via its dependence receptor activity |
| Q99612665 | DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner |
| Q90733790 | DDN-AS1-miR-15a/16-TCF3 feedback loop regulates tumor progression in cervical cancer |
| Q92445481 | DDX3X Multifunctionally Modulates Tumor Progression and Serves as a Prognostic Indicator to Predict Cancer Outcomes |
| Q98731782 | DEAD-Box Helicase 4 (Ddx4)+ Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers |
| Q26773107 | DEC1 and DEC2 Crosstalk between Circadian Rhythm and Tumor Progression |
| Q54341974 | DEPTOR expression negatively correlates with mTORC1 activity and tumor progression in colorectal cancer. |
| Q42114708 | DGCR8 is essential for tumor progression following PTEN loss in the prostate |
| Q92972413 | DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer |
| Q58717634 | DNA Replication Licensing Protein MCM10 Promotes Tumor Progression and Is a Novel Prognostic Biomarker and Potential Therapeutic Target in Breast Cancer |
| Q67998158 | DNA content, nuclear grading and early tumor progression in renal cell cancer: a prospective study on frozen specimens |
| Q89987016 | DNA damage response proteins and its role in tumor progression of uveal melanoma with patient outcome |
| Q41857715 | DNA damage response: a barrier or a path to tumor progression? |
| Q37027188 | DNA damage signalling guards against activated oncogenes and tumour progression |
| Q30913473 | DNA demethylation is directly related to tumour progression: evidence in normal, pre-malignant and malignant cells from uterine cervix samples |
| Q44398292 | DNA distribution pattern of the so-called severe dysplasias and small carcinomas of the colon and rectum and its possible significance in the tumor progression |
| Q73665779 | DNA hypomethylation in breast cancer: an independent parameter of tumor progression? |
| Q39831220 | DNA methylation and histone modification regulate silencing of OPG during tumor progression |
| Q70325011 | DNA profile and tumour progression in patients with superficial bladder tumours |
| Q74088062 | DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance |
| Q38919233 | DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression |
| Q36414395 | DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer |
| Q34994312 | DNMT3B7 expression promotes tumor progression to a more aggressive phenotype in breast cancer cells |
| Q53610626 | DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma. |
| Q37687294 | DRG1 is a potential oncogene in lung adenocarcinoma and promotes tumor progression via spindle checkpoint signaling regulation |
| Q48641906 | Dancing eyes and uvula after brain tumour extirpation--a sign of tumour progression? |
| Q58779890 | Data on tumor progression of deficiency in murine models of lung and colorectal cancer |
| Q38721935 | Death-associated protein kinase 3 controls the tumor progression of A549 cells through ERK MAPK/c-Myc signaling |
| Q39098655 | Decalepis hamiltonii inhibits tumor progression and metastasis by regulating the inflammatory mediators and nuclear factor κB subunits |
| Q38325685 | Deciphering the insights of poly(ADP-ribosylation) in tumor progression. |
| Q38459111 | Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast |
| Q67540459 | Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression |
| Q42259172 | Decoding the knots of initiation of oncogenic epithelial-mesenchymal transition in tumor progression |
| Q39404570 | Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages |
| Q51325620 | Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. |
| Q38710241 | Decreased RNA-binding motif 5 expression is associated with tumor progression in gastric cancer |
| Q33885996 | Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients |
| Q30830686 | Decreased VDR expression in cutaneous melanomas as marker of tumor progression: new data and analyses |
| Q33764517 | Decreased annexin A3 expression correlates with tumor progression in papillary thyroid cancer. |
| Q40887514 | Decreased circadian component Bmal1 predicts tumor progression and poor prognosis in human pancreatic ductal adenocarcinoma |
| Q39136151 | Decreased expression and aberrant methylation of Gadd45G is associated with tumor progression and poor prognosis in esophageal squamous cell carcinoma |
| Q47757915 | Decreased expression of MLH1, MSH2, PMS1 and PMS2 in pigmented lesions indicates accumulation of failed DNA repair along with malignant transformation and tumour progression |
| Q48679960 | Decreased expression of NDRG1 in glioma is related to tumor progression and survival of patients. |
| Q53591172 | Decreased expression of NDRG1 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. |
| Q34658794 | Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer |
| Q40010850 | Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. |
| Q41740566 | Decreased expression of SOX17 is associated with tumor progression and poor prognosis in breast cancer |
| Q39884680 | Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression |
| Q71102493 | Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression |
| Q93172345 | Decreased expression of long non-coding LOC285194 predicts tumour progression and poor prognosis of hepatocellular carcinoma after curative hepatectomy |
| Q36261847 | Decreased expression of microRNA-20a promotes tumor progression and predicts poor prognosis of cutaneous squamous cell carcinoma |
| Q54272050 | Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. |
| Q90371815 | Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma |
| Q83516552 | Decreased expression of repulsive guidance molecule member A by DNA methylation in colorectal cancer is related to tumor progression |
| Q33573050 | Decreased expression of the Nkx2.8 gene correlates with tumor progression and a poor prognosis in HCC cancer |
| Q46483696 | Decreased ezrin and paxillin expression in human urothelial bladder tumors correlate with tumor progression |
| Q34766871 | Decreased tumor progression and invasion by a novel anti-cell motility target for human colorectal carcinoma cells. |
| Q50503284 | Decursin inhibits vasculogenesis in early tumor progression by suppression of endothelial progenitor cell differentiation and function. |
| Q70709107 | Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progression |
| Q39102177 | Defective expression of Protein 4.1N is correlated to tumor progression, aggressive behaviors and chemotherapy resistance in epithelial ovarian cancer |
| Q34859485 | Deficiency for the cysteine protease cathepsin L promotes tumor progression in mouse epidermis |
| Q100303690 | Defined Mathematical Relationships Among Cancer Cells Suggest Modular Growth in Tumor Progression and Highlight Developmental Features Consistent With a Para-Embryonic Nature of Cancer |
| Q51549257 | Defining the role of cooperation in early tumor progression. |
| Q36140879 | Deguelin inhibits vasculogenic function of endothelial progenitor cells in tumor progression and metastasis via suppression of focal adhesion |
| Q53459080 | Delayed mammary tumor progression in Muc-1 null mice. |
| Q34422096 | Delaying/reducing the risk of clinical tumour progression after primary curative procedures |
| Q73507934 | Deletion analysis at the DEL-27, APC and MTS1 loci in bladder cancer: LOH at the DEL-27 locus on 5p13-12 is a prognostic marker of tumor progression |
| Q34170633 | Deletion and down-regulation of HRH4 gene in gastric carcinomas: a potential correlation with tumor progression |
| Q83162381 | Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon tumor progression in a murine model of carcinogenesis |
| Q35518564 | Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression |
| Q36540069 | Deletion of tumor progression locus 2 attenuates alcohol-induced hepatic inflammation |
| Q33532630 | Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines |
| Q91020454 | Delirium and topographical disorientation associated with glioblastoma multiforme tumour progression into the isthmus of the cingulate gyrus |
| Q27320755 | Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression |
| Q35584599 | Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression? |
| Q46418096 | Dendrobium chrysanthum ethanolic extract induces apoptosis via p53 up-regulation in HeLa cells and inhibits tumor progression in mice |
| Q44763447 | Deoxyribonucleic acid profile and tumor progression in primary carcinoma in situ of the bladder: a study of 63 patients with grade 3 lesions |
| Q28298762 | Dependence receptors: when apoptosis controls tumor progression |
| Q33915812 | Depleted tumor suppressor miR-107 in plasma relates to tumor progression and is a novel therapeutic target in pancreatic cancer |
| Q47791595 | Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression |
| Q30239759 | Depression in cancer: The many biobehavioral pathways driving tumor progression. |
| Q37257188 | Deregulation of IKBKE is associated with tumor progression, poor prognosis, and cisplatin resistance in ovarian cancer |
| Q55453582 | Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression. |
| Q64103579 | Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer |
| Q28254729 | Deregulation of glyceraldehyde-3-phosphate dehydrogenase expression during tumor progression of human cutaneous melanoma |
| Q91766761 | Desmoglein-2 Modulates Tumor Progression and Osimertinib Drug Resistance through the EGFR/Src/PAK1 Pathway in Lung Adenocarcinoma |
| Q33816463 | Desmosomal plakophilins in the prostate and prostatic adenocarcinomas: implications for diagnosis and tumor progression |
| Q47212563 | Destabilization of DNA G-Quadruplexes by Chemical Environment Changes during Tumor Progression Facilitates Transcription. |
| Q31132701 | Detecting tumor progression in glioma: Current standards and new techniques. |
| Q47626022 | Detection Rates of Ductal Carcinoma in Situ with Biennial Digital Mammography Screening: Radiologic Findings Support Pathologic Model of Tumor Progression |
| Q90353326 | Detection of Lung Tumor Progression in Mice by Ultrasound Imaging |
| Q54689516 | Detection of circulating tumor cells and of tumor DNA in plasma during tumor progression in rats. |
| Q27334728 | Detection of intra-tumor self antigen recognition during melanoma tumor progression in mice using advanced multimode confocal/two photon microscope |
| Q51271983 | Detection of local tumor progression by (18)F-FDG PET/CT following lung radiofrequency ablation: PET versus CT. |
| Q54790629 | Detection of loss of heterozygosity by high-resolution fluorescent system in non-small cell lung cancer: association of loss of heterozygosity with smoking and tumor progression. |
| Q40538213 | Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers |
| Q46115074 | Detection of tumor progression by signal intensity increase on fluid-attenuated inversion recovery magnetic resonance images in the resection cavity of high-grade gliomas |
| Q30671849 | Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1 |
| Q48460606 | Detection of tumour progression in the follow-up of irradiated low-grade astrocytomas: comparison of 3-[123I]iodo-alpha-methyl- L-tyrosine and 99mTc-MIBI SPET. |
| Q67691103 | Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy |
| Q73569368 | Determination of imbalance between MMP-2 and TIMP-2 in human neuroblastoma by reverse-transcription polymerase chain reaction and its correlation with tumor progression |
| Q43580902 | Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma |
| Q38320495 | Development and validation of H11B2C2 monoclonal antibody-reactive hyaluronic acid binding protein: overexpression of HABP during human tumor progression |
| Q34997451 | Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression |
| Q41749717 | Development of an in vitro model of tumor progression using v-raf and v-raf/v-myc transformed rat liver epithelial cells: correlation of tumorigenicity with the downregulation of specific proteins |
| Q40872859 | Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-beta during tumor progression |
| Q53889254 | Developmentally imprinted genes as markers for bladder tumor progression. |
| Q90196804 | Diagnostic Accuracy of PET Tracers for the Differentiation of Tumor Progression from Treatment-Related Changes in High-Grade Glioma: A Systematic Review and Metaanalysis |
| Q40143568 | Diagnostic accuracy of different magnetic resonance imaging sequences for detecting local tumor progression after radiofrequency ablation of hepatic malignancies |
| Q90705948 | Diagnostic and prognostic value of microRNA-193b in patients with glioma and its effect on tumor progression |
| Q64057273 | Diagnostic value of procalcitonin, C-reactive protein and lactate dehydrogenase in paediatric malignant solid tumour concurrent with infection and tumour progression |
| Q92635164 | Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination |
| Q43086153 | Dickkopf-3 function in the prostate: implications for epithelial homeostasis and tumor progression |
| Q44625917 | Diencephalic syndrome as sign of tumor progression in a child with neurofibromatosis type 1 and optic pathway glioma: a case report. |
| Q58577791 | Diet Supplementation with Soy Protein Isolate, but Not the Isoflavone Genistein, Protects Against Alcohol-Induced Tumor Progression in DEN-Treated Male Mice |
| Q44968477 | Dietary Soybean Isolate and Methionine Supplementation Affect Mammary Tumor Progression in Rats |
| Q35945856 | Dietary calcium does not affect prostate tumor progression in LPB-Tag transgenic mice. |
| Q37293711 | Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models |
| Q92546424 | Dietary palmitate cooperates with Src kinase to promote prostate tumor progression |
| Q73838225 | Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice |
| Q38797885 | Dietary restriction: could it be considered as speed bump on tumor progression road? |
| Q55012429 | Difference in allelic expression of genes probably associated with tumor progression in murine fibrosarcomas and cell lines. |
| Q69570505 | Differences in the phenotypes of cells mediating anti-tumour immunity at various stages of tumour progression in mice |
| Q40315031 | Different breakage-prone regions on chromosome 1 detected in t(11;14)-positive mantle cell lymphoma cell lines and multiple myeloma cell lines are associated with different tumor progression-related mechanisms |
| Q40026321 | Different immune correlates associated with tumor progression and regression: implications for prevention and treatment of cancer |
| Q51835594 | Different mRNA expression profile during tumor progression in a well-differentiated liposarcoma--A microdissection approach. |
| Q39069971 | Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment |
| Q73453134 | Differential CD45 isoform expression accompanies reduced natural antibody binding in L5178Y-F9 tumor progression |
| Q37429867 | Differential Expression of SPARC in Intestinal-type Gastric Cancer Correlates with Tumor Progression and Nodal Spread |
| Q39063857 | Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration |
| Q36847939 | Differential cadherin expression: potential markers for epithelial to mesenchymal transformation during tumor progression |
| Q36697241 | Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon |
| Q38708902 | Differential expression of ST6GAL1 in the tumor progression of colorectal cancer |
| Q42140194 | Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. |
| Q53476342 | Differential expression of cytokeratin proteins during tumour progression in oral mucosa. |
| Q82793681 | Differential expression of galectin-3 in advancing thyroid cancer cells: a clue toward understanding tumour progression and metastasis |
| Q42521861 | Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression |
| Q74067195 | Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis |
| Q73820427 | Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast |
| Q39018011 | Differential expression of secretoglobins in normal ovary and in ovarian carcinoma--overexpression of mammaglobin-1 is linked to tumor progression. |
| Q41001518 | Differential expression of the murine Ly-6A/E antigen homolog of human squamous cell carcinoma antigen E48 during malignant transformation and tumor progression of squamous cell carcinoma line Pam 212. |
| Q40531661 | Differential expression of the prion-like protein doppel gene (PRND) in astrocytomas: a new molecular marker potentially involved in tumor progression. |
| Q40059586 | Differential gene expression profiling linked to tumor progression of splenic marginal zone lymphoma |
| Q55459936 | Differential gene methylation in paired glioblastomas suggests a role of immune response pathways in tumor progression. |
| Q37394572 | Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. |
| Q33931394 | Differential methylation of the c-H-ras gene in normal mouse cells and during skin tumour progression |
| Q41207014 | Differential regulation of integrins and extracellular matrix binding in epidermal differentiation and squamous tumor progression |
| Q30891043 | Differential screening of cDNA libraries for analysis of gene expression during tumor progression |
| Q47280873 | Differential tumor progression patterns in skull base versus non-skull base meningiomas: A critical analysis from a long-term follow-up study and review of literature |
| Q74599395 | Differentially expressed genes associated with mouse lung tumor progression |
| Q52148215 | Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI. |
| Q83328932 | Differentiating radiation effect from tumor progression after stereotactic radiosurgery: T1/T2 matching |
| Q48213133 | Differentiating radiation necrosis from tumor progression in brain metastases treated with stereotactic radiotherapy: utility of intravoxel incoherent motion perfusion MRI and correlation with histopathology |
| Q40401999 | Differentiation and tumor progression |
| Q47352648 | Differentiation between Radiation Necrosis and Tumor Progression Using Chemical Exchange Saturation Transfer. |
| Q98298626 | Differentiation between True Tumor Progression of Glioblastoma and Pseudoprogression using Diffusion-weighted imaging and Perfusion-weighted imaging: A Systematic Review and Meta-analysis |
| Q39750239 | Differentiation between intra-axial metastatic tumor progression and radiation injury following fractionated radiation therapy or stereotactic radiosurgery using MR spectroscopy, perfusion MR imaging or volume progression modeling |
| Q48635805 | Differentiation of radiation necrosis from tumor progression using proton magnetic resonance spectroscopy. |
| Q92775780 | Differentiation of treatment-related changes from tumour progression: a direct comparison between dynamic FET PET and ADC values obtained from DWI MRI |
| Q30590102 | Differentiation of tumor progression and radiation-induced effects after intracranial radiosurgery |
| Q44104947 | Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. |
| Q53656532 | Differentiation-dependent expression and mitogenic action of interleukin-6 in human colon carcinoma cells: relevance for tumour progression. |
| Q90103345 | Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response |
| Q93172134 | Diffuse reflectance spectroscopy to monitor murine colorectal tumor progression and therapeutic response (Erratum) |
| Q43236738 | Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab |
| Q73100868 | Dim light during darkness stimulates tumor progression by enhancing tumor fatty acid uptake and metabolism |
| Q36423404 | Dioxin-mediated tumor progression through activation of mitochondria-to-nucleus stress signaling |
| Q36212504 | Dipeptidyl peptidase IV in tumor progression |
| Q46190030 | Direct and tumor microenvironment mediated influences of 5'-deoxy-5'-(methylthio)adenosine on tumor progression of malignant melanoma |
| Q35147034 | Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression |
| Q34020614 | Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model |
| Q55461557 | Disappearance of breach rhythm heralding recurrent tumor progression in a patient with astrocytoma. |
| Q90067227 | Discovery of novel tertiary amide derivatives as NEDDylation pathway activators to inhibit the tumor progression in vitro and in vivo |
| Q34560322 | Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality? |
| Q90239259 | Dishevelled 1-Regulated Superpotent Cancer Stem Cells Mediate Wnt Heterogeneity and Tumor Progression in Hepatocellular Carcinoma |
| Q39951928 | Dishevelled family proteins are expressed in non-small cell lung cancer and function differentially on tumor progression |
| Q31814836 | Disruption of FAT10-MAD2 binding inhibits tumor progression. |
| Q62623090 | Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells |
| Q33842928 | Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. |
| Q41903123 | Dissecting HDAC3-mediated tumor progression |
| Q46086075 | Disseminated tumor cells and enhanced level of some cytokines in bone marrow and peripheral blood of breast cancer patients as predictive factors of tumor progression |
| Q40546351 | Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression |
| Q47406043 | Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. |
| Q37737861 | Distinct biological roles for the akt family in mammary tumor progression |
| Q39940947 | Distinct karyotypes in three breast cancer cell lines --21PTCi, 21NTCi, and 21MT-1 --derived from the same patient and representing different stages of tumor progression |
| Q93354282 | Distinct lung cancer subtypes associate to distinct drivers of tumor progression |
| Q40180982 | Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression. |
| Q73221136 | Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations |
| Q79330536 | Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression |
| Q72809000 | Distribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis |
| Q35811170 | Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression |
| Q38801768 | Disturbed balance of expression between XIAP and Smac/DIABLO during tumour progression in renal cell carcinomas |
| Q61446661 | Disulfiram and BKM120 in Combination with Chemotherapy Impede Tumor Progression and Delay Tumor Recurrence in Tumor Initiating Cell-Rich TNBC |
| Q34385041 | Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment |
| Q35653376 | Diverse animal models to examine potential role(s) and mechanism of endocrine disrupting chemicals on the tumor progression and prevention: Do they have tumorigenic or anti-tumorigenic property? |
| Q38889980 | Diverse effects of LPA4, LPA5 and LPA6 on the activation of tumor progression in pancreatic cancer cells |
| Q47198804 | Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms |
| Q37148117 | Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma |
| Q37223509 | Diverse roles of tissue factor-expressing cell subsets in tumor progression |
| Q98619453 | Diversity in the Extracellular Vesicle-Derived Microbiome of Tissues According to Tumor Progression in Pancreatic Cancer |
| Q37876491 | Do bacterial genotoxins contribute to chronic inflammation, genomic instability and tumor progression? |
| Q57169309 | Do hepatocellular carcinomas located in subcapsular space or in proximity to vessels increase the rate of local tumor progression? A meta-analysis |
| Q36522966 | Do myoepithelial cells hold the key for breast tumor progression? |
| Q99558025 | Does sympathetic nervous system modulate tumor progression? A narrative review of the literature |
| Q90455232 | Donkey milk inhibits triple-negative breast tumor progression and is associated with increased cleaved-caspase-3 expression |
| Q33344012 | Dose and timing of total-body irradiation mediate tumor progression and immunomodulation. |
| Q84080151 | Dose escalation of octreotide LAR is safe and effective in patients with advanced gastrointestinal neuroendocrine tumours for control of symptoms and tumor progression |
| Q36530674 | Dose-dependent effects of calorie restriction on gene expression, metabolism, and tumor progression are partially mediated by insulin-like growth factor-1 |
| Q53255500 | Down-regulated ECRG4 expression in breast cancer and its correlation with tumor progression and poor prognosis--A short Report. |
| Q33947304 | Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas |
| Q37061845 | Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma |
| Q54692840 | Down-regulation of Ku 70 and Ku 80 mRNA expression in transitional cell carcinomas of the urinary bladder related to tumor progression. |
| Q92417915 | Down-regulation of MARCO associates with tumor progression in hepatocellular carcinoma |
| Q53519698 | Down-regulation of an abundant cellular protein associated with tumor progression. |
| Q81249140 | Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression |
| Q39939616 | Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. |
| Q53392766 | Down-regulation of human X-box binding protein 1 (hXBP-1) expression correlates with tumor progression in human prostate cancers. |
| Q92138357 | Down-regulation of long noncoding RNA PGM5-AS1 correlates with tumor progression and predicts poor prognosis in clear cell renal cell carcinoma |
| Q35357827 | Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. |
| Q35886642 | Down-regulation of osteopontin attenuates breast tumour progression in vivo |
| Q51062624 | Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer. |
| Q39217541 | Down-regulation of the ErbB3 binding protein 1 in human bladder cancer promotes tumor progression and cell proliferation |
| Q28280736 | Down-regulation of the down-regulated in adenoma (DRA) gene correlates with colon tumor progression |
| Q45091351 | Down-regulation of the homeodomain factor Cdx2 in colorectal cancer by collagen type I: an active role for the tumor environment in malignant tumor progression |
| Q38943073 | Downexpression of Matriptase-2 Correlates With Tumor Progression and Clinical Prognosis in Oral Squamous-Cell Carcinoma |
| Q52670046 | Downregulated CDK10 expression in gastric cancer: Association with tumor progression and poor prognosis. |
| Q93124557 | Downregulated MEG3 contributes to tumour progression and poor prognosis in oesophagal squamous cell carcinoma by interacting with miR-4261, downregulating DKK2 and activating the Wnt/β-catenin signalling |
| Q88914394 | Downregulation of AGR2, p21, and cyclin D and alterations in p53 function were associated with tumor progression and chemotherapy resistance in epithelial ovarian carcinoma |
| Q88804423 | Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer |
| Q51250068 | Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma. |
| Q90754387 | Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma |
| Q112575669 | Downregulation of CYP2E1 is associated with poor prognosis and tumor progression of gliomas |
| Q100728150 | Downregulation of DUSP9 Promotes Tumor Progression and Contributes to Poor Prognosis in Human Colorectal Cancer |
| Q33600774 | Downregulation of HNF-1B in renal cell carcinoma is associated with tumor progression and poor prognosis |
| Q40071671 | Downregulation of IFN-gammaR in association with loss of Fas function is linked to tumor progression |
| Q33598578 | Downregulation of LKB1 promotes tumor progression and predicts unfavorable prognosis in patients with glioma |
| Q59126036 | Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer |
| Q96945983 | Downregulation of Per2 Promotes Tumor Progression by Enhancing Glycolysis via the PI3K/AKT Pathway in Oral Squamous Cell Carcinoma |
| Q36545666 | Downregulation of RPL15 may predict poor survival and associate with tumor progression in pancreatic ductal adenocarcinoma |
| Q30008980 | Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma |
| Q41979607 | Downregulation of a novel long non-coding RNA, LOC389332, is associated with poor prognosis and tumor progression in clear cell renal cell carcinoma |
| Q51421650 | Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma. |
| Q39858194 | Downregulation of carcinoembryonic antigen-related cell adhesion molecule 1 in oral squamous cell carcinoma: correlation with tumor progression and poor prognosis |
| Q99589726 | Downregulation of m6 A reader YTHDC2 promotes tumor progression and predicts poor prognosis in non-small cell lung cancer |
| Q90398031 | Downregulation of miR-1294 associates with prognosis and tumor progression in epithelial ovarian cancer |
| Q39809297 | Downregulation of miR-193b contributes to enhance urokinase-type plasminogen activator (uPA) expression and tumor progression and invasion in human breast cancer |
| Q91265226 | Downregulation of miR-302b is associated with poor prognosis and tumor progression of breast cancer |
| Q90464540 | Downregulation of miR-484 is associated with poor prognosis and tumor progression of gastric cancer |
| Q37445814 | Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer |
| Q91340629 | Downregulation of miR-519a Predicts Poor Prognosis and Contributes to Tumor Progression in Gastric Cancer |
| Q54191982 | Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer. |
| Q48031390 | Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in hepatocellular carcinoma |
| Q37354017 | Downregulation of microRNA-362-3p and microRNA-329 promotes tumor progression in human breast cancer |
| Q44964849 | Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma |
| Q37190785 | Downregulation of thrombospondin-1 by DNA hypermethylation is associated with tumor progression in laryngeal squamous cell carcinoma |
| Q37725527 | Doxycycline directly targets PAR1 to suppress tumor progression |
| Q44712908 | Drug-induced tumor progression in a rat rhabdomyosarcoma. |
| Q92692141 | Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis |
| Q38928655 | Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma |
| Q93365786 | Dual actions of the antioxidant chlorophyllin, a glutathione transferase P1-1 inhibitor, in tumorigenesis and tumor progression |
| Q64072752 | Dual complementary liposomes inhibit triple-negative breast tumor progression and metastasis |
| Q91286158 | Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity |
| Q91652804 | Dual role of TGF-β in early pregnancy: clues from tumor progression |
| Q45710962 | Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression |
| Q34163763 | Dual-wavelength imaging of tumor progression by activatable and targeting near-infrared fluorescent probes in a bioluminescent breast cancer model |
| Q38899245 | Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer |
| Q47111525 | Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression. |
| Q52788687 | Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal adenocarcinoma. |
| Q90764865 | Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression |
| Q113926336 | Dynamic regulation of tumour progression by phenotype‐switching drivers |
| Q57307348 | Dysplasia in normal-looking urothelium increases the risk of tumour progression in primary superficial bladder cancer |
| Q34501566 | Dysregulation of JAM-A plays an important role in human tumor progression |
| Q93077356 | Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy |
| Q39054413 | Dysregulation of mitophagy in carcinogenesis and tumor progression |
| Q42468352 | Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression |
| Q33506633 | Dysregulation of ribosome biogenesis and translational capacity is associated with tumor progression of human breast cancer cells. |
| Q52531695 | Dysregulation of the type 1 IGF receptor as a paradigm in tumor progression. |
| Q35791328 | Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. |
| Q84417704 | Dystroglycan is associated with tumor progression and patient survival in gastric cancer |
| Q41983985 | Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors |
| Q49976724 | E-cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma. |
| Q73403844 | E-cadherin and alpha-catenin expression during tumor progression of cervical carcinoma |
| Q26865483 | E-cadherin's dark side: possible role in tumor progression |
| Q112642785 | E2F1-mediated GINS2 transcriptional activation promotes tumor progression through PI3K/AKT/mTOR pathway in hepatocellular carcinoma |
| Q34490640 | E2f binding-deficient Rb1 protein suppresses prostate tumor progression in vivo |
| Q47773147 | EBUS-TBNA Can Distinguish Sarcoid-Like Side Effect of Nivolumab Treatment from Tumor Progression in Non-Small Cell Lung Cancer |
| Q112700883 | ECSIT inhibits cell death to increase tumor progression and metastasis via p53 in human breast cancer |
| Q24335999 | EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance |
| Q37589139 | EI24 regulates epithelial-to-mesenchymal transition and tumor progression by suppressing TRAF2-mediated NF-κB activity |
| Q38912492 | EIF2C, Dicer, and Drosha are up-regulated along tumor progression and associated with poor prognosis in bladder carcinoma |
| Q36557452 | ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression |
| Q92139810 | ELK1-induced upregulation of lncRNA TRPM2-AS promotes tumor progression in gastric cancer by regulating miR-195/ HMGA1 axis |
| Q45735952 | ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity. |
| Q39374878 | EMMPRIN/CD147 up-regulates urokinase-type plasminogen activator: implications in oral tumor progression |
| Q90804085 | EMT Transition States during Tumor Progression and Metastasis |
| Q38256604 | EMT in cervical cancer: its role in tumour progression and response to therapy. |
| Q39201315 | EMX2 is downregulated in endometrial cancer and correlated with tumor progression |
| Q98176737 | EN2 as an oncogene promotes tumor progression via regulating CCL20 in colorectal cancer |
| Q36393499 | ER stress, hypoxia tolerance and tumor progression. |
| Q58414018 | ERADicate Tumor Progression with Metformin |
| Q45179853 | ERBB2 gene amplification in oral squamous cell malignancies: a correlation with tumor progression and gene expression |
| Q91401992 | ERG the modulates Warburg effect and tumor progression in cervical cancer |
| Q91014908 | ERO1α promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer |
| Q55371844 | ET-55THE LONG TERM RISK OF TUMOR PROGRESSION HAS NOT CHANGED OVER TIME FOR SUPRATENTORIAL GRADE II GLIOMAS AND IS NOT INFLUENCED BY THE MODE OF SURGICAL TREATMENT. |
| Q90929833 | EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma |
| Q38978900 | EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma |
| Q52971488 | EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. |
| Q37472017 | EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma |
| Q99247256 | EZH2 regulates pancreatic cancer subtype identity and tumor progression via transcriptional repression of GATA6 |
| Q46178508 | Early clinical and neuroradiological worsening after radiotherapy and concomitant temozolomide in patients with glioblastoma: tumour progression or radionecrosis? |
| Q74592260 | Early effects of cis-dichlorodiammine platinum (II) on tumor progression and programmed death of Ehrlich ascites carcinoma cells |
| Q80142499 | Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice |
| Q36201020 | Early impact of social isolation and breast tumor progression in mice. |
| Q37736028 | Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials |
| Q36012652 | Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer |
| Q35763563 | Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression |
| Q52968870 | Ectopic Gastric and Intestinal Phenotypes, Neuroendocrine Cell Differentiation, and SOX2 Expression Correlated With Early Tumor Progression in Colorectal Laterally Spreading Tumors. |
| Q95658624 | Ectopic expression of SOX18 in Basal cell carcinoma negatively regulates tumour progression |
| Q46053158 | Editorial comment. The goals of minimizing resource use and treatment burden must be weighed against the risks of tumor progression and compromised cancer-specific outcomes |
| Q42839738 | Editorial: PGE2-producing MDSC: a role in tumor progression? |
| Q31145516 | Effect of Pantethine on Ovarian Tumor Progression and Choline Metabolism. |
| Q73218319 | Effect of androgen deprivation therapy on local symptoms and tumour progression in men with metastatic carcinoma of the prostate |
| Q36837995 | Effect of dietary green tea extract and aerosolized difluoromethylornithine during lung tumor progression in A/J strain mice |
| Q44315403 | Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial |
| Q41390078 | Effect of exogenous glutathione on tumor progression in the murine skin multistage carcinogenesis model |
| Q37126585 | Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. |
| Q58545022 | Effect of mesenchymal stem cells-derived exosomes on tumor microenvironment: Tumor progression versus tumor suppression |
| Q48349013 | Effect of neuraxial anaesthesia on tumour progression in cervical cancer patients treated with brachytherapy: a retrospective cohort study |
| Q44009131 | Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer |
| Q53816071 | Effect of propranolol on IL-10, visfatin, Hsp70, iNOS, TLR2, and survivin in amelioration of tumor progression and survival in Solid Ehrlich Carcinoma-bearing mice. |
| Q48467043 | Effect of surgery on tumor progression and malignant degeneration in hemispheric diffuse low-grade astrocytomas. |
| Q77193693 | Effect of the protein kinase inhibitors, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine H-7 and N-(2-[methylamino]ethyl)-5-isoquinoline-sulfonamide H-8 on Lewis lung carcinoma tumor progression |
| Q36612465 | Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis |
| Q36755204 | Effect of treatment with epoetin-beta on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients |
| Q72102792 | Effect of tumour progression on the androgenic regulation of the androgen receptor, TRPM-2 and YPT1 genes in the Shionogi carcinoma |
| Q72849615 | Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression |
| Q40258923 | Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways. |
| Q43186928 | Effects of Rapamycin on angiogenesis and tumor progression in human hepatocellular carcinoma implantation mice |
| Q45134031 | Effects of chronic jet lag on tumor progression in mice. |
| Q46703444 | Effects of exogenous melatonin and circadian synchronization on tumor progression in melanoma-bearing C57BL6 mice. |
| Q28298016 | Effects of expression of hRFI on adenoma formation and tumor progression in colorectal adenoma-carcinoma sequence |
| Q120968906 | Effects of extracellular vesicle-derived noncoding RNAs on pre-metastatic niche and tumor progression |
| Q55491761 | Effects of indole-3-carbinol on steroid hormone profile and tumor progression in a mice model of canine inflammatory mammarycancer. |
| Q80247043 | Effects of meal timing on tumor progression in mice |
| Q72428427 | Effects of natural human interleukin-6 on thrombopoiesis and tumor progression in tumor-bearing mice |
| Q40971262 | Effects of p53 mutation on tumor progression: recent insights from mouse tumor models |
| Q74106614 | Effects of retinoic acid (all-trans and 9-cis) on tumor progression in small-cell lung carcinoma |
| Q92706295 | Effects of sex hormones on liver tumor progression and regression in Myc/xmrk double oncogene transgenic zebrafish |
| Q39201899 | Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells |
| Q34017818 | Effects of thrombin/thrombosis in angiogenesis and tumour progression |
| Q38075423 | Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses |
| Q88709633 | Efficacy of punarnavine in restraining organ-specific tumour progression in 4T1-induced murine breast tumour model |
| Q37254306 | Eicosanoids in tumor progression and metastasis |
| Q33640998 | Electronystagmographic changes in patients with unilateral vestibular schwannomas in relation to tumor progression and central compensation |
| Q112642191 | Elevated DNA Polymerase Delta 1 Expression Correlates With Tumor Progression and Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma |
| Q112644570 | Elevated LINC00909 Promotes Tumor Progression of Ovarian Cancer via Regulating the miR-23b-3p/MRC2 Axis |
| Q53433384 | Elevated Rictor expression is associated with tumor progression and poor prognosis in patients with gastric cancer. |
| Q104104969 | Elevated TIAM2 expression promotes tumor progression and is associated with unfavorable prognosis in pancreatic cancer |
| Q34392800 | Elevated expression of LSD1 (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast |
| Q58733629 | Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer |
| Q90906609 | Elevated expression of Tiam1 is associated with poor prognosis and promotes tumor progression in pancreatic cancer |
| Q92709219 | Elevated kindlin-2 promotes tumour progression and angiogenesis through the mTOR/VEGFA pathway in melanoma |
| Q34141638 | Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma |
| Q74635266 | Elevated serum levels of transforming growth factor-beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection |
| Q37001123 | Elevated snail expression mediates tumor progression in areca quid chewing-associated oral squamous cell carcinoma via reactive oxygen species |
| Q60689210 | Elevated telomerase activity,c-MYC-, andhTERTmRNA expression: association with tumour progression in malignant lipomatous tumours |
| Q42776019 | Elevation of GPRC5A expression in colorectal cancer promotes tumor progression through VNN-1 induced oxidative stress. |
| Q73853950 | Elevations in cathepsin B protein content and enzyme activity occur independently of glycosylation during colorectal tumor progression |
| Q41267608 | Elucidating the role of incidental use of beta-blockers in patients with metastatic brain tumors in controlling tumor progression and survivability |
| Q71625851 | Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression |
| Q34136617 | Emerging concepts in tumor progression and therapy |
| Q34592412 | Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration |
| Q36328595 | Emerging role of the endothelin axis in ovarian tumor progression. |
| Q38034093 | Emerging roles of RB family: new defense mechanisms against tumor progression |
| Q38264092 | Emerging roles of regulatory T cells in tumour progression and metastasis |
| Q31104596 | Empirical Bayes identification [correction of identication] of tumor progression genes from microarray data |
| Q50850891 | End Binding 1 (EB1) overexpression in oral lesions and cancer: A biomarker of tumor progression and poor prognosis. |
| Q45259468 | Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage |
| Q92282534 | Endoplasmic Reticulum Stress Pathway, the Unfolded Protein Response, Modulates Immune Function in the Tumor Microenvironment to Impact Tumor Progression and Therapeutic Response |
| Q73401913 | Endoreduplication in conjunction with tumor progression in an aneuploid laryngeal squamous cell carcinoma |
| Q36676341 | Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression |
| Q49884417 | Endothelial Tie1-mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis. |
| Q48649719 | Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. |
| Q44993410 | Enhanced cell lysis by natural effectors--a necessary stage of tumor progression |
| Q38801536 | Enhanced cytotoxic T-cell function and inhibition of tumor progression by Mst1 deficiency |
| Q46119162 | Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression |
| Q46804879 | Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer |
| Q53529141 | Enhanced expression of insulin-like growth factor II is not a necessary event in Wilms' tumour progression. |
| Q39859720 | Enhanced expression of the high affinity glutamate transporter GLT-1 in C6 glioma cells delays tumour progression in rat. |
| Q40735845 | Enhanced expression of vascular endothelial growth factor (VEGF) plays a critical role in the tumor progression potential induced by simian virus 40 large T antigen |
| Q90210849 | Enhanced mLST8 Expression Correlates with Tumor Progression in Hepatocellular Carcinoma |
| Q39675374 | Enhanced mammary progesterone receptor-A isoform activity in the promotion of mammary tumor progression by dietary soy in rats. |
| Q39279856 | Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients |
| Q35127787 | Enhanced tumour cell nuclear targeting in a tumour progression model |
| Q30388067 | Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model |
| Q88462578 | Enhancer reprogramming in tumor progression: a new route towards cancer cell plasticity |
| Q100414750 | Environment Influences Tumor Progression and Transcriptional Subtype in a New Model of Pancreatic Cancer |
| Q42034458 | Environmental conditions favorable for tumor progression in peritoneal cavity induced by peritoneal cells without tumor selectivity |
| Q38904945 | Environmentally relevant concentration of arsenic trioxide and humic acid promoted tumor progression of human cervical cancer cells: In vivo and in vitro studies |
| Q97527138 | Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression |
| Q34691519 | EpCAM knockdown alters microRNA expression in retinoblastoma--functional implication of EpCAM regulated miRNA in tumor progression. |
| Q99726855 | EpCAM signaling promotes tumor progression and protein stability of PD-L1 through the EGFR pathway |
| Q36331949 | Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression |
| Q112725828 | EphA2 super-enhancer promotes tumor progression by recruiting FOSL2 and TCF7L2 to activate the target gene EphA2 |
| Q46670164 | Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. |
| Q79359648 | Epidermal growth factor receptor-dependent activation of Gab1 is involved in ErbB-2-mediated mammary tumor progression |
| Q41561121 | Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: role in tumor progression |
| Q64226431 | Epigallocatechin-3-gallate in the prevention and treatment of hepatocellular carcinoma: experimental findings and translational perspectives |
| Q39433158 | Epigenetic Modifications and Head and Neck Cancer: Implications for Tumor Progression and Resistance to Therapy |
| Q88595388 | Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma |
| Q37665344 | Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. |
| Q40085455 | Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression |
| Q104111289 | Epigenetic landscape of pancreatic neuroendocrine tumours reveals distinct cells of origin and means of tumour progression |
| Q46275669 | Epigenetic modification of miR-663 controls mitochondria-to-nucleus retrograde signaling and tumor progression |
| Q97686529 | Epigenomic State Transitions Characterize Tumor Progression in Mouse Lung Adenocarcinoma |
| Q42787796 | Epithelial "Plasticity" in Tumor Progression and Wound Repair: Potential Therapeutic Targets in the Stromal Microenvironment |
| Q37071016 | Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression |
| Q33743247 | Epithelial cell plasticity in development and tumor progression |
| Q36413175 | Epithelial derived CTGF promotes breast tumor progression via inducing EMT and collagen I fibers deposition |
| Q34397291 | Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression |
| Q36857749 | Epithelial-mesenchymal transition and colorectal cancer: gaining insights into tumor progression using LIM 1863 cells |
| Q24633875 | Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression |
| Q39954485 | Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation |
| Q38349021 | Epithelial-mesenchymal transition is regulated at post-transcriptional levels by transforming growth factor-β signaling during tumor progression |
| Q41441070 | Epithelial-mesenchymal transition: potential regulator of ABC transporters in tumor progression |
| Q35102335 | Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression |
| Q40926638 | Epithelial-mesenchymal transitions in development and tumor progression. |
| Q27860487 | Epithelial-mesenchymal transitions in tumour progression |
| Q28186012 | Epithelial-stromal interactions and tumor progression: meeting summary and future directions |
| Q39768604 | Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase |
| Q34502015 | Epithelial-to-mesenchymal transition in human esophageal cancer associates with tumor progression and patient's survival. |
| Q39339887 | Epithelial-to-mesenchymal transition in tumor progression |
| Q37481924 | Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events |
| Q40563126 | ErbB2 and TGF-beta: a cooperative role in mammary tumor progression? |
| Q43228545 | Erratum to: Mechanistic attributes of S100A7 (psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity. |
| Q89286377 | Erratum to: Significance of endothelial progenitor cells (EPC) for tumorigenesis of head and neck squamous cell carcinoma (HNSCC): possible marker of tumor progression and neovascularization? |
| Q42516123 | Erratum to: The effect of soluble E-selectin on tumor progression and metastasis. |
| Q88621043 | Erratum to: miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma |
| Q98733936 | Erratum: Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma [Corrigendum] |
| Q92060277 | Erratum: Long Non-Coding RNA PVT1 Regulates BAMBI to Promote Tumor Progression in Non-Small Cell Lung Cancer by Sponging miR-17-5p [Corrigendum] |
| Q42320573 | Erratum: SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression. |
| Q94365481 | Erratum: α5β1-Integrin Expression Is Essential for Tumor Progression in Experimental Lung Cancer |
| Q38433021 | Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression |
| Q34544350 | Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes |
| Q60929706 | Establishment of a bioluminescent canine B-cell lymphoma xenograft model for monitoring tumor progression and treatment response in preclinical studies |
| Q74142015 | Establishment of primary cultures from human colonic tissue during tumor progression: vitamin-D responses and vitamin-D-receptor expression |
| Q41047590 | Establishment of two human small cell lung cancer cell lines: the evidence of accelerated production of parathyroid hormone-related protein with tumor progression |
| Q50757251 | Estimating cancer survival and clinical outcome based on genetic tumor progression scores. |
| Q47438355 | Estimating screening test sensitivity and tumour progression using tumour size and time since previous screening |
| Q53184778 | Estrogen Receptor β as a Prognostic Marker of Tumor Progression in Colorectal Cancer with Familial Adenomatous Polyposis and Sporadic Polyps. |
| Q73393604 | Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression |
| Q46570569 | Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma |
| Q47671734 | Estrogen receptor signaling in prostate cancer: Implications for carcinogenesis and tumor progression. |
| Q41121589 | Estrogen receptor-negative breast cancer cells transfected with estrogen receptor exhibit decreased tumour progression and sensitivity to growth inhibition by estrogen |
| Q37718338 | Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone |
| Q48515626 | Ethanol increases tumor progression in rats: possible involvement of natural killer cells |
| Q28298208 | Ethanol stimulates tumor progression and expression of vascular endothelial growth factor in chick embryos |
| Q35457074 | Ethynyldeoxyuridine (EdU) suppresses in vitro population expansion and in vivo tumor progression of human glioblastoma cells. |
| Q42136215 | Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression |
| Q98647813 | Eupatorin Suppressed Tumor Progression and Enhanced Immunity in a 4T1 Murine Breast Cancer Model |
| Q49796264 | Evaluating different breast tumor progression models using screening data. |
| Q26995317 | Evaluating digestive neuroendocrine tumor progression and therapeutic responses in the era of targeted therapies: state of the art |
| Q34024987 | Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial |
| Q91511792 | Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis |
| Q78638700 | Evaluation of argyrophilic nucleolar organizer regions in oral tumor progression |
| Q78962183 | Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival |
| Q38945140 | Evaluation of imaging techniques for the assessment of tumour progression in an orthotopic rat model of malignant pleural mesothelioma†. |
| Q39204188 | Evaluation of mitochondrial function and metabolic reprogramming during tumor progression in a cell model of skin carcinogenesis |
| Q48428399 | Evaluation of molecular genetic alterations associated with tumor progression in a case of gliomatosis cerebri. |
| Q104556389 | Evaluation of perfusion MRI value for tumor progression assessment after glioma radiotherapy: A systematic review and meta-analysis |
| Q41654243 | Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma |
| Q37718751 | Evaluation of the effects of hyaluronic acid-carboxymethyl cellulose barrier on ovarian tumor progression. |
| Q30470304 | Evaluation of the increase in permeability of the blood-brain barrier during tumor progression after pulsed focused ultrasound |
| Q91212571 | Evaluation of the relationship between the IL-17A gene expression level and regulatory miRNA-9 in relation to tumor progression in patients with non-small cell lung cancer: a pilot study |
| Q48523686 | Evaluation of tumor progression and detection of new tumors during repeat Gamma Knife® stereotactic radiosurgery utilizing the co-registration tool in Leksell Gamma Plan®: technical note. |
| Q68590017 | Evaluation of tumor progression by repeated fine needle biopsies in prostate adenocarcinoma: modal deoxyribonucleic acid value and cytological differentiation |
| Q42248321 | Evidence for a new model of tumor progression from carcinogenesis and tumor promotion studies with 7-bromomethylbenz[a]anthracene |
| Q28383815 | Evidence for the Influence of the Iron Regulatory MHC Class I Molecule HFE on Tumor Progression in Experimental Models and Clinical Populations |
| Q40412468 | Evidence of dual function of macrophage migration inhibitory factor relevant to tumor progression and regression |
| Q41125826 | Evidence that loss of chromosome 18q is associated with tumor progression |
| Q42542809 | Evolution from heterozygous to homozygous KIT mutation in gastrointestinal stromal tumor correlates with the mechanism of mitotic nondisjunction and significant tumor progression. |
| Q37746398 | Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression |
| Q42451818 | Evolutionary dynamics of tumor progression with random fitness values |
| Q53489902 | Evolutionary somatic cell changes in cervical tumour progression quantitatively evaluated with morphological, histochemical and kinetic parameters. |
| Q54701076 | Excision repair cross complementing 3 expression is involved in patient prognosis and tumor progression in esophageal cancer. |
| Q90708631 | Exercise training and tumour progression: Younger, harder, better, faster and stronger |
| Q60272246 | Existence of tumor-derived endothelial cells suggests an additional role for endothelial-to-mesenchymal transition in tumor progression |
| Q97565233 | Exosomal Circ-HIPK3 Facilitates Tumor Progression and Temozolomide Resistance by Regulating miR-421/ZIC5 Axis in Glioma |
| Q96945870 | Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy |
| Q48432578 | Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. |
| Q61812643 | Exosome-Mediated Signaling in Epithelial to Mesenchymal Transition and Tumor Progression |
| Q112638355 | Exosome-depleted MiR-148a-3p derived from Hepatic Stellate Cells Promotes Tumor Progression via ITGA5/PI3K/Akt Axis in Hepatocellular Carcinoma |
| Q57494142 | Exosome-mediated cell-cell communication in tumor progression |
| Q97073441 | Exosomes Derived from Hypoxic Colorectal Cancer Cells Transfer miR-410-3p to Regulate Tumor Progression |
| Q64286876 | Exosomes from the tumour-adipocyte interplay stimulate beige/brown differentiation and reprogram metabolism in stromal adipocytes to promote tumour progression |
| Q91531345 | Exosomes in HNSCC plasma as surrogate markers of tumour progression and immune competence |
| Q37507018 | Exosomes in Plasma of Patients with Ovarian Carcinoma: Potential Biomarkers of Tumor Progression and Response to Therapy |
| Q54966511 | Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. |
| Q38746614 | Expanding roles of ZEB factors in tumorigenesis and tumor progression. |
| Q68814711 | Experimental strategies and interpretations in the analysis of changes in MHC gene expression during tumour progression. Opposing influences of T cell and natural killer mediated resistance? |
| Q91965634 | Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development |
| Q38782046 | Exploiting Secreted Luciferases to Monitor Tumor Progression In Vivo |
| Q64245289 | Exploring Differential Connexin Expression across Melanocytic Tumor Progression Involving the Tumor Microenvironment |
| Q112305976 | Exploring photoacoustic spectroscopy-based machine learning together with metabolomics to assess breast tumor progression in a xenograft model ex vivo |
| Q64110972 | Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression |
| Q37236007 | Exposure to ACEI/ARB and β-Blockers Is Associated with Improved Survival and Decreased Tumor Progression and Hospitalizations in Patients with Advanced Colon Cancer |
| Q80794925 | Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression |
| Q55471506 | Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. |
| Q37488785 | Expression and localization of maspin in cervical cancer and its role in tumor progression and lymphangiogenesis |
| Q80938609 | Expression and localization of membrane-type-1 matrix metalloproteinase, CD 44, and laminin-5gamma2 chain during colorectal carcinoma tumor progression |
| Q35944627 | Expression and mutation analysis of Cyclin A and Ki-67 in glioma and their correlation with tumor progression |
| Q82499369 | Expression and prognostic roles of PABPC1 in esophageal cancer: correlation with tumor progression and postoperative survival |
| Q77626767 | Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival |
| Q36299435 | Expression features of SOX9 associate with tumor progression and poor prognosis of hepatocellular carcinoma |
| Q80286745 | Expression levels of heat shock protein 20 decrease in parallel with tumor progression in patients with hepatocellular carcinoma |
| Q36085456 | Expression of ALDH1A1 and CD44 in primary head and neck squamous cell carcinoma and their value for carcinogenesis, tumor progression and cancer stem cell identification |
| Q85097467 | Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis |
| Q35823028 | Expression of Beclin Family Proteins Is Associated with Tumor Progression in Oral Cancer |
| Q47760381 | Expression of Beta-1 integrin in human gastric carcinomas - correlation with histological type and tumor progression. |
| Q45159290 | Expression of CD10 predicts tumor progression and unfavorable prognosis in malignant melanoma |
| Q73312538 | Expression of CD44 isoforms and beta 1,6-branched oligosaccharides in human malignant melanoma is correlated with tumor progression but not with metastatic potential |
| Q33200284 | Expression of CD44 on two lines of transplantable melanoma cells--relationship with cytokine secretion and tumor progression |
| Q71669544 | Expression of CD44 splice variants during lymphocyte activation and tumor progression |
| Q71702894 | Expression of CD44 splice variants in human cutaneous melanoma and melanoma cell lines is related to tumor progression and metastatic potential |
| Q71874676 | Expression of CD44 variant isoforms in peripheral blood leukocytes in malignant lymphoma and leukemia: inverse correlation between expression and tumor progression |
| Q72097100 | Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression |
| Q99241691 | Expression of CD73 is associated with tumor progression and intratumoral inflammation in breast cancer |
| Q41194997 | Expression of CDC5L is associated with tumor progression in gliomas |
| Q40584331 | Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma |
| Q78016109 | Expression of DCC protein in colorectal tumors and its relationship to tumor progression and metastasis |
| Q85046573 | Expression of EMMPRIN in adenoid cystic carcinoma of salivary glands: correlation with tumor progression and patients' prognosis |
| Q82797878 | Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis |
| Q45706500 | Expression of Epstein-Barr virus in thyroid carcinoma correlates with tumor progression |
| Q57565135 | Expression of Estrogen Related Proteins in Hormone Refractory Prostate Cancer: Association With Tumor Progression |
| Q37082782 | Expression of G protein-coupled receptor 56 is associated with tumor progression in non-small-cell lung carcinoma patients |
| Q50922723 | Expression of GFRα3 correlates with tumor progression and promotes cell metastasis in urothelial carcinoma. |
| Q36831403 | Expression of GSDML Associates with Tumor Progression in Uterine Cervix Cancer |
| Q43137955 | Expression of HAb18G is associated with tumor progression and prognosis of breast carcinoma |
| Q73021377 | Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression |
| Q39307263 | Expression of KITENIN and its association with tumor progression in oral squamous cell carcinoma |
| Q53256242 | Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with β-catenin in tumor progression. |
| Q72861081 | Expression of Kirsten-ras p21 in gastric cancer correlates with tumor progression and is prognostic |
| Q91439452 | Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome |
| Q38959710 | Expression of Livin and the inhibition of tumor progression by Livin silencing in laryngohypopharyngeal cancer. |
| Q45921343 | Expression of MMPs and TIMPs in different tumor progression stages of oral cavity squamous cells carcinoma (experience of 30 cases in Instituto Nacional de Cancerología, México 1999–2004). |
| Q44396939 | Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis |
| Q33675074 | Expression of MYSM1 is associated with tumor progression in colorectal cancer. |
| Q40030528 | Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death |
| Q54649133 | Expression of Neuropilin-2 in salivary adenoid cystic carcinoma: its implication in tumor progression and angiogenesis. |
| Q70670737 | Expression of P-cadherin in gastric carcinomas and its reduction in tumor progression |
| Q49225961 | Expression of PIM-1 in salivary gland adenoid cystic carcinoma: Association with tumor progression and patients' prognosis. |
| Q37719954 | Expression of RECK and MMP-2 in salivary adenoid cystic carcinoma: Correlation with tumor progression and patient prognosis |
| Q81078177 | Expression of RUNX3 in salivary adenoid cystic carcinoma: implications for tumor progression and prognosis |
| Q81631324 | Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis |
| Q38714543 | Expression of Rab5a correlates with tumor progression in pancreatic carcinoma |
| Q40354042 | Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression |
| Q53251842 | Expression of SKA1 and MMP-9 in primary salivary adenoid cystic carcinoma: Correlation with tumor progression and patient prognosis. |
| Q92645437 | Expression of Tim-3 in breast cancer tissue promotes tumor progression |
| Q37011129 | Expression of Transforming Growth Factor β1 and E-Cadherin Proteins in Pulmonary Adenocarcinoma: Its Significance in Tumor Progression |
| Q41721249 | Expression of a disintegrin and metalloprotease 8 and endostatin in human osteosarcoma: implication in tumor progression and prognosis |
| Q73803380 | Expression of a novel factor, com1, in early tumor progression of breast cancer |
| Q34321615 | Expression of a novel human gene, human wings apart-like (hWAPL), is associated with cervical carcinogenesis and tumor progression |
| Q39204475 | Expression of alpha 1,6-fucosyltransferase 8 in hepatitis B virus-related hepatocellular carcinoma influences tumour progression |
| Q43840619 | Expression of angiogenic factors and tumor progression in human neuroblastoma. |
| Q34768498 | Expression of axl in lung adenocarcinoma and correlation with tumor progression |
| Q47820409 | Expression of bcl-2 in testicular carcinoma: correlation with tumor progression and MDR1/Pgp |
| Q42804610 | Expression of carcinoembryonic antigen by adenoma and carcinoma derived epithelial cell lines: possible marker of tumour progression and modulation of expression by sodium butyrate |
| Q47436566 | Expression of cell cycle proteins in T1a and T1b urothelial bladder carcinoma and their value in predicting tumor progression |
| Q83187267 | Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression |
| Q96224350 | Expression of concern: Reduced interleukin-38 in non-small cell lung cancer is associated with tumour progression |
| Q96224353 | Expression of concern: Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression |
| Q42509490 | Expression of cytokeratin 34βE12 is a good indicator of tumor progression in esophageal squamous cell carcinoma |
| Q40334938 | Expression of death-associated protein kinase during tumour progression of human renal cell carcinomas: hypermethylation-independent mechanisms of inactivation |
| Q38282663 | Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression |
| Q47757142 | Expression of e-cadherin, alpha-catenins and Beta-catenins in human gastric carcinomas - correlation with histology and tumor progression. |
| Q62632344 | Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression |
| Q73104077 | Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus |
| Q64377329 | Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer |
| Q47987237 | Expression of far upstream element-binding protein 1 correlates with c-Myc expression in sacral chordomas and is associated with tumor progression and poor prognosis |
| Q35145053 | Expression of flotillin-2 in human non-small cell lung cancer and its correlation with tumor progression and patient survival |
| Q89307481 | Expression of follicle stimulating hormone receptors in intra-tumoral vasculature and in tumoral cells - the involvement in tumour progression and the perspectives of application in cancer diagnosis and therapy |
| Q38065866 | Expression of girdin in human colorectal cancer and its association with tumor progression. |
| Q48181354 | Expression of granulocyte colony-stimulating factor in recurrent glial tumors is inversely correlated with tumor progression |
| Q86041537 | Expression of growth arrest and DNA damage inducible 45a in human oral squamous cell carcinoma is associated with tumor progression and clinical outcome: Erratum |
| Q46197377 | Expression of growth hormone receptor, plakoglobin and NEDD9 protein in association with tumour progression and metastasis in human breast cancer |
| Q53503896 | Expression of growth-related genes during tumor progression in v-raf-transformed rat liver epithelial cells |
| Q86052997 | Expression of heat shock protein 20 inversely correlated with tumor progression in patients with ovarian cancer |
| Q34647080 | Expression of heat shock protein 70 in renal cell carcinoma and its relation to tumor progression and prognosis |
| Q25256742 | Expression of hyaluronan in human tumor progression |
| Q73072089 | Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression |
| Q74481526 | Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival |
| Q39144655 | Expression of integrin-linked kinase in adenoid cystic carcinoma of salivary glands correlates with epithelial-mesenchymal transition markers and tumor progression |
| Q30487456 | Expression of lactate/H⁺ symporters MCT1 and MCT4 and their chaperone CD147 predicts tumor progression in clear cell renal cell carcinoma: immunohistochemical and The Cancer Genome Atlas data analyses |
| Q39254776 | Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival |
| Q48462444 | Expression of long non-coding RNA CRNDE in glioma and its correlation with tumor progression and patient survival. |
| Q36262129 | Expression of long non-coding RNA ZEB1-AS1 in esophageal squamous cell carcinoma and its correlation with tumor progression and patient survival |
| Q34345203 | Expression of mast cell proteases correlates with mast cell maturation and angiogenesis during tumor progression |
| Q53075335 | Expression of matriptase correlates with tumour progression and clinical prognosis in oral squamous cell carcinoma. |
| Q71910740 | Expression of metastasis suppressor gene product, nm23 protein, is not inversely correlated with the tumour progression in human malignant melanomas |
| Q35145259 | Expression of miR-32 in human non-small cell lung cancer and its correlation with tumor progression and patient survival |
| Q39069297 | Expression of microRNA-218 in human pancreatic ductal adenocarcinoma and its correlation with tumor progression and patient survival |
| Q36437747 | Expression of molecular biomarkers in primary breast tumors implanted into a surrogate host: increased levels of cyclins correlate with tumor progression |
| Q53261574 | Expression of multiple cytokines and cutaneous lymphocyte antigen in adult T-cell leukaemia/lymphoma cells with tumour progression and skin involvement. |
| Q40266975 | Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression |
| Q77751586 | Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis |
| Q73439099 | Expression of nm23 protein in pulmonary adenocarcinomas: inverse 1orrelation to tumor progression |
| Q40014631 | Expression of nonsteroidal anti-inflammatory drug-activated gene-1 (NAG-1) inversely correlates with tumor progression in gastric adenomas and carcinomas |
| Q38444747 | Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression. |
| Q51307444 | Expression of orphan GPR56 correlates with tumor progression in human epithelial ovarian cancer. |
| Q44661510 | Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression |
| Q52536265 | Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. |
| Q78793240 | Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma |
| Q52167702 | Expression of polysialic acid and STX, a human polysialyltransferase, is correlated with tumor progression in non-small cell lung cancer. |
| Q87702906 | Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival |
| Q53464608 | Expression of protease activated receptor-2 in human colorectal cancer and its association with tumor progression. |
| Q47098483 | Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer |
| Q45973885 | Expression of receptors tyrosine kinase c-kit and EGF-R in colorectal adenocarcinomas: is there a relationship with epithelial-mesenchymal transition during tumor progression? |
| Q39027926 | Expression of stress-induced phosphoprotein1 (STIP1) is associated with tumor progression and poor prognosis in epithelial ovarian cancer. |
| Q40853389 | Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression |
| Q47414682 | Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression |
| Q34599172 | Expression of the GLI family genes is associated with tumor progression in advanced lung adenocarcinoma |
| Q92670536 | Expression of the Receptor for Hyaluronic Acid-Mediated Motility (RHAMM) in Endometrial Cancer is Associated With Adverse Histologic Parameters and Tumor Progression |
| Q41104091 | Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression |
| Q42389733 | Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression |
| Q50505009 | Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. |
| Q53286824 | Expression of the helicase-like transcription factor and its variants during carcinogenesis of the uterine cervix: implications for tumour progression. |
| Q28200947 | Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis |
| Q39298765 | Expression of the receptor tyrosine kinase recepteur d'origine nantais and its association with tumor progression in hypopharyngeal cancer |
| Q39613028 | Expression of the soluble vascular endothelial growth factor receptor-1 in cutaneous melanoma: role in tumour progression. |
| Q41012933 | Expression of thrombospondin-1 in cancer: a role in tumor progression |
| Q35833728 | Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression |
| Q88065270 | Expression of tumour progression-associated genes in circulating tumour cells of patients at different stages of prostate cancer |
| Q42811750 | Expression of type VI collagen in uveal melanoma: its role in pattern formation and tumor progression. |
| Q74430086 | Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer |
| Q37227768 | Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status |
| Q38881921 | Expression of vasohibin-2 in pancreatic ductal adenocarcinoma promotes tumor progression and is associated with a poor clinical outcome |
| Q39586570 | Expression of wild-type and variant estrogen receptor alpha in liver carcinogenesis and tumor progression |
| Q42790493 | Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. |
| Q67255864 | Expression pattern of a gene for a secreted metalloproteinase during late stages of tumor progression |
| Q38310451 | Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression |
| Q34014610 | Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression |
| Q40625666 | Expression profiling of epithelial plasticity in tumor progression |
| Q51116868 | Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression. |
| Q58132105 | Extracellular Matrix Stiffness Exists in a Feedback Loop that Drives Tumor Progression |
| Q64951417 | Extracellular Ubiquitin is the Causal Link between Stored Blood Transfusion Therapy and Tumor Progression in a Melanoma Mouse Model. |
| Q49645578 | Extracellular Vesicles As miRNA Nano-Shuttles: Dual Role in Tumor Progression. |
| Q110596159 | Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression |
| Q38781015 | Extracellular Vesicles in Brain Tumor Progression |
| Q96644146 | Extracellular Vesicles in the Tumor Microenvironment: Various Implications in Tumor Progression |
| Q40097136 | Extracellular Vesicles, Tunneling Nanotubes, and Cellular Interplay: Synergies and Missing Links. |
| Q38046685 | Extracellular acidity as favouring factor of tumor progression and metastatic dissemination |
| Q89453045 | Extracellular domain of EpCAM enhances tumor progression through EGFR signaling in colon cancer cells |
| Q38225141 | Extracellular galectin-3 in tumor progression and metastasis. |
| Q58725635 | Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment |
| Q42459287 | Extracellular matrix receptors and mouse skin carcinogenesis: altered expression linked to appearance of early markers of tumor progression |
| Q90242925 | Extracellular vesicle packaged LMP1-activated fibroblasts promote tumor progression via autophagy and stroma-tumor metabolism coupling |
| Q49838785 | Extracellular vesicle-mediated EBAG9 transfer from cancer cells to tumor microenvironment promotes immune escape and tumor progression. |
| Q95825136 | Extracellular vesicle-mediated crosstalk between melanoma and the immune system: Impact on tumor progression and therapy response |
| Q45338563 | Extracellular vesicle-mediated transport of non-coding RNAs between stem cells and cancer cells: implications in tumor progression and therapeutic resistance. |
| Q36724866 | Extract of Vernonia condensata, Inhibits Tumor Progression and Improves Survival of Tumor-allograft Bearing Mouse |
| Q34447791 | Extracts of strawberry fruits induce intrinsic pathway of apoptosis in breast cancer cells and inhibits tumor progression in mice |
| Q98159083 | Extravasated platelet aggregation contributes to tumor progression via the accumulation of myeloid-derived suppressor cells in gastric cancer with peritoneal metastasis |
| Q33840437 | Extrinsic regulators of epithelial tumor progression: metalloproteinases |
| Q55423815 | Eya3 partners with PP2A to induce c-Myc stabilization and tumor progression. |
| Q53424425 | Ezrin and E-cadherin expression profile in cervical cytology: a prognostic marker for tumor progression in cervical cancer. |
| Q57096492 | Ezrin and its emerging role in tumor progression in systemic malignancies |
| Q42562691 | Ezrin and its emerging role in tumor progression: response |
| Q64240685 | F-box/WD-40 repeat-containing protein 7: A potential target in the progression and treatment of gastrointestinal malignancy |
| Q47577382 | FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk |
| Q90914939 | FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival |
| Q114138029 | FBXO39 predicts poor prognosis and correlates with tumor progression in cervical squamous cell carcinoma |
| Q96165816 | FCHO1560-571 peptide, a PKB kinase motif, inhibits tumor progression |
| Q33787365 | FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer |
| Q88893706 | FEN1 promotes tumor progression and confers cisplatin resistance in non-small-cell lung cancer |
| Q24294440 | FERM-containing protein FRMD5 is a p120-catenin interacting protein that regulates tumor progression |
| Q104560708 | FET PET Radiomics for Differentiating Pseudoprogression from Early Tumor Progression in Glioma Patients Post-Chemoradiation |
| Q90481635 | FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity |
| Q36262850 | FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7 |
| Q38780109 | FGF19 Contributes to Tumor Progression in Gastric Cancer by Promoting Migration and Invasion |
| Q42425420 | FGFR3-expressing smooth muscle-like stromal cells differentiate in response to FGFR2IIIb-expressing prostate tumor cells and delay tumor progression |
| Q100958422 | FGFR3△7-9 promotes tumor progression via the phosphorylation and destabilization of ten-eleven translocation-2 in human hepatocellular carcinoma |
| Q61118475 | FGL2 promotes tumor progression in the CNS by suppressing CD103 dendritic cell differentiation |
| Q78107687 | FHIT gene in gastric cancer: association with tumour progression and prognosis |
| Q36164237 | FLJ10540 is associated with tumor progression in nasopharyngeal carcinomas and contributes to nasopharyngeal cell proliferation, and metastasis via osteopontin/CD44 pathway. |
| Q43581860 | FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer |
| Q31083556 | FOXA1 promotes tumor progression in prostate cancer via the insulin-like growth factor binding protein 3 pathway |
| Q98905604 | FOXC1-mediated LINC00301 facilitates tumor progression and triggers an immune-suppressing microenvironment in non-small cell lung cancer by regulating the HIF1α pathway |
| Q91723183 | FOXD4 induces tumor progression in colorectal cancer by regulation of the SNAI3/CDH1 axis |
| Q100534910 | FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma |
| Q39322343 | FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape |
| Q38706570 | FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3β - dependent manner in hepatocellular carcinoma |
| Q72537455 | Facilitation of tumour progression by cancer therapy |
| Q44757431 | Factor-inhibiting hypoxia-inducible factor expression in patients with high-risk locally advanced renal cell carcinoma and its relationship with tumor progression |
| Q96349258 | Factors Associated with Tumor Progression After Percutaneous Ablation of Hepatocellular Carcinoma: Comparison Between Monopolar Radiofrequency and Microwaves. Results of a Propensity Score Matching Analysis |
| Q33276178 | Factors for tumor progression in patients with skull base chordoma |
| Q44109786 | Fas function and tumor progression: use it and lose it. |
| Q73562298 | Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression |
| Q80122645 | Fascin expression is correlated with tumor progression of extrahepatic bile duct cancer |
| Q92264530 | Fatty acid oxidation inhibitor etomoxir suppresses tumor progression and induces cell cycle arrest via PPARγ-mediated pathway in bladder cancer |
| Q41569397 | Feasibility of quantitative parameters of dynamically enhanced patterns of spiral computed tomography scanning integrated into tumour progression before targeted treatment of non-small cell lung cancer |
| Q38888155 | Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression |
| Q54626338 | Fermented wheat aleurone enriched with probiotic strains LGG and Bb12 modulates markers of tumor progression in human colon cells. |
| Q38271804 | Fetal alcohol exposure increases susceptibility to carcinogenesis and promotes tumor progression in prostate gland |
| Q72771530 | Fetal-like fibroblasts: their production of migration-stimulating factor and role in tumor progression |
| Q91229374 | Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma |
| Q37546757 | Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression |
| Q40420815 | Fibroblast control on epithelial differentiation is gradually lost during in vitro tumor progression |
| Q83367655 | Fibroblast gene expression profile reflects the stage of tumour progression in oral squamous cell carcinoma |
| Q34151946 | Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma |
| Q38349736 | Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. |
| Q34973710 | Fibroblast growth factor receptor-2 expression in thyroid tumor progression: potential diagnostic application |
| Q40926684 | Fibroblast subpopulations as accelerators of tumor progression: the role of migration stimulating factor |
| Q95785912 | Fibroblast-derived MT1-MMP promotes tumor progression in vitro and in vivo |
| Q92053423 | Fibroblast-specific ERK5 deficiency changes tumor vasculature and exacerbates tumor progression in a mouse model |
| Q85169334 | Fibulin-3 is associated with tumour progression and a poor prognosis in nasopharyngeal carcinomas and inhibits cell migration and invasion via suppressed AKT activity |
| Q35177014 | Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas |
| Q58572892 | Filamin A inhibits tumor progression through regulating BRCA1 expression in human breast cancer |
| Q38641298 | First follow-up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases |
| Q41025189 | Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer |
| Q91635356 | Flavonoid Compounds Contained in Epimedii Herba Inhibit Tumor Progression by Suppressing STAT3 Activation in the Tumor Microenvironment |
| Q34414400 | Fluorescence laparoscopy imaging of pancreatic tumor progression in an orthotopic mouse model |
| Q54262938 | Focal Adhesion Proteins α- and β-Parvin are Overexpressed in Human Colorectal Cancer and Correlate with Tumor Progression. |
| Q54111710 | Focal adhesion kinase (FAK) deficiency in mononuclear phagocytes alters murine breast tumor progression. |
| Q42516547 | Focal degeneration of basal cells and the resultant auto-immunoreactions: a novel mechanism for prostate tumor progression and invasion |
| Q64244523 | Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs |
| Q98282296 | Focus on the morphogenesis, fate and the role in tumor progression of multivesicular bodies |
| Q37499293 | Folic acid supplementation promotes mammary tumor progression in a rat model |
| Q69948335 | Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression |
| Q37759334 | Follicular lymphoma: a model of lymphoid tumor progression in man. |
| Q73941787 | Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice |
| Q34315046 | Force engages vinculin and promotes tumor progression by enhancing PI3K activation of phosphatidylinositol (3,4,5)-triphosphate |
| Q54211181 | Formyl Peptide receptor 1 expression is associated with tumor progression and survival in gastric cancer. |
| Q30581656 | Four individually druggable MET hotspots mediate HGF-driven tumor progression. |
| Q89285162 | FoxM1 is regulated by both HIF-1α and HIF-2α and contributes to gastrointestinal stromal tumor progression |
| Q47634621 | Frankincense, pine needle and geranium essential oils suppress tumor progression through the regulation of the AMPK/mTOR pathway in breast cancer |
| Q53339358 | Frequent genetic alterations and reduced expression of the Axin1 gene in oral squamous cell carcinoma: involvement in tumor progression and metastasis. |
| Q73118222 | Frequent loss of chromosome 14 in atypical and malignant meningioma: identification of a putative 'tumor progression' locus |
| Q41719613 | Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression |
| Q47617840 | Frequent translocalization of beta-catenin in gastric cancers and its relevance to tumor progression. |
| Q35665238 | From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression. |
| Q84849015 | From cirrhosis to hepatocellular carcinoma in HCV-infected patients: genes involved in tumor progression |
| Q36687275 | From the Guest Editors: Role of Tumor Microenvironment in Tumor Progression and Treatment Response: A 30 Years' Journey |
| Q53703015 | Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy. |
| Q35724544 | Fukutin, identified by the Escherichia coli ampicillin secretion trap (CAST) method, participates in tumor progression in gastric cancer |
| Q64060371 | Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression |
| Q45921927 | Functional IL-17R in glioma stem cells: potential role in tumor progression and therapeutic implications. |
| Q35223535 | Functional Role of Glycosphingolipids in Tumor Progression |
| Q26770838 | Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies |
| Q53426189 | Functional involvement of CD44, a family of cell adhesion molecules, in immune responses, tumour progression and haematopoiesis. |
| Q39294774 | Functional vascular endothelial growth factor -2578 C/A polymorphism in relation to nasopharyngeal carcinoma risk and tumor progression |
| Q33716333 | Functions of the extracellular matrix and matrix degrading proteases during tumor progression |
| Q70648883 | Further validation of the prognostic model for stage I malignant melanoma based on tumor progression |
| Q35146561 | Fusion transcript discovery in formalin-fixed paraffin-embedded human breast cancer tissues reveals a link to tumor progression. |
| Q30413082 | G protein-coupled receptor kinase 6 deficiency promotes angiogenesis, tumor progression, and metastasis |
| Q24802461 | G-protein inwardly rectifying potassium channel 1 (GIRK 1) gene expression correlates with tumor progression in non-small cell lung cancer |
| Q55346727 | G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas. |
| Q92077022 | GABRP regulates chemokine signalling, macrophage recruitment and tumour progression in pancreatic cancer through tuning KCNN4-mediated Ca2+ signalling in a GABA-independent manner |
| Q38904689 | GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways. |
| Q33674751 | GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer |
| Q36399068 | GIT1 is a novel prognostic biomarker and facilitates tumor progression via activating ERK/MMP9 signaling in hepatocellular carcinoma |
| Q38974569 | GIV/Girdin is a rheostat that fine-tunes growth factor signals during tumor progression |
| Q55457294 | GLUT5 increases fructose utilization and promotes tumor progression in glioma. |
| Q51843579 | GM-CSF secreted by murine adenocarcinoma cells modulates tumor progression and immune activity. |
| Q36346388 | GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer |
| Q64119899 | GPER Mediates a Feedforward FGF2/FGFR1 Paracrine Activation Coupling CAFs to Cancer Cells toward Breast Tumor Progression |
| Q37543846 | GRK3 is essential for metastatic cells and promotes prostate tumor progression |
| Q91736268 | GRK5 promotes tumor progression in renal cell carcinoma |
| Q102053485 | GSK3β-mediated expression of CUG-translated WT1 is critical for tumor progression |
| Q54978826 | GSTM3 and GSTP1: novel players driving tumor progression in cervical cancer. |
| Q99553999 | GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer |
| Q98502290 | GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma |
| Q38294589 | Gab1 but not Grb2 mediates tumor progression in Met overexpressing colorectal cancer cells |
| Q47744553 | Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression |
| Q40840854 | Gains and losses of CD44 expression during breast carcinogenesis and tumour progression |
| Q40627879 | Gains and losses of adhesion molecules (CD44, E-cadherin, and beta-catenin) during oral carcinogenesis and tumour progression |
| Q33274095 | Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer |
| Q36879539 | Galectin-1 mediates TGF-β-induced transformation from normal fibroblasts into carcinoma-associated fibroblasts and promotes tumor progression in gastric cancer |
| Q46011748 | Galectin-1 promotes tumor progression via NF-κB signaling pathway in epithelial ovarian cancer. |
| Q33814898 | Galectin-1 upregulates CXCR4 to promote tumor progression and poor outcome in kidney cancer |
| Q57741332 | Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma |
| Q38724586 | Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer |
| Q62621386 | Galectin-3 Upregulation During Tumor Progression in Head and Neck Cancer |
| Q73310501 | Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma: possible relation to tumour progression |
| Q53319954 | Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. |
| Q91809663 | Galectin-3: An Early Marker of Gestational Diabetes, Subclinical Atherosclerosis, and Tumor Progression |
| Q38469772 | Galectin-8 up-regulation during hypopharyngeal and laryngeal tumor progression and comparison with galectin-1, -3 and -7. |
| Q36742111 | Galectins as modulators of tumor progression in head and neck squamous cell carcinomas |
| Q34381235 | Galectins as modulators of tumour progression |
| Q37763394 | Gamma-glutamyltransferase of cancer cells at the crossroads of tumor progression, drug resistance and drug targeting |
| Q43735241 | Ganglioside expression of human melanoma and tumor progression. Ganglioside composition of a plaque and a nodule of acral lentiginous melanoma |
| Q34588622 | Gap junctions and tumour progression |
| Q37892680 | Gastric cancer - The role of matrix metalloproteinases in tumor progression |
| Q73488831 | Gastric cancer associated with overexpression of parathyroid hormone-related peptide (PTHrP) and PTH/PTHrP receptor in relation to tumor progression |
| Q38010943 | Gastric cancer carcinogenesis and tumor progression. |
| Q41595475 | Gastric gland mucin-specific O-glycan expression decreases with tumor progression from precursor lesions to pancreatic cancer |
| Q79909983 | Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour |
| Q90573245 | Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking |
| Q54230919 | Gelatinase B (-1562C/T) polymorphism in tumor progression and invasion of breast cancer. |
| Q53338894 | Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer. |
| Q35702425 | Gene Expression Signatures Based on Variability can Robustly Predict Tumor Progression and Prognosis |
| Q83818621 | Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient |
| Q35192114 | Gene amplification and splice variants of 25-hydroxyvitamin D3 1,alpha-hydroxylase (CYP27B1) in glioblastoma multiforme--a possible role in tumor progression? |
| Q40912793 | Gene amplification and tumor progression |
| Q69419999 | Gene amplification and tumor progression |
| Q47134153 | Gene editing of the extra domain A positive fibronectin in various tumors, amplified the effects of CRISPR/Cas system on the inhibition of tumor progression |
| Q40923346 | Gene expression disorders of innate antibacterial signaling pathway in pancreatic cancer patients: implications for leukocyte dysfunction and tumor progression |
| Q51719980 | Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression. |
| Q53676771 | Gene expression profiles of different clinical stages of colorectal carcinoma: toward a molecular genetic understanding of tumor progression. |
| Q38510015 | Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis |
| Q33738887 | Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker |
| Q33272950 | Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues |
| Q36864387 | Gene expression, cellular diversification and tumor progression to the metastatic phenotype |
| Q51600332 | Gene-chip technology and prostate cancer: the identification of new genes regulating tumour progression. |
| Q51996819 | Gene-expression profile changes correlated with tumor progression and lymph node metastasis in esophageal cancer. |
| Q84531638 | Gene-expression-based analysis of local and metastatic neuroblastoma variants reveals a set of genes associated with tumor progression in neuroblastoma patients |
| Q36905908 | Generation and characterization of a tetraspanin CD151/integrin α6β1-binding domain competitively binding monoclonal antibody for inhibition of tumor progression in HCC. |
| Q92703125 | Genes Controlled by DNA Methylation Are Involved in Wilms Tumor Progression |
| Q53446941 | Genes differentially expressed with malignant transformation and metastatic tumor progression of murine squamous cell carcinoma. |
| Q53368188 | Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. |
| Q55162327 | Genetic alterations in thyroid tumor progression: association with p53 gene mutations. |
| Q74689002 | Genetic analyses of mouse skin tumor progression susceptibility using SENCAR inbred derived strains |
| Q51835602 | Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. |
| Q53946441 | Genetic and epigenetic aspects of tumor progression and tumor heterogeneity. |
| Q54693735 | Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. |
| Q38103747 | Genetic and non-genetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells |
| Q41734552 | Genetic changes in skin tumor progression: correlation between presence of a mutant ras gene and loss of heterozygosity on mouse chromosome 7. |
| Q39525185 | Genetic convergence and divergence in tumor progression |
| Q78016664 | Genetic differences detected by comparative genomic hybridization in head and neck squamous cell carcinomas from different tumor sites: construction of oncogenetic trees for tumor progression |
| Q39831814 | Genetic dissection of growth factor-mediated controls of cell proliferation as an approach to analyze the process of tumor progression |
| Q33643339 | Genetic events and the role of TGF beta in epithelial tumour progression |
| Q87430112 | Genetic evolution during tumor progression: from basic research to clinical practice |
| Q39663818 | Genetic instability and tumor progression |
| Q44291670 | Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system |
| Q33913937 | Genetic methylation and lymphoid malignancies: biomarkers of tumor progression and targeted therapy |
| Q53330748 | Genetic removal of Smad3 from inhibin-null mice attenuates tumor progression by uncoupling extracellular mitogenic signals from the cell cycle machinery. |
| Q41192145 | Genetic susceptibility to tumor progression in mouse skin carcinogenesis. |
| Q40771498 | Genetics of astrocytic tumor progression. |
| Q33908395 | Genistein increases epidermal growth factor receptor signaling and promotes tumor progression in advanced human prostate cancer |
| Q33720872 | Genome organizing function of SATB1 in tumor progression |
| Q91523132 | Genome remodeling upon mesenchymal tumor cell fusion contributes to tumor progression and metastatic spread |
| Q90981602 | Genome-wide analysis of ETV1 targets: Insights into the role of ETV1 in tumor progression |
| Q43030699 | Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. |
| Q42182032 | Genome-wide profiling of DNA methylation and tumor progression in human hepatocellular carcinoma |
| Q37064043 | Genome-wide screen identified let-7c/miR-99a/miR-125b regulating tumor progression and stem-like properties in cholangiocarcinoma |
| Q57782669 | Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer |
| Q54536992 | Genomic analysis of early adenocarcinoma of the esophagus or gastroesophageal junction: tumor progression is associated with alteration of 1q and 8p sequences. |
| Q35634196 | Genomic approaches to understanding mammary tumor progression in transgenic mice and responses to therapy |
| Q37678826 | Genomic architecture characterizes tumor progression paths and fate in breast cancer patients |
| Q40867748 | Genomic instability and tumor progression: mechanistic considerations. |
| Q39574504 | Genomic loss of miR-486 regulates tumor progression and the OLFM4 antiapoptotic factor in gastric cancer |
| Q30754497 | Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression |
| Q59938913 | Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression |
| Q48530123 | Genotypic monoclonality in immunophenotypically polyclonal orbital lymphoid tumors. A model of tumor progression in the lymphoid system. The 1986 Wendell Hughes lecture. |
| Q43747239 | Germ-line deletion of p53 reveals a multistage tumor progression in spi-1/PU.1 transgenic proerythroblasts |
| Q102140617 | Germline Variants That Affect Tumor Progression |
| Q46855629 | Germline genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian cervical cancer: associations with tumor progression, age and human papillomavirus infection |
| Q34689297 | Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. |
| Q90360670 | Gli promotes tumor progression and metastasis through regulating EMT in non-small-cell lung cancer |
| Q92605335 | Gli promotes tumor progression through regulating epithelial-mesenchymal transition in non-small-cell lung cancer |
| Q40192439 | Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma |
| Q58546908 | Glioma Cell Secretion: A Driver of Tumor Progression and a Potential Therapeutic Target |
| Q95940507 | Glioma-derived extracellular vesicles promote tumor progression by conveying WT1 |
| Q77916758 | Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression |
| Q96821104 | Glucosamine-6-Phosphate Isomerase 1 Promotes Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma |
| Q33651012 | Glutamate receptor GRIA3--target of CUX1 and mediator of tumor progression in pancreatic cancer |
| Q90168517 | Glutamatergic synaptic input to glioma cells drives brain tumour progression |
| Q92358635 | Glutathione S-transferase A1 suppresses tumor progression and indicates better prognosis of human primary hepatocellular carcinoma |
| Q84568214 | Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients |
| Q62086759 | Glutathione S-transferases as molecular markers of tumour progression and prognosis in renal cell carcinoma |
| Q54168957 | Glutathione and related enzymes in tumor progression and metastases of human melanoma. |
| Q68092484 | Glycoprotein P3.58, associated with tumor progression in malignant melanoma, is a novel leukocyte activation antigen |
| Q54981682 | Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. |
| Q104136660 | Gold nanoparticles carrying or not anti-VEGF antibody do not change glioblastoma multiforme tumor progression in mice |
| Q52641579 | Gram-negative bacteria facilitate tumor progression through TLR4/IL-33 pathway in patients with non-small-cell lung cancer. |
| Q36582834 | Grapefruit-derived Nanovectors Delivering Therapeutic miR17 Through an Intranasal Route Inhibit Brain Tumor Progression |
| Q34531593 | Grhl2 determines the epithelial phenotype of breast cancers and promotes tumor progression |
| Q85923440 | Grim-19 expression and its close association with tumor progression in systemic malignancies |
| Q40763080 | Growth factor balance and tumor progression |
| Q55617657 | H3K4me3 and Wdr82 are associated with tumor progression and a favorable prognosis in human colorectal cancer. |
| Q39037287 | HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome. |
| Q92307514 | HAVCR1 Affects the MEK/ERK Pathway in Gastric Adenocarcinomas and Influences Tumor Progression and Patient Outcome |
| Q91228663 | HDAC inhibition induces expression of scaffolding proteins critical for tumor progression in pediatric glioma: focus on EBP50 and IRSp53 |
| Q96590436 | HDAC9 deficiency promotes tumor progression by decreasing the CD8+ dendritic cell infiltration of the tumor microenvironment |
| Q36751137 | HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer |
| Q84566644 | HER2 status in a population-derived breast cancer cohort: discordances during tumor progression |
| Q36112574 | HER3 Expression Is a Marker of Tumor Progression in Premalignant Lesions of the Gastroesophageal Junction |
| Q36027374 | HGF/SF-Met signaling in tumor progression |
| Q28212023 | HIF-1 and tumor progression: pathophysiology and therapeutics |
| Q35294475 | HIF-1 in cell cycle regulation, apoptosis, and tumor progression |
| Q90731617 | HIF1α/PD-L1 axis mediates hypoxia-induced cell apoptosis and tumor progression in follicular thyroid carcinoma |
| Q44916685 | HLA-DR and 96-K antigens and intratumoral lymphocytic infiltrate in primary cutaneous melanoma as markers of tumor progression. |
| Q36134648 | HLA-DR antigen expression in colorectal carcinomas: influence of expression by IFN-gamma in situ and its association with tumour progression |
| Q44503506 | HLA-E/β2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression |
| Q92500103 | HMGA1 exacerbates tumor progression by activating miR-222 through PI3K/Akt/MMP-9 signaling pathway in uveal melanoma |
| Q38755003 | HMGA1 facilitates tumor progression through regulating Wnt/β-catenin pathway in endometrial cancer |
| Q34140330 | HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells |
| Q34713175 | HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells |
| Q26830858 | HMGB1--its role in tumor progression and anticancer therapy |
| Q37206750 | HMGB1: a two-headed signal regulating tumor progression and immunity |
| Q62082780 | HORMONE EFFECTS ON PROSTATE AND MAMMARY TUMOR PROGRESSION IN TRANSGENIC MICE: ALTERATIONS IN ONCOGENE EXPRESSION. † 938 |
| Q61811900 | HOXA1 upregulation is associated with poor prognosis and tumor progression in breast cancer |
| Q38814227 | HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma |
| Q50884625 | HRG regulates tumor progression, epithelial to mesenchymal transition and metastasis via platelet-induced signaling in the pre-tumorigenic microenvironment. |
| Q35742468 | HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients |
| Q92519795 | HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy |
| Q91800150 | HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular Targeted Cancer Therapy |
| Q53590809 | HVEM expression contributes to tumor progression and prognosis in human colorectal cancer. |
| Q50281812 | Hakai overexpression effectively induces tumour progression and metastasis in vivo. |
| Q94473319 | Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression |
| Q53398865 | Haploid loss of Ki-ras delays mammary tumor progression in C3 (1)/SV40 Tag transgenic mice. |
| Q37360236 | Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression |
| Q34098053 | Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression |
| Q46939248 | Head and neck squamous cell carcinoma cell lines as a model system for the study of oncogene expression during tumor progression and metastasis. |
| Q83141508 | Head and neck squamous cell carcinoma: role of the human papillomavirus in tumour progression |
| Q90080306 | Heat Shock Proteins Are Essential Components in Transformation and Tumor Progression: Cancer Cell Intrinsic Pathways and Beyond |
| Q35807282 | Heat shock transcription factor Hsf1 is involved in tumor progression via regulation of hypoxia-inducible factor 1 and RNA-binding protein HuR |
| Q53359886 | Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associated with tumour progression and promotes migration and invasion. |
| Q38475633 | Helicase-like transcription factor exhibits increased expression and altered intracellular distribution during tumor progression in hypopharyngeal and laryngeal squamous cell carcinomas |
| Q73163179 | Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression |
| Q36260643 | Heme oxygenase-1 promotes tumor progression and metastasis of colorectal carcinoma cells by inhibiting antitumor immunity |
| Q31133925 | Hemochromatosis enhances tumor progression via upregulation of intracellular iron in head and neck cancer |
| Q61982594 | Heparan Sulfate Proteoglycans, Tumour Progression and the Cancer Stem Cell Niche |
| Q37194268 | Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression |
| Q35613227 | Heparanase localization and expression by head and neck cancer: correlation with tumor progression and patient survival |
| Q37000500 | Heparin in tumor progression and metastatic dissemination. |
| Q35783006 | Hepatic SirT1-Dependent Gain of Function of Stearoyl-CoA Desaturase-1 Conveys Dysmetabolic and Tumor Progression Functions |
| Q44193555 | Hepatic artery embolization for control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors |
| Q36352452 | Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases |
| Q39051077 | Hepatic stellate cells promote tumor progression by enhancement of immunosuppressive cells in an orthotopic liver tumor mouse model |
| Q54124731 | Hepatitis B virus X protein represses LKB1 expression to promote tumor progression and poor postoperative outcome in hepatocellular carcinoma. |
| Q40053186 | Hepatitis B virus surface proteins accelerate cholestatic injury and tumor progression in Abcb4-knockout mice |
| Q44093535 | Hepatocellular carcinoma in HCV-infected patients awaiting liver transplantation: genes involved in tumor progression |
| Q60931606 | Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts |
| Q42153446 | Hepatocyte growth factor produced in lung fibroblasts enhances non-small cell lung cancer cell survival and tumor progression |
| Q73154782 | Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death |
| Q83401524 | Heterogeneous distribution of LOH (loss of heterozygosity) and tumor progression |
| Q44288059 | Heterogeneous protooncogene amplification correlates with tumor progression and presence of metastases in gastric cancer patients |
| Q37696123 | Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung |
| Q40453995 | Hic-5 remodeling of the stromal matrix promotes breast tumor progression. |
| Q38116862 | Hidden keys in stroma: Unlocking the tumor progression. |
| Q38708346 | High Annexin A5 expression promotes tumor progression and poor prognosis in renal cell carcinoma |
| Q104793871 | High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer |
| Q35000400 | High CD49f expression is associated with osteosarcoma tumor progression: a study using patient-derived primary cell cultures |
| Q104680655 | High Expression of COL17A1 Predicts Poor Prognosis and Promotes the Tumor Progression via NF-κB Pathway in Pancreatic Adenocarcinoma |
| Q64108464 | High Expression of Human AugminComplex Submit 3 Indicates Poor Prognosis and Associates with Tumor Progression in Hepatocellular Carcinoma |
| Q36219980 | High Expression of KIF20A Is Associated with Poor Overall Survival and Tumor Progression in Early-Stage Cervical Squamous Cell Carcinoma |
| Q92205661 | High Expression of TGF-β1 Predicting Tumor Progression in Skull Base Chordomas |
| Q54354556 | High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event. |
| Q37670687 | High KRT8 expression promotes tumor progression and metastasis of gastric cancer |
| Q92240245 | High LINC00536 expression promotes tumor progression and poor prognosis in bladder cancer |
| Q58763910 | High LINC01605 expression predicts poor prognosis and promotes tumor progression via up-regulation of MMP9 in bladder cancer |
| Q52430776 | High MLL2 expression predicts poor prognosis and promotes tumor progression by inducing EMT in esophageal squamous cell carcinoma. |
| Q64075768 | High Membranous Expression of Fatty Acid Transport Protein 4 Is Associated with Tumorigenesis and Tumor Progression in Clear Cell Renal Cell Carcinoma |
| Q36441522 | High MicroRNA-370 Expression Correlates with Tumor Progression and Poor Prognosis in Breast Cancer |
| Q55310865 | High NUCB2 expression level is associated with metastasis and may promote tumor progression in colorectal cancer. |
| Q61450101 | High PLK4 expression promotes tumor progression and induces epithelial‑mesenchymal transition by regulating the Wnt/β‑catenin signaling pathway in colorectal cancer |
| Q94552617 | High PRMT5 expression is associated with poor overall survival and tumor progression in bladder cancer |
| Q79924753 | High Pin1 expression is associated with tumor progression in colorectal cancer |
| Q36162776 | High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells. |
| Q36742080 | High c-Cbl expression in gliomas is associated with tumor progression and poor prognosis |
| Q90627144 | High calpain-1 expression predicts a poor clinical outcome and contributes to tumor progression in pancreatic cancer patients |
| Q27853357 | High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma. |
| Q48263052 | High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers |
| Q38954408 | High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer |
| Q33913978 | High expression of B7-H6 in human glioma tissues promotes tumor progression |
| Q92142683 | High expression of CDCA7 predicts tumor progression and poor prognosis in human colorectal cancer |
| Q64914231 | High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC. |
| Q86509597 | High expression of FOXP3 in primary melanoma is associated with tumour progression |
| Q41471375 | High expression of GPR116 indicates poor survival outcome and promotes tumor progression in colorectal carcinoma |
| Q91896209 | High expression of MLANA in the plasma of patients with head and neck squamous cell carcinoma as a predictor of tumor progression |
| Q38713836 | High expression of RBM8A predicts poor patient prognosis and promotes tumor progression in hepatocellular carcinoma. |
| Q89784137 | High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma |
| Q53129560 | High expression of Rab3D predicts poor prognosis and associates with tumor progression in colorectal cancer. |
| Q36057106 | High expression of S100P is associated with unfavorable prognosis and tumor progression in patients with epithelial ovarian cancer |
| Q91482084 | High expression of SHMT2 is correlated with tumor progression and predicts poor prognosis in gastrointestinal tumors |
| Q89484932 | High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancer |
| Q59339872 | High expression of Tob1 indicates poor survival outcome and promotes tumour progression via a Wnt positive feedback loop in colon cancer |
| Q53961022 | High expression of WWP1 predicts poor prognosis and associates with tumor progression in human colorectal cancer. |
| Q91167959 | High expression of agrin is associated with tumor progression and poor prognosis in hepatocellular carcinoma |
| Q38708301 | High expression of atonal homolog 8 predicts a poor clinical outcome in patients with colorectal cancer and contributes to tumor progression |
| Q37021243 | High expression of substance P and its receptor neurokinin-1 receptor in colorectal cancer is associated with tumor progression and prognosis |
| Q91040058 | High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas |
| Q44281904 | High expression of the proliferation and apoptosis associated CSE1L/CAS gene in hepatitis and liver neoplasms: correlation with tumor progression. |
| Q49973501 | High fat diet and leptin promote tumor progression by inducing myeloid-derived suppressor cells. |
| Q54405771 | High interstitial fluid pressure promotes tumor progression through inducing lymphatic metastasis-related protein expressions in oral squamous cell carcinoma. |
| Q24623958 | High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance |
| Q85804519 | High levels of phosphatase and tensin homolog expression are associated with tumor progression, tumor recurrence, and systemic metastases in pT1 urothelial carcinoma of the bladder: a tissue microarray study of 156 patients treated by transurethral |
| Q55216970 | High lncRNA HULC expression is associated with poor prognosis and promotes tumor progression by regulating epithelial-mesenchymal transition in prostate cancer. |
| Q27308667 | High milk consumption does not affect prostate tumor progression in two mouse models of benign and neoplastic lesions |
| Q34040079 | High mobility group I/Y: multifunctional chromosomal proteins causally involved in tumor progression and malignant transformation (review). |
| Q37052716 | High rates of chromosome missegregation suppress tumor progression but do not inhibit tumor initiation |
| Q101122011 | High serum CCL20 is associated with tumor progression in penile cancer |
| Q37520349 | High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer |
| Q44001281 | High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia |
| Q77068395 | High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression |
| Q90192070 | High-Dose Dexamethasone Manipulates the Tumor Microenvironment and Internal Metabolic Pathways in Anti-Tumor Progression |
| Q46209851 | High-LET Radiation Increases Tumor Progression in a K-Ras-Driven Model of Lung Adenocarcinoma. |
| Q33706519 | High-grade transformation of low-grade non-Hodgkin's lymphomas: mechanisms of tumor progression |
| Q92991529 | Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression |
| Q35213325 | Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions |
| Q92644443 | Highlight report: Role of choline phospholipid metabolism in tumor progression |
| Q67770379 | Histologic Grade, DNA Ploidy, and Intraglandular Tumor Extent as Indicators of Tumor Progression of Clinical Stage B Prostatic Carcinoma |
| Q36229751 | Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell |
| Q80379673 | Histological changes pertinent to local tumor progression in hereditary nonpolyposis colorectal cancer (HNPCC). A preliminary report |
| Q73302710 | Histological characteristics of tumors in blood vessels play an important role in tumor progression of invasive ductal carcinoma of the breast |
| Q58204764 | Histological features pertinent to local tumour progression in Barrett's adenocarcinoma |
| Q89531420 | Histone Demethylase JMJD1A Promotes Tumor Progression via Activating Snail in Prostate Cancer |
| Q100693708 | Histone H3.3 G34 mutations promote aberrant PRC2 activity and drive tumor progression |
| Q90641503 | Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1β/VEGFA signalling |
| Q37271084 | Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: initial results. |
| Q64912248 | HnRNPL promotes Wilms tumor progression by regulating the p53 and Bcl2 pathways. |
| Q40759189 | Homologous blood transfusion in patients with prostate cancer: no effect on tumor progression or survival |
| Q28611377 | Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance |
| Q46847965 | Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient |
| Q61813049 | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells Via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| Q36140810 | Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner. |
| Q38643054 | Hormonal control of carcinogenesis and tumor progression. |
| Q58786597 | Hornerin promotes tumor progression and is associated with poor prognosis in hepatocellular carcinoma |
| Q91858994 | Host IDO2 Gene Status Influences Tumor Progression and Radiotherapy Response in KRAS-Driven Sporadic Pancreatic Cancers |
| Q43976271 | Host circadian clock as a control point in tumor progression. |
| Q48292682 | Hostile takeover: glioma stem cells recruit TAMs to support tumor progression |
| Q37561867 | How Little Is Too Much? - How Transient Tumor-Stromal Crosstalk Can Control Tumor Progression. |
| Q41852683 | How do benign myoepithelial cells from in situ areas of carcinoma ex-pleomorphic adenoma favor tumor progression? |
| Q91973843 | How the ageing microenvironment influences tumour progression |
| Q92023434 | How tissue fluidity influences brain tumor progression |
| Q104129744 | Hsa_circ_0079480 promotes tumor progression in acute myeloid leukemia via miR-654-3p/HDGF axis |
| Q94446559 | Hsp90 facilitates acquired drug resistance of tumor cells through cholesterol modulation however independent of tumor progression |
| Q35698941 | Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression |
| Q37631040 | Human breast adipose tissue: characterization of factors that change during tumor progression in human breast cancer. |
| Q70275583 | Human cutaneous nevi transplanted onto nude mice: a model for the study of the lesional steps in tumor progression |
| Q38760685 | Human cytomegalovirus may promote tumour progression by upregulating arginase-2. |
| Q40868885 | Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression |
| Q71394615 | Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression |
| Q68475487 | Human neuroblastoma metastases in a nude mouse model: tumor progression and onc gene amplification |
| Q38310066 | Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. |
| Q34588630 | Human placental trophoblast as an in vitro model for tumor progression |
| Q38328491 | Human prostate cancer in a clinically relevant xenograft mouse model: identification of β(1,6)-branched oligosaccharides as a marker of tumor progression |
| Q35088390 | Human subperitoneal fibroblast and cancer cell interaction creates microenvironment that enhances tumor progression and metastasis |
| Q42066713 | Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. |
| Q95661166 | Humanin Promotes Tumor Progression in Experimental Triple Negative Breast Cancer |
| Q34026088 | Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis |
| Q36116059 | Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells |
| Q39599761 | Hyaluronan-CD44 interaction promotes microRNA signaling and RhoGTPase activation leading to tumor progression |
| Q38235802 | Hyaluronan-CD44 interaction promotes oncogenic signaling, microRNA functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. |
| Q37152303 | Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression |
| Q40396971 | Hyaluronate receptors: key players in growth, differentiation, migration and tumor progression. |
| Q91151731 | Hyaluronic Acid and Hyaluronidase: Accurate Tumor Markers and Tumor Progression Regulators |
| Q96429861 | Hydrogen therapy can be used to control tumor progression and alleviate the adverse events of medications in patients with advanced non-small cell lung cancer |
| Q48159837 | Hyperglycaemia and aberrated insulin signalling stimulate tumour progression via induction of the extracellular matrix component hyaluronan |
| Q50098159 | Hyperglycemia and aberrant O-GlcNAcylation: contributions to tumor progression. |
| Q43520655 | Hyperglycemia of tumor microenvironment modulates stage-dependent tumor progression and multidrug resistance: implication of cell survival regulatory molecules and altered glucose transport |
| Q47861773 | Hypothyroidism reduces mammary tumor progression via Β-catenin-activated intrinsic apoptotic pathway in rats |
| Q35723085 | Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis |
| Q35117865 | Hypoxia and free radicals: role in tumor progression and the use of engineering-based platforms to address these relationships |
| Q40078084 | Hypoxia and reoxygenation: a pressure for mutant p53 cell selection and tumour progression |
| Q38793165 | Hypoxia and tumor-associated macrophages: A deadly alliance in support of tumor progression |
| Q83390272 | Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target |
| Q88505553 | Hypoxia induced EMT: A review on the mechanism of tumor progression and metastasis in OSCC |
| Q39335098 | Hypoxia upregulates CD147 through a combined effect of HIF-1α and Sp1 to promote glycolysis and tumor progression in epithelial solid tumors. |
| Q33924693 | Hypoxia, clonal selection, and the role of HIF-1 in tumor progression |
| Q38121493 | Hypoxia, lactate accumulation, and acidosis: siblings or accomplices driving tumor progression and resistance to therapy? |
| Q51554659 | Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression. |
| Q95322326 | Hypoxia-induced GBE1 expression promotes tumor progression through metabolic reprogramming in lung adenocarcinoma |
| Q36688644 | Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression |
| Q77626770 | Hypoxia-induced, perinecrotic expression of endothelial Per-ARNT-Sim domain protein-1/hypoxia-inducible factor-2alpha correlates with tumor progression, vascularization, and focal macrophage infiltration in bladder cancer |
| Q35791446 | Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression |
| Q33382510 | Hypoxia-inducible factor 1 alpha expression increases during colorectal carcinogenesis and tumor progression |
| Q27025445 | Hypoxia-inducible factor-1: a possible link between inhalational anesthetics and tumor progression? |
| Q33908602 | Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer |
| Q34433163 | Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression |
| Q37062821 | Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. |
| Q81951836 | ICER expression inhibits leukemia phenotype and controls tumor progression |
| Q101242088 | IDH1-R132H-FAT1-ROS-HIF-1α Signaling Pathway Inhibits Glioblastoma Tumor Progression |
| Q73289660 | IFN-gamma-dependent delay of in vivo tumor progression by Fas overexpression on murine renal cancer cells |
| Q43521595 | IGF1 dependence of dietary energy balance effects on murine Met1 mammary tumor progression, epithelial-to-mesenchymal transition, and chemokine expression |
| Q104289805 | IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway |
| Q39590514 | IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma |
| Q53075829 | IL-17 and IL-4 producing CD8+ T cells in tumor draining lymph nodes of breast cancer patients: positive association with tumor progression. |
| Q35847817 | IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma |
| Q47870435 | IL-2 gene and antisense TGF-beta1 strategies counteract HSV-2 transformed tumor progression |
| Q39547267 | IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma |
| Q37564530 | IL-35 expression in hepatocellular carcinoma cells is associated with tumor progression |
| Q40503359 | IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer |
| Q41549864 | IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment |
| Q87956622 | IL18 receptors are required for IL-37-mediated epithelial ovarian tumor progression |
| Q41217881 | IL2 triggers a tumor progression process in a melanoma cell line MELP derived from a patient whose metastasis increased in size during IL2/INFalpha biotherapy |
| Q98578724 | IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression |
| Q94066437 | IMMU-18. PDL-1 EXPRESSION ON CIRCULATING CD68 (-) MONOCYTE-LIKE CELLS IN NF2 MENINGIOMA AS A BIOMARKER FOR TUMOR PROGRESSION |
| Q94408761 | IMMU-38. GLIOBLASTOMA-DERIVED IL-6 INDUCES IMMUNOSUPPRESSIVE PERIPHERAL MYELOID CELL PD-L1 EXPRESSION AND TUMOR PROGRESSION |
| Q41364326 | IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression |
| Q35956268 | IQGAP1 and IQGAP3 Serve Individually Essential Roles in Normal Epidermal Homeostasis and Tumor Progression |
| Q89464808 | ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma |
| Q64231142 | ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7 |
| Q53237230 | ITF2 prevents activation of the β-catenin-TCF4 complex in colon cancer cells and levels decrease with tumor progression. |
| Q35579455 | Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturation |
| Q112640190 | Identification of Carcinogenesis and Tumor Progression Processes in Pancreatic Ductal Adenocarcinoma Using High-Throughput Proteomics |
| Q112289932 | Identification of Glycolysis-Related lncRNAs and the Novel lncRNA WAC-AS1 Promotes Glycolysis and Tumor Progression in Hepatocellular Carcinoma |
| Q35077803 | Identification of SLAMF3 (CD229) as an inhibitor of hepatocellular carcinoma cell proliferation and tumour progression |
| Q102376585 | Identification of VRK1 as a New Neuroblastoma Tumor Progression Marker Regulating Cell Proliferation |
| Q41766631 | Identification of a G-CSF-Granulocytic MDSC axis that promotes tumor progression |
| Q41986525 | Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein |
| Q40992247 | Identification of a novel mechanism of regulation of the adherens junction by E1A, Rac1, and cortical actin filaments that contributes to tumor progression |
| Q35222185 | Identification of alterations in DNA copy number in host stromal cells during tumor progression |
| Q53299548 | Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. |
| Q54652719 | Identification of genes associated with tumor progression using microarrays. |
| Q38293825 | Identification of genes involved in epithelial-mesenchymal transition and tumor progression |
| Q47972934 | Identification of novel molecular markers which correlate with HPV-induced tumor progression |
| Q38678296 | Identification of tumor-autonomous and indirect effects of vitamin D action that inhibit breast cancer growth and tumor progression |
| Q43952583 | Identifying genetic changes associated with tumor progression in squamous cell carcinoma. |
| Q35602998 | Identifying restrictions in the order of accumulation of mutations during tumor progression: effects of passengers, evolutionary models, and sampling |
| Q112635958 | Identity of MMP1 and its effects on tumor progression in head and neck squamous cell carcinoma |
| Q47989008 | Imaging changes over 18 months following stereotactic radiosurgery for brain metastases: both late radiation necrosis and tumor progression can occur. |
| Q91551491 | Imaging of Preclinical Endometrial Cancer Models for Monitoring Tumor Progression and Response to Targeted Therapy |
| Q41815158 | Imiquimod Induces Apoptosis in Human Endometrial Cancer Cells In vitro and Prevents Tumor Progression In vivo |
| Q50036604 | Immediate Post-ablation FDG-injection and corresponding Standardized Uptake Value is a Surrogate Biomarker of Local Tumor Progression after Thermal Ablation of Colorectal Carcinoma Liver Metastases. |
| Q30951772 | Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression |
| Q44513920 | Immortalization of a human colorectal adenoma cell line by continuous in vitro passage: Possible involvement of chromosome 1 in tumour progression |
| Q90832794 | Immune Escape during Breast Tumor Progression |
| Q103836754 | Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma |
| Q36178400 | Immune microenvironment in tumor progression: characteristics and challenges for therapy |
| Q41450328 | Immunity to Murine Sarcoma Virus Induced Tumours. III. Analysis of the Cell Populations Involved in Protection from Lethal Tumour Progression of Sublethally Irradiated, MSV Inoculated, Mice |
| Q72875303 | Immunoendocrine mechanisms in mammary tumor progression: direct prolactin modulation of peripheral and preneoplastic hyperplastic-alveolar-nodule- infiltrating lymphocytes |
| Q55055409 | Immunoglobulin G Fc N-glycan profiling in patients with gastric cancer by LC-ESI-MS: relation to tumor progression and survival. |
| Q35955383 | Immunoglobulin-like transcript 4 promotes tumor progression and metastasis and up-regulates VEGF-C expression via ERK signaling pathway in non-small cell lung cancer |
| Q61700546 | Immunohistochemical Expression of Hsp60 Correlates With Tumor Progression and Hormone Resistance in Prostate Cancer |
| Q43907575 | Immunohistochemical analysis of cyclooxygenase (COX)-2 expression in pancreatic endocrine tumors: association with tumor progression and proliferation |
| Q38305893 | Immunohistochemical analysis of nm23/NDP kinase expression in human lung adenocarcinoma: association with tumor progression in Clara cell type |
| Q46129430 | Immunohistochemical detection of p53 protein expression in various childhood astrocytoma subtypes: significance in tumor progression |
| Q77169120 | Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome |
| Q39423531 | Immunohistochemical expression of TLR4 and TLR9 in various grades of oral epithelial dysplasia and squamous cell carcinoma, and their roles in tumor progression: a pilot study |
| Q44679606 | Immunohistochemical expression of cycloxygenase-2 in astrocytoma: correlation with angiogenesis, tumor progression and survival |
| Q45204419 | Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents |
| Q38483630 | Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression |
| Q92662565 | Immunologic and immunogenomic aspects of tumor progression |
| Q38840291 | Immunological Consequences of Epithelial-Mesenchymal Transition in Tumor Progression. |
| Q58731797 | Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression |
| Q42467556 | Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. |
| Q36333541 | Immunosenescence, suppression and tumour progression |
| Q58561592 | Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression |
| Q39402703 | Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice |
| Q55031317 | Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy. |
| Q64934586 | Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes. |
| Q50066860 | Impact of Prior Hepatectomy History on Local Tumor Progression after Percutaneous Ablation of Colorectal Liver Metastases. |
| Q64890463 | Impact of cell fusion in myeloma marrow microenvironment on tumor progression. |
| Q46200660 | Impact of inducible nitric oxide synthase gene on tumor progression |
| Q35204983 | Impact of proapoptotic proteins Bax and Bak in tumor progression and response to treatment |
| Q69696872 | Impact of the category of early tumor recurrence on tumor progression in bladder tumors treated by transurethral resection |
| Q29299789 | Impact of the physical microenvironment on tumor progression and metastasis |
| Q37103785 | Impact of tumor progression on cancer incidence curves |
| Q33845565 | Impact of tumor-associated macrophages in LH(BETA)T(AG) mice on retinal tumor progression: relation to macrophage subtype |
| Q34015084 | Impacts of cytosolic phospholipase A2, 15-prostaglandin dehydrogenase, and cyclooxygenase-2 expressions on tumor progression in colorectal cancer |
| Q114107457 | Impairment of IgG Fc functions promotes tumor progression and suppresses NK cell antitumor actions |
| Q24306324 | Impairment of cytoplasmic eIF6 activity restricts lymphomagenesis and tumor progression without affecting normal growth |
| Q64075361 | Implication of Voltage-Gated Potassium Channels in Neoplastic Cell Proliferation |
| Q35802796 | Implication of duration of clinical presentation on tumor progression and short-term recurrence in patients with early breast cancer |
| Q80880961 | Implication of tumstatin in tumor progression of human bronchopulmonary carcinomas |
| Q34092195 | Implications of Proprotein Convertases in Ovarian Cancer Cell Proliferation and Tumor Progression: Insights for PACE4 as a Therapeutic Target. |
| Q38151113 | Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression |
| Q104563386 | Implications of androgen receptor and FUS expression on tumor progression in urothelial carcinoma |
| Q42554040 | Implications of quantum metabolism and natural selection for the origin of cancer cells and tumor progression |
| Q39831938 | Implications of tumor progression on clinical oncology |
| Q97591360 | Importance of Aberrantly Activated Hedgehog/Gli Pathway in Tumour Progression |
| Q80305797 | Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients |
| Q98626182 | Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma |
| Q92931036 | Important roles of protein tyrosine phosphatase PTPN12 in tumor progression |
| Q40400350 | Improved Brain Tumor Classification by Sodium MR Imaging: Prediction of IDH Mutation Status and Tumor Progression |
| Q98566692 | In Vitro Models for Studying Tumor Progression |
| Q48184127 | In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression. |
| Q43763789 | In reply: maspin and it's evolving role in tumor progression in systemic malignancies. |
| Q78450503 | In situ analysis of telomerase RNA gene expression as a marker for tumor progression |
| Q54701349 | In situ gelatinolytic activity correlates with tumor progression and prognosis in patients with bladder cancer. |
| Q41654403 | In vitro maintenance of a new ovarian cancer cell line in protein-free media: a potential model for autonomous growth and tumor progression |
| Q41202507 | In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines |
| Q40837496 | In vitro transformation and tumor progression. |
| Q35904176 | In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression |
| Q41604029 | In vivo generation and selection of variants with altered sensitivity to natural resistance (NR): a model of tumor progression |
| Q39741959 | In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance |
| Q84040479 | In vivo monitoring of splenocytes in NMRI nu/nu- and nu/+,- mice during Lewis lung tumor progression or regression |
| Q38993947 | In vivo rat model to study horizontal tumor progression |
| Q47408555 | In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. |
| Q73069065 | In vivo transfer of bacterial marker genes results in differing levels of gene expression and tumor progression in immunocompetent and immunodeficient mice |
| Q89626915 | Inactivation of endothelial ZEB1 impedes tumor progression and sensitizes tumors to conventional therapies |
| Q24647958 | Inactivation of the UNC5C Netrin-1 receptor is associated with tumor progression in colorectal malignancies |
| Q43203616 | Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo |
| Q78206871 | Inactivation of the p53 pathway in prostate cancer: impact on tumor progression |
| Q36361484 | Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis. |
| Q71566792 | Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression |
| Q90958816 | Increase in Carbohydrate Antigen 19-9 Levels without Tumor Progression after Polaprezinc Administration that Induced Deep Vein Thrombosis in a Colon Cancer Patient |
| Q39002181 | Increase in IkappaB kinase alpha expression suppresses the tumor progression and improves the prognosis for nasopharyngeal carcinoma |
| Q68054749 | Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasis |
| Q28536329 | Increase in sialylation and branching in the mouse serum N-glycome correlates with inflammation and ovarian tumour progression |
| Q71805120 | Increase in suprabasilar integrin adhesion molecule expression in human epidermal neoplasms accompanies increased proliferation occurring with immortalization and tumor progression |
| Q84072085 | Increased CD4(+) CD69(+) CD25(-) T cells in patients with hepatocellular carcinoma are associated with tumor progression |
| Q40450069 | Increased Expression of FGF19 Contributes to Tumor Progression and Cell Motility of Human Thyroid Cancer. |
| Q38347973 | Increased Expression of Thomsen-Friedenreich Antigens during Tumor Progression in Breast Cancer Patients |
| Q104576960 | Increased Expression of miR-487b Is Associated With Poor Prognosis and Tumor Progression of HBV-Related Hepatocellular Carcinoma |
| Q73782280 | Increased apoptosis during papilloma development in mice susceptible to tumor progression |
| Q48712650 | Increased argonaute 2 expression in gliomas and its association with tumor progression and poor prognosis. |
| Q100488909 | Increased canonical NF-kappaB signaling specifically in macrophages is sufficient to limit tumor progression in syngeneic murine models of ovarian cancer |
| Q74060895 | Increased cellularity of tumor-encased native vessels in prostate carcinoma is a marker for tumor progression |
| Q47421892 | Increased circulating Th22 and Th17 cells are associated with tumor progression and patient survival in human gastric cancer |
| Q42831221 | Increased detection of specific tyrosine phosphoproteins correlates with tumor progression of Abelson virus-infected lymphocytes |
| Q62621444 | Increased expression and altered intracellular distribution of adhesion/growth-regulatory lectins galectins-1 and -7 during tumour progression in hypopharyngeal and laryngeal squamous cell carcinomas |
| Q35679527 | Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma. |
| Q53262282 | Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma. |
| Q53669529 | Increased expression of CD55 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. |
| Q53445623 | Increased expression of G1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. |
| Q40213412 | Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms |
| Q36761921 | Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer |
| Q36916003 | Increased expression of TRPS1 affects tumor progression and correlates with patients' prognosis of colon cancer. |
| Q84055426 | Increased expression of a disintegrin and metalloprotease-9 in hepatocellular carcinoma: implications for tumor progression and prognosis |
| Q42442579 | Increased expression of cytokeratins 14, 18 and 19 correlates with tumor progression in the uterine cervix |
| Q80391930 | Increased expression of h-prune is associated with tumor progression and poor survival in gastric cancer |
| Q38305393 | Increased expression of insulin-like growth factor-II messenger RNA-binding protein 1 is associated with tumor progression in patients with lung cancer |
| Q40385177 | Increased expression of interleukin-1alpha and cyclooxygenase-2 in human gastric cancer: a possible role in tumor progression. |
| Q64258640 | Increased expression of lncRNA CASC9 promotes tumor progression by suppressing autophagy-mediated cell apoptosis via the AKT/mTOR pathway in oral squamous cell carcinoma |
| Q57056008 | Increased expression of long non-coding RNA SNHG16 correlates with tumor progression and poor prognosis in non-small cell lung cancer |
| Q90119265 | Increased expression of miR-181d is associated with poor prognosis and tumor progression of gastric cancer |
| Q90235958 | Increased expression of miR-601 is associated with poor prognosis and tumor progression of gastric cancer |
| Q35038659 | Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma |
| Q77321925 | Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma |
| Q82617558 | Increased expressions of vascular endothelial growth factor (VEGF), VEGF-C and VEGF receptor-3 in prostate cancer tissue are associated with tumor progression |
| Q74115964 | Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas |
| Q104616122 | Increased fibrillarin expression is associated with tumor progression and an unfavorable prognosis in hepatocellular carcinoma |
| Q53472187 | Increased incidence of undifferentiated type of gastric cancer with tumor progression in 912 patients with early gastric cancer and 1245 with advanced gastric cancer. |
| Q38801879 | Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients |
| Q41595426 | Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment |
| Q39398949 | Increased miR-222 in H. pylori-associated gastric cancer correlated with tumor progression by promoting cancer cell proliferation and targeting RECK. |
| Q47435485 | Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. |
| Q71625765 | Increased numbers of argyrophilic nucleolar organizer regions between primary and metastatic sites predict tumor progression in stage IV and IV-S neuroblastoma |
| Q77220732 | Increased p53 mutation frequency during tumor progression--results from a breast cancer cohort |
| Q42829537 | Increased proteinase expression during tumor progression of cell lines down-modulated for TIMP levels: a new transformation paradigm? [corrected]. |
| Q73513608 | Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival |
| Q43916071 | Increased tumor-infiltrating CD8(+)Foxp3(+) T lymphocytes are associated with tumor progression in human gastric cancer |
| Q68205108 | Increasing Epidermal Growth Factor Receptor Expression in Human Melanocytic Tumor Progression |
| Q61627311 | Increasing levels of MYC and MET co-amplification during tumor progression of a case of gastric cancer |
| Q93357083 | Indicaxanthin from Opuntia Ficus Indica (L. Mill) impairs melanoma cell proliferation, invasiveness, and tumor progression |
| Q120204235 | Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression |
| Q37690882 | Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression |
| Q40708002 | Induction and inhibition of tumor progression |
| Q35798927 | Induction of antigen-specific T cell anergy: An early event in the course of tumor progression |
| Q68088600 | Induction of oncofetal antigen-specific suppressor pathways, involving Thy-1+ cells, during the early stages of tumor progression |
| Q68944818 | Induction of thymidine kinase activity in a spontaneously enzyme-deficient murine tumor cell line by exposure in vivo to the DNA-hypomethylating agent 5-aza-2'-deoxycytidine: implications for mechanisms of tumor progression |
| Q104130290 | Infectious disease and sickness behaviour: tumour progression affects interaction patterns and social network structure in wild Tasmanian devils |
| Q31003390 | Inferring a tumor progression model for neuroblastoma from genomic data |
| Q28749457 | Inferring tumor progression from genomic heterogeneity |
| Q100508783 | Inferring tumor progression in large datasets |
| Q35843361 | Infiltration of neutrophils is required for acquisition of metastatic phenotype of benign murine fibrosarcoma cells: implication of inflammation-associated carcinogenesis and tumor progression |
| Q30414501 | Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression |
| Q36732552 | Inflammation and Hras signaling control epithelial-mesenchymal transition during skin tumor progression. |
| Q46060755 | Inflammation and tumor progression: a lesson from TNF-alpha-dependent FAK signaling in cholangiocarcinoma |
| Q91525197 | Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy |
| Q40338318 | Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression |
| Q39787551 | Inflammation, immune suppression, and tumor progression |
| Q38869361 | Inflammation-Related Tumor Progression in Murine Fibrosarcoma Exhibited Over-expression of Sex-determining Region Y-box 2 (Sox2) Compared to Parental Regressor Cells. |
| Q70383933 | Inflammatory cell infiltrates in human melanoma at different stages of tumor progression |
| Q36618294 | Inflammatory cell-mediated tumour progression and minisatellite mutation correlate with the decrease of antioxidative enzymes in murine fibrosarcoma cells |
| Q37968688 | Inflammatory mediators hold the key to dendritic cell suppression and tumor progression |
| Q34185536 | Influence of ablative margin on local tumor progression and survival in patients with HCC ≤4 cm after laser ablation |
| Q36623274 | Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer |
| Q71010898 | Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice |
| Q48564563 | Influence of methotrexate and cisplatin on tumor progression and survival in the VM mouse model of systemic metastatic cancer. |
| Q38764411 | Inhibiting DX2-p14/ARF Interaction Exerts Antitumor Effects in Lung Cancer and Delays Tumor Progression |
| Q90838595 | Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma |
| Q35760817 | Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression |
| Q46967437 | Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression |
| Q40561055 | Inhibition of B16BL6 tumor progression by coadministration of recombinant angiostatin K1-3 and endostatin genes with cationic liposomes |
| Q47365099 | Inhibition of CIP2A attenuates tumor progression by inducing cell cycle arrest and promoting cellular senescence in hepatocellular carcinoma |
| Q39291599 | Inhibition of Cdc42-interacting protein 4 (CIP4) impairs osteosarcoma tumor progression |
| Q42160926 | Inhibition of LDHA suppresses tumor progression in prostate cancer |
| Q40038407 | Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis |
| Q91387331 | Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma |
| Q35088031 | Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model |
| Q43131752 | Inhibition of TC-1 tumor progression by cotransfection of Saxatilin and IL-12 genes mediated by lipofection or electroporation |
| Q39758292 | Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma |
| Q40330266 | Inhibition of angiogenesis and tumor progression by hydrodynamic cotransfection of angiostatin K1-3, endostatin, and saxatilin genes |
| Q74717016 | Inhibition of apoptosis in human breast cancer cells: role in tumor progression to the metastatic state |
| Q45886218 | Inhibition of breast tumor progression by systemic delivery of the maspin gene in a syngeneic tumor model |
| Q73013865 | Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus |
| Q36754457 | Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression. |
| Q39885220 | Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma |
| Q37731507 | Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer |
| Q28272474 | Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression |
| Q39677173 | Inhibition of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation blocks tumor progression in mice. |
| Q39758471 | Inhibition of nuclear factor kappa B attenuates tumour progression in an animal model of renal cell carcinoma |
| Q53330585 | Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. |
| Q91283008 | Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma |
| Q90787927 | Inhibition of stearoyl CoA desaturase-1 activity suppresses tumour progression and improves prognosis in human bladder cancer |
| Q112351439 | Inhibition of tumor progression and M2 microglial polarization by extracellular vesicle-mediated microRNA-124 in a 3D microfluidic glioblastoma microenvironment |
| Q44293592 | Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats |
| Q46990341 | Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin |
| Q37936436 | Inhibition of tumor progression by naturally occurring terpenoids |
| Q50438098 | Inhibition of tumor progression by oral piceatannol in mouse 4T1 mammary cancer is associated with decreased angiogenesis and macrophage infiltration. |
| Q37433487 | Inhibition of tumor progression by suppression of stress protein GRP78/BiP induction in fibrosarcoma B/C10ME. |
| Q35967977 | Inhibition of tumor progression during allergic airway inflammation in a murine model: significant role of TGF-β. |
| Q39683710 | Inhibition of tumor progression locus 2 protein kinase decreases lipopolysaccharide-induced tumor necrosis factor alpha production due to the inhibition of the tip-associated protein induction in RAW264.7 cells |
| Q39756438 | Inhibition of tumor progression locus 2 protein kinase suppresses receptor activator of nuclear factor-kappaB ligand-induced osteoclastogenesis through down-regulation of the c-Fos and nuclear factor of activated T cells c1 genes |
| Q50668664 | Inhibitors of tumor progression loci-2 (Tpl2) kinase and tumor necrosis factor alpha (TNF-alpha) production: selectivity and in vivo antiinflammatory activity of novel 8-substituted-4-anilino-6-aminoquinoline-3-carbonitriles. |
| Q53306400 | Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. |
| Q38785018 | Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma |
| Q92379096 | Innate immunity, inflammation and tumour progression: double-edged swords |
| Q44676780 | Insular glioma resection: assessment of patient morbidity, survival, and tumor progression |
| Q33934670 | Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy |
| Q92230122 | Insulin receptor isoform A favors tumor progression in human hepatocellular carcinoma by increasing stem/progenitor cell features |
| Q33688576 | Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression |
| Q35832157 | Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators |
| Q33968921 | Integrated genomics of ovarian xenograft tumor progression and chemotherapy response |
| Q91068791 | Integrative Epigenetic and Gene Expression Analysis of Renal Tumor Progression to Metastasis |
| Q49583565 | Integrin Alpha V Beta 3 Targeted Dendrimer-Rapamycin Conjugate Reduces Fibroblast-Mediated Prostate Tumor Progression and Metastasis. |
| Q68547014 | Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression |
| Q70670741 | Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression |
| Q35906078 | Integrin signalling during tumour progression |
| Q38908887 | Integrin trafficking and tumor progression |
| Q91506210 | Integrin α11 in non-small cell lung cancer is associated with tumor progression and postoperative recurrence |
| Q40973841 | Integrin α5 promotes tumor progression and is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma |
| Q37505641 | Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer |
| Q43122600 | Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. |
| Q40529437 | Integrins and other adhesion molecules involved in melanocytic tumor progression |
| Q72577683 | Integrins and tumour progression |
| Q36140759 | Intelectin 1 suppresses tumor progression and is associated with improved survival in gastric cancer |
| Q58772874 | Interaction between Tumor-Associated Dendritic Cells and Colon Cancer Cells Contributes to Tumor Progression via CXCL1 |
| Q40380902 | Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance |
| Q64268061 | Interaction of tumor-associated macrophages and cancer chemotherapy |
| Q41508300 | Interactive effects of nitric oxide and the p53 tumor suppressor gene in carcinogenesis and tumor progression |
| Q37350929 | Interferon-Gamma Receptor Signaling Plays an Important Role in Restraining Murine Ovarian Tumor Progression |
| Q91040277 | Interim Tumor Progression and Volumetric Changes of Surgical Cavities during the Surgery-to-Radiotherapy Interval in Anaplastic Gliomas: Implications for Additional Pre-radiotherapy Magnetic Resonance Imaging |
| Q37228532 | Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression |
| Q28390678 | Interleukin enhancer-binding factor 3 promotes breast tumor progression by regulating sustained urokinase-type plasminogen activator expression |
| Q38637324 | Interleukin-1-induced changes in the glioblastoma secretome suggest its role in tumor progression |
| Q38930857 | Interleukin-17 and interleukin-22 promote tumor progression in human nonmelanoma skin cancer. |
| Q50929994 | Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity. |
| Q38797202 | Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade |
| Q62735594 | Interleukin-17A is involved in enhancement of tumor progression in murine intestine |
| Q86725828 | Interleukin-17FT7488 allele is associated with a decreased risk of colorectal cancer and tumor progression |
| Q33648885 | Interleukin-22 promotes aerobic glycolysis associated with tumor progression via targeting hexokinase-2 in human colon cancer cells |
| Q39018065 | Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis |
| Q41730916 | Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment |
| Q90032301 | Interleukin-35 Expression in Non-Small Cell Lung Cancer is Associated with Tumor Progression |
| Q37582274 | Interleukin-6 promotes tumor progression in colitis-associated colorectal cancer through HIF-1α regulation |
| Q44984368 | Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. |
| Q40419858 | Intermediate biomarkers in the colorectal tumor progression |
| Q89556053 | Intermittent hypoxia exacerbates tumor progression in a mouse model of lung cancer |
| Q73923528 | Interphase cytogenetics of prostatic tumor progression: specific chromosomal abnormalities are involved in metastasis to the bone |
| Q99400968 | Interplay between HMGA and TP53 in cell cycle control along tumor progression |
| Q30427503 | Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression |
| Q28818464 | Interstitial Inorganic Phosphate as a Tumor Microenvironment Marker for Tumor Progression |
| Q34130340 | Interstitial collagenases as markers of tumor progression |
| Q81307171 | Interval period tumor progression: does delayed hepatectomy detect occult metastases in synchronous colorectal liver metastases? |
| Q98305219 | Intervening Tumor Progression by Coupling Bacteria Respiration with Tumor Metabolism |
| Q28579165 | Intestinal tumor progression is associated with altered function of KLF5 |
| Q39985739 | Intestinal tumor progression is promoted by decreased apoptosis and dysregulated Wnt signaling in Ceacam1-/- mice |
| Q28066445 | Intra- and Extra-Cellular Events Related to Altered Glycosylation of MUC1 Promote Chronic Inflammation, Tumor Progression, Invasion, and Metastasis |
| Q57640952 | Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection |
| Q94523982 | Intracellular Entropy-driven Multi-bit DNA Computing for Tumor Progression Discrimination |
| Q36180381 | Intracellular Iron Chelation Modulates the Macrophage Iron Phenotype with Consequences on Tumor Progression |
| Q89839785 | Intracellular matrix Gla protein promotes tumor progression by activating JAK2/STAT5 signaling in gastric cancer |
| Q36658322 | Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. |
| Q89950790 | Intracranial glioma xenograft model rapidly reestablishes blood-brain barrier integrity for longitudinal imaging of tumor progression using fluorescence molecular tomography and contrast agents |
| Q92048587 | Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis |
| Q58024996 | Intranuclear post-transcriptional down-regulation responsible for loss of a keratin differentiation marker in tumour progression |
| Q92731874 | Intraprocedural contrast-enhanced ultrasound-CT/MR fusion imaging assessment in HCC thermal ablation to reduce local tumor progression: compared with routine contrast-enhanced ultrasound |
| Q39578441 | Intratumor RNA interference of cell cycle genes slows down tumor progression |
| Q35065519 | Intratumor heterogeneity in evolutionary models of tumor progression |
| Q98885193 | Intratumoral Distribution of Lactate and the Monocarboxylate Transporters 1 and 4 in Human Glioblastoma Multiforme and Their Relationships to Tumor Progression-Associated Markers |
| Q39740382 | Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients |
| Q44049203 | Intratumoral dihydropyrimidine dehydrogenase messenger RNA level reflects tumor progression in human colorectal cancer |
| Q39962735 | Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. |
| Q39663267 | Intratumoral macrophage counts correlate with tumor progression in colorectal cancer |
| Q53715480 | Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. |
| Q81401644 | Intravesical bacille calmette-guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression |
| Q72240695 | Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial |
| Q26745311 | Intravital imaging reveals new ancillary mechanisms co-opted by cancer cells to drive tumor progression |
| Q50104763 | Invasive Pituitary Adenoma-Derived Tumor-Associated Fibroblasts Promote Tumor Progression both In Vitro and In Vivo. |
| Q47987124 | Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. |
| Q33291801 | Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression |
| Q90429110 | Investigation of solid tumor progression with account of proliferation/migration dichotomy via Darwinian mathematical model |
| Q42438664 | Involucrin and tumor progression in the uterine cervix |
| Q61814609 | Involvement of -glycan in Multiple Receptor Tyrosine Kinases Targeted by Ling-Zhi-8 for Suppressing HCC413 Tumor Progression |
| Q27001182 | Involvement of 14-3-3 Proteins in Regulating Tumor Progression of Hepatocellular Carcinoma |
| Q88641332 | Involvement of FFA1 and FFA4 in the regulation of cellular functions during tumor progression in colon cancer cells |
| Q39652862 | Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation |
| Q79077062 | Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas |
| Q41588566 | Involvement of cell motility in tumor progression. |
| Q53876189 | Involvement of chemokine receptor 4/stromal cell-derived factor 1 system during osteosarcoma tumor progression. |
| Q40835141 | Involvement of epidermal growth factor receptor in chemically induced mouse bladder tumour progression |
| Q91609211 | Involvement of exchange protein directly activated by cAMP and tumor progression locus 2 in IL-1β production in microglial cells following activation of β-adrenergic receptors |
| Q73899352 | Involvement of heparanase in tumor progression and normal differentiation |
| Q38229393 | Involvement of platelet-derived microparticles in tumor progression and thrombosis |
| Q46672355 | Involvement of reactive nitrogen oxides for acquisition of metastatic properties of benign tumors in a model of inflammation-based tumor progression |
| Q35703715 | Involvement of stromal proteoglycans in tumour progression |
| Q46148645 | Involvement of thyroid hormones in the alterations of T-cell immunity and tumor progression induced by chronic stress. |
| Q39653835 | In vivo inhibition of tumor progression by 5 hydroxy-1,4-naphthoquinone (juglone) and 2-(4-hydroxyanilino)-1,4-naphthoquinone (Q7) in combination with ascorbate. |
| Q61796322 | Iron as a Central Player and Promising Target in Cancer Progression |
| Q44887846 | Irradiated tumor cell vaccine for treatment of an established glioma. II. Expansion of myeloid suppressor cells that promote tumor progression |
| Q37073819 | Irs2 inactivation suppresses tumor progression in Pten+/- mice |
| Q80556193 | Is breast tumor progression really linear? |
| Q24791429 | Is cumulative frequency of mitochondrial DNA variants a biomarker for colorectal tumor progression? |
| Q82599919 | Is extramedullary plasmacytoma an oligoclonal tumour with clonal selection during tumour progression? |
| Q90777200 | Is the Simpson Grading System Applicable to Estimate the Risk of Tumor Progression After Microsurgery for Recurrent Intracranial Meningioma? |
| Q35088750 | Isolation and preliminary characterisation of cDNA clones representing mRNAs associated with tumour progression and metastasis in colorectal cancer |
| Q90644178 | Isotope tracing assisted metabolic profiling: Application to understanding HSP60 silencing mediated tumor progression |
| Q54432756 | Isozyme patterns of hepatomas and tumour progression. |
| Q84035856 | It is possible that tumour-infiltrating granulocytes promote tumour progression |
| Q53435093 | JNK and Yorkie drive tumor progression by generating polyploid giant cells in Drosophila. |
| Q90024073 | JNK2 silencing and caspase-9 activation by hyperosmotic polymer inhibits tumor progression |
| Q98617462 | Jaceidin Flavonoid Isolated from Chiliadenus montanus Attenuates Tumor Progression in Mice via VEGF Inhibition: In Vivo and In Silico Studies |
| Q112696028 | Junctional adhesion molecule-like protein promotes tumor progression via the Wnt/β-catenin signaling pathway in lung adenocarcinoma |
| Q98574018 | Junctional adhesion molecules in cancer: a paradigm for the diverse functions of cell-cell interactions in tumor progression |
| Q37500984 | K63-polyubiquitinated HAUSP deubiquitinates HIF-1α and dictates H3K56 acetylation promoting hypoxia-induced tumour progression |
| Q96353468 | KDELR2 is an unfavorable prognostic biomarker and regulates CCND1 to promote tumor progression in glioma |
| Q58612654 | KIF14 promotes tumor progression and metastasis and is an independent predictor of poor prognosis in human gastric cancer |
| Q91411912 | KIF18B as a regulator in microtubule movement accelerates tumor progression and triggers poor outcome in lung adenocarcinoma |
| Q96687256 | KIF18B promotes tumor progression in osteosarcoma by activating β-catenin |
| Q52595286 | KIF18B promotes tumor progression through activating the Wnt/β-catenin pathway in cervical cancer. |
| Q97644876 | KIF20A Predicts Poor Survival of Patients and Promotes Colorectal Cancer Tumor Progression through the JAK/STAT3 Signaling Pathway |
| Q39644642 | KITENIN is associated with tumor progression in human gastric cancer. |
| Q26742030 | KSHV-Mediated Angiogenesis in Tumor Progression |
| Q92304183 | Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer |
| Q53532150 | Karyotype instability of Chinese hamster cells during in vivo tumor progression. |
| Q81119310 | Karyotypic evolution and tumor progression in head and neck squamous cell carcinomas |
| Q42507936 | Keratin 17 expression correlates with tumor progression and poor prognosis in gastric adenocarcinoma |
| Q90383752 | Ketohexokinase is involved in fructose utilization and promotes tumor progression in glioma |
| Q55478989 | Ki-67 as a marker of proliferation activity in tumor progression of recurrent gliomas of supratentorial localization. Immunocytochemical quantitative studies. |
| Q43412232 | Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma |
| Q84880766 | Kidney cancer: Is incomplete renal ablation linked to tumour progression? |
| Q24298749 | Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF |
| Q39354689 | Kinesin spindle protein SiRNA slows tumor progression |
| Q64889885 | Kinetic profiles of intraepithelial and invasive prostatic neoplasias: the key role of down-regulated apoptosis in tumor progression. |
| Q47139880 | Klf4 reduces stemness phenotype, triggers mesenchymal-epithelial transition (MET)-like molecular changes, and prevents tumor progression in nasopharygeal carcinoma |
| Q38705908 | Klotho suppresses tumor progression via inhibiting IGF-1R signaling in T‑cell lymphoma |
| Q86188408 | Klotho suppresses tumor progression via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell carcinoma |
| Q38792973 | Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma |
| Q55398048 | Knockdown of B7H6 inhibits tumor progression in triple-negative breast cancer. |
| Q38715520 | Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy |
| Q57483486 | Knockdown of PKM2 suppresses tumor progression in human cervical cancer by modulating epithelial-mesenchymal transition via Wnt/β-catenin signaling |
| Q37275734 | Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines |
| Q36916054 | Ku protein levels, localization and association to replication origins in different stages of breast tumor progression. |
| Q36367423 | L1 cell adhesion molecule overexpression in hepatocellular carcinoma associates with advanced tumor progression and poor patient survival |
| Q38507413 | L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer |
| Q37028791 | L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer |
| Q94600770 | LAMB3 promotes tumour progression through the AKT-FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer |
| Q98771240 | LC3-Associated Phagocytosis (LAP): A Potentially Influential Mediator of Efferocytosis-Related Tumor Progression and Aggressiveness |
| Q39103791 | LEF1 reduces tumor progression and induces myodifferentiation in a subset of rhabdomyosarcoma |
| Q63634164 | LETTER TO THE EDITOR. TURNOVER INDEX—A PREDICTOR OF ‘TUMOUR PROGRESSION’ AT PRESENTATION? |
| Q103049170 | LGR5 induces β activation and augments tumor progression by activating STAT3 in human intrahepatic cholangiocarcinoma |
| Q57816463 | LIMD1 is a survival prognostic marker of gastric cancer and hinders tumor progression by suppressing activation of YAP1 |
| Q30588724 | LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase |
| Q91979173 | LINC00355 Promotes Tumor Progression in HNSCC by Hindering MicroRNA-195-Mediated Suppression of HOXA10 Expression |
| Q98471404 | LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression |
| Q92318416 | LINC00909 promotes tumor progression in human glioma through regulation of miR-194/MUC1-C axis |
| Q89739057 | LINC02595 promotes tumor progression in colorectal cancer by inhibiting miR-203b-3p activity and facilitating BCL2L1 expression |
| Q34303455 | LOXL2 in epithelial cell plasticity and tumor progression |
| Q38968661 | LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC. |
| Q93027849 | LRP8, modulated by miR-1262, promotes tumour progression and forecasts the prognosis of patients in breast cancer |
| Q39000978 | LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses |
| Q52714204 | LW106, A Novel Inhibitor of IDO1, Suppresses Tumor Progression by Limiting Stroma-Immune Crosstalk and Cancer Stem Cell Enrichment in the Tumor Microenvironment. |
| Q37562470 | Lack of M30 expression correlates with factors reflecting tumor progression in rectal cancer with preoperative chemoradiotherapy |
| Q35274375 | Lack of gp130 expression in hepatocytes attenuates tumor progression in the DEN model |
| Q53443092 | Lack of involvement of p53 gene mutations in N-methyl-N-nitrosourea-induced bladder tumor progression in N-butyl-N-(4-hydroxybutyl)nitrosamine-treated rats and no suppression by indomethacin. |
| Q64229903 | Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α-mediated tumor progression |
| Q38334678 | Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression |
| Q101044511 | Lamin B1 promotes tumor progression and metastasis in primary prostate cancer patients |
| Q89916936 | Laminin 521 enhances self-renewal via STAT3 activation and promotes tumor progression in colorectal cancer |
| Q36887594 | Laminin C1 expression by uterine carcinoma cells is associated with tumor progression |
| Q37428997 | Laminin-5γ-2 (LAMC2) is highly expressed in anaplastic thyroid carcinoma and is associated with tumor progression, migration, and invasion by modulating signaling of EGFR. |
| Q41084416 | Laminin-binding integrins in tumor progression and metastasis |
| Q92640709 | Large extracellular vesicles: Size matters in tumor progression |
| Q111518497 | Learning-Based Analysis of Amide Proton Transfer-Weighted MRI to Identify Tumor Progression in Patients with Post-Treatment Malignant Gliomas |
| Q53317126 | Leaving home early: reexamination of the canonical models of tumor progression. |
| Q71320968 | Lectin histochemistry of oral premalignant and malignant lesions: correlation of JFL and PNA binding pattern with tumour progression |
| Q98180429 | Lentinan Inhibits Tumor Progression by Immunomodulation in a Mouse Model of Bladder Cancer |
| Q38272827 | Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer |
| Q52606640 | Lessons from the Crypt: HMGA1-Amping up Wnt for Stem Cells and Tumor Progression. |
| Q70579461 | Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent |
| Q47119379 | Leucine-rich repeat-containing G protein-coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer. |
| Q64081265 | Leukocyte Heparanase: A Double-Edged Sword in Tumor Progression |
| Q46376244 | Leukotriene B4-receptor-1 mediated host response shapes gut microbiota and controls colon tumor progression |
| Q44418604 | Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas |
| Q34636473 | Levels of human replication factor C4, a clamp loader, correlate with tumor progression and predict the prognosis for colorectal cancer |
| Q33582990 | Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer |
| Q33920934 | Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression |
| Q55070669 | Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer. |
| Q53702052 | Linc00210 drives Wnt/β-catenin signaling activation and liver tumor progression through CTNNBIP1-dependent manner. |
| Q35782042 | Link between tumor progression, proteases, and cell motility. Pathology B workshop |
| Q64098068 | Linking Binary Gene Relationships to Drivers of Renal Cell Carcinoma Reveals Convergent Function in Alternate Tumor Progression Paths |
| Q33847837 | Lipid nanocapsules loaded with rhenium-188 reduce tumor progression in a rat hepatocellular carcinoma model |
| Q92976989 | Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy |
| Q46468014 | Lipoxin A4 selectively programs the profile of M2 tumor-associated macrophages which favour control of tumor progression |
| Q36974347 | Lipoxygenase metabolism: roles in tumor progression and survival |
| Q52661560 | Live-Cell Mesothelioma Biobank to Explore Mechanisms of Tumor Progression. |
| Q98568076 | Liver X Receptor β Related to Tumor Progression and Ribosome Gene Expression in Papillary Thyroid Cancer |
| Q40692653 | Liver-infiltrating CD11b(-)CD27(-) NK subsets account for NK-cell dysfunction in patients with hepatocellular carcinoma and are associated with tumor progression |
| Q101458100 | Livin promotes tumor progression through YAP activation in ovarian cancer |
| Q34794465 | Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas |
| Q112619020 | Lnc-GAN1 expression is associated with good survival and suppresses tumor progression by sponging mir-26a-5p to activate PTEN signaling in non-small cell lung cancer |
| Q91153099 | LncRNA CASC15 Functions As An Unfavorable Predictor Of Ovarian Cancer Prognosis And Inhibits Tumor Progression Through Regulation Of miR-221/ARID1A Axis |
| Q91885886 | LncRNA CASC15 promotes tumour progression through SOX4/Wnt/β-catenin signalling pathway in hepatocellular carcinoma |
| Q98568499 | LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma |
| Q64095940 | LncRNA DANCR contributes to tumor progression via targetting miR-216a-5p in breast cancer: lncRNA DANCR contributes to tumor progression |
| Q64908011 | LncRNA GAS5-mediated miR-1323 promotes tumor progression by targeting TP53INP1 in hepatocellular carcinoma. |
| Q97596493 | LncRNA GATA3-AS1 facilitates tumour progression and immune escape in triple-negative breast cancer through destabilization of GATA3 but stabilization of PD-L1 |
| Q97562486 | LncRNA MEG8 promotes tumor progression of non-small cell lung cancer via regulating miR-107/CDK6 axis |
| Q101473802 | LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma |
| Q112296168 | LncRNA NKX2-1-AS1 promotes tumor progression and angiogenesis via upregulation of SERPINE1 expression and activation of the VEGFR-2 signaling pathway in gastric cancer |
| Q91059484 | LncRNA PCAT6 promotes tumor progression in osteosarcoma via activation of TGF-β pathway by sponging miR-185-5p |
| Q104757049 | LncRNA PVT1 Acts as a Tumor Promoter in Thyroid Cancer and Promotes Tumor Progression by Mediating miR-423-5p-PAK3 |
| Q112292684 | LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma |
| Q98945419 | LncRNA TBX5-AS1 Regulates the Tumor Progression Through the PI3K/AKT Pathway in Non-Small Cell Lung Cancer |
| Q57111655 | LncRNA TP73-AS1 accelerates tumor progression in gastric cancer through regulating miR-194-5p/SDAD1 axis |
| Q91557678 | LncRNA-135528 inhibits tumor progression by up-regulating CXCL10 through the JAK/STAT pathway |
| Q37311478 | Local Tumor Progression of Hepatocellular Carcinoma After Microwave Percutaneous Ablation: A Preliminary Report |
| Q39855131 | Local angiotensin II-generation in human gastric cancer: correlation with tumor progression through the activation of ERK1/2, NF-kappaB and survivin |
| Q47106745 | Local blockage of self-sustainable erythropoietin signaling suppresses tumor progression in non-small cell lung cancer |
| Q59196061 | Local recurrence of myxofibrosarcoma is associated with increase in tumour grade and cytogenetic aberrations, suggesting a multistep tumour progression model |
| Q53465388 | Local tumor progression after radiofrequency ablation of colorectal liver metastases: evaluation of ablative margin and three-dimensional volumetric analysis. |
| Q81311375 | Local tumor progression after radiofrequency ablation of liver tumors: analysis of morphologic pattern and site of recurrence |
| Q88883475 | Local tumor progression after ultrasound-guided percutaneous microwave ablation of stage T1a renal cell carcinoma: risk factors analysis of 171 tumors |
| Q41910212 | Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin |
| Q30370000 | Local tumor progression patterns after radiofrequency ablation of colorectal cancer liver metastases |
| Q91546619 | Local tumor progression treated with Gamma Knife radiosurgery: differences between patients with 2-4 versus 5-10 brain metastases based on an update of a multi-institutional prospective observational study (JLGK0901) |
| Q38170739 | Local tumour progression after loco-regional therapy of hepatocellular carcinomas: value of fusion imaging-guided radiofrequency ablation |
| Q40317208 | Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. |
| Q86017391 | Local tumour progression after ultrasound-guided microwave ablation of liver malignancies: risk factors analysis of 2529 tumours |
| Q42868269 | Localisation of phosphorylated mTOR expression is critical to tumour progression and outcomes in patients with endometrial cancer |
| Q33908476 | Locoregional tumor progression after radiation therapy influences overall survival in pediatric patients with neuroblastoma |
| Q100644980 | Long Non-Coding RNA GAS5 Suppresses Tumor Progression and Enhances the Radiosensitivity of Prostate Cancer Through the miR-320a/RAB21 Axis |
| Q112292125 | Long Non-Coding RNA LINC01410 Promoted Tumor Progression via the ErbB Signaling Pathway by Targeting STAT5 in Gallbladder Cancer |
| Q89537490 | Long Non-Coding RNA PVT1 Regulates BAMBI To Promote Tumor Progression In Non-Small Cell Lung Cancer By Sponging miR-17-5p |
| Q100645515 | Long Non-Coding RNA SNHG14 Regulates SPIN1 Expression to Accelerate Tumor Progression in Non-Small Cell Lung Cancer by Sponging miR-382-5p |
| Q92581332 | Long Noncoding RNA LINC00202 Promotes Tumor Progression by Sponging miR-3619-5p in Retinoblastoma |
| Q102141995 | Long Noncoding RNA LINC00551 Suppresses Glycolysis and Tumor Progression by Regulating c-Myc-Mediated PKM2 Expression in Lung Adenocarcinoma |
| Q104566542 | Long non-coding RNA (LncRNA) MRPL23-AS1 promotes tumor progression and carcinogenesis in osteosarcoma by activating Wnt/β-catenin signaling via inhibiting microRNA miR-30b and upregulating myosin heavy chain 9 (MYH9) |
| Q104575888 | Long non-coding RNA AK001903 regulates tumor progression in cervical cancer |
| Q42378415 | Long non-coding RNA CARLo-5 promotes tumor progression in hepatocellular carcinoma via suppressing miR-200b expression |
| Q91630425 | Long non-coding RNA DNM3OS promotes tumor progression and EMT in gastric cancer by associating with Snail |
| Q92481000 | Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis |
| Q55006226 | Long non-coding RNA HOXD-AS1 promotes tumor progression and predicts poor prognosis in colorectal cancer. |
| Q90341601 | Long non-coding RNA KDM5B anti-sense RNA 1 enhances tumor progression in non-small cell lung cancer |
| Q93157676 | Long non-coding RNA LINC00174 promotes glycolysis and tumor progression by regulating miR-152-3p/SLC2A1 axis in glioma |
| Q47146557 | Long non-coding RNA LINC00959 predicts colorectal cancer patient prognosis and inhibits tumor progression |
| Q58770077 | Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-β A |
| Q90731672 | Long non-coding RNA NAP1L6 promotes tumor progression and predicts poor prognosis in prostate cancer by targeting Inhibin-β A [Corrigendum] |
| Q95848924 | Long non-coding RNA NEAT1 promotes human glioma tumor progression via miR-152-3p/CCT6A pathway |
| Q92540209 | Long non-coding RNA PCAT-1 promotes tumor progression by inhibiting miR-129-5p in human ovarian cancer |
| Q34993975 | Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients |
| Q52765967 | Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma. |
| Q64072315 | Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer |
| Q102380000 | Long non-coding RNA TMPO-AS1 promotes tumor progression via sponging miR-140-5p in breast cancer |
| Q91338511 | Long non-coding RNA XIST regulates miR-106b-5p/P21 axis to suppress tumor progression in renal cell carcinoma |
| Q61795833 | Long non-coding RNA ZNFX1-AS1 promotes the tumor progression and metastasis of colorectal cancer by acting as a competing endogenous RNA of miR-144 to regulate EZH2 expression |
| Q91107350 | Long non-coding RNA-ENST00000434223 suppresses tumor progression in gastric cancer cells through the Wnt/β-catenin signaling pathway |
| Q92758246 | Long non-coding RNAs as the critical factors during tumor progressions among Iranian population: an overview |
| Q42747196 | Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer |
| Q38793774 | Long noncoding RNA ENST00000434223 suppressed tumor progression in non-small cell lung cancer |
| Q92441618 | Long noncoding RNA HAS2-AS1 promotes tumor progression in glioblastoma via functioning as a competing endogenous RNA |
| Q38439427 | Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of high mobility group AT-hook 2 (HMGA2) gene |
| Q93117411 | Long noncoding RNA JPX correlates with poor prognosis and tumor progression in non-small cell lung cancer by interacting with miR-145-5p and CCND2 |
| Q91283158 | Long noncoding RNA PROX1-AS1 promotes tumor progression and aggressiveness by sponging miR-647 in gastric cancer |
| Q97533470 | Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma |
| Q92194083 | Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer |
| Q51619088 | Long noncoding ribonucleic acids maternally expressed gene 3 inhibits lung cancer tumor progression through downregulation of MYC. |
| Q89522218 | Long non‑coding RNA BCYRN1 promotes glycolysis and tumor progression by regulating the miR‑149/PKM2 axis in non‑small‑cell lung cancer |
| Q42794066 | Long-lasting drop in perfusion of a non-small cell lung cancer induced by monotherapy with the epithelial growth factor receptor inhibitor erlotinib persisting despite tumor progression at remote sites |
| Q91381505 | Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer |
| Q33929786 | Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review |
| Q38807946 | Long-term ex vivo and in vivo monitoring of tumor progression by using dual luciferases |
| Q31029187 | Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice |
| Q45907542 | Long-term outcomes and patterns of tumor progression after gamma knife radiosurgery for benign meningiomas. |
| Q73083195 | Longer time to tumor progression with exemestane vs tamoxifen in advanced breast cancer |
| Q34163525 | Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFβ activation |
| Q91833664 | Loss of ALDH1L1 folate enzyme confers a selective metabolic advantage for tumor progression |
| Q63444329 | Loss of APAF-1 expression is associated with tumour progression and adverse prognosis in colorectal cancer |
| Q52372086 | Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma. |
| Q37208036 | Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma |
| Q36285026 | Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma |
| Q38398071 | Loss of ARID1A/BAF250a expression is linked to tumor progression and adverse prognosis in cervical cancer. |
| Q48200427 | Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma |
| Q57522084 | Loss of Bcl-2 expression in Barrett’s dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation |
| Q38771868 | Loss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism |
| Q35888377 | Loss of ERbeta expression as a common step in estrogen-dependent tumor progression |
| Q28261753 | Loss of Expression of Reprimo, a p53-induced Cell Cycle Arrest Gene, Correlates with Invasive Stage of Tumor Progression and p73 Expression in Gastric Cancer |
| Q95937074 | Loss of Interleukin-17RA Expression is Associated with Tumour Progression in Colorectal Carcinoma |
| Q33925773 | Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression |
| Q28191748 | Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis |
| Q33925601 | Loss of Progesterone Receptor Expression Is an Early Tumorigenesis Event Associated with Tumor Progression and Shorter Survival in Pancreatic Neuroendocrine Tumor Patients. |
| Q70600410 | Loss of RB protein expression in primary bladder cancer correlates with loss of heterozygosity at the RB locus and tumor progression |
| Q63444330 | Loss of Raf-1 Kinase Inhibitor Protein Expression Is Associated With Tumor Progression and Metastasis in Colorectal Cancer |
| Q39738412 | Loss of SFRP1 expression is associated with aberrant beta-catenin distribution and tumor progression in mucoepidermoid carcinoma of salivary glands |
| Q47813949 | Loss of SIRT1 histone deacetylase expression associates with tumour progression in colorectal adenocarcinoma |
| Q35562695 | Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors |
| Q37693612 | Loss of TRPV2 Homeostatic Control of Cell Proliferation Drives Tumor Progression |
| Q92714418 | Loss of Wnt7a expression correlates with tumor progression and poor prognosis in colorectal carcinoma |
| Q37246954 | Loss of a reporter gene for green fluorescent protein during tumor progression suggests the recruitment of host cells in rats with experimentally induced colon cancer |
| Q30502324 | Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression |
| Q73270773 | Loss of anti-mitotic effects of Bcl-2 with retention of anti-apoptotic activity during tumor progression in a mouse model |
| Q81115619 | Loss of basement membrane heparan sulfate expression is associated with tumor progression in endometrial cancer |
| Q42365263 | Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium |
| Q37690429 | Loss of caveolin-1 in prostate cancer stroma correlates with reduced relapse-free survival and is functionally relevant to tumour progression |
| Q40529805 | Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. |
| Q36185967 | Loss of circadian clock gene expression is associated with tumor progression in breast cancer. |
| Q39375793 | Loss of desmocollin 1-3 and homeobox genes PITX1 and CDX2 are associated with tumor progression and survival in colorectal carcinoma |
| Q80880496 | Loss of estrogen receptor beta expression at cancer front correlates with tumor progression and poor prognosis of gallbladder cancer |
| Q28187473 | Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer |
| Q72347536 | Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression |
| Q36737879 | Loss of gastrokine-2 drives premalignant gastric inflammation and tumor progression |
| Q73645117 | Loss of heterozygosity analysis on chromosome 5p defines 5p13-12 as the critical region involved in tumor progression of bladder carcinomas |
| Q42818179 | Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma |
| Q84066339 | Loss of heterozygosity at chromosome 6q correlates with tumor progression and patient survival |
| Q22010806 | Loss of heterozygosity on 8p in prostate cancer implicates a role for dematin in tumor progression |
| Q74490570 | Loss of heterozygosity on chromosome 18q in cohesive-type gastric cancer is associated with tumor progression and poor prognosis |
| Q34082811 | Loss of keratin 8 phosphorylation leads to increased tumor progression and correlates with clinico-pathological parameters of OSCC patients |
| Q82207406 | Loss of lactate dehydrogenase B subunit expression is correlated with tumour progression and independently predicts inferior disease-specific survival in urinary bladder urothelial carcinoma |
| Q77932389 | Loss of membranous expression of beta-catenin is associated with tumor progression in cutaneous melanoma and rarely caused by exon 3 mutations |
| Q91723073 | Loss of miR-16 contributes to tumor progression by activation of tousled-like kinase 1 in oral squamous cell carcinoma |
| Q59800904 | Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma |
| Q44614804 | Loss of microRNA-200a expression correlates with tumor progression in breast cancer |
| Q40013705 | Loss of nephronectin promotes tumor progression in malignant melanoma |
| Q36026081 | Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression |
| Q42850901 | Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression |
| Q53658491 | Loss of p21WAF1/CIP1 expression in invasive fronts of oral tongue squamous cell carcinomas is correlated with tumor progression and poor prognosis. |
| Q51989002 | Loss of p27Kip1 enhances tumor progression in chronic hepatocyte injury-induced liver tumorigenesis with widely ranging effects on Cdk2 or Cdc2 activation. |
| Q28535183 | Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer |
| Q35789205 | Loss of p63 expression is associated with tumor progression in bladder cancer |
| Q45253711 | Loss of pSer2448-mTOR expression is linked to adverse prognosis and tumor progression in ERG-fusion-positive cancers |
| Q81249390 | Loss of phenotypic expression is related to tumour progression in early gastric differentiated adenocarcinoma |
| Q35947555 | Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression |
| Q71058155 | Loss of responsiveness to transforming growth factor beta (TGFbeta) is tightly linked to tumorigenicity in a model of thyroid tumour progression |
| Q35244952 | Loss of retinal cadherin facilitates mammary tumor progression and metastasis |
| Q52625338 | Loss of the 14-3-3σ tumor suppressor is a critical event in ErbB2-mediated tumor progression. |
| Q33865925 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment |
| Q30436152 | Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms |
| Q24633009 | Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis |
| Q92747680 | Loss of zinc-finger protein 143 contributes to tumour progression by interleukin-8-CXCR axis in colon cancer |
| Q38411193 | Loss/Down-regulation of tumor suppressor in lung cancer 1 expression is associated with tumor progression and is a biomarker of poor prognosis in ovarian carcinoma |
| Q91893603 | Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells |
| Q102142017 | Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma |
| Q36095258 | Low PBRM1 identifies tumor progression and poor prognosis in breast cancer |
| Q35166555 | Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmö Diet and Cancer Study |
| Q47863101 | Low SIRT3 expression contributes to tumor progression, development and poor prognosis in human pancreatic carcinoma |
| Q98177961 | Low UGP2 Expression Is Associated with Tumour Progression and Predicts Poor Prognosis in Hepatocellular Carcinoma |
| Q37687592 | Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma |
| Q60953228 | Low expression of LACTB promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma |
| Q42221103 | Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma |
| Q28394495 | Low level exposure to monomethyl arsonous acid-induced the over-production of inflammation-related cytokines and the activation of cell signals associated with tumor progression in a urothelial cell model |
| Q21195193 | Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes |
| Q37215894 | Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression |
| Q47125854 | Low plasma levels of miR-101 are associated with tumor progression in gastric cancer |
| Q43460633 | Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma |
| Q37668068 | Low-dose radiation decreases tumor progression via the inhibition of the JAK1/STAT3 signaling axis in breast cancer cell lines. |
| Q48471144 | Lower expression of Nrdp1 in human glioma contributes tumor progression by reducing apoptosis. |
| Q26823441 | Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins |
| Q73147333 | Luminal epithelial antigen (LEA.135) expression correlates with tumor progression for transitional carcinoma of the bladder |
| Q54578946 | Luteolin, a novel natural inhibitor of tumor progression locus 2 serine/threonine kinase, inhibits tumor necrosis factor-alpha-induced cyclooxygenase-2 expression in JB6 mouse epidermis cells. |
| Q33304146 | Lymphangiogenesis and tumor progression |
| Q83821994 | Lymphatic differentiation in classic Kaposi's sarcoma: patterns of D2-40 immunoexpression in the course of tumor progression |
| Q35984450 | Lymphatic vascular density and lymphangiogenesis during tumour progression of carcinoma ex pleomorphic adenoma |
| Q72842408 | Lymphocytosis decline is not responsible for tumor progression in cancer patients chronically treated with interleukin-2 |
| Q37486804 | Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression |
| Q90857624 | Lysophosphatidic acid receptor-2 (LPA2) and LPA5 regulate cellular functions during tumor progression in fibrosarcoma HT1080 cells |
| Q50897995 | Lysophosphatidic acid signaling via LPA1 and LPA3 regulates cellular functions during tumor progression in pancreatic cancer cells. |
| Q53809263 | Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence. |
| Q33587066 | Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. |
| Q34187677 | Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo |
| Q86891684 | M-CSF from Cancer Cells Induces Fatty Acid Synthase and PPARβ/δ Activation in Tumor Myeloid Cells, Leading to Tumor Progression |
| Q91502020 | M2 tumor-associated macrophages promote tumor progression in non-small-cell lung cancer |
| Q37134780 | M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma |
| Q28743550 | M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis |
| Q52857955 | MACC1 Induces Tumor Progression in Transgenic Mice and Colorectal Cancer Patients via Increased Pluripotency Markers Nanog and Oct4. |
| Q104617797 | MAFG-AS1 promotes tumor progression via regulation of the HuR/PTBP1 axis in bladder urothelial carcinoma |
| Q46028244 | MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. |
| Q90292063 | MAGI-2 downregulation: a potential predictor of tumor progression and early recurrence in Han Chinese patients with prostate cancer |
| Q64926667 | MAPK4 overexpression promotes tumor progression via noncanonical activation of AKT/mTOR signaling. |
| Q64115759 | MAPKAPK2: the master regulator of RNA-binding proteins modulates transcript stability and tumor progression |
| Q64111928 | MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT-β-catenin pathways |
| Q101051995 | MBD2 Correlates with a Poor Prognosis and Tumor Progression in Renal Cell Carcinoma |
| Q71820198 | MDM2 gene amplification in bone and soft‐tissue tumors: Association with tumor progression in differentiated adipose‐tissue tumors |
| Q80806778 | MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers |
| Q90777866 | MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma |
| Q60922828 | MEOX1 Promotes Tumor Progression and Predicts Poor Prognosis in Human Non-Small-Cell Lung Cancer |
| Q41056161 | MEP1A contributes to tumor progression and predicts poor clinical outcome in human hepatocellular carcinoma. |
| Q92966476 | METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma |
| Q52661925 | MFAP5 promotes tumor progression and bone metastasis by regulating ERK/MMP signaling pathways in breast cancer. |
| Q39291148 | MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer |
| Q52718712 | MK2 contributes to tumor progression by promoting M2 macrophage polarization and tumor angiogenesis. |
| Q36020961 | MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction |
| Q112296736 | MMP9 and IGFBP1 Regulate Tumor Immune and Drive Tumor Progression in Clear Cell Renal Cell Carcinoma |
| Q41880269 | MMP9 processing of HSPB1 regulates tumor progression |
| Q34598895 | MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma |
| Q43038404 | MRI changes associated with vigabatrin treatment mimicking tumor progression |
| Q51887930 | MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer. |
| Q46312463 | MRPL33 and its splicing regulator hnRNPK are required for mitochondria function and implicated in tumor progression |
| Q90012567 | MRPS16 facilitates tumor progression via the PI3K/AKT/Snail signaling axis |
| Q57293797 | MSCs inhibit tumor progression and enhance radiosensitivity of breast cancer cells by down-regulating Stat3 signaling pathway |
| Q33898816 | MT2-MMP expression associates with tumor progression and angiogenesis in human lung cancer |
| Q42408410 | MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model |
| Q92190728 | MTHFD1L-Mediated Redox Homeostasis Promotes Tumor Progression in Tongue Squamous Cell Carcinoma |
| Q37059144 | MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma |
| Q74442598 | MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma |
| Q35021578 | MUC1 regulates expression of multiple microRNAs involved in pancreatic tumor progression, including the miR-200c/141 cluster |
| Q28578563 | MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression |
| Q48230714 | MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance |
| Q34325680 | MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily |
| Q80682652 | MYC amplification and TERT expression in breast tumor progression |
| Q91133531 | MYST1/KAT8 contributes to tumor progression by activating EGFR signaling in glioblastoma cells |
| Q96341293 | Macphatics and PoEMs in Postpartum Mammary Development and Tumor Progression |
| Q90699538 | Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk |
| Q37554550 | Macrophage cathepsin K promotes prostate tumor progression in bone |
| Q29615847 | Macrophage diversity enhances tumor progression and metastasis |
| Q34168497 | Macrophage expression of hypoxia-inducible factor-1 alpha suppresses T-cell function and promotes tumor progression |
| Q39836887 | Macrophage infiltration and tumor progression |
| Q39503895 | Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression |
| Q37158140 | Macrophage polarization in tumour progression |
| Q35221807 | Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies |
| Q36717573 | Macrophage scavenger receptor a promotes tumor progression in murine models of ovarian and pancreatic cancer |
| Q39492081 | Macroscopy predicts tumor progression in gastric cancer: A retrospective patho-historical analysis based on Napoleon Bonaparte's autopsy report |
| Q40989838 | Magnetic resonance imaging with gadoxetic acid for local tumour progression after radiofrequency ablation in patients with hepatocellular carcinoma |
| Q49510141 | Malignant Astrocytic Tumor Progression Potentiated by JAK-mediated Recruitment of Myeloid Cells. |
| Q35106573 | Malignant glioma physiology: cellular response to hypoxia and its role in tumor progression |
| Q40552166 | Mammalian cysteine protease inhibitors: biochemical properties and possible roles in tumor progression |
| Q22010222 | Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis |
| Q33849666 | Mammalian target of rapamycin inhibition abrogates insulin-mediated mammary tumor progression in type 2 diabetes |
| Q52562793 | Mammary ducts with and without focal myoepithelial cell layer disruptions show a different frequency of white blood cell infiltration and growth pattern: implications for tumor progression and invasion. |
| Q36299911 | Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression |
| Q34413051 | Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression |
| Q43145240 | Management of an esophageal metallic stent obstructed by tumor progression: endoscopic alcohol injection therapy instead of restenting. |
| Q53545573 | Manganese superoxide dismutase (SOD2/MnSOD)/catalase and SOD2/GPx1 ratios as biomarkers for tumor progression and metastasis in prostate, colon, and lung cancer. |
| Q74591584 | Mapping loss of heterozygosity at chromosome 13q: loss at 13q12-q13 is associated with breast tumour progression and poor prognosis |
| Q34003713 | Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases |
| Q77343995 | Markers of melanocytic tumour progression |
| Q40908567 | Markov models of breast tumor progression: some age-specific results |
| Q45906167 | Maspin and it's evolving role in tumor progression in systemic malignancies. |
| Q43771758 | Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model |
| Q36216782 | Maspin protein expression correlates with tumor progression in non-muscle invasive bladder cancer |
| Q35950541 | Mast cell contribution to angiogenesis related to tumour progression. |
| Q38107752 | Mast cells and macrophages exert beneficial and detrimental effects on tumor progression and angiogenesis |
| Q37363243 | Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: tissue microarray analysis of immunostaining scores with clinicopathological parameters |
| Q26748929 | Matrix Hyaluronan Promotes Specific MicroRNA Upregulation Leading to Drug Resistance and Tumor Progression |
| Q91786123 | Matrix Hyaluronan-CD44 Interaction Activates MicroRNA and LncRNA Signaling Associated With Chemoresistance, Invasion, and Tumor Progression |
| Q24646370 | Matrix crosslinking forces tumor progression by enhancing integrin signaling |
| Q33359599 | Matrix metalloproteinase 13 is induced in fibroblasts in polyomavirus middle T antigen-driven mammary carcinoma without influencing tumor progression |
| Q81369465 | Matrix metalloproteinase 9 in the uterine cervix during tumor progression |
| Q35829631 | Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression |
| Q33619919 | Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors |
| Q71870892 | Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value |
| Q36784767 | Matrix metalloproteinase-induced epithelial-mesenchymal transition: tumor progression at Snail's pace |
| Q40642341 | Matrix metalloproteinases and their inhibitors in tumor progression |
| Q35195972 | Matrix metalloproteinases and tumor progression |
| Q35110130 | Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. |
| Q79799751 | Matrix metalloproteinases-2 and -9 in cervical cancer: different roles in tumor progression |
| Q36422976 | Matrix metalloproteinases: changing roles in tumor progression and metastasis |
| Q28140150 | Matrix metalloproteinases: multifunctional contributors to tumor progression |
| Q74056696 | Matrix metalloproteinases: promoters of tumor progression and invasiveness |
| Q34706668 | Matrix-directed regulation of pericellular proteolysis and tumor progression |
| Q52975051 | Mean platelet volume as a possible biomarker of tumor progression in rectal cancer. |
| Q98193083 | Mechanical stimulations can inhibit local and remote tumor progression by downregulating WISP1 |
| Q41640097 | Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression |
| Q91798143 | Mechanism of HPSE Gene SNPs Function: From Normal Processes to Inflammation, Cancerogenesis and Tumor Progression |
| Q35579915 | Mechanisms of DNA Damage, DNA Hypomethylation, and Tumor Progression in the Folate/Methyl-Deficient Rat Model of Hepatocarcinogenesis |
| Q34347733 | Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. |
| Q40812968 | Mechanisms of inhibition of tumor progression |
| Q39731560 | Mechanisms of tumor progression |
| Q40679047 | Mechanistic attributes of S100A7 (psoriasin) in resistance of anoikis resulting tumor progression in squamous cell carcinoma of the oral cavity |
| Q97412137 | Mechanosensitive Piezo Channels in Cancer: Focus on altered Calcium Signaling in Cancer Cells and in Tumor Progression |
| Q48309391 | Mechanosignalling in tumour progression |
| Q50422425 | Mechanotransduction in tumor progression: The dark side of the force. |
| Q50855532 | Mechanotransduction pathways promoting tumor progression are activated in invasive human squamous cell carcinoma. |
| Q37698759 | Mecp2-mediated Epigenetic Silencing of miR-137 Contributes to Colorectal Adenoma-Carcinoma Sequence and Tumor Progression via Relieving the Suppression of c-Met |
| Q71915631 | Medical Research: Tumour Progression |
| Q48343226 | Meeting report: The international conference on tumor progression and therapeutic resistance. |
| Q72085592 | Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor |
| Q40838852 | Melanocytic nevi and tumor progression: perspectives concerning histomorphology, melanoma risk and molecular genetics |
| Q40524563 | Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer |
| Q51769704 | Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. |
| Q57732795 | Melanoma susceptibility as a complex trait: genetic variation controls all stages of tumor progression |
| Q91082955 | Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming |
| Q47227422 | Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells |
| Q39290492 | Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model |
| Q93009622 | Melatonin/PGC1A/UCP1 promotes tumor slimming and represses tumor progression by initiating autophagy and lipid browning |
| Q41550052 | Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model |
| Q92728069 | Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression |
| Q38189042 | Membrane changes during tumor progression. Host control of metastatic spread. |
| Q35145340 | Membrane protein CNNM4-dependent Mg2+ efflux suppresses tumor progression |
| Q36076513 | Membrane type-matrix metalloproteinases and tumor progression. |
| Q22000761 | Mena deficiency delays tumor progression and decreases metastasis in polyoma middle-T transgenic mouse mammary tumors |
| Q33193876 | Meningiomas: analysis of loss of heterozygosity on chromosome 10 in tumor progression and the delineation of four regions of chromosomal deletion in common with other cancers. |
| Q48444754 | Mental neuropathy (numb chin syndrome). A harbinger of tumor progression or relapse. |
| Q52038307 | Mental neuropathy (numb chin syndrome): a harbinger of tumor progression or relapse. |
| Q55456110 | Mesenchymal Stem Cells Promote Tumor Progression via Inducing Stroma Remodeling on Rabbit VX2 Bladder Tumor Model. |
| Q33427809 | Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression |
| Q39250469 | Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells |
| Q90683248 | Mesenchymal stromal cells in cancer: a review of their immunomodulatory functions and dual effects on tumor progression |
| Q33864981 | Mesenchymal stromal cells promote tumor progression in fibrosarcoma and gastric cancer cells |
| Q96580186 | Mesoporous Bi-contained Radiosensitizer Loading with DOX to Repolarize Tumor Associated Macrophages and Elicit Immunogenic Tumor Cell Death to Inhibit Tumor Progression |
| Q37416083 | Met amplification and tumor progression in Cdkn2a-deficient melanocytes |
| Q92316777 | Metabolic Dysregulations and Epigenetics: A Bidirectional Interplay that Drives Tumor Progression |
| Q104749152 | Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis |
| Q98829704 | Metabolic ageing drives tumour progression |
| Q38168678 | Metabolic control of tumour progression and antitumour immunity |
| Q33772469 | Metabolic genes in cancer: their roles in tumor progression and clinical implications |
| Q39189962 | Metabolic reprogramming in cancer cells, consequences on pH and tumour progression: Integrated therapeutic perspectives with dietary lipids as adjuvant to anticancer treatment |
| Q92838079 | Metabolic reprogramming induced by inhibition of SLC2A1 suppresses tumor progression in lung adenocarcinoma |
| Q91190916 | Metabolic tumor volume and total lesion glycolysis predict tumor progression and survival after salvage surgery for recurrent oral cavity squamous cell carcinoma |
| Q40860422 | Metalloproteases and urokinase in angiogenesis and tumor progression. |
| Q40472703 | Metalloproteinases in tumor progression: the contribution of MMP-9. |
| Q42476151 | Metallothionein and zinc homeostasis during tumor progression. Effect of methotrexate treatment |
| Q54355487 | Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival. |
| Q45297117 | Metastasis-Associated genes and metastatic tumor progression. |
| Q55161480 | Metastasis-associated lung adenocarcinoma transcript 1 regulates tumor progression: old wine in a new bottle. |
| Q39675529 | Metastasis-associated protein 1 nuclear expression is associated with tumor progression and clinical outcome in patients with non-small cell lung cancer |
| Q83309858 | Metastasis-associated protein 1 nuclear expression is closely associated with tumor progression and angiogenesis in patients with esophageal squamous cell cancer |
| Q39707595 | Metastasis-inducing S100A4 and RANTES cooperate in promoting tumor progression in mice |
| Q33347932 | Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level |
| Q41092469 | Metastatic variants derived following in vivo tumor progression of an in vitro transformed squamous cell carcinoma line acquire a differential growth advantage requiring tumor-host interaction |
| Q55365837 | Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer. |
| Q52653320 | Metformin suppresses tumor progression by inactivating stromal fibroblasts in ovarian cancer. |
| Q43893572 | Methotrexate exacerbates tumor progression in a murine model of chronic myeloid leukemia |
| Q38651448 | MiR-130b attenuates vascular inflammation via negatively regulating tumor progression locus 2 (Tpl2) expression |
| Q33703121 | MiR-200c Inhibits the Tumor Progression of Glioma via Targeting Moesin |
| Q35791401 | MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells |
| Q90916068 | MiR-372-3p promotes tumor progression by targeting LATS2 in colorectal cancer |
| Q37296909 | MiR-424/503-mediated Rictor upregulation promotes tumor progression |
| Q50984266 | MiR-425-5p promotes tumor progression via modulation of CYLD in gastric cancer. |
| Q92866604 | MiR-4282 inhibits tumor progression through down-regulation of ZBTB2 by targeting LIN28B in oral squamous cell carcinoma |
| Q94521152 | MiR-93 is related to poor prognosis in pancreatic cancer and promotes tumor progression by targeting microtubule dynamics |
| Q33520915 | MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression |
| Q34159602 | MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. |
| Q30537249 | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression |
| Q36729381 | MicroRNA-107: a novel promoter of tumor progression that targets the CPEB3/EGFR axis in human hepatocellular carcinoma |
| Q90705781 | MicroRNA-1258 suppresses tumour progression via GRB2/Ras/Erk pathway in non-small-cell lung cancer |
| Q91695263 | MicroRNA-1298 is downregulated in non-small cell lung cancer and suppresses tumor progression in tumor cells |
| Q92839486 | MicroRNA-140 inhibits tumor progression in nasopharyngeal carcinoma by targeting CXCR4 |
| Q38882970 | MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2. |
| Q41901440 | MicroRNA-145 downregulation associates with advanced tumor progression and poor prognosis in patients suffering osteosarcoma |
| Q52671363 | MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma. |
| Q38741262 | MicroRNA-153 inhibits tumor progression in esophageal squamous cell carcinoma by targeting SNAI1. |
| Q34555750 | MicroRNA-193b enhances tumor progression via down regulation of neurofibromin 1. |
| Q64946738 | MicroRNA-200c-3p/ZEB2 loop plays a crucial role in the tumor progression of prostate carcinoma. |
| Q89121386 | MicroRNA-202 inhibits tumor progression by targeting LAMA1 in esophageal squamous cell carcinoma |
| Q91719486 | MicroRNA-221 and MicroRNA-222 in Common Human Cancers: Expression, Function, and Triggering of Tumor Progression as a Key Modulator |
| Q99565352 | MicroRNA-221-3p is related to survival and promotes tumour progression in pancreatic cancer: a comprehensive study on functions and clinicopathological value |
| Q37735957 | MicroRNA-222 Expression as a Predictive Marker for Tumor Progression in Hormone Receptor-Positive Breast Cancer |
| Q38712799 | MicroRNA-223 Promotes Tumor Progression in Lung Cancer A549 Cells via Activation of the NF-κB Signaling Pathway |
| Q35946366 | MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer |
| Q40949289 | MicroRNA-27b suppresses tumor progression by regulating ARFGEF1 and focal adhesion signaling |
| Q98771278 | MicroRNA-27b-3p Promotes Tumor Progression and Metastasis by Inhibiting Peroxisome Proliferator-Activated Receptor Gamma in Triple-Negative Breast Cancer |
| Q38667750 | MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma |
| Q90992396 | MicroRNA-320a suppresses tumor progression by targeting PBX3 in gastric cancer and is downregulated by DNA methylation |
| Q33684869 | MicroRNA-335 and its target Rock1 synergistically influence tumor progression and prognosis in osteosarcoma |
| Q100736592 | MicroRNA-363-3p downregulation in papillary thyroid cancer inhibits tumor progression by targeting NOB1 |
| Q37452209 | MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression |
| Q38950198 | MicroRNA-495 mimics delivery inhibits lung tumor progression |
| Q38839257 | MicroRNA-498 is downregulated in non-small cell lung cancer and correlates with tumor progression |
| Q54171415 | MicroRNA-503 promotes tumor progression and acts as a novel biomarker for prognosis in oesophageal cancer. |
| Q34469678 | MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer |
| Q38674286 | MicroRNA-613 is downregulated in HCMV-positive glioblastoma and inhibits tumour progression by targeting arginase-2. |
| Q102067129 | MicroRNA-623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer |
| Q61814805 | MicroRNA-761 is downregulated in colorectal cancer and regulates tumor progression by targeting Rab3D |
| Q100509663 | MicroRNA-761 suppresses tumor progression in osteosarcoma via negatively regulating ALDH1B1 |
| Q58700017 | MicroRNA-766-3p Inhibits Tumour Progression by Targeting Wnt3a in Hepatocellular Carcinoma |
| Q92383025 | MicroRNA-769-3p inhibits tumor progression in glioma by suppressing ZEB2 and inhibiting the Wnt/β-catenin signaling pathway |
| Q53266940 | MicroRNA-9 is associated with epithelial-mesenchymal transition, breast cancer stem cell phenotype, and tumor progression in breast cancer. |
| Q38331867 | MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression |
| Q34210068 | MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression |
| Q39084498 | MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma |
| Q26796592 | MicroRNAs and Growth Factors: An Alliance Propelling Tumor Progression |
| Q96688004 | MicroRNA‑103 modulates tumor progression by targeting KLF7 in non‑small cell lung cancer |
| Q89533193 | MicroRNA‑29c‑3p acts as a tumor suppressor gene and inhibits tumor progression in hepatocellular carcinoma by targeting TRIM31 |
| Q90868620 | MicroRNA‑4500 suppresses tumor progression in non‑small cell lung cancer by regulating STAT3 |
| Q98511597 | Microbiota-Derived Metabolites in Tumor Progression and Metastasis |
| Q97412156 | Microenvironment Molecular Profile Combining Glycation Adducts and Cytokines Patterns on Secretome of Short-term Blood-derived Cultures during Tumour Progression |
| Q38049368 | Microenvironment and tumor progression of melanoma: new therapeutic prospectives |
| Q42932576 | Microenvironment-a role in tumour progression and prognosis |
| Q92511346 | Microenvironmental Regulation of Tumor Progression and Therapeutic Response in Brain Metastasis |
| Q37964757 | Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response |
| Q37439314 | Microenvironmental independence associated with tumor progression |
| Q29615504 | Microenvironmental regulation of tumor progression and metastasis |
| Q38101533 | Microfluidic culture models to study the hydrodynamics of tumor progression and therapeutic response |
| Q55364205 | Microglial SMAD4 regulated by microRNA-146a promotes migration of microglia which support tumor progression in a glioma environment. |
| Q39603636 | Microparticles in tumor progression. |
| Q76390846 | Microsatellite instability and p53 mutation associated with tumor progression in dermatofibrosarcoma protuberans |
| Q81492590 | Microsatellite instability caused by hMLH1 promoter methylation increases with tumor progression in right-sided sporadic colorectal cancer |
| Q35028164 | Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression |
| Q55262485 | Microtubule-Associated Protein 4 Is a Prognostic Factor and Promotes Tumor Progression in Lung Adenocarcinoma. |
| Q36615803 | Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression |
| Q64100377 | Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression |
| Q35028818 | Microvesicles as a Biomarker for Tumor Progression versus Treatment Effect in Radiation/Temozolomide-Treated Glioblastoma Patients |
| Q34987500 | Microvesicles: messengers and mediators of tumor progression |
| Q101408758 | Mifepristone Treatment Promotes Testicular Leydig Cell Tumor Progression in Transgenic Mice |
| Q89459374 | Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation |
| Q37106795 | Mitochondria and tumor progression in ulcerative colitis. |
| Q100746501 | Mitochondria at Center of Exchanges between Cancer Cells and Cancer-Associated Fibroblasts during Tumor Progression |
| Q28362221 | Mitochondria-to-nucleus stress signaling induces phenotypic changes, tumor progression and cell invasion |
| Q60532151 | Mitochondrial Dysfunctions in Type I Endometrial Carcinoma: Exploring Their Role in Oncogenesis and Tumor Progression |
| Q49918002 | Mitochondrial Metabolism: Yin and Yang for Tumor Progression. |
| Q26749592 | Mitochondrial Redox Signaling and Tumor Progression |
| Q41817959 | Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine |
| Q112643499 | Mitochondrial calcium uptake regulates tumour progression in embryonal rhabdomyosarcoma |
| Q52744366 | Mitochondrial defect drives non-autonomous tumour progression through Hippo signalling in Drosophila. |
| Q91329485 | Mitochondrial fission regulator 2 (MTFR2) promotes growth, migration, invasion and tumour progression in breast cancer cells |
| Q39141387 | Mitochondrial metabolism and energy sensing in tumor progression |
| Q33909212 | Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention? |
| Q36078557 | Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis |
| Q40278381 | Mobility and integration sites of a murine C57BL/6 melanoma endogenous retrovirus involved in tumor progression in vivo. |
| Q38598918 | Model free audit methodology for bias evaluation of tumour progression in oncology |
| Q34669608 | Model predicting survival in stage I melanoma based on tumor progression |
| Q28484612 | Modeling of tumor progression in NSCLC and intrinsic resistance to TKI in loss of PTEN expression |
| Q39215523 | Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. |
| Q38690430 | Modeling tumor progression via the comparison of stage-specific graphs. |
| Q38489683 | Modelling gene expression profiles related to prostate tumor progression using binary states. |
| Q43212807 | Modelling the evolution of genetic instability during tumour progression |
| Q73685179 | Modified basement membrane composition during bronchopulmonary tumor progression |
| Q31165128 | Modifiers of mammary tumor progression and metastasis on mouse chromosomes 7, 9, and 17. |
| Q92379756 | Modulation of Mitochondrial ERβ Expression Inhibits Triple-Negative Breast Cancer Tumor Progression by Activating Mitochondrial Function |
| Q33469954 | Modulation of macrophage cytokine profiles during solid tumor progression: susceptibility to Candida albicans infection |
| Q38088881 | Modulation of neutrophil granulocytes in the tumor microenvironment: mechanisms and consequences for tumor progression |
| Q38374300 | Modulations in the Peripheral Immune System of Glioblastoma Patient Is Connected to Therapy and Tumor Progression-A Case Report from the IMMO-GLIO-01 Trial |
| Q55456941 | Moesin Up-regulation Is Associated with Enhanced Tumor Progression Imaged Non-invasively in an Orthotopic Mouse Model of Human Glioblastoma. |
| Q38701849 | Molecular Imaging of Inducible VEGF Expression and Tumor Progression in a Breast Cancer Model |
| Q36535726 | Molecular Pathways: Mitochondrial Reprogramming in Tumor Progression and Therapy. |
| Q53332686 | Molecular alterations in oral carcinogenesis: significant risk predictors in malignant transformation and tumor progression. |
| Q48019433 | Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression |
| Q96302650 | Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis |
| Q40919638 | Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. |
| Q37756399 | Molecular biology of breast tumor progression: a view from the other side |
| Q122068510 | Molecular biology of microRNA-342 during tumor progression and invasion |
| Q92009380 | Molecular changes in solitary fibrous tumor progression |
| Q37388585 | Molecular characterization and clinical implications of spindle cells in nasopharyngeal carcinoma: a novel molecule-morphology model of tumor progression proposed |
| Q92614727 | Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression |
| Q60644049 | Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression |
| Q81323841 | Molecular characterization of hsp90 isoforms in colorectal cancer cells and its association with tumour progression |
| Q28297078 | Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression |
| Q112285955 | Molecular drivers of tumor progression in microsatellite stable APC mutation-negative colorectal cancers |
| Q44298707 | Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression |
| Q35122647 | Molecular interactions of ‘high risk’ human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression |
| Q40758588 | Molecular markers of melanocytic tumor progression |
| Q37641784 | Molecular markers of tumor progression in melanoma |
| Q43428619 | Molecular mechanisms of SENPs in regulating tumor progression |
| Q40472769 | Molecular mechanisms of invasion and metastasis during mouse skin tumour progression. |
| Q34178900 | Molecular mechanisms of tumor angiogenesis and tumor progression |
| Q72350624 | Molecular mechanisms of tumor progression in chronic myeloproliferative disorders |
| Q37577479 | Molecular pathways in tumor progression: from discovery to functional understanding |
| Q47359581 | Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas |
| Q81284425 | Molecular profiling of tumor progression in head and neck cancer |
| Q29618960 | Molecular requirements for epithelial-mesenchymal transition during tumor progression |
| Q93270738 | Molecular signatures of tumor progression in myxoid liposarcoma identified by N-glycan mass spectrometry imaging |
| Q30312213 | Molecular targets for tumour progression in gastrointestinal stromal tumours |
| Q38829897 | Monitoring breast tumor progression by photoacoustic measurements: a xenograft mice model study. |
| Q57403101 | Monitoring mammary tumor progression and effect of tamoxifen treatment in MMTV-PymT using MRI and magnetic resonance spectroscopy with hyperpolarized [1-13C]pyruvate |
| Q39398956 | Monitoring of tumour progression using bioluminescence imaging and computed tomography scanning in a nude mouse orthotopic model of human small cell lung cancer. |
| Q34070645 | Monitoring radiographic brain tumor progression |
| Q69053632 | Monoclonal antibodies as prognostic indicators of tumor progression in breast cancer |
| Q73536076 | Monosomy 7p in meningiomas: a rare constituent of tumor progression |
| Q43407297 | Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression |
| Q43532604 | Morphological marker of tumor progression in laryngeal cancer |
| Q38763159 | Mouse Models of Brain Metastasis for Unravelling Tumour Progression |
| Q42477655 | Mouse skin tumor progression results in differential expression of retinoic acid and retinoid X receptors. |
| Q50953058 | Msi1 promotes tumor progression by epithelial-to-mesenchymal transition in cervical cancer. |
| Q42799580 | Mucin-mediated tumor progression |
| Q100526078 | Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression |
| Q35032270 | Multi-targeted DATS prevents tumor progression and promotes apoptosis in ectopic glioblastoma xenografts in SCID mice via HDAC inhibition |
| Q53115950 | Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression. |
| Q74151097 | Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model |
| Q46672677 | Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model |
| Q104283104 | Multiparameter quantitative histological MRI values in high-grade gliomas: a potential biomarker of tumor progression |
| Q34593810 | Multiphoton microscopic imaging of esophagus during the early phase of tumor progression |
| Q35880596 | Multiple functions of maspin in tumor progression and mouse development |
| Q33944735 | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression |
| Q78654714 | Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis |
| Q88237156 | Multiple roles of lymphatic vessels in tumor progression |
| Q40991506 | Multiple stages and genetic alterations in immortalization, malignant transformation, and tumor progression of human skin keratinocytes |
| Q35778224 | Multitasking in tumor progression: signaling functions of cell adhesion molecules. |
| Q52885225 | Multiwalled Carbon Nanotubes Inhibit Tumor Progression in a Mouse Model. |
| Q35890028 | Multiwalled carbon nanotubes interact with macrophages and influence tumor progression and metastasis |
| Q92423970 | Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2 |
| Q40266096 | Muscarinic receptors autoantibodies purified from mammary adenocarcinoma-bearing mice sera stimulate tumor progression |
| Q38763202 | Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression |
| Q30313610 | Mutant p53 promotes tumor progression and metastasis by the endoplasmic reticulum UDPase ENTPD5. |
| Q88428668 | Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4 |
| Q94561340 | Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism |
| Q73442780 | Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy |
| Q36081152 | Mutation of the nm23 gene, loss of heterozygosity at the nm23 locus and K-ras mutation in ovarian carcinoma: correlation with tumour progression and nm23 gene expression |
| Q41055861 | Mutation selection and tumour progression |
| Q52537115 | Mutational analysis of transgenic mouse B cell lymphomas: indication of a Trp53-independent pathway in tumor progression. |
| Q91591992 | Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy |
| Q33611147 | Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability |
| Q72804997 | Mutations in the P53 and RAS family genes are associated with tumor progression of BCR/ABL negative chronic myeloproliferative disorders |
| Q35861503 | Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer |
| Q84089652 | Mutations of p53 gene in hepatocellular-carcinoma (hcc) correlate with tumor progression and patient prognosis - a study of 138 patients with unifocal hcc |
| Q40013923 | Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression |
| Q93071125 | Mycoplasma infection promotes tumor progression via interaction of the mycoplasmal protein p37 and epithelial cell adhesion molecule in hepatocellular carcinoma |
| Q64102304 | Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression |
| Q34991284 | Myeloid cell leukemia-1 is associated with tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer |
| Q42403217 | Myeloid cells: Prime drivers of tumor progression |
| Q87774090 | Myeloid-derived suppressor cells attenuate TH1 development through IL-6 production to promote tumor progression |
| Q38702891 | Myeloid-derived suppressor cells: Important contributors to tumor progression and metastasis. |
| Q37893621 | Myeloperoxidase: the yin and yang in tumour progression. |
| Q47758380 | Myristoylation of Src kinase mediates Src-induced and high-fat diet-accelerated prostate tumor progression in mice |
| Q73430052 | Myxoid liposarcoma with transition to round-cell lesion-cell cycle regulator genes and telomerase activity characterizing tumor progression: a case report |
| Q28477083 | NADPH oxidase subunit 4-mediated reactive oxygen species contribute to cycling hypoxia-promoted tumor progression in glioblastoma multiforme |
| Q112275998 | NAP1L1 Functions as a Novel Prognostic Biomarker Associated With Macrophages and Promotes Tumor Progression by Influencing the Wnt/β-Catenin Pathway in Hepatocellular Carcinoma |
| Q112280127 | NCAPG Promotes Tumor Progression and Modulates Immune Cell Infiltration in Glioma |
| Q114093255 | NDUFS4 promotes tumor progression and predicts prognosis in gastric cancer |
| Q58577448 | NEDD8 promotes the tumor progression and predicts the poor prognosis of patients with bladder cancer |
| Q33957938 | NETosis: a new factor in tumor progression and cancer-associated thrombosis |
| Q38813417 | NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression |
| Q47434576 | NFκB mediated elevation of KCNJ11 promotes tumor progression of hepatocellular carcinoma through interaction of lactate dehydrogenase A. |
| Q39210909 | NG2 Proteoglycan Enhances Brain Tumor Progression by Promoting Beta-1 Integrin Activation in both Cis and Trans Orientations |
| Q94353896 | NI-68F-FDOPA PET IN TREATED LOW-GRADE GLIOMAS WITH NON-ENHANCING T2 CHANGES ON MRI IS PROGNOSTIC OF TUMOR PROGRESSION AND OVERALL SURVIVAL |
| Q45834330 | NIMG-18EVALUATING TUMOR PROGRESSION AND IMMUNOLOGIC REACTIONS DURING IMMUNOTHERAPY: NEUROIMAGING OBSERVATIONS FROM A MULTICENTER STUDY OF NIVOLUMAB MONOTHERAPY AND NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN RECURRENT GLIOBLASTOMA (CHECKMATE-143). |
| Q94408102 | NIMG-32. DIFFERENTIATION OF PSEUDOPROGRESSION FROM TUMOR PROGRESSION IN GLIOBLASTOMA PATIENTS BASED ON FET PET RADIOMICS |
| Q94407121 | NIMG-34. TC-MIBI SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY (SPECT-CT) TO DETECT TUMOR PROGRESSION IN GLIOBLASTOMAS (GB) |
| Q45834481 | NIMG-40MRI TUMOR PROGRESSION PATTERNS IN THE GLARIUS TRIAL. |
| Q94149052 | NIMG-76. POST-GADOLINIUM 3-DIMENSIONAL SPATIAL, SURFACE, AND STRUCTURAL CHARACTERISTICS OF GLIOBLASTOMAS DIFFERENTIATE PSEUDOPROGRESSION FROM TRUE TUMOR PROGRESSION |
| Q26746478 | NK Cells, Tumor Cell Transition, and Tumor Progression in Solid Malignancies: New Hints for NK-Based Immunotherapy? |
| Q37395723 | NLRC4 suppresses melanoma tumor progression independently of inflammasome activation |
| Q73081860 | NM23 gene expression in human breast carcinomas: loss of correlation with cell proliferation in the advanced phase of tumor progression |
| Q51625712 | NOK/STYK1 promotes the genesis and remodeling of blood and lymphatic vessels during tumor progression. |
| Q93123368 | NOP2/Sun RNA methyltransferase 2 promotes tumor progression via its interacting partner RPL6 in gallbladder carcinoma |
| Q31034352 | NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. |
| Q38392559 | NRP-1 expression in bladder cancer and its implications for tumor progression |
| Q112276981 | NSUN2 Promotes Tumor Progression and Regulates Immune Infiltration in Nasopharyngeal Carcinoma |
| Q37578536 | NT5E and FcGBP as key regulators of TGF-1-induced epithelial-mesenchymal transition (EMT) are associated with tumor progression and survival of patients with gallbladder cancer |
| Q35997684 | Nanodiamond modified copolymer scaffolds affects tumour progression of early neoplastic oral keratinocytes. |
| Q64263658 | Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model |
| Q92794916 | Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects |
| Q90492358 | Negative Predictive Value of Contrast-Enhanced Ultrasound of Liver and Kidney Thermal Ablation Sites for Local Tumour Progression During Long-term Follow-up: A Retrospective Consecutive Study |
| Q39830915 | Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression |
| Q79421171 | Neoadjuvant chemotherapy for advanced stage cervical cancer in a pregnant patient: report of one case with rapid tumor progression |
| Q50073445 | Neoisoliquiritigenin inhibits tumor progression by targeting GRP78-β-catenin signaling in breast cancer. |
| Q36152614 | Nerve fibers in breast cancer tissues indicate aggressive tumor progression |
| Q38386204 | Nerve-Cancer Cell Cross-talk: A Novel Promoter of Tumor Progression |
| Q46699427 | Nestin and its emerging role in tumor progression and carcinogenesis in systemic tumors besides pancreatic carcinomas |
| Q39160349 | Nestin(+) tissue-resident multipotent stem cells contribute to tumor progression by differentiating into pericytes and smooth muscle cells resulting in blood vessel remodeling. |
| Q44265089 | Netrin-4 overexpression suppresses primary and metastatic colorectal tumor progression |
| Q21184029 | Network analysis of skin tumor progression identifies a rewired genetic architecture affecting inflammation and tumor susceptibility |
| Q42777743 | Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression. |
| Q72178777 | Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression |
| Q112636889 | Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1 |
| Q112283318 | Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation |
| Q43878025 | Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis |
| Q93140980 | Neuropilin-2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors |
| Q48344451 | Neuropsychological Deterioration Predicts Tumor Progression in a Young Boy With Bithalamic Glioma |
| Q41193076 | Neurotrophin receptors, tumor progression and tumor maturation |
| Q104479200 | Neutralization of TGF-β improves tumor immunity and reduces tumor progression in ovarian carcinoma |
| Q97643316 | Neutrophil diversity and plasticity in tumour progression and therapy |
| Q36694910 | Neutrophil extracellular traps: A new link to cancer-associated thrombosis and potential implications for tumor progression |
| Q44151403 | Neutrophil gelatinase-associated lipocalin and its influence on tumor progression in systemic malignancies |
| Q26765238 | Neutrophil-Derived Proteases in the Microenvironment of Pancreatic Cancer -Active Players in Tumor Progression |
| Q36895360 | Neutrophils drive accelerated tumor progression in the collagen-dense mammary tumor microenvironment. |
| Q38585102 | Neutrophils: important contributors to tumor progression and metastasis. |
| Q91900438 | New Functions of Long Noncoding RNAs during EMT and Tumor Progression |
| Q28072045 | New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy |
| Q91933758 | New Roles for Glycogen in Tumor Progression |
| Q41955600 | New evidence of lncRNA role in tumor progression and metastasis |
| Q37948607 | New facets of matrix metalloproteinases MMP-2 and MMP-9 as cell surface transducers: outside-in signaling and relationship to tumor progression |
| Q34267663 | New functions of stromal proteases and their inhibitors in tumor progression |
| Q38972265 | New twists in the AXL(e) of tumor progression |
| Q93133967 | Newly identified LMO3-BORCS5 fusion oncogene in Ewing sarcoma at relapse is a driver of tumor progression |
| Q94472589 | Nicotine promotes tumor progression and epithelial-mesenchymal transition by regulating the miR-155-5p/NDFIP1 axis in pancreatic ductal adenocarcinoma |
| Q28395572 | Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers |
| Q59166158 | Nicotinic receptors increase cell proliferation and tumour progression in non-small cell lung cancer cell line |
| Q73361298 | Nitric Oxide-Independent CTL Suppression during Tumor Progression: Association with Arginase-Producing (M2) Myeloid Cells |
| Q37166559 | Nitric oxide, apoptosis and macrophage polarization during tumor progression. |
| Q37679906 | Nitric oxide: pros and cons in tumor progression |
| Q37225293 | Nitrilase 1 modulates lung tumor progression in vitro and in vivo. |
| Q28260087 | Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity |
| Q48564051 | Nocardia abscesses mimicking tumor progression in gliomatosis cerebri responding to temozolomide. |
| Q36998286 | Non-coding RNA LINC00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer |
| Q39509049 | Non-invasive in vivo imaging for liver tumour progression using an orthotopic hepatocellular carcinoma model in immunocompetent mice |
| Q36338306 | Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist |
| Q46618702 | Non-invasive monitoring of pancreatic tumor progression in the RIP1-Tag2 mouse by magnetic resonance imaging |
| Q50280090 | Non-invasive quantification of cell-free DNA mutations in plasma during lung tumor progression in mice. |
| Q34207052 | Non-muscle myosins in tumor progression, cancer cell invasion, and metastasis |
| Q35773122 | Non-stem cancer cell kinetics modulate solid tumor progression. |
| Q42795740 | Non-steroidal anti-inflammatory drugs and tumor progression: inhibition of fibroblast hyaluronic acid production by indomethacin and mefenamic acid |
| Q37416715 | Noncanonical Wnt signaling in tumor progression and metastasis |
| Q91863543 | Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix |
| Q39029442 | Noninvasive near-infrared fluorescent protein-based imaging of tumor progression and metastases in deep organs and intraosseous tissues |
| Q35938402 | Noninvasive real-time in vivo bioluminescent imaging of gene expression and of tumor progression and metastasis. |
| Q68026587 | Nonrandom abnormalities involving chromosome 1 and Harvey-ras-1 alleles in rat mammary tumor progression |
| Q37120838 | Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression |
| Q94550294 | Norrin mediates opposing effects on tumor progression of glioblastoma stem cells |
| Q34018569 | Notch and TGFβ: Functional partners facilitating tumor progression |
| Q35805302 | Notch and epithelial-mesenchyme transition in development and tumor progression: another turn of the screw. |
| Q36881446 | Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. |
| Q54391802 | Notch1 expression is upregulated in glioma and is associated with tumor progression. |
| Q48253445 | Notch1 induces endothelial senescence and promotes tumor progression. |
| Q92875466 | Novel Carbazole-Piperazine Hybrid Small Molecule Induces Apoptosis by Targeting BCL-2 and Inhibits Tumor Progression in Lung Adenocarcinoma in Vitro and Xenograft Mice Model |
| Q36559474 | Novel functions for Rab GTPases in multiple aspects of tumour progression |
| Q44823194 | Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma |
| Q100524683 | Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression |
| Q91924748 | Novel insights into the combined effect of triorganotin compounds and all-trans retinoic acid on expression of selected proteins associated with tumor progression in breast cancer cell line MDA-MB-231: Proteomic approach |
| Q34412094 | Novel levamisole derivative induces extrinsic pathway of apoptosis in cancer cells and inhibits tumor progression in mice |
| Q53682024 | Novel long noncoding RNA NMR promotes tumor progression via NSUN2 and BPTF in esophageal squamous cell carcinoma. |
| Q93345417 | Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression |
| Q39012277 | Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism |
| Q91606421 | Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death |
| Q80290638 | Nuclear expression of S100A4 is associated with aggressive behavior of epithelial ovarian carcinoma: an important autocrine/paracrine factor in tumor progression |
| Q33495389 | Nuclear expression of Snail1 in borderline and malignant epithelial ovarian tumours is associated with tumour progression |
| Q53326621 | Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression. |
| Q37101017 | Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. |
| Q34266894 | Nuclear localization of heme oxygenase-1 is associated with tumor progression of head and neck squamous cell carcinomas. |
| Q71858304 | Nuclear oncoprotein expression in lung precancer and cancer at various stages of tumor progression studies at the level of light- and electron-immunohistochemistry |
| Q45848710 | Nuclear translocation of β-catenin and decreased expression of epithelial cadherin in human papillomavirus-positive tonsillar cancer: an early event in human papillomavirus-related tumour progression? |
| Q37109600 | Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression. |
| Q40141924 | Nucleic acids from subcellular fractions of N-nitrosodiethylamine-induced hepatoma in mice. II. Changes in gene expression during tumor progression |
| Q91259745 | Nucleostemin reveals a dichotomous nature of genome maintenance in mammary tumor progression |
| Q99590070 | Nutritional Supplements in Combination with Chemotherapy or Targeted Therapy Reduces Tumor Progression in Mice bearing Triple-negative Breast Cancer |
| Q100401969 | N‑Myc induces the tumor progression of prostate cancer by regulating FSCN1 |
| Q48230357 | O6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy |
| Q35558576 | OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer |
| Q91870474 | OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma |
| Q54458570 | OS06.2 Combination RNAi therapy against glioma stem cells via sustained lipopolymeric nanoparticle delivery delays tumor progression. |
| Q39981838 | OSU-HDAC42, a histone deacetylase inhibitor, blocks prostate tumor progression in the transgenic adenocarcinoma of the mouse prostate model |
| Q37392807 | OTUB1-catalyzed deubiquitination of FOXM1 facilitates tumor progression and predicts a poor prognosis in ovarian cancer |
| Q91642391 | OTUB1-mediated deubiquitination of FOXM1 up-regulates ECT-2 to promote tumor progression in renal cell carcinoma |
| Q98623437 | OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity |
| Q39345207 | OV6⁺ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma |
| Q96764458 | Obesity and Breast Cancer: The Role of Crown-Like Structures in Breast Adipose Tissue in Tumor Progression, Prognosis, and Therapy |
| Q34425077 | Obesity and cancer--mechanisms underlying tumour progression and recurrence |
| Q34808435 | Obesity, independent of p53 gene dosage, promotes mammary tumor progression and upregulates the p53 regulator microRNA-504. |
| Q89655153 | Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma |
| Q55547334 | Obstructive Sleep Apnea Monocytes Exhibit High Levels of Vascular Endothelial Growth Factor Secretion, Augmenting Tumor Progression. |
| Q44039872 | Occurrence of H-ras codon 61 CAA to AAA mutation during mouse liver tumor progression. |
| Q64376527 | Oct-3/4 expression reflects tumor progression and regulates motility of bladder cancer cells |
| Q53130548 | Oesophageal tumour progression between the diagnostic ¹⁸F-FDG-PET and the ¹⁸F-FDG-PET for radiotherapy treatment planning. |
| Q39388489 | Oestrogen attenuates tumour progression in hepatocellular carcinoma |
| Q54659529 | Oestrogen receptor-related receptor alpha (ERRalpha) and oestrogen receptors (ERalpha and ERbeta) exhibit different gene expression in human colorectal tumour progression. |
| Q37662385 | Old age at diagnosis increases risk of tumor progression in nasopharyngeal cancer |
| Q89719668 | Oligo-Fucoidan Prevents M2 Macrophage Differentiation and HCT116 Tumor Progression |
| Q41717692 | Oligo-Fucoidan prevents IL-6 and CCL2 production and cooperates with p53 to suppress ATM signaling and tumor progression |
| Q91761286 | Oligosaccharyltransferase: A Gatekeeper of Health and Tumor Progression |
| Q35185365 | Omega-3 fatty acids reduce obesity-induced tumor progression independent of GPR120 in a mouse model of postmenopausal breast cancer. |
| Q52735014 | On the persistence of tumour initiation and the acceleration of tumour progression in mouse skin tumorigenesis. |
| Q40172271 | Oncogene activation and tumor progression |
| Q38729025 | Oncogenes and tumor progression |
| Q69594887 | Oncogenes and tumor progression |
| Q112610376 | Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma |
| Q38844554 | Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression |
| Q36103287 | Oncogenic Ras in tumour progression and metastasis |
| Q40502054 | Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis |
| Q36193774 | Oncogenic extracellular vesicles in brain tumor progression |
| Q38697673 | Oncogenic function of angiopoietin-2 in vitro and its modulation of tumor progression in colorectal carcinoma. |
| Q35671858 | Oncomodulatory signals by regulatory proteins encoded by human cytomegalovirus: a novel role for viral infection in tumor progression |
| Q46043697 | Oncoprotein signaling mediates tumor-specific inflammation and enhances tumor progression |
| Q71088983 | Oncoproteins and tumor progression in papillary thyroid carcinoma: presence of epidermal growth factor receptor, c-erbB-2 protein, estrogen receptor related protein, p21-ras protein, and proliferation indicators in relation to tumor recurrences and |
| Q60050999 | Oncostatin M is overexpressed in skin squamous-cell carcinoma and promotes tumor progression |
| Q28271211 | Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression |
| Q34295401 | Opposing roles for complement component C5a in tumor progression and the tumor microenvironment |
| Q35576310 | Opposing roles for mammary epithelial-specific PPARγ signaling and activation during breast tumour progression |
| Q41948921 | Opposing roles of the oncogene Akt isoforms in tumour progression: is there a dark side to Akt pathway inhibition? |
| Q37540029 | Optimal presentation modes for detecting brain tumor progression |
| Q51938755 | Optimizing randomized phase II trials assessing tumor progression. |
| Q30833237 | Orai1 promotes tumor progression by enhancing cancer stemness via NFAT signaling in oral/oropharyngeal squamous cell carcinoma |
| Q87083802 | Oral Administration of Aloe vera (L.) Burm. f. (Xanthorrhoeaceae) and Honey Improves the Host Body Composition and Modulates Proteolysis Through Reduction of Tumor Progression and Oxidative Stress in Rats |
| Q51473098 | Oral ingestion of Streptococcus thermophilus does not affect mucositis severity or tumor progression in the tumor-bearing rat. |
| Q43632365 | Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. |
| Q40574105 | Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. |
| Q59808618 | Oscillatory brain activity associates with neuroligin-3 expression and predicts progression free survival in patients with diffuse glioma |
| Q112732531 | Osteopontin (OPN/SPP1), a Mediator of Tumor Progression, Is Regulated by the Mesenchymal Transcription Factor Slug/SNAI2 in Colorectal Cancer (CRC) |
| Q42539445 | Osteopontin Overexpression Induced Tumor Progression and Chemoresistance to Oxaliplatin through Induction of Stem-Like Properties in Human Colorectal Cancer |
| Q73451082 | Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas |
| Q41099667 | Osteopontin at the Crossroads of Inflammation and Tumor Progression |
| Q35088334 | Osteopontin expression in intratumoral astrocytes marks tumor progression in gliomas induced by prenatal exposure to N-ethyl-N-nitrosourea |
| Q57248490 | Osteopontin identified as colon cancer tumor progression marker |
| Q38932540 | Osteopontin promotes EZH2 expression and tumor progression in nasopharyngeal carcinoma |
| Q102139167 | Osteopontin: A Key Regulator of Tumor Progression and Immunomodulation |
| Q112636614 | Osteosarcoma-Specific Genes as a Diagnostic Tool and Clinical Predictor of Tumor Progression |
| Q55187122 | Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature. |
| Q73196773 | Over-expression and lack of retinoblastoma protein are associated with tumor progression and metastasis in hepatocellular carcinoma |
| Q39834634 | Over-expression of CDH22 is associated with tumor progression in colorectal cancer |
| Q47257197 | Over-expression of E2F-1 in esophageal squamous cell carcinoma correlates with tumor progression |
| Q52529449 | Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. |
| Q58804589 | Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma |
| Q39760353 | Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer |
| Q33864140 | Over-expression of eukaryotic translation initiation factor 4 gamma 1 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma |
| Q54508477 | Over-expression of integrin-linked kinase correlates with aberrant expression of Snail, E-cadherin and N-cadherin in oral squamous cell carcinoma: implications in tumor progression and metastasis. |
| Q36261877 | Over-expression of lncRNA DANCR is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer |
| Q39557594 | Over-expression of lncRNA SBF2-AS1 is associated with advanced tumor progression and poor prognosis in patients with non-small cell lung cancer |
| Q35038385 | Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer |
| Q34700856 | Over-expression of nerve growth factor-β in human cholangiocarcinoma QBC939 cells promote tumor progression |
| Q38423558 | Over-expression of phosphatase of regenerating liver-3 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma |
| Q45922519 | Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma. |
| Q24805089 | Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis |
| Q43207315 | OverAKT3: tumor progression and chemoresistance |
| Q26749333 | Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction |
| Q90327677 | Overexpressed CDR1as functions as an oncogene to promote the tumor progression via miR-7 in non-small-cell lung cancer |
| Q37062452 | Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma |
| Q91153382 | Overexpressed PKMYT1 promotes tumor progression and associates with poor survival in esophageal squamous cell carcinoma |
| Q40346813 | Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer |
| Q60956607 | Overexpression Is Associated With Tumor Progression and Poor Survival in Colorectal Cancer |
| Q49082801 | Overexpression of ANCCA/ATAD2 in endometrial carcinoma and its correlation with tumor progression and poor prognosis. |
| Q90935134 | Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer |
| Q53204875 | Overexpression of C35 in breast carcinomas is associated with tumor progression and lymphnode metastasis. |
| Q28483701 | Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression |
| Q64085240 | Overexpression of CBX2 in breast cancer promotes tumor progression through the PI3K/AKT signaling pathway |
| Q55638534 | Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression. |
| Q92648705 | Overexpression of CD55 correlates with tumor progression and poor prognosis in gastric stromal tumors |
| Q37687048 | Overexpression of CHKA contributes to tumor progression and metastasis and predicts poor prognosis in colorectal carcinoma |
| Q54976480 | Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer. |
| Q92243734 | Overexpression of CLN3 contributes to tumour progression and predicts poor prognosis in hepatocellular carcinoma |
| Q64235056 | Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma |
| Q34304058 | Overexpression of Chemokine (C-X-C) ligand 1 (CXCL1) associated with tumor progression and poor prognosis in hepatocellular carcinoma |
| Q90173571 | Overexpression of Cullin4A correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma |
| Q35043581 | Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma |
| Q84595305 | Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis |
| Q55457150 | Overexpression of Fn14 in gliomas: tumor progression and poor prognosis. |
| Q36380333 | Overexpression of FoxM1 is associated with tumor progression in patients with clear cell renal cell carcinoma |
| Q36279859 | Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression |
| Q112296915 | Overexpression of GINS4 Is Associated With Tumor Progression and Poor Survival in Hepatocellular Carcinoma |
| Q54090659 | Overexpression of HDAC9 is associated with poor prognosis and tumor progression of breast cancer in Chinese females. |
| Q90392849 | Overexpression of ID1 promotes tumor progression in penile squamous cell carcinoma |
| Q35050440 | Overexpression of JAM-A in non-small cell lung cancer correlates with tumor progression |
| Q36095225 | Overexpression of L1 cell adhesion molecule correlates with aggressive tumor progression of patients with breast cancer and promotes motility of breast cancer cells |
| Q44609521 | Overexpression of L1CAM is associated with tumor progression and prognosis via ERK signaling in gastric cancer |
| Q94552574 | Overexpression of LBX2 associated with tumor progression and poor prognosis in colorectal cancer |
| Q52666444 | Overexpression of Long Non-Coding RNA NNT-AS1 Correlates with Tumor Progression and Poor Prognosis in Osteosarcoma. |
| Q41593164 | Overexpression of Lysine-Specific Demethylase 1 Is Associated With Tumor Progression and Unfavorable Prognosis in Chinese Patients With Endometrioid Endometrial Adenocarcinoma |
| Q50311627 | Overexpression of MICAL2, a novel tumor-promoting factor, accelerates tumor progression through regulating cell proliferation and EMT. |
| Q34356517 | Overexpression of MTA3 Correlates with Tumor Progression in Non-Small Cell Lung Cancer |
| Q52717140 | Overexpression of Myosin Phosphatase Target Subunit 1 (MYPT1) Inhibits Tumor Progression and Metastasis of Gastric Cancer. |
| Q33779573 | Overexpression of NOX4 predicts poor prognosis and promotes tumor progression in human colorectal cancer |
| Q92866338 | Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma |
| Q54967855 | Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma. |
| Q55365652 | Overexpression of PLOD3 promotes tumor progression and poor prognosis in gliomas. |
| Q36020877 | Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer |
| Q44166758 | Overexpression of PTP1B in human colorectal cancer and its association with tumor progression and prognosis |
| Q39380579 | Overexpression of Paxillin Correlates with Tumor Progression and Predicts Poor Survival in Glioblastoma. |
| Q38760287 | Overexpression of Phosphoserine Aminotransferase 1 (PSAT1) Predicts Poor Prognosis and Associates with Tumor Progression in Human Esophageal Squamous Cell Carcinoma |
| Q47630025 | Overexpression of RAB34 correlates with poor prognosis and tumor progression in hepatocellular carcinoma |
| Q33354559 | Overexpression of Rho GDP-dissociation inhibitor alpha is associated with tumor progression and poor prognosis of colorectal cancer |
| Q39485959 | Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma |
| Q96690250 | Overexpression of Rictor protein and Rictor-H. pylori interaction impact on tumor progression and prognosis in patients with gastric cancer |
| Q47429788 | Overexpression of Rictor protein in colorectal cancer is correlated with tumor progression and prognosis |
| Q57464468 | Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma |
| Q90388886 | Overexpression of SLC12A5 is associated with tumor progression and poor survival in ovarian carcinoma |
| Q38997891 | Overexpression of SPAG9 correlates with poor prognosis and tumor progression in hepatocellular carcinoma |
| Q57148633 | Overexpression of Sig1R is closely associated with tumor progression and poor outcome in patients with hilar cholangiocarcinoma |
| Q92839569 | Overexpression of Sox3 is associated with promoted tumor progression and poor prognosis in hepatocellular carcinoma |
| Q34292571 | Overexpression of TRIM24 correlates with tumor progression in non-small cell lung cancer |
| Q35972831 | Overexpression of TRPV3 Correlates with Tumor Progression in Non-Small Cell Lung Cancer. |
| Q90986470 | Overexpression of UQCRC2 is correlated with tumor progression and poor prognosis in colorectal cancer |
| Q37446726 | Overexpression of WDR79 in non-small cell lung cancer is linked to tumour progression |
| Q46697258 | Overexpression of Wnt7a is associated with tumor progression and unfavorable prognosis in endometrial cancer |
| Q38774648 | Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer |
| Q90763110 | Overexpression of absent in melanoma 2 in oral squamous cell carcinoma contributes to tumor progression |
| Q43121452 | Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression |
| Q44111880 | Overexpression of alpha enolase in hepatitis C virus-related hepatocellular carcinoma: association with tumor progression as determined by proteomic analysis |
| Q36545629 | Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer |
| Q43907190 | Overexpression of carbonic anhydrase IX (CAIX) in vulvar cancer is associated with tumor progression and development of locoregional lymph node metastases |
| Q58321560 | Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays |
| Q91883671 | Overexpression of connective tissue growth factor is associated with tumor progression and unfavorable prognosis in endometrial cancer |
| Q44185778 | Overexpression of fibrinogen-like protein 2 induces epithelial-to-mesenchymal transition and promotes tumor progression in colorectal carcinoma |
| Q87690914 | Overexpression of fibulin-4 is associated with tumor progression and poor prognosis in patients with cervical carcinoma |
| Q38419290 | Overexpression of high-mobility group box 1 correlates with tumor progression and poor prognosis in human colorectal carcinoma |
| Q38400105 | Overexpression of integrin-linked kinase (ILK) is associated with tumor progression and an unfavorable prognosis in patients with colorectal cancer |
| Q39865005 | Overexpression of interleukin-13 in a murine T-cell lymphoma: a possible factor of DL-induced immunosuppression and tumor progression |
| Q58746841 | Overexpression of kinesin family member 20A is associated with unfavorable clinical outcome and tumor progression in epithelial ovarian cancer |
| Q38800573 | Overexpression of long non-coding RNA LOC400891 promotes tumor progression and poor prognosis in prostate cancer |
| Q47146235 | Overexpression of long non-coding RNA colon cancer-associated transcript 2 is associated with advanced tumor progression and poor prognosis in patients with colorectal cancer |
| Q57816329 | Overexpression of long noncoding RNA NORAD in colorectal cancer associates with tumor progression |
| Q34265702 | Overexpression of membrane-type 2 matrix metalloproteinase induced by hypoxia-inducible factor-1α in pancreatic cancer: Implications for tumor progression and prognosis |
| Q91467838 | Overexpression of miR-425-5p is associated with poor prognosis and tumor progression in non-small cell lung cancer |
| Q64108356 | Overexpression of miR-664 is associated with poor overall survival and accelerates cell proliferation, migration and invasion in hepatocellular carcinoma |
| Q92867365 | Overexpression of molecule GRP94 favors tumor progression in lung adenocarcinoma by interaction with regulatory T cells |
| Q70918894 | Overexpression of nucleoside diphosphate/kinase A/nm23-H1 protein in human lung tumors: association with tumor progression in squamous carcinoma |
| Q41677878 | Overexpression of oncogene products can cause tumor progression without parenchymal infiltration in the rat brain |
| Q30538395 | Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer |
| Q38394383 | Overexpression of pituitary tumor transforming gene (PTTG) is associated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma |
| Q24813774 | Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression |
| Q34786434 | Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma |
| Q33804529 | Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer |
| Q36329328 | Overexpression of runt-related transcription factor-2 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer |
| Q37588358 | Overexpression of semaphorin 3A promotes tumor progression and predicts poor prognosis in hepatocellular carcinoma after curative resection |
| Q36613980 | Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis |
| Q71681433 | Overexpression of the 67-kD laminin receptor correlates with tumour progression in human colorectal carcinoma |
| Q63548690 | Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression |
| Q92645230 | Overexpression of the galectin-3 during tumor progression in prostate cancer and its clinical implications |
| Q38780794 | Overexpression of the metastasis-associated gene MTA3 correlates with tumor progression and poor prognosis in hepatocellular carcinoma |
| Q59135881 | Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma |
| Q91029926 | Oxalomalate reduces tumor progression in melanoma via ROS-dependent proapoptotic and antiangiogenic effects |
| Q71106412 | Oxidant-antioxidant status alterations in cancer patients: relationship to tumor progression |
| Q45938824 | Oxidative stress and tumor progression in colorectal cancer. |
| Q45751605 | P-206Effects of eribulin mesilate for tumor progression and fibrosis in gastric cancer. |
| Q54204932 | P-glycoprotein and tumor progression. |
| Q53487236 | P-glycoprotein expression during tumor progression in the rat liver |
| Q40630952 | P-glycoprotein, multidrug resistance and tumor progression |
| Q94088515 | P01.054 Patterns of first tumor progression and impact on survival of salvage therapies in low-grade gliomas following initial chemotherapy with temozolomide |
| Q46880335 | P01.08LINEAGE-SPECIFIC SPLICING OF AN ALTERNATIVE EXON OF ANXA7 PROMOTES EGFR SIGNALING ACTIVATION AND TUMOR PROGRESSION IN GLIOBLASTOMA. |
| Q94088536 | P02.01 Altered FoxM1 expression contributes to the meningioma malignancy and can be a critical target for the tumor progression |
| Q94088003 | P04.69 Differential microglia - glioma cell interaction during tumor progression |
| Q55122069 | P08.38 Irradiation of Subventricular Zone in Glioblastoma: Its Impact on Tumor Progression and Survival. |
| Q46085864 | P14ARF is down-regulated during tumour progression and predicts the clinical outcome in human breast cancer |
| Q114091497 | P15.07.A Predicting sites of local tumour progression - what should be our imaging biomarker? |
| Q81537128 | P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma |
| Q46884339 | P16.29POST-OPERATIVE DIFFUSION TENSOR IMAGING IDENTIFIES RESIDUAL INVASIVE TUMOR FOLLOWING MAXIMAL RESECTION OF GLIOBLASTOMAS AND PREDICTS LOCATION OF TUMOUR PROGRESSION. |
| Q46885198 | P17.46LATE PSEUDOPROGRESSION IN GLIOBLASTOMA PATIENTS: COMPARABLE ANALYSIS WITH REAL TUMOR PROGRESSION. |
| Q46521309 | P17.89EFFECTS OF GLIOBLASTOMA FIRST-LINE TRIALS ON TIME DELAY TO INITIATION OF TREATMENT, SIGNS OF EARLY TUMOR PROGRESSION AND PROGRESSION-FREE SURVIVAL. |
| Q98619329 | P2X7 Receptor Promotes Mouse Mammary Cancer Cell Invasiveness and Tumour Progression, and Is a Target for Anticancer Treatment |
| Q58764032 | P2Y2R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer |
| Q47328492 | P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas |
| Q44965676 | P53-independent induction of p21(waf1) pathway is preserved during tumor progression. |
| Q53627225 | P53R2, p53 inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. |
| Q42482716 | PACE4 expression in mouse basal keratinocytes results in basement membrane disruption and acceleration of tumor progression |
| Q38909525 | PACE4 inhibitors and their peptidomimetic analogs block prostate cancer tumor progression through quiescence induction, increased apoptosis and impaired neovascularisation |
| Q38710228 | PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression |
| Q94407720 | PALL-10. INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS |
| Q52597868 | PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. |
| Q93161427 | PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers |
| Q52859514 | PART-1 functions as a competitive endogenous RNA for promoting tumor progression by sponging miR-143 in colorectal cancer. |
| Q44849667 | PAX3 promotes tumor progression via CD105 signaling |
| Q91839736 | PCK1 Regulates Glycolysis and Tumor Progression in Clear Cell Renal Cell Carcinoma Through LDHA |
| Q53468073 | PCNA and protein P53 in recurrent supratentorial glial brain tumors: studies on correlation between morphology and tumor progression. |
| Q93038516 | PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas |
| Q49968394 | PD-L1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer. |
| Q38261131 | PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. |
| Q39982179 | PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity |
| Q34189404 | PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. |
| Q58786432 | PEG10 as an oncogene: expression regulatory mechanisms and role in tumor progression |
| Q44836718 | PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis. |
| Q101212328 | PET imaging of meningioma with 18F-FLT: a predictor of tumour progression |
| Q24337364 | PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice |
| Q46964419 | PI3Kγ Activates Integrin α4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression. |
| Q90169916 | PIK3CA and p53 mutations promote 4NQO-initated head and neck tumor progression and metastasis in mice |
| Q39733876 | PIM-1 gene RNA interference induces growth inhibition and apoptosis of prostate cancer cells and suppresses tumor progression in vivo |
| Q35793653 | PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma |
| Q93068898 | PIWI-interacting RNA 39980 promotes tumor progression and reduces drug sensitivity in neuroblastoma cells |
| Q36869444 | PKCiota promotes ovarian tumor progression through deregulation of cyclin E. |
| Q53575936 | PKCε-mediated c-Met endosomal processing directs fluctuant c-Met-JNK-paxillin signaling for tumor progression of HepG2. |
| Q92397068 | POFUT1 and PLAGL2 gene pair linked by a bidirectional promoter: the two in one of tumour progression in colorectal cancer? |
| Q38593326 | PPARα regulates tumor progression, foe or friend? |
| Q50656567 | PPARδ promotes tumor progression via activation of Glut1 and SLC1-A5 transcription. |
| Q72132823 | PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas |
| Q39025372 | PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities |
| Q113206755 | PRIM2 Promotes Cell Cycle and Tumor Progression in p53-Mutant Lung Cancer |
| Q90753294 | PRMT6 Promotes Lung Tumor Progression via the Alternate Activation of Tumor-Associated Macrophages |
| Q53590746 | PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer. |
| Q112288025 | PSMC2 knockdown suppressed tumor progression of skin cutaneous melanoma |
| Q37141742 | PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression |
| Q92024428 | PSPC1-interchanged interactions with PTK6 and β-catenin synergize oncogenic subcellular translocations and tumor progression |
| Q90222693 | PSPC1: a contextual determinant of tumor progression |
| Q36278234 | PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer |
| Q73739349 | PTEN/MMAC1 in malignant melanoma and its importance for tumor progression |
| Q34484195 | PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma |
| Q101053790 | PUF60/AURKA Axis Contributes to Tumor Progression and Malignant Phenotypes in Bladder Cancer |
| Q92509199 | PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells |
| Q95939285 | PYGB Promoted Tumor Progression by Regulating Wnt/β-Catenin Pathway in Gastric Cancer |
| Q99352234 | Pain May Promote Tumor Progression via Substance P-Dependent Modulation of Toll-like Receptor-4 |
| Q93369247 | Paip1 predicts poor prognosis and promotes tumor progression through AKT/GSK-3β pathway in lung adenocarcinoma |
| Q100438033 | Palliative Radiofrequency Ablation Accelerates the Residual Tumor Progression Through Increasing Tumor-Infiltrating MDSCs and Reducing T-Cell-Mediated Anti-Tumor Immune Responses in Animal Model |
| Q92123069 | Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer |
| Q38813632 | Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation |
| Q87723999 | Pancreatic cancer: A new model for imaging tumour progression |
| Q37829604 | Pancreatic cancer: the role of pancreatic stellate cells in tumor progression |
| Q40182528 | Pancreatic stellate cells are an important source of MMP-2 in human pancreatic cancer and accelerate tumor progression in a murine xenograft model and CAM assay |
| Q35771674 | Papillary carcinoma of the thyroid: difficult yet fascinating model of oncogenesis and tumour progression |
| Q54476646 | Papillary thyroid microcarcinoma with fatal outcome: evidence of tumor progression in lymph node metastases: report of 3 cases, with morphological and molecular analysis. |
| Q49997063 | Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression. |
| Q64075446 | Paracrine Induction of Epithelial-Mesenchymal Transition Between Colorectal Cancer Cells and its Suppression by a p53/miR-192/215/NID1 Axis |
| Q64940878 | Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. |
| Q35014280 | Paradoxical role of apoptosis in tumor progression |
| Q90804577 | Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression |
| Q68644967 | Parallel karyotypic evolution and tumor progression in uterine leiomyoma |
| Q36279602 | Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma. |
| Q35539955 | Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer. |
| Q52959848 | Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. |
| Q47132104 | Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. |
| Q96028810 | Parkin ubiquitinates phosphoglycerate dehydrogenase to suppress serine synthesis and tumor progression |
| Q36911589 | Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression |
| Q77573775 | Passive but not active CD8+ T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model |
| Q36960893 | Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression |
| Q73906985 | Pathologic significance of tumor progression in locally recurrent rectal cancer: different nature from primary cancer |
| Q78478250 | Pathological features of betel quid-related oral epithelial lesions in taiwan with special emphasis on the tumor progression and human papillomavirus association |
| Q36893654 | Pathological significance of intracytoplasmic connexin proteins: implication in tumor progression |
| Q70843327 | Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival |
| Q42500268 | Pathophysiology of tumor progression in human gallbladder: flow cytometry, CEA, and CA 19-9 levels in bile and serum in different stages of gallbladder disease |
| Q47300936 | Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression? |
| Q50446050 | Pattern of tumor progression in liver cancer: The missing partner in trial design. |
| Q61449569 | Patterns of Tumor Progression Predict Small and Tissue-Specific Tumor-Originating Niches |
| Q42509445 | Patterns of basal cell keratin 14 expression in Bowen's disease: a possible marker for tumour progression |
| Q48512965 | Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography/magnetic resonance imaging era. |
| Q42214756 | Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting |
| Q84591528 | Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: its association with tumor progression and proliferation |
| Q89765923 | Percutaneous cryoablation in early stage hepatocellular carcinoma: analysis of local tumor progression factors |
| Q89429923 | Percutaneous radiofrequency ablation of tumor feeding artery before target tumor ablation may reduce local tumor progression in hepatocellular carcinoma |
| Q50527907 | Percutaneous radiofrequency ablation therapy for hepatocellular carcinoma: a proposed new grading system for the ablative margin and prediction of local tumor progression and its validation. |
| Q64102666 | Pericardial Mesothelioma in a Dog: The Feasibility of Ultrasonography in Monitoring Tumor Progression |
| Q92185348 | Perineural invasion on biopsy specimen as predictor of tumor progression in aging male treated with radical prostatectomy. Could we use it for pre-surgical screening? |
| Q41116266 | Periodontal pathogens Porphyromonas gingivalis and Fusobacterium nucleatum promote tumor progression in an oral-specific chemical carcinogenesis model |
| Q39003784 | Perioperative Anesthesia Care and Tumor Progression |
| Q40327193 | Peripheral blood leucocytes show differential expression of tumour progression-related genes in colorectal cancer patients who have a postoperative intra-abdominal infection: a prospective matched cohort study |
| Q84283908 | Peritumoral lymphatic microvessel density associated with tumor progression and poor prognosis in gastric carcinoma |
| Q40601264 | Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. |
| Q37424793 | Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome |
| Q39019006 | Personalized dynamic prediction of death according to tumour progression and high-dimensional genetic factors: Meta-analysis with a joint model |
| Q91825120 | Phage display-identified PD-L1-binding peptides reinvigorate T-cell activity and inhibit tumor progression |
| Q104495061 | Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review |
| Q24632276 | Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer |
| Q55254953 | Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. |
| Q92393665 | Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer |
| Q38766568 | Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma |
| Q52726553 | Pharmacologically targeting the myristoylation of the scaffold protein FRS2α inhibits FGF/FGFR-mediated oncogenic signaling and tumor progression. |
| Q33382596 | Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma |
| Q104487889 | Phenotypic Heterogeneity in Tumor Progression, and Its Possible Role in the Onset of Cancer |
| Q21195198 | Phenotypic and genetic alterations in mammary stroma: implications for tumour progression |
| Q70224139 | Phenotypic and genotypic differences between high- and low-metastatic related tumor lines and the problem of tumor progression and variant generation |
| Q45254203 | Phenotypic dynamics of tumor progression in human malignant melanoma |
| Q33719284 | Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression |
| Q34135631 | Phosphatidylinositol 3-kinases in tumor progression |
| Q91168681 | Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression |
| Q39662794 | Phosphoglycerate kinase 1 promoting tumor progression and metastasis in gastric cancer - detected in a tumor mouse model using positron emission tomography/magnetic resonance imaging |
| Q37003826 | Phosphoinositide 3-OH kinase p85alpha and p110beta are essential for androgen receptor transactivation and tumor progression in prostate cancers |
| Q35773385 | Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. |
| Q35175975 | Phospholipase C-gamma1 in tumor progression. |
| Q50954736 | Phosphorylated 4E-BP1 is associated with tumor progression and adverse prognosis in colorectal cancer. |
| Q36741509 | Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma |
| Q44062331 | Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma |
| Q36750540 | Phosphorylation of eIF4E serine 209 is associated with tumour progression and reduced survival in malignant melanoma |
| Q91563538 | Physical Activity Plus Energy Restriction Prevents 4T1.2 Mammary Tumor Progression, MDSC Accumulation, and an Immunosuppressive Tumor Microenvironment |
| Q38701491 | Phytol induces ROS mediated apoptosis by induction of caspase 9 and 3 through activation of TRAIL, FAS and TNF receptors and inhibits tumor progression factor Glucose 6 phosphate dehydrogenase in lung carcinoma cell line (A549). |
| Q30393905 | Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells |
| Q64097870 | Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway |
| Q38999733 | Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. |
| Q36750665 | Pin1 facilitates NF-κB activation and promotes tumour progression in human hepatocellular carcinoma |
| Q37181702 | Pin1-Nanog expression in human glioma is correlated with advanced tumor progression |
| Q96137889 | Pineal gland protects against chemically induced oral carcinogenesis and inhibits tumor progression in rats |
| Q90487338 | Pitavastatin slows tumor progression and alters urine-derived volatile organic compounds through the mevalonate pathway |
| Q38780268 | Pivotal role of microRNA-9 in osteosarcoma tumorigenesis and tumor progression |
| Q90216204 | Pivotal roles of protein 4.1B/DAL‑1, a FERM‑domain containing protein, in tumor progression (Review) |
| Q37014054 | PlGF/VEGFR-1 Signaling Promotes Macrophage Polarization and Accelerated Tumor Progression in Obesity |
| Q52920833 | Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T-cell Lymphoma. |
| Q30009601 | Plakophilin-associated RNA-binding proteins in prostate cancer and their implications in tumor progression and metastasis |
| Q41644933 | Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients |
| Q97095429 | Plasma Level of Circular RNA hsa_circ_0000190 Correlates with Tumor Progression and Poor Treatment Response in Advanced Lung Cancers |
| Q53349273 | Plasma cell tumour progression in iMycEmu gene-insertion mice. |
| Q35103289 | Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. |
| Q85969106 | Plasmacytoid dendritic cells play a key role in tumor progression in lipopolysaccharide-stimulated lung tumor-bearing mice |
| Q79793990 | Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and proinflammatory pathways |
| Q42754658 | Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression |
| Q53605043 | Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. |
| Q37077231 | Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms |
| Q38764247 | Plasticity underlies tumor progression: role of Nodal signaling |
| Q84023917 | Platelet count and tumor progression in gastric cancer patients |
| Q48423939 | Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas |
| Q38174455 | Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. |
| Q42208908 | Pleiotrophin and N-syndecan promote perineural invasion and tumor progression in an orthotopic mouse model of pancreatic cancer |
| Q81162832 | Pleiotrophin expression correlates with melanocytic tumor progression and metastatic potential |
| Q39410987 | Pleiotropic Roles of Non-Coding RNAs in TGF-β-Mediated Epithelial-Mesenchymal Transition and Their Functions in Tumor Progression |
| Q73074317 | Pleiotropic over-expression of multidrug-resistance-related genes is correlated to MYCN and max mRNA accumulation during tumour progression in the IGR-N-91 human neuroblastoma model |
| Q39492048 | Plexin-A4 promotes tumor progression and tumor angiogenesis by enhancement of VEGF and bFGF signaling |
| Q38489312 | Ploidy level and tumor progression in prostatic carcinoma |
| Q42774421 | Pml represses tumour progression through inhibition of mTOR. |
| Q39230467 | Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer |
| Q37562162 | Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. |
| Q39537008 | Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression |
| Q39380065 | Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice. |
| Q99404959 | Poly C Binding Protein 1 Regulates p62/SQSTM1 mRNA Stability and Autophagic Degradation to Repress Tumor Progression |
| Q100298628 | Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8+ T Cell Memory and Delayed Tumor Progression |
| Q57781681 | Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression |
| Q46835660 | Polymorphisms in the glutathione S-transferase mu cluster are associated with tumour progression and patient outcome in colorectal cancer. |
| Q33923958 | Polyoma virus middle t antigen: a tumor progression factor |
| Q104735410 | Polyphenolic Fraction Obtained From Thalassia testudinum Marine Plant and Thalassiolin B Exert Cytotoxic Effects in Colorectal Cancer Cells and Arrest Tumor Progression in a Xenograft Mouse Model |
| Q36453190 | Polyploid cells rewire DNA damage response networks to overcome replication stress-induced barriers for tumour progression |
| Q38399917 | Populational equilibrium through exosome-mediated Wnt signaling in tumor progression of diffuse large B-cell lymphoma |
| Q73886936 | Porphyrin analogues as novel antagonists of fibroblast growth factor and vascular endothelial growth factor receptor binding that inhibit endothelial cell proliferation, tumor progression, and metastasis |
| Q102132337 | Porphyromonas gingivalis promotes tumor progression in esophageal squamous cell carcinoma |
| Q21136141 | Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis |
| Q45109371 | Positive association of up-regulated Cripto-1 and down-regulated E-cadherin with tumour progression and poor prognosis in gastric cancer |
| Q94488025 | Positive correlation of expression of L-type amino-acid transporter 1 with colorectal tumor progression and prognosis: Higher expression in sporadic colorectal tumors compared with ulcerative colitis-associated neoplasia |
| Q64387490 | Positive immunohistochemical staining of gammaH2AX is associated with tumor progression in gastric cancers from radiation-exposed patients |
| Q40110850 | Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment |
| Q73169907 | Possible mechanism of local tumor progression in experimentally-induced colorectal carcinomas in rats |
| Q73792847 | Possible role of telomerase activation in the multistep tumor progression of periampullary lesions in patients with familial adenomatous polyposis |
| Q40052805 | Post-Sepsis State Induces Tumor-Associated Macrophage Accumulation through CXCR4/CXCL12 and Favors Tumor Progression in Mice. |
| Q89036607 | Post-gadolinium 3-dimensional spatial, surface, and structural characteristics of glioblastomas differentiate pseudoprogression from true tumor progression |
| Q31117832 | Postictal Magnetic Resonance Imaging Changes Masquerading as Brain Tumor Progression: A Case Series |
| Q36857851 | Posttranslational truncation of E-cadherin and significance for tumour progression |
| Q38762825 | Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma |
| Q52307374 | Potential biological markers for the staging of tumor progression in oral mucosa: a multivariate analysis. |
| Q35035576 | Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study |
| Q38519784 | Potential markers of tongue tumor progression selected by cDNA microarray. |
| Q73567582 | Potential use of serum CD44 as an indicator of tumour progression in acute leukemia |
| Q104556461 | Pre-radiofrequency ablation MRI imaging features predict the local tumor progression in hepatocellular carcinoma |
| Q101128178 | Preablation three-dimensional ultrasonography can predict therapeutic effect and local tumor progression after radiofrequency ablation for hepatocellular carcinoma |
| Q41116840 | Prebiopsy neo-adjuvant endocrine therapy for breast cancer to prevent post-surgery trauma-induced growth factor and immune-suppression mediated tumour progression |
| Q33343248 | Precise mapping of increased sialylation pattern and the expression of acute phase proteins accompanying murine tumor progression in BALB/c mouse by integrated sera proteomics and glycomics. |
| Q36545796 | Preclinical model in HCC: the SGK1 kinase inhibitor SI113 blocks tumor progression in vitro and in vivo and synergizes with radiotherapy |
| Q34995167 | Preclinical trials for prevention of tumor progression of hepatocellular carcinoma by LZ-8 targeting c-Met dependent and independent pathways |
| Q58565410 | Prediction of Local Tumor Progression after Radiofrequency Ablation (RFA) of Hepatocellular Carcinoma by Assessment of Ablative Margin Using Pre-RFA MRI and Post-RFA CT Registration |
| Q34565015 | Prediction of breast tumor progression by integrity of free circulating DNA in serum. |
| Q35674236 | Prediction of desmoid tumor progression using miRNA expression profiling |
| Q112282479 | Prediction of occult tumor progression via platelet RNAs in a mouse melanoma model: a potential new platform for early detection of cancer |
| Q43939336 | Prediction of tumour progression in superficial bladder carcinoma |
| Q95305605 | Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy |
| Q53455845 | Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer. |
| Q34540982 | Predictive value of clinical judgment of tumour progression in phase II trials |
| Q44321839 | Predictors of tumor progression among children with gangliogliomas. Clinical article |
| Q33813431 | Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer |
| Q83356626 | Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndrome |
| Q77392052 | Preneoplastic mammary tumor markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumor progression in transgenic mice |
| Q37485620 | Preparation of a "chemical vaccine" against tumor progression |
| Q40242701 | Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma |
| Q69842513 | Preservation of cytometric DNA distribution and epithelial marker expression after tumor progression of human large bowel carcinomas |
| Q79929848 | Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus |
| Q112312775 | Preventing tumor progression to the bone by induced tumor-suppressing MSCs |
| Q53744390 | Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein. |
| Q73977846 | Prevention of colorectal cancer: tumor progression, chemoprevention, and COX-2 inhibition |
| Q91890664 | Prevention of tumor progression in Stewart-Treves syndrome with a low dose of pazopanib |
| Q43853176 | Primary tumor vascularity in esophagus cancer. CD34 and HIF1-α expression correlate with tumor progression |
| Q39765093 | Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification |
| Q54396439 | Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. |
| Q36683597 | Pro-oxidant milieu blunts scissors: insight into tumor progression, drug resistance, and novel druggable targets |
| Q92728545 | Pro-survival autophagy: An emerging candidate of tumor progression through maintaining hallmarks of cancer |
| Q34099842 | Probabilistic reconstruction of the tumor progression process in gene regulatory networks in the presence of uncertainty |
| Q83892051 | Procathepsin L secretion, which triggers tumour progression, is regulated by Rab4a in human melanoma cells |
| Q39078284 | Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis |
| Q37709723 | Progastriscin: structure, function, and its role in tumor progression. |
| Q43728401 | Progesterone receptor expression in human prostate cancer: correlation with tumor progression |
| Q100313243 | Prognostic Value of the Pace of Tumor Progression as Assessed by Serial 18F-FDG PET/CT Scan and Liquid Biopsy in Refractory Colorectal Cancer: The CORIOLAN Trial |
| Q41613152 | Prognostic significance of tumour progression and human papillomavirus in advanced tonsillar cancer classified as stage IVa. |
| Q94543178 | Prognostic value of miR-892a in gastric cancer and its regulatory effect on tumor progression |
| Q84188020 | Prognostic value of tumor progression-related gene expression in colorectal cancer patients |
| Q98617603 | Programmed Death 1 Ligand Expression in the Monocytes of Patients with Hepatocellular Carcinoma Depends on Tumor Progression |
| Q108589189 | Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis |
| Q40511730 | Progression elevated gene-3 (PEG-3) induces pleiotropic effects on tumor progression: modulation of genomic stability and invasion |
| Q47854825 | Progression of hepatic neoplasms is severely retarded in mice lacking the bisecting N-acetylglucosamine on N-glycans: evidence for a glycoprotein factor that facilitates hepatic tumor progression. |
| Q41602632 | Progressive abrogation of TGF-beta 1 and EGF growth control is associated with tumour progression in ras-transfected human keratinocytes |
| Q35694216 | Proinflammatory cytokines, immune response and tumour progression |
| Q44807460 | Proinflammatory mediators and genetic background in oncogene mediated tumor progression |
| Q90265119 | Proinvasive extracellular matrix remodeling for tumor progression |
| Q52974521 | Prolonged Ezh2 Depletion in Glioblastoma Causes a Robust Switch in Cell Fate Resulting in Tumor Progression. |
| Q43099160 | Prominin-1 and its role in tumor progression and assessment of clinical prognosis in systemic malignancies |
| Q43917863 | Promoter hypermethylation during tumor progression: quantitative analysis employing kinetic PCR |
| Q44688630 | Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in hepatocellular carcinoma |
| Q51657031 | Promoter hypermethylation of the O6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression. |
| Q53350741 | Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas. |
| Q92999000 | Promotion effect of liver tumor progression in male kras transgenic zebrafish induced by tris (1, 3-dichloro-2-propyl) phosphate |
| Q67239621 | Promotion of benign hyperplastic lesions by calcium, magnesium and cAMP, and inhibition of tumor progression by magnesium in hamster cheek pouch |
| Q58695612 | Promotion of tumor progression and cancer stemness by MUC15 in thyroid cancer via the GPCR/ERK and integrin-FAK signaling pathways |
| Q112742441 | Promotion of tumor progression by exosome transmission of circular RNA circSKA3 |
| Q28084050 | Proposal of a hybrid approach for tumor progression and tumor-induced angiogenesis |
| Q34679398 | Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy |
| Q104061521 | Prostaglandin E2 and Cancer: Insight into Tumor Progression and Immunity |
| Q80274418 | Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells |
| Q83169209 | Prostate cancer cells lose their sensitivity to TGFβI growth inhibition with tumor progression |
| Q87166109 | Prostate cancer: a role for neoneurogenesis in tumour progression? |
| Q69104878 | Prostate specific antigen: not detectable despite tumor progression after radical prostatectomy |
| Q39677575 | Prostate tumor progression and metastasis |
| Q30306149 | Prostate tumor progression and prognosis. interplay of tumor and host factors |
| Q39305976 | Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis |
| Q74322511 | Prostatic sarcoma with rapid tumor progression after nerve sparing radical cystoprostatectomy |
| Q40176984 | Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse |
| Q58567259 | Protease activated receptor-1 impedes prostate and intestinal tumor progression in mice: comment |
| Q51801232 | Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. |
| Q46251817 | Protease signaling in tumor progression |
| Q40156340 | Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression |
| Q91177070 | Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice |
| Q41684225 | Proteases and protease inhibitors in tumor progression. |
| Q35541218 | Proteases in brain tumour progression |
| Q51563338 | Protective Effect of Perindopril on Tumor Progression and Angiogenesis in Animal Model of Breast Cancer. |
| Q71123353 | Protective activity of thymosin alpha 1 against tumor progression in immunosuppressed mice |
| Q50898301 | Protein N-arginine methyltransferase 5 promotes the tumor progression and radioresistance of nasopharyngeal carcinoma. |
| Q89547247 | Protein disulfide isomerases are promising targets for predicting the survival and tumor progression in glioma patients |
| Q46129074 | Protein kinase C-theta is required for NK cell activation and in vivo control of tumor progression. |
| Q64928562 | Protein overexpression and gene amplification of epidermal growth factor receptor in adult testicular germ cell tumors: potential role in tumor progression. |
| Q50517026 | Protein profiling of angiogenesis-related growth factors in laryngeal carcinoma: Pattern of protein expression in relation to tumour progression. |
| Q40695460 | Protein tyrosine phosphatase PTPRB regulates Src phosphorylation and tumour progression in NSCLC. |
| Q71624645 | Proteinase activity in invasive cancer of the breast. Correlation with tumor progression |
| Q42815606 | Proteinase-activated receptor-1-triggered activation of tumor progression locus-2 promotes actin cytoskeleton reorganization and cell migration. |
| Q34706643 | Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. |
| Q34398151 | Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis |
| Q40839677 | Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression |
| Q34218154 | Proteolyzed matrix as a template for the regulation of tumor progression |
| Q34999444 | Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression |
| Q38445377 | Proteomic Analysis of Exosomes and Exosome-Free Conditioned Media From Human Osteosarcoma Cell Lines Reveals Secretion of Proteins Related to Tumor Progression. |
| Q39023397 | Proteomic analysis indicates that overexpression and nuclear translocation of lactoylglutathione lyase (GLO1) is associated with tumor progression in murine fibrosarcoma. |
| Q39926532 | Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. |
| Q40310884 | Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression |
| Q36355173 | Proteomics in tumor progression and metastasis |
| Q36585720 | Proteostasis modulators prolong missense VHL protein activity and halt tumor progression |
| Q39763406 | Proto-oncogene amplification: role in tumour progression. |
| Q73733145 | Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression |
| Q36197642 | Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. |
| Q91816227 | Proton beam radiotherapy (PBR) for the treatment of retinal capillary haemangioblastoma stabilises tumour progression but with poor visual outcomes |
| Q35526292 | Proton irradiation augments the suppression of tumor progression observed with advanced age. |
| Q37917316 | Protons and Ca2+: ionic allies in tumor progression? |
| Q34307830 | Provirus insertion in Tpl-1, an Ets-1-related oncogene, is associated with tumor progression in Moloney murine leukemia virus-induced rat thymic lymphomas |
| Q42231851 | Pseudomonas aeruginosa mannose-sensitive hemagglutinin promotes T-cell response via toll-like receptor 4-mediated dendritic cells to slow tumor progression in mice |
| Q36337560 | Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape |
| Q52722046 | Pseudotime Dynamics in Melanoma Single-Cell Transcriptomes Reveals Different Mechanisms of Tumor Progression. |
| Q96136423 | Publisher Correction: ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism |
| Q94466437 | Pulmonary artery coil embolisation prevented tumour progression in a patient with advanced squamous cell lung carcinoma |
| Q34398382 | Pyk2 promotes tumor progression in multiple myeloma |
| Q57788719 | Pyk2 promotes tumor progression in renal cell carcinoma |
| Q50048524 | Pyruvate dehydrogenase PDH-E1β controls tumor progression by altering the metabolic status of cancer cells. |
| Q36381459 | Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer |
| Q41271051 | Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study |
| Q41151353 | Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression |
| Q36597182 | Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats |
| Q102071284 | Quantitative CEST and MT at 1.5T for monitoring treatment response in glioblastoma: early and late tumor progression during chemoradiation |
| Q48495257 | Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI. |
| Q37187727 | Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival |
| Q90885998 | Quantitative Volumetric Assessment of Ablative Margins in Hepatocellular Carcinoma: Predicting Local Tumor Progression Using Nonrigid Registration Software |
| Q40711982 | Quantitative analysis of VEGF-isoforms in head and neck squamous cell carcinoma cell lines: relation to xenotransplantability and tumour progression in mice. |
| Q39824295 | Quantitative genetic analysis of tumor progression |
| Q73671369 | Quantitative image analysis of oesophageal squamous cell carcinoma from the high-incidence area of China, with special reference to tumour progression and papillomavirus (HPV) involvement |
| Q112277395 | Quantitative phosphoproteomics reveals ectopic ATP synthase on mesenchymal stem cells to promote tumor progression via ERK/c-Fos pathway activation |
| Q36851587 | Quantitative variations in gene expression: Possible role in cellular diversification and tumor progression |
| Q37734886 | Quantitatively controlling expression of miR-17~92 determines colon tumor progression in a mouse tumor model |
| Q112642216 | Quiescin Sulfhydryl Oxidase 2 Overexpression Predicts Poor Prognosis and Tumor Progression in Patients With Colorectal Cancer: A Study Based on Data Mining and Clinical Verification |
| Q61805780 | RAC1B: A Rho GTPase with Versatile Functions in Malignant Transformation and Tumor Progression |
| Q37087082 | RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer |
| Q33705675 | RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma. |
| Q39544703 | RANKL expression specifically observed in vivo promotes epithelial mesenchymal transition and tumor progression |
| Q57782091 | RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer |
| Q58321397 | RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma |
| Q91676950 | RB constrains lineage fidelity and multiple stages of tumour progression and metastasis |
| Q58907015 | RB1 oncosuppressor gene over-expression inhibits tumor progression and induces melanogenesis in metastatic melanoma cells |
| Q36623359 | RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer |
| Q54978328 | REGγ deficiency suppresses tumor progression via stabilizing CK1ε in renal cell carcinoma. |
| Q97590360 | RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma |
| Q51324892 | RET/PTC3 Rearrangement in Papillary Thyroid Carcinoma: Possible Marker of Tumor Progression. |
| Q91927245 | RETRACTED ARTICLE: Inhibition of Tumor Progression by NG-Nitro-L-arginine Methyl Ester in 7,12- dimethylbenz(a)anthracene Induced Breast Cancer: Nitric Oxide Synthase Inhibition as an Antitumor Prevention |
| Q37330849 | RETRACTED: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma |
| Q84463291 | RGS16 and FosB underexpressed in pancreatic cancer with lymph node metastasis promote tumor progression |
| Q52758657 | RIP off STAT3 to counteract tumor progression. |
| Q40517753 | RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC. |
| Q38772396 | RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer |
| Q64108135 | RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3 |
| Q37426219 | RNA splicing factors regulated by HPV16 during cervical tumour progression. |
| Q97546454 | RNA-binding proteins in tumor progression |
| Q95831986 | ROCK-mediated selective activation of PERK signalling causes fibroblast reprogramming and tumour progression through a CRELD2-dependent mechanism |
| Q36634247 | ROCK1 & 2 perform overlapping and unique roles in angiogenesis and angiosarcoma tumor progression |
| Q61442716 | ROCK1-PredictedmicroRNAs Dysregulation Contributes to Tumor Progression in Ewing Sarcoma |
| Q39052528 | RON (recepteur d'origine nantais) expression and its association with tumor progression in laryngeal squamous cell carcinoma |
| Q53591553 | RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. |
| Q39412662 | RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer |
| Q36096934 | RON, a tyrosine kinase receptor involved in tumor progression and metastasis |
| Q41697040 | RORα2 requires LSD1 to enhance tumor progression in breast cancer. |
| Q38116287 | ROS-major mediators of extracellular matrix remodeling during tumor progression. |
| Q101567604 | RUNX1 promotes MAPK signaling to increase tumor progression and metastasis via OPN in head and neck cancer |
| Q26800112 | RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression |
| Q54297164 | RUNX3 methylation in normal surrounding urothelium of patients with non-muscle-invasive bladder cancer: potential role in the prediction of tumor progression. |
| Q37350643 | Rab11-FIP1C Is a Critical Negative Regulator in ErbB2-Mediated Mammary Tumor Progression |
| Q39302103 | Rab27a supports exosome-dependent and -independent mechanisms that modify the tumor microenvironment and can promote tumor progression |
| Q93153167 | Rac1-dependent phagocytosis of apoptotic cells by oral squamous cell carcinoma cells: A possible driving force for tumor progression |
| Q36436106 | Rad9 protein contributes to prostate tumor progression by promoting cell migration and anoikis resistance |
| Q51790445 | Radiofrequency Ablation of Lung Tumors Using a Multitined Expandable Electrode: Impact of the Electrode Array Diameter on Local Tumor Progression. |
| Q53474413 | Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression. |
| Q50066363 | Radiofrequency ablation for colorectal cancer liver metastases initially greater than 25 mm but downsized by neo-adjuvant chemotherapy is associated with increased rate of local tumor progression. |
| Q87795744 | Radiofrequency ablation of hepatic metastases: factors influencing local tumor progression |
| Q84567554 | Radiofrequency ablation of hepatic tumours: effect of post-ablation margin on local tumour progression |
| Q44732156 | Radiofrequency ablation of hepatocellular carcinoma: correlation between local tumor progression after ablation and ablative margin |
| Q51731081 | Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models. |
| Q101129710 | Radiotherapy-Resistant Breast Cancer Cells Enhance Tumor Progression by Enhancing Premetastatic Niche Formation through the HIF-1α-LOX Axis |
| Q47347933 | Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF-1R activation |
| Q96304790 | Ran GTPase: A Key Player in Tumor Progression and Metastasis |
| Q38716506 | Rap1GAP inhibits tumor progression in endometrial cancer. |
| Q44013375 | Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy |
| Q36926010 | Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer |
| Q93022372 | Rapid Early Tumor Progression is Prognostic in Glioblastoma Patients |
| Q40077194 | Rapid xenograft tumor progression in beta-arrestin1 transgenic mice due to enhanced tumor angiogenesis |
| Q37219204 | RasGRP1 overexpression in the epidermis of transgenic mice contributes to tumor progression during multistage skin carcinogenesis |
| Q33651997 | Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma |
| Q42584896 | Rb/E2F4 and Smad2/3 link survivin to TGF-beta-induced apoptosis and tumor progression |
| Q112639281 | Rcl1 suppresses tumor progression of hepatocellular carcinoma: a comprehensive analysis of bioinformatics and in vitro experiments |
| Q53172229 | Re: Expression of Nuclear Matrix Proteins Binding Matrix Attachment Regions in Prostate Cancer. PARP-1: New Player in Tumor Progression. |
| Q84386435 | Re: Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. O. Celhay, M. Yacoub, J. Irani, B. Dore, O. Cussenot and G. Fromont. J Urol 2010; 184: 2172-2178 |
| Q54134109 | Re: Mitochondria and tumor progression in ulcerative colitis. |
| Q83153159 | Re: Sven van den Bosch, J. Alfred Witjes. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60:493-500 |
| Q48892097 | Re: Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. |
| Q48841352 | Re: Tumour progression or pseudoprogression? A review of posttreatment radiological appearances of glioblastoma. A reply. |
| Q91122315 | Re: p27 Transcriptionally Coregulates cJun to Drive Programs of Tumor Progression |
| Q92310461 | Re: p27 Transcriptionally Coregulates cJun to Drive Programs of Tumor Progression |
| Q24306210 | Reactivation of embryonic nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells |
| Q33949075 | Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression |
| Q36486116 | Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression |
| Q90266043 | Reactive oxygen species in colorectal cancer: The therapeutic impact and its potential roles in tumor progression via perturbation of cellular and physiological dysregulated pathways |
| Q36071787 | Reactive oxygen species in tumor progression |
| Q54567802 | Reactive oxygen species-mediated PKC and integrin signaling promotes tumor progression of human hepatoma HepG2. |
| Q35678603 | Real-time imaging of tumor progression in a fluorescent orthotopic mouse model of thyroid cancer |
| Q41561800 | Real-time monitoring of tumor progression and drug responses in a preclinical mouse model of prostate cancer |
| Q43164376 | Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma |
| Q78205498 | Recancostat compositum therapy does not prevent tumor progression in young cancer patients |
| Q36954366 | Recent advances in tumor hypoxia: tumor progression, molecular mechanisms, and therapeutic implications |
| Q34313996 | Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression |
| Q38756065 | Receptor for activated protein kinase C 1 suppresses gastric tumor progression through nuclear factor-kB pathway |
| Q122528723 | Receptor for hyaluronan‐mediated motility ( |
| Q91574615 | Receptor tyrosine kinase, RON, promotes tumor progression by regulating EMT and the MAPK signaling pathway in human oral squamous cell carcinoma |
| Q36399807 | Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression |
| Q40020050 | Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. |
| Q47869837 | Recombinant protein rMBP-NAP restricts tumor progression by triggering antitumor immunity in mouse metastatic lung cancer |
| Q36875744 | Recombination between two integrated proviruses, one of which was inserted near c-myc in a retrovirus-induced rat thymoma: implications for tumor progression. |
| Q39049644 | Recruited brain tumor-derived mesenchymal stem cells contribute to brain tumor progression |
| Q33960280 | Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression |
| Q46170131 | Recurrent chemical reactivations of EBV promotes genome instability and enhances tumor progression of nasopharyngeal carcinoma cells. |
| Q42455944 | Redistribution and enhanced protein kinase C-mediated phosphorylation of alpha- and gamma-adducin during renal tumor progression |
| Q38059262 | Redox molecular machines involved in tumor progression |
| Q55008876 | Reduced Expression of Deubiquitinase USP33 Is Associated with Tumor Progression and Poor Prognosis of Gastric Adenocarcinoma. |
| Q44657248 | Reduced FHIT expression is associated with tumor progression in sporadic colon adenocarcinoma. |
| Q44533917 | Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis |
| Q74309789 | Reduced angiogenesis and tumor progression in gelatinase A-deficient mice |
| Q33590428 | Reduced expression of AMPK-β1 during tumor progression enhances the oncogenic capacity of advanced ovarian cancer |
| Q43778503 | Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype |
| Q36649049 | Reduced expression of Axin correlates with tumour progression of oesophageal squamous cell carcinoma |
| Q37301807 | Reduced expression of CD109 in tumor-associated endothelial cells promotes tumor progression by paracrine interleukin-8 in hepatocellular carcinoma |
| Q54269263 | Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis. |
| Q36230464 | Reduced expression of TRF1 is associated with tumor progression and poor prognosis in oral squamous cell carcinoma. |
| Q39442418 | Reduced expression of activin receptor-like kinase 7 in breast cancer is associated with tumor progression |
| Q79917761 | Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma |
| Q34514322 | Reduced expression of the polymeric immunoglobulin receptor in pancreatic and periampullary adenocarcinoma signifies tumour progression and poor prognosis |
| Q44666142 | Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III. |
| Q35478848 | Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression |
| Q58090585 | Reduced interleukin-38 in non-small cell lung cancer is associated with tumour progression |
| Q40876215 | Reduced levels of connexin43 in cervical dysplasia: inducible expression in a cervical carcinoma cell line decreases neoplastic potential with implications for tumor progression |
| Q73367502 | Reduced mammary tumor progression in WAP-TAg/WAP-maspin bitransgenic mice |
| Q46462972 | Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate. |
| Q57285777 | Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression |
| Q80677190 | Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients |
| Q84376244 | Reduced tumour progression and angiogenesis in 1,2-dimethylhydrazine mice treated with NS-398 is associated with down-regulation of cyclooxygenase-2 and decreased beta-catenin nuclear localisation |
| Q99350780 | Reduction of Polyunsaturated Fatty Acids with Tumor Progression in a Lean Non-Alcoholic Steatohepatitis-Associated Hepatocellular Carcinoma Mouse Model |
| Q44916079 | Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs |
| Q36048166 | Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival |
| Q42951047 | Regarding: 'Epoetin beta treatment in patients with cancer chemotherapy induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events'. |
| Q61797822 | Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment |
| Q28603650 | Registered report: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF |
| Q51734206 | Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice. |
| Q62825344 | Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo |
| Q40957737 | Regulation of E-cadherin gene expression during tumor progression: the role of a new Ets-binding site and the E-pal element |
| Q38156210 | Regulation of EMT by Notch signaling pathway in tumor progression |
| Q37096248 | Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains |
| Q35833837 | Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. |
| Q52720171 | Regulation of Tumor Progression by Programmed Necrosis. |
| Q112289936 | Regulation of follistatin-like 3 expression by miR-486-5p modulates gastric cancer cell proliferation, migration and tumor progression |
| Q82303831 | Regulation of invasive growth: similar epigenetic mechanisms underpin tumour progression and implantation in human pregnancy |
| Q37779938 | Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance |
| Q37486777 | Regulation of the colonic vitamin D system for prevention of tumor progression: an update. |
| Q35636559 | Regulation of tumor progression by anti-neoplastic T cell responses |
| Q43164816 | Regulation of tumor progression by extracellular galectin-3. |
| Q38978893 | Regulation of tumor progression via the Snail-RKIP signaling pathway by nicotine exposure in head and neck squamous cell carcinoma |
| Q35942178 | Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer. |
| Q38161416 | Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? |
| Q40532835 | Regulatory T cells function at the early stage of tumor progression in a mouse model of tongue squamous cell carcinoma |
| Q54346592 | Relationship between CaMBr1 expression and tumor progression in small cell lung carcinomas. |
| Q40123783 | Relationship between folate status and tumour progression in patients with hepatocellular carcinoma |
| Q43763382 | Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination. |
| Q39260129 | Relationship of computed tomography perfusion and positron emission tomography to tumour progression in malignant glioma |
| Q71126294 | Relationship of p53 gene alterations with tumor progression and recurrence in olfactory neuroblastoma |
| Q41619750 | Relative resistance to 1,25-dihydroxyvitamin D3 in a keratinocyte model of tumor progression |
| Q73851246 | Release from apoptosis correlates with tumor progression in the AKR lymphoma |
| Q81792220 | Release of cell-free DNA into the bloodstream leads to high levels of non-tumor plasma DNA during tumor progression in rats |
| Q40185858 | Relevance of spontaneous in vivo tumor-host cell fusion to tumor progression and metastasis evaluated using a series of lectin-resistant mutant tumor sublines. |
| Q36803543 | Remodeling of calcium signaling in tumor progression |
| Q80068358 | Renal-cell carcinoma: vaccination and risk of tumour progression |
| Q42521042 | Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression |
| Q94346561 | Reply: CIITA methylation and decreased levels of HLA-DR in tumour progression |
| Q39765359 | Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets. |
| Q37679199 | Repression of GPRC5A is associated with activated STAT3, which contributes to tumor progression of head and neck squamous cell carcinoma |
| Q38325627 | Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma |
| Q114872519 | Reprogrammed transsulfuration promotes basal-like breast tumor progression via realigning cellular cysteine persulfidation |
| Q88938033 | Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer |
| Q35591891 | Requirement for BUB1B/BUBR1 in tumor progression of lung adenocarcinoma |
| Q92859340 | Requirement for epithelial p38α in KRAS-driven lung tumor progression |
| Q104797606 | Research advances in the role of gastric cancer‑derived mesenchymal stem cells in tumor progression (Review) |
| Q37482078 | Researches toward potassium channels on tumor progressions |
| Q53627672 | Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression |
| Q37873771 | Resistance to tgf-Beta-induced elimination of transformed-cells is required during tumor progression (review-hypothesis). |
| Q56334535 | Response Assessment of Meningioma: 1D, 2D and Volumetric Criteria for Treatment Response and Tumor Progression |
| Q39227418 | Restore the brake on tumor progression |
| Q89668189 | Restriction Spectrum Imaging Differentiates True Tumor Progression From Immune-Mediated Pseudoprogression: Case Report of a Patient With Glioblastoma |
| Q98501144 | Resveratrol Suppresses Tumor Progression via Inhibiting STAT3/HIF-1α/VEGF Pathway in an Orthotopic Rat Model of Non-Small-Cell Lung Cancer (NSCLC) |
| Q38949643 | Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. |
| Q98626416 | Resveratrol inhibits tumor progression by down-regulation of NLRP3 in renal cell carcinoma |
| Q39216146 | Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase |
| Q35156138 | Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression |
| Q69833760 | Retardation of prostate tumor progression in the Noble rat by 4-methyl-4-aza-steroidal inhibitors of 5 alpha-reductase |
| Q53631585 | Retention of platinum sensitivity till late stages of tumour progression may imply improved prognosis of oesophageal and gastric cancers. |
| Q33382723 | Retinoblastoma loss modulates DNA damage response favoring tumor progression |
| Q39518102 | Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression |
| Q97640412 | Retraction 'Reduced interleukin-38 in non-small cell lung cancer is associated with tumour progression' |
| Q97640411 | Retraction 'Reduced miR-125a-5p level in non-small-cell lung cancer is associated with tumour progression' |
| Q48664086 | Retraction Note to: MicroRNA-495 mimics delivery inhibits lung tumor progression. |
| Q90210441 | Retraction Note to: Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression |
| Q93086602 | Retraction Note: BRD7 inhibits the Warburg effect and tumor progression through inactivation of HIF1α/LDHA axis in breast cancer |
| Q61443697 | Retraction Note: Hsa-miR-623 suppresses tumor progression in human lung adenocarcinoma |
| Q64279666 | Retraction Note: Up-regulation of CDK16 by multiple mechanisms in hepatocellular carcinoma promotes tumor progression |
| Q89121044 | Retraction: The Potential Role of Hypoxia Inducible Factor 1α in Tumor Progression after Hypoxia and Chemotherapy in Hepatocellular Carcinoma |
| Q35070297 | Reverse engineering the neuroblastoma regulatory network uncovers MAX as one of the master regulators of tumor progression |
| Q41067268 | Reversible and irreversible tumor progression of a weakly malignant rat mammary carcinoma cell line by in vitro exposure to epidermal growth factor |
| Q91455511 | Reversible regulation of SATB1 ubiquitination by USP47 and SMURF2 mediates colon cancer cell proliferation and tumor progression |
| Q33940795 | Review: peptidases and peptidase inhibitors in the pathogenesis of diseases. Disturbances in the ubiquitin-mediated proteolytic system. Protease-antiprotease imbalance in inflammatory reactions. Role of cathepsins in tumour progression |
| Q83186808 | Revisiting the canonical tumour progression model |
| Q91904097 | Rgnef promotes ovarian tumor progression and confers protection from oxidative stress |
| Q46336004 | Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression |
| Q39856628 | Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia |
| Q77323954 | Rho GTPases as early markers for tumour progression |
| Q90640791 | Ricinus communis L. fruit extract inhibits migration/invasion, induces apoptosis in breast cancer cells and arrests tumor progression in vivo |
| Q98580692 | Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells |
| Q98386417 | Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer |
| Q40407022 | Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. |
| Q80229911 | Risk factors for occurrence of local tumor progression after percutaneous radiofrequency ablation for lung neoplasms |
| Q48543475 | Risk of tumor progression in colon carcinoma resection and perioperative prophylaxis with polyvalent immunoglobulins - per aspera ad astra. |
| Q84069178 | Risk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation |
| Q80425894 | Rituximab-induced tumor progression: does it really happen? |
| Q74318103 | Roentgen screening of mammary tumor progression |
| Q42611535 | Role for catecholamines in tumor progression: possible use for β-blockers in the treatment of cancer |
| Q38023546 | Role of CD44 in tumour progression and strategies for targeting |
| Q99555702 | Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival |
| Q55263195 | Role of DKK4 in Tumorigenesis and Tumor Progression. |
| Q26745758 | Role of DUSP1/MKP1 in tumorigenesis, tumor progression and therapy |
| Q92408525 | Role of Epithelial-Mesenchymal Transition in Tumor Progression |
| Q34562878 | Role of GalNAc4S-6ST in astrocytic tumor progression |
| Q28297138 | Role of HER2/neu in tumor progression and therapy |
| Q38696076 | Role of HSPA1L as a cellular prion protein stabilizer in tumor progression via HIF-1α/GP78 axis |
| Q50073062 | Role of Immune System in Tumor Progression and Carcinogenesis. |
| Q35186460 | Role of MAP kinase in tumor progression and invasion |
| Q47671158 | Role of MUC1 Expression in Tumor Progression |
| Q99569411 | Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance |
| Q47886024 | Role of PTEN in gastrointestinal stromal tumor progression |
| Q47647274 | Role of Proteoglycans in Tumor Progression |
| Q37949289 | Role of SOCS1 in tumor progression and therapeutic application |
| Q40377759 | Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression |
| Q89534946 | Role of SSH1 in colorectal cancer prognosis and tumor progression |
| Q92080256 | Role of Tissue Factor in Tumor Progression and Cancer-Associated Thrombosis |
| Q39278171 | Role of YAP-1 in Thyroid Tumor Progression and Outcome. |
| Q38978207 | Role of adenosine A2b receptor overexpression in tumor progression |
| Q80856824 | Role of angiogenic and non-angiogenic mechanisms in oral squamous cell carcinoma: correlation with histologic differentiation and tumor progression |
| Q37762199 | Role of carcinoma-associated fibroblasts and hypoxia in tumor progression |
| Q37102391 | Role of cyclooxygenase-2 in tumor progression and immune regulation in lung cancer. |
| Q34021476 | Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma |
| Q34706657 | Role of elastin-matrix interactions in tumor progression |
| Q41011298 | Role of epidermal-growth-factor receptor in tumor progression in transformed human mammary epithelial cells |
| Q84605091 | Role of epithelial-mesenchymal transition in tumor progression |
| Q40670451 | Role of gangliosides in tumor progression. |
| Q49142914 | Role of gangliosides in tumour progression: a molecular target for cancer therapy? |
| Q37132658 | Role of gene methylation in antitumor immune response: implication for tumor progression |
| Q92205038 | Role of heparanase in tumor progression: Molecular aspects and therapeutic options |
| Q42816366 | Role of heterochromatin variation in the instability of a marker chromosome during tumor progression |
| Q44468591 | Role of immune and/or natural factors of resistance of the host to tumor progression on the effectiveness of antitumor treatment |
| Q71755774 | Role of immune response as determinant of tumor progression in function of host age in the B16 melanoma |
| Q40870661 | Role of integrins and other cell adhesion molecules in tumor progression and metastasis |
| Q41095034 | Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient. |
| Q37476026 | Role of macrophages in tumour progression. |
| Q40616913 | Role of matrix, fibroblasts and type IV collagenases in tumor progression and invasion |
| Q92452815 | Role of miRNAs in tumor and endothelial cell interactions during tumor progression |
| Q33995825 | Role of myoepithelial cells in breast tumor progression |
| Q74468728 | Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer |
| Q34570058 | Role of nitric oxide in carcinogenesis and tumour progression |
| Q41739537 | Role of nitric oxide in tumor progression: lessons from experimental tumors |
| Q34588612 | Role of nitric oxide in tumour progression with special reference to a murine breast cancer model |
| Q41051336 | Role of nitric oxide in tumour progression: lessons from human tumours |
| Q35770935 | Role of osteopontin in tumour progression |
| Q80376459 | Role of p16/INK4a in gastrointestinal stromal tumor progression |
| Q37664171 | Role of platelet-derived microparticles in angiogenesis and tumor progression |
| Q88561410 | Role of the Apparent Diffusion Coefficient as a Predictor of Tumor Progression in Patients with Chordoma |
| Q92372937 | Role of the RAB7 Protein in Tumor Progression and Cisplatin Chemoresistance |
| Q46541959 | Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. |
| Q37228734 | Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression |
| Q38778089 | Role of the tumor microenvironment in tumor progression and the clinical applications (Review). |
| Q34307545 | Role of thrombin in angiogenesis and tumor progression |
| Q44235591 | Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients |
| Q81314538 | Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma |
| Q36591374 | Role of tumor-associated macrophages in tumor progression and invasion |
| Q46132798 | Role of tyrosine kinases in tumor progression of the head and neck |
| Q36997616 | Role of urokinase receptor in tumor progression and development |
| Q96770169 | Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment |
| Q100416717 | Roles of IFN-γ in tumor progression and regression: a review |
| Q98620028 | Roles of IL-1 in Cancer: From Tumor Progression to Resistance to Targeted Therapies |
| Q37790755 | Roles of Sema4D and Plexin-B1 in tumor progression |
| Q28081193 | Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets |
| Q39133948 | Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer |
| Q38250158 | Roles of glycosaminoglycans and glycanmimetics in tumor progression and metastasis |
| Q37636221 | Roles of laminin-332 and alpha6beta4 integrin in tumor progression |
| Q38086009 | Roles of microRNAs during prostatic tumorigenesis and tumor progression |
| Q88973505 | Roles of the CLEC-2-podoplanin interaction in tumor progression |
| Q28235067 | Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression |
| Q43996209 | Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer |
| Q42511518 | Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression |
| Q91181452 | Rpn10 promotes tumor progression by regulating hypoxia-inducible factor 1 alpha through the PTEN/Akt signaling pathway in hepatocellular carcinoma |
| Q53615786 | Runt-related transcription factor 3 expression in human oral squamous cell carcinomas; implication for tumor progression and prognosis. |
| Q47760367 | S-100 protein-positive dendritic cells detected in hepatocellular-carcinoma in relation to tumor progression and prognosis. |
| Q98389558 | S-Adenosylmethionine Treatment of Colorectal Cancer Cell Lines Alters DNA Methylation, DNA Repair and Tumor Progression-Related Gene Expression |
| Q53211899 | S-Allylcysteine inhibits tumour progression and the epithelial-mesenchymal transition in a mouse xenograft model of oral cancer. |
| Q36720882 | S-Nitrosation Mediates Multiple Pathways That Lead to Tumor Progression in Estrogen Receptor-Negative Breast Cancer |
| Q53550565 | S100A12 and RAGE expression in human bladder transitional cell carcinoma: a role for the ligand/RAGE axis in tumor progression? |
| Q37959812 | S100A4 calcium-binding protein is key player in tumor progression and metastasis: preclinical and clinical evidence |
| Q35104378 | S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance |
| Q34802977 | S100A8/A9 activate key genes and pathways in colon tumor progression |
| Q98657705 | SALL4 promotes tumor progression in breast cancer by targeting EMT |
| Q58568978 | SATB family chromatin organizers as master regulators of tumor progression |
| Q53528748 | SCC-112 gene is involved in tumor progression and promotes the cell proliferation in G2/M phase. |
| Q34473389 | SEL1L a multifaceted protein playing a role in tumor progression. |
| Q101458091 | SHCBP1 regulates STAT3/c-Myc signaling activation to promote tumor progression in penile cancer |
| Q48262388 | SIAH1 inactivation correlates with tumor progression in hepatocellular carcinomas |
| Q39102994 | SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis |
| Q38756184 | SLC25A22 Promotes Proliferation and Survival of Colorectal Cancer Cells With KRAS Mutations and Xenograft Tumor Progression in Mice via Intracellular Synthesis of Aspartate |
| Q48232383 | SLC34A2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells |
| Q96132757 | SLC39A4 as a Novel Prognosis Marker Promotes Tumor Progression in Esophageal Squamous Cell Carcinoma |
| Q92190797 | SMAD4 Somatic Mutations in Head and Neck Carcinoma Are Associated With Tumor Progression |
| Q38220764 | SMAD7: a timer of tumor progression targeting TGF-β signaling |
| Q37285370 | SMAR1 binds to T(C/G) repeat and inhibits tumor progression by regulating miR-371-373 cluster. |
| Q37581437 | SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression |
| Q43055924 | SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases |
| Q35833703 | SOX2 boosts major tumor progression genes in prostate cancer and is a functional biomarker of lymph node metastasis. |
| Q54345176 | SOX7 inhibits tumor progression of glioblastoma and is regulated by miRNA-24. |
| Q92668907 | SOX9 promotes tumor progression through the axis BMI1-p21CIP |
| Q88130771 | SP1 upregulated FoxO3a promotes tumor progression in colorectal cancer |
| Q38823959 | SPARC overexpression alters microRNA expression profiles involved in tumor progression |
| Q96125728 | SPON2 Is Upregulated through Notch Signaling Pathway and Promotes Tumor Progression in Gastric Cancer |
| Q38749330 | SPOP promotes tumor progression via activation of β-catenin/TCF4 complex in clear cell renal cell carcinoma |
| Q47636995 | SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer |
| Q100423970 | ST09, A Novel Curcumin Derivative, Blocks Cell Migration by Inhibiting Matrix Metalloproteases in Breast Cancer Cells and Inhibits Tumor Progression in EAC Mouse Tumor Models |
| Q38097515 | STAT activation in malignancies: roles in tumor progression and in the generation of antineoplastic effects of IFNs |
| Q38952130 | STAT1 drives tumor progression in serous papillary endometrial cancer. |
| Q89742443 | STAT1-induced upregulation of lncRNA RHPN1-AS1 predicts a poor prognosis of hepatocellular carcinoma and contributes to tumor progression via the miR-485/CDCA5 axis |
| Q37162367 | STAT3 in epithelial cells regulates inflammation and tumor progression to malignant state in colon. |
| Q58716603 | STAT3 promotes tumour progression in glioma by inducing FOXP1 transcription |
| Q91107556 | STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway |
| Q60800418 | STMC-25. GPR133 PROMOTES HYPOXIA-DRIVEN TUMOR PROGRESSION IN GLIOBLASTOMA |
| Q96128228 | SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma |
| Q64927912 | SUN-340 Prolactinoma Response to Bevacizumab Is Influenced by Tumor Progression Stage at the Beginning of Treatment. |
| Q36721105 | SV40 T Antigen Transgenic Mice: Cytotoxic T Lymphocytes as a Selective Force in Tumor Progression |
| Q104471099 | SWI/SNF complex mutations promote thyroid tumor progression and insensitivity to redifferentiation therapies |
| Q52648065 | Salivary gland cancer patient-derived xenografts enable characterization of cancer stem cells and new gene fusions associated with tumor progression. |
| Q34072796 | Sapodilla plum (Achras sapota) induces apoptosis in cancer cell lines and inhibits tumor progression in mice |
| Q46058203 | Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment |
| Q80352278 | Scavenger receptor-A-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression |
| Q90473938 | Screening of Chemopreventive Agents in Animal Models: Results on Reproducibility, Agents of a Given Class, and Agents Tested During Tumor Progression |
| Q78508829 | Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression |
| Q30471825 | Sebaceous carcinoma. Tumor progression through mutational inactivation of p53. |
| Q36679133 | Second harmonic generation reveals matrix alterations during breast tumor progression |
| Q33519056 | Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases |
| Q88345251 | Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice |
| Q92446516 | Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas |
| Q55456689 | Seizures and Tumor Progression in Glioma Patients with Uncontrollable Epilepsy Treated with Perampanel. |
| Q45106263 | Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. |
| Q36206974 | Selective evolutionary pressure from the tissue microenvironment drives tumor progression |
| Q33969381 | Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability |
| Q73738455 | Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice |
| Q45999099 | Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole blood. |
| Q34026203 | Selective recruitment of regulatory T cell through CCR6-CCL20 in hepatocellular carcinoma fosters tumor progression and predicts poor prognosis |
| Q91626394 | Selenium-lentinan inhibits tumor progression by regulating epithelial-mesenchymal transition |
| Q88644906 | Self-assembled nanomicelles of amphiphilic clotrimazole glycyl-glycine analogue augmented drug delivery, apoptosis and restrained melanoma tumour progression |
| Q41985319 | Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression. |
| Q37069435 | Semaphorin 4D cooperates with VEGF to promote angiogenesis and tumor progression. |
| Q47099359 | Semaphorin 7a exerts pleiotropic effects to promote breast tumor progression |
| Q38161405 | Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression |
| Q35658200 | Semaphorins in angiogenesis and tumor progression |
| Q33833881 | Senescent cells as a source of inflammatory factors for tumor progression |
| Q40303893 | Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players |
| Q54044410 | Sensitivity to macrophages decreases with tumor progression in the AKR lymphoma. |
| Q50669341 | Sensorimotor deficits associated with brain tumor progression and tumor-induced brain plasticity mechanisms. |
| Q55457270 | Sequential Apparent Diffusion Coefficient for Assessment of Tumor Progression in Patients with Low-Grade Glioma. |
| Q39411457 | Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. |
| Q57660640 | Sequestration of connexin43 in the early endosomes: An early event of Leydig cell tumor progression |
| Q71321797 | Serial passage of tumors in mice in the study of tumor progression and testing of antineoplastic drugs |
| Q39159055 | Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells |
| Q57784963 | Serine/threonine kinase 32C is overexpressed in bladder cancer and contributes to tumor progression |
| Q100436722 | Serpin peptidase inhibitor clade A member 1-overexpression in gastric cancer promotes tumor progression in vitro and is associated with poor prognosis |
| Q99565174 | Serum CXCL13 Level is Associated with Tumor Progression and Unfavorable Prognosis in Penile Cancer |
| Q35053419 | Serum CXCL9 levels are associated with tumor progression and treatment outcome in patients with nasopharyngeal carcinoma |
| Q33764534 | Serum biomarkers which correlate with failure to respond to immunotherapy and tumor progression in a murine colorectal cancer model |
| Q42123999 | Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection |
| Q71018359 | Serum carcinoembryonic antigen levels and proliferating cell nuclear antigen labeling index for patients with colorectal carcinoma. Correlation with tumor progression and survival |
| Q91804639 | Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease |
| Q77869234 | Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma |
| Q50906136 | Serum levels of chemokine (C-X-C motif) ligand 9 (CXCL9) are associated with tumor progression and treatment outcome in patients with oral cavity squamous cell carcinoma. |
| Q74324656 | Serum levels of interleukin-2 and tumor necrosis factor-alpha correlate to tumor progression in gastric cancer |
| Q84504782 | Serum midkine correlates with tumor progression and imatinib response in gastrointestinal stromal tumors |
| Q51743732 | Sex chromosome alterations associate with tumor progression in sporadic colorectal carcinomas. |
| Q70789675 | Sex-related differences in tumor progression associated with altered lymphocyte circulation |
| Q89974141 | Shallow whole genome sequencing of adenoid cystic carcinomas of the salivary glands identifies specific chromosomal aberrations related to tumor progression |
| Q58618713 | Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study |
| Q28590157 | ShcA signalling is essential for tumour progression in mouse models of human breast cancer |
| Q80686677 | Sheep stromal-epithelial cell interactions and ovarian tumor progression |
| Q38831652 | Shemamruthaa, a Herbal Formulation Induces Apoptosis in Breast Cancer Cells and Inhibits Tumor Progression in Rats |
| Q40213078 | Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression |
| Q34578690 | Short telomeres limit tumor progression in vivo by inducing senescence |
| Q39429457 | Sialylation regulates galectin-3/ligand interplay during mammary tumour progression--a case of targeted uncloaking. |
| Q41709668 | Sialyllactose suppresses angiogenesis by inhibiting VEGFR-2 activation, and tumor progression |
| Q38960961 | Signal Peptide Peptidase, Encoded by HM13, Contributes to Tumor Progression by Affecting EGFRvIII Secretion Profiles in Glioblastoma |
| Q57805015 | Signal peptide peptidase promotes tumor progression via facilitating FKBP8 degradation |
| Q51824352 | Signal regulatory protein α is associated with tumor-polarized macrophages phenotype switch and plays a pivotal role in tumor progression. |
| Q37330984 | Signaling mechanism(s) of reactive oxygen species in Epithelial-Mesenchymal Transition reminiscent of cancer stem cells in tumor progression |
| Q44555355 | Signaling network analysis of ubiquitin-mediated proteins suggests correlations between the 26S proteasome and tumor progression |
| Q53625554 | Significance of Fas expression alteration during tumor progression of renal cell carcinoma. |
| Q85856935 | Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer |
| Q46698436 | Significance of adenomyosis on tumor progression and survival outcome of endometrial cancer. |
| Q40423643 | Significance of angiogenesis in tumour progression and metastasis |
| Q53195484 | Significance of endothelial progenitor cells (EPC) for tumorigenesis of head and neck squamous cell carcinoma (HNSCC): possible marker of tumor progression and neovascularization? |
| Q31107681 | Significance of loss of heterozygosity of the RB1 gene during tumour progression in well-differentiated liposarcomas |
| Q74448861 | Significance of nitric oxide in carcinogenesis, tumor progression and cancer therapy |
| Q37145164 | Significance of pH regulation and carbonic anhydrases in tumour progression and implications for diagnostic and therapeutic approaches. |
| Q90696154 | Significant association of DIRC1 overexpression with tumor progression and poor prognosis in gastric cancer |
| Q36284970 | Signification of Hypermethylated in Cancer 1 (HIC1) as Tumor Suppressor Gene in Tumor Progression |
| Q39898379 | Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells |
| Q112645410 | Silencing HIPPI Suppresses Tumor Progression in Non-Small-Cell Lung Cancer by Inhibiting DNA Replication |
| Q34395225 | Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice |
| Q43774171 | Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer |
| Q90397860 | Silencing stomatin-like protein 2 attenuates tumor progression and inflammatory response through repressing CD14 in liver cancer |
| Q37675705 | Silencing vimentin expression decreases pulmonary metastases in a pre-diabetic mouse model of mammary tumor progression |
| Q38891137 | Simple quantitative PCR analysis for allelic Pten loss in tumor progression |
| Q36876322 | Simultaneous Activation of Induced Heterodimerization between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression |
| Q72687473 | Simultaneous appearance of keratin modifications and gamma-glutamyltransferase activity as indicators of tumor progression in mouse skin papillomas |
| Q37141599 | Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis |
| Q30912170 | Simultaneous inference of cancer pathways and tumor progression from cross-sectional mutation data |
| Q112712740 | Single cell imaging-based chromatin biomarkers for tumor progression |
| Q112719574 | Single-cell CUT&Tag analysis of chromatin modifications in differentiation and tumor progression |
| Q112714733 | Single-cell transcriptomics reveal the heterogeneity and dynamic of cancer stem-like cells during breast tumor progression |
| Q64097847 | Single-centre retrospective review of risk factors for local tumour progression and complications in radiofrequency ablation of 555 hepatic lesions |
| Q104460749 | Sinusoidal Endothelial Cell Progenitor Cells Promote Tumour Progression in Patients with Hepatocellular Carcinoma |
| Q94449895 | Sirtuins' Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion |
| Q42733062 | Skin squamous cell carcinoma propagating cells increase with tumour progression and invasiveness. |
| Q42068000 | Smad4/DPC4: A barrier against tumor progression driven by RTK/Ras/Erk and Wnt/GSK3 signaling |
| Q28590372 | Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression |
| Q38202537 | Small but mighty: microparticles as mediators of tumor progression |
| Q36299674 | Snail and serpinA1 promote tumor progression and predict prognosis in colorectal cancer |
| Q30434154 | Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma |
| Q29547559 | Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? |
| Q91143137 | Snail-induced claudin-11 prompts collective migration for tumour progression |
| Q51017570 | Solitary plasmacytoma of the spine: relationship of IGM to tumour progression and recurrence. |
| Q50454055 | Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression. |
| Q47815750 | Soluble serum E-cadherin as a marker of tumour progression in colorectal cancer patients |
| Q47690666 | Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor |
| Q57147386 | Somatic aberrations of BRCA1 gene are associated with ALDH1, EGFR and tumor progression in prostate cancer |
| Q40771425 | Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: implications for mechanisms of tumor progression |
| Q51744127 | Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study. |
| Q35967096 | Soy Protein Isolate Protects Against Ethanol-Mediated Tumor Progression in Diethylnitrosamine-Treated Male Mice |
| Q30524654 | Sp1 expression regulates lung tumor progression. |
| Q59103157 | Specific MUC1 Splice Variants Are Correlated With Tumor Progression in Esophageal Cancer |
| Q39494223 | Specific expression of the human voltage-gated proton channel Hv1 in highly metastatic breast cancer cells, promotes tumor progression and metastasis |
| Q38865772 | Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. |
| Q40831454 | Speculations on the roles of RB1 in tissue-specific differentiation, tumor initiation, and tumor progression. |
| Q56889963 | Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression |
| Q95831762 | Sphingomyelin synthase 2 facilitates M2-like macrophage polarization and tumor progression in a mouse model of triple-negative breast cancer |
| Q38187302 | Sphingosin 1-phosphate contributes in tumor progression. |
| Q114150297 | Spindle pole body component 24 homolog potentiates tumor progression via regulation of SRY‐box transcription factor 2 in clear cell renal cell carcinoma |
| Q92717221 | Spindle-cell variant of ameloblastic carcinoma: a report of 3 cases and demonstration of epithelial-mesenchymal transition in tumor progression |
| Q37690917 | Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy |
| Q41176015 | Spontaneous de-differentiation correlates with extended lifespan in transformed thyroid epithelial cells: an epigenetic mechanism of tumour progression? |
| Q36937836 | Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor |
| Q24311656 | Src family kinases in tumor progression and metastasis |
| Q91233445 | Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer |
| Q64084735 | Src in endosomal membranes promotes exosome secretion and tumor progression |
| Q47890448 | Stable expression of α1-antitrypsin Portland in MDA-MB-231 cells increased MT1-MMP and MMP-9 levels, but reduced tumour progression |
| Q40870801 | Stage of tumor progression, progressor agents, and human risk |
| Q36984420 | Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model |
| Q26767514 | Starved and Asphyxiated: How Can CD8(+) T Cells within a Tumor Microenvironment Prevent Tumor Progression |
| Q28266642 | Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice |
| Q54598997 | Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. |
| Q112303557 | Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis |
| Q43008722 | Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer |
| Q26865967 | Steering tumor progression through the transcriptional response to growth factors and stroma |
| Q40222370 | Stem cell factor affects tumour progression markers in metastatic melanoma cells. |
| Q44931415 | Stem cell marker nestin is critical for TGF-β1-mediated tumor progression in pancreatic cancer. |
| Q38586627 | Stem cell-derived exosomes: roles in stromal remodeling, tumor progression, and cancer immunotherapy |
| Q53494140 | Stepwise transformation of primary thyroid epithelial cells by a mutant Ha-ras oncogene: an in vitro model of tumor progression |
| Q45261595 | Stimulation of MCF-7 tumor progression in athymic nude mice by 17beta-estradiol induces WISP-2/CCN5 expression in xenografts: a novel signaling molecule in hormonal carcinogenesis. |
| Q26745894 | Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types |
| Q91461716 | Stochastic modeling of tumor progression and immune evasion |
| Q93108895 | Store-Operated Ca2+ Entry in Tumor Progression: From Molecular Mechanisms to Clinical Implications |
| Q38596229 | Stress Hormone-Mediated DNA Damage Response--Implications for Cellular Senescence and Tumour Progression |
| Q73671139 | Stress and chemotherapy. Combined effects on tumor progression and immunity in animal models |
| Q48120364 | Stress, melatonin and tumor progression in mice |
| Q39088864 | Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer |
| Q101131863 | Strobilanthes crispus bioactive subfraction inhibits tumor progression and improves hematological and morphological parameters in mouse mammary carcinoma model |
| Q36170102 | Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression |
| Q112695490 | Stromal AR inhibits prostate tumor progression by restraining secretory luminal epithelial cells |
| Q90408722 | Stromal Cell-Derived CCL20 Promotes Tumor Progression and Osteolysis in Giant Cell Tumor of Bone |
| Q47696132 | Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression |
| Q35068998 | Stromal alterations as quantitative optical biomarkers of epithelial tumor progression |
| Q36413616 | Stromal expression of ALDH1 in human breast carcinomas indicates reduced tumor progression. |
| Q42316344 | Stromal expression of Fer suppresses tumor progression in renal cell carcinoma and is a predictor of survival |
| Q35813085 | Stromal-cell-derived Factor 1-α Promotes Tumor Progression in Colorectal Cancer |
| Q43189377 | Stromal-epithelial interactions are responsible for prostate tumor progression through an androgen-related mechanism |
| Q36135363 | Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression |
| Q37802611 | Stromelysin in tumor progression and metastasis |
| Q41127397 | Stromelysin-3 and other stromelysins in breast cancer: importance of epithelial-stromal interactions during tumor progression. |
| Q37804967 | Stromelysin/transin and tumor progression. |
| Q37565559 | Structure and function of IQ-domain GTPase-activating protein 1 and its association with tumor progression (Review). |
| Q40553482 | Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance |
| Q72384112 | Studies of mammary carcinoma metastasis in a mouse model system. I: Derivation and characterization of cells with different metastatic properties during tumour progression in vivo |
| Q40152626 | Study of blood porphyrin spectral profile for diagnosis of tumor progression |
| Q33187907 | Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents |
| Q98780358 | Study of the gastrointestinal tumor progression during the COVID-19 epidemic in Wuhan |
| Q37332674 | Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. |
| Q30771818 | Subsurface tumor progression investigated by noninvasive optical second harmonic tomography |
| Q101048115 | Subtraction Maps Derived from Longitudinal Magnetic Resonance Imaging in Patients with Glioma Facilitate Early Detection of Tumor Progression |
| Q38933860 | Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment |
| Q55177532 | Super enhancer inhibitors suppress MYC driven transcriptional amplification and tumor progression in osteosarcoma. |
| Q52542764 | Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. |
| Q44810439 | Superficial bladder cancer: intravesical chemotherapy and tumour progression to muscle invasion or metastases |
| Q34486341 | Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, KI-67 and CK20 with histologic grade, recurrence and tumor progression |
| Q44564932 | Suppressing tumor progression of in vitro prostate cancer cells by emitted psychosomatic power through Zen meditation |
| Q95323523 | Suppression of PKCδ/NF-κB Signaling and Apoptosis Induction through Extrinsic/Intrinsic Pathways Are Associated Magnolol-Inhibited Tumor Progression in Colorectal Cancer In Vitro and In Vivo |
| Q52728270 | Suppression of YAP by DDP disrupts colon tumor progression. |
| Q45303116 | Suppression of angiogenesis and tumour progression by combretastatin and derivatives |
| Q38809719 | Suppression of lactate dehydrogenase A compromises tumor progression by downregulation of the Warburg effect in glioblastoma |
| Q33414933 | Suppression of membrane microvesiculation--a possible anticoagulant and anti-tumor progression effect of heparin |
| Q40410279 | Suppression of pancreatic tumor progression by systemic delivery of a pancreatic-cancer-specific promoter driven Bik mutant |
| Q36523547 | Suppression of signal transducers and activators of transcription 1 in hepatocellular carcinoma is associated with tumor progression. |
| Q57794781 | Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma |
| Q48254991 | Suppression of the Smurf1 Expression Inhibits Tumor Progression in Gliomas |
| Q42378295 | Suppression of tumor-derived Semaphorin 7A and genetic ablation of host-derived Semaphorin 7A impairs tumor progression in a murine model of advanced breast carcinoma |
| Q104560571 | Surgical Stress Promotes Tumor Progression: A Focus on the Impact of the Immune Response |
| Q80109226 | Surgical stress and tumor behavior: impact of ischemia-reperfusion and hepatic resection on tumor progression |
| Q40705749 | Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. |
| Q44302037 | Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. |
| Q57765196 | Survivin, a Potential Early Predictor of Tumor Progression in the Oral Mucosa |
| Q45711089 | Survivin: anti-apoptosis protein and a prognostic marker for tumor progression and recurrence |
| Q35231517 | Sustained endothelial expression of HoxA5 in vivo impairs pathological angiogenesis and tumor progression |
| Q92232173 | Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression |
| Q41827081 | Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system |
| Q91174524 | Synaptic input drives brain tumor progression |
| Q43110125 | Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression. |
| Q35856558 | Synchronous clear cell renal cell carcinoma and tubulocystic carcinoma: genetic evidence of independent ontogenesis and implications of chromosomal imbalances in tumor progression |
| Q46059085 | Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis |
| Q39719381 | Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression. |
| Q44615088 | Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model. |
| Q38412535 | Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression |
| Q64066145 | Systems biology based meth-miRNA-mRNA regulatory network identifies metabolic imbalance and hyperactive cell cycle signaling involved in hepatocellular carcinoma onset and progression |
| Q33919802 | T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma |
| Q92534116 | T-Regulatory Cells In Tumor Progression And Therapy |
| Q40956150 | T-antigens in primary non-invasive and superficially invasive human urinary bladder tumors: the correlation to tumor recurrence and tumor progression. A mini-review. |
| Q111492118 | T1177 Tumor Progression, Invasion and Metastasis in a Genetically Defined Model of Esophageal Squamous Carcinogenesis |
| Q91787149 | TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma |
| Q91738289 | TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer |
| Q98514420 | TDG-regulated TAZ promotes radioresistance by targeting non-homologous end joining and tumor progression in esophageal cancer |
| Q41345579 | TDP-43/HDAC6 axis promoted tumor progression and regulated nutrient deprivation-induced autophagy in glioblastoma |
| Q94513874 | TESC Promotes TGF-α/EGFR-FOXM1-Mediated Tumor Progression in Cholangiocarcinoma |
| Q37294488 | TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions. |
| Q38479905 | TGF alpha expression in meningioma--tumor progression and therapeutic response |
| Q37002892 | TGF-beta and BMP7 interactions in tumour progression and bone metastasis |
| Q37663174 | TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect |
| Q54697386 | TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. |
| Q34065919 | TGF-beta/SMAD signaling and its involvement in tumor progression. |
| Q38998817 | TGF-beta1, WNT, and SHH signaling in tumor progression and in fibrotic diseases |
| Q55515543 | TGF-β Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction. |
| Q37693902 | TGF-β autocrine pathway and MAPK signaling promote cell invasiveness and in vivo mammary adenocarcinoma tumor progression |
| Q48188314 | TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone. |
| Q39025848 | TGF-β1 in tumor microenvironments induces immunosuppression in the tumors and sentinel lymph nodes and promotes tumor progression |
| Q38991532 | TGF-β1-induced expression of Id-1 is associated with tumor progression in gastric cancer |
| Q41550017 | TGF-β2-induced ANGPTL4 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone |
| Q38843099 | TIF1γ Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability. |
| Q64935682 | TIMM50 promotes tumor progression via ERK signaling and predicts poor prognosis of non-small cell lung cancer patients. |
| Q58741597 | TIPE3 hypermethylation correlates with worse prognosis and promotes tumor progression in nasopharyngeal carcinoma |
| Q90725991 | TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression |
| Q39136868 | TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells |
| Q38970486 | TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer |
| Q39868541 | TLR9 signaling promotes tumor progression of human lung cancer cell in vivo |
| Q39089387 | TMEM43/LUMA is a key signaling component mediating EGFR-induced NF-κB activation and tumor progression |
| Q37565322 | TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. |
| Q47821913 | TPL2 (Therapeutic Targeting Tumor Progression Locus-2)/ATF4 (Activating Transcription Factor-4)/SDF1α (Chemokine Stromal Cell-Derived Factor-α) Axis Suppresses Diabetic Retinopathy. |
| Q51053007 | TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing. |
| Q52997142 | TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression. |
| Q89737191 | TRIM21 overexpression promotes tumor progression by regulating cell proliferation, cell migration and cell senescence in human glioma |
| Q57816336 | TRIM28 is overexpressed in glioma and associated with tumor progression |
| Q37317615 | TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer |
| Q112724134 | TRIM39 deficiency inhibits tumor progression and autophagic flux in colorectal cancer via suppressing the activity of Rab7 |
| Q91830935 | TRIP13 upregulation is correlated with poor prognosis and tumor progression in esophageal squamous cell carcinoma |
| Q112283347 | TRIP13, identified as a hub gene of tumor progression, is the target of microRNA-4693-5p and a potential therapeutic target for colorectal cancer |
| Q52664598 | TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. |
| Q93271402 | TUG1 Promoted Tumor Progression by Sponging miR-335-5p and Regulating CXCR4-Mediated Infiltration of Pro-Tumor Immunocytes in CTNNB1-Mutated Hepatoblastoma |
| Q91670462 | TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death |
| Q44552336 | Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression |
| Q31383013 | Tagged tumor cells reveal regulatory steps during earliest stages of tumor progression and micrometastasis |
| Q96226205 | Taking a SPOP at renal cell carcinoma - unraveling a novel pathway for Tumor progression in clear cell RCC |
| Q39091969 | Tanespimycin and tipifarnib exhibit synergism in inducing apoptosis in melanoma cell lines from later stages of tumor progression |
| Q34085366 | Targeted deletion of hepatic Igf1 in TRAMP mice leads to dramatic alterations in the circulating insulin-like growth factor axis but does not reduce tumor progression |
| Q36612156 | Targeted imaging of breast tumor progression and therapeutic response in a human uMUC-1 expressing transgenic mouse model |
| Q88550350 | Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II |
| Q39616516 | Targeted removal of migratory tumor cells by functionalized magnetic nanoparticles impedes metastasis and tumor progression |
| Q38212160 | Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression. |
| Q34647792 | Targeting CDH17 suppresses tumor progression in gastric cancer by downregulating Wnt/β-catenin signaling |
| Q98202284 | Targeting Hypoxia-Driven Metabolic Reprogramming to Constrain Tumor Progression and Metastasis |
| Q35064627 | Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer |
| Q57470576 | Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression |
| Q60531852 | Targeting PGE2 Signaling in Tumor Progression and Angiogenesis |
| Q57142667 | Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression |
| Q36447669 | Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression |
| Q54969561 | Targeting YAP-dependent MDSC infiltration impairs tumor progression. |
| Q35213463 | Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis |
| Q42290800 | Targeting growth hormone receptor in human melanoma cells attenuates tumor progression and epithelial mesenchymal transition via suppression of multiple oncogenic pathways |
| Q40353426 | Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma |
| Q34386415 | Targeting key steps in metastatic tumour progression |
| Q33897308 | Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. |
| Q46166101 | Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model |
| Q36567735 | Targeting matriptase in breast cancer abrogates tumour progression via impairment of stromal-epithelial growth factor signalling. |
| Q50856138 | Targeting miR-21 with Sophocarpine Inhibits Tumor Progression and Reverses Epithelial-Mesenchymal Transition in Head and Neck Cancer. |
| Q42371632 | Targeting of CCN2 suppresses tumor progression and improves chemo-sensitivity in urothelial bladder cancer |
| Q39410020 | Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression |
| Q92118454 | Targeting self-assembly peptide for inhibiting breast tumor progression and metastasis |
| Q64993624 | Targeting the SLIT/ROBO pathway in tumor progression: molecular mechanisms and therapeutic perspectives. |
| Q77061112 | Targeting the extracellular matrix to stop tumour progression |
| Q36970728 | Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression |
| Q36951553 | Targeting the therapeutic effects of exercise on redox-sensitive mechanisms in the vascular endothelium during tumor progression |
| Q57811691 | TdIF1: a putative oncogene in NSCLC tumor progression |
| Q42541161 | Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression |
| Q48947695 | Teaching NeuroImages: MRI changes of ictal cortical edema and tumor progression in a patient with astrocytoma. |
| Q92576152 | Teaching NeuroImages: Unilateral focal segmental hyperhidrosis from spinal tumor progression |
| Q58220567 | Telomerase activation in neoplastic cell immortalization and tumour progression |
| Q40941977 | Telomere dynamics and telomerase activation in tumor progression: prospects for prognosis and therapy |
| Q92699812 | Telomere length measurement in tumor and non-tumor cells as a valuable prognostic for tumor progression |
| Q77697435 | Telomere length, telomerase activity and telomerase RNA expression during mouse mammary tumor progression |
| Q52936563 | Telomere shortening in breast cancer correlates with the pathological features of tumor progression. |
| Q34168735 | Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression |
| Q36407251 | Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response |
| Q98191446 | Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression |
| Q38539501 | Tenascin C and its modulatory role in tumor progression in systemic malignancies |
| Q48693019 | Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas. |
| Q48191673 | Testicular orphan receptor 4 promotes tumor progression and implies poor survival through AKT3 regulation in seminoma. |
| Q64054403 | Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression |
| Q37823853 | Tetraspanins and tumor progression |
| Q58129687 | Th17 cell-derived IL-17A promoted tumor progression via STAT3/NF-κB/Notch1 signaling in non-small cell lung cancer |
| Q41117101 | The 67-kDa laminin receptor and tumor progression. |
| Q47741061 | The Adenosine A1 Receptor Antagonist DPCPX Inhibits Tumor Progression via the ERK/JNK Pathway in Renal Cell Carcinoma |
| Q92546197 | The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma |
| Q50431809 | The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. |
| Q112707527 | The Antimalarial Drug Pyronaridine Inhibits Topoisomerase II in Breast Cancer Cells and Hinders Tumor Progression In Vivo |
| Q40368929 | The Arkadia-ESRP2 axis suppresses tumor progression: analyses in clear-cell renal cell carcinoma |
| Q100435999 | The Basic Characteristics of the Pentraxin Family and Their Functions in Tumor Progression |
| Q53429740 | The C terminus of E1A regulates tumor progression and epithelial cell differentiation. |
| Q92493876 | The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment |
| Q47675226 | The CD44 protein family: roles in embryogenesis and tumor progression. |
| Q112571666 | The Characterization of Structure and Prediction for Aquaporin in Tumour Progression by Machine Learning |
| Q56958863 | The Circadian Clock Regulates Metabolic Phenotype Rewiring Via HKDC1 and Modulates Tumor Progression and Drug Response in Colorectal Cancer |
| Q91553587 | The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression |
| Q59806470 | The Crosstalk between Cancer Stem Cells and Microenvironment Is Critical for Solid Tumor Progression: The Significant Contribution of Extracellular Vesicles |
| Q36696198 | The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival |
| Q40043771 | The E-cadherin repressor snail plays a role in tumor progression of endometrioid adenocarcinomas |
| Q100518508 | The Emerging Role of Neutrophil Extracellular Traps (NETs) in Tumor Progression and Metastasis |
| Q91849262 | The Epithelial-Mesenchymal Transition, E-cadherin and Tumor Progression in Ovarian Serous Tumors |
| Q39276754 | The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy |
| Q114870856 | The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression |
| Q39096007 | The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy |
| Q36865026 | The Histone Methyltransferase EZH2 Mediates Tumor Progression on the Chick Chorioallantoic Membrane Assay, a Novel Model of Head and Neck Squamous Cell Carcinoma |
| Q97871255 | The LGMN pseudogene promotes tumor progression by acting as a miR-495-3p sponge in glioblastoma |
| Q41690163 | The LIM-domain only protein 4 contributes to lung epithelial cell proliferation but is not essential for tumor progression. |
| Q113879282 | The MAP3K1/c-JUN signaling axis regulates glioblastoma stem cell invasion and tumor progression |
| Q50199828 | The Mediator complex subunit MED15, a promoter of tumour progression and metastatic spread in renal cell carcinoma. |
| Q84784144 | The Minimal Ablative Margin of Radiofrequency Ablation of Hepatocellular Carcinoma (> 2 and < 5 cm) Needed to Prevent Local Tumor Progression: 3D Quantitative Assessment Using CT Image Fusion |
| Q43276607 | The Monascus metabolite monacolin K reduces tumor progression and metastasis of Lewis lung carcinoma cells |
| Q91849951 | The Morphology of Tumor Progression in Melanoma In Situ |
| Q91629008 | The Multiaspect Functions of Periostin in Tumor Progression |
| Q37501595 | The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non-small-cell Lung Cancer Through Altering STAT3 Expression |
| Q35739962 | The Overexpression of IQGAP1 and β-Catenin Is Associated with Tumor Progression in Hepatocellular Carcinoma In Vitro and In Vivo |
| Q47160125 | The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma |
| Q104070320 | The PGC1α/NRF1-MPC1 axis suppresses tumor progression and enhances the sensitivity to sorafenib/doxorubicin treatment in hepatocellular carcinoma |
| Q116178853 | The Proprotein Convertases Furin and PACE4 Play a Significant Role in Tumor Progression |
| Q34175437 | The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression. |
| Q40229870 | The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models |
| Q64245953 | The Role of Androgen Receptor Signaling in Ovarian Cancer |
| Q98734020 | The Role of CTHRC1 in Regulation of Multiple Signaling and Tumor Progression and Metastasis |
| Q114828998 | The Role of Cancer-Associated Fibroblasts in Tumor Progression |
| Q114921685 | The Role of Chemokines and their Receptors in Tumor Progression and Invasion: Potential New Targets of Biological Therapy |
| Q99571028 | The Role of Extracellular Proteases in Tumor Progression and the Development of Innovative Metal Ion Chelators that Inhibit their Activity |
| Q60312794 | The Role of Galectins in Tumor Progression, Treatment and Prognosis of Gynecological Cancers |
| Q96124737 | The Role of MSCs in the Tumor Microenvironment and Tumor Progression |
| Q35751821 | The Role of Nitric Oxide Synthase Uncoupling in Tumor Progression. |
| Q92875491 | The Role of SATB1 in Tumour Progression and Metastasis |
| Q38202820 | The Role of Tricho-Rhino-Phalangeal Syndrome (TRPS) 1 in Apoptosis during Embryonic Development and Tumor Progression |
| Q79342613 | The Role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Commentary re: F. Koga et al., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma |
| Q64248879 | The Role of the ER-Induced UPR Pathway and the Efficacy of Its Inhibitors and Inducers in the Inhibition of Tumor Progression |
| Q28068986 | The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress |
| Q93167129 | The Roles of Siglec7 and Siglec9 on Natural Killer Cells in Virus Infection and Tumour Progression |
| Q64069006 | The SIAH2-NRF1 axis spatially regulates tumor microenvironment remodeling for tumor progression |
| Q56965945 | The Soluble Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer |
| Q97541407 | The Upregulation of hsa-mir-181b-1 and Downregulation of Its Target CYLD in the Late-Stage of Tumor Progression of Breast Cancer |
| Q38773860 | The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas. |
| Q37579645 | The Use of Second Harmonic Generation to Image the Extracellular Matrix During Tumor Progression |
| Q34332654 | The Warburg effect in tumor progression: mitochondrial oxidative metabolism as an anti-metastasis mechanism |
| Q35107174 | The Way to the End Matters: The Role of Telomerase in Tumor Progression |
| Q52522951 | The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. |
| Q41472094 | The adenosine A2b receptor promotes tumor progression of bladder urothelial carcinoma by enhancing MAPK signaling pathway |
| Q95938905 | The aegis: platelets as biomarkers of tumor progression |
| Q40815918 | The alphaVbeta6 integrin regulates its own expression with cell crowding: implications for tumour progression |
| Q53446484 | The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. |
| Q39296184 | The anti-angiogenic activities of glycyrrhizic acid in tumor progression |
| Q37389659 | The antidepressant desipramine and α2-adrenergic receptor activation promote breast tumor progression in association with altered collagen structure |
| Q73526224 | The association between tumour progression and vascularity in myxofibrosarcoma and myxoid/round cell liposarcoma |
| Q73882543 | The association between tumour progression and vascularity in the oral mucosa |
| Q57795458 | The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression |
| Q36546773 | The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors |
| Q73521342 | The basement membrane and tumor progression in the uterine cervix |
| Q39324757 | The basic helix-loop-helix transcription factor DEC2 inhibits TGF-β-induced tumor progression in human pancreatic cancer BxPC-3 cells |
| Q42147161 | The bcl-2 proto-oncogene and the gastrointestinal epithelial tumor progression model |
| Q44220776 | The bioenergetic signature of cancer: a marker of tumor progression. |
| Q36286854 | The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs |
| Q38000062 | The bisecting GlcNAc in cell growth control and tumor progression |
| Q34198892 | The bladder tumor suppressor protein TERE1 (UBIAD1) modulates cell cholesterol: implications for tumor progression |
| Q35674347 | The c-Myc-LDHA axis positively regulates aerobic glycolysis and promotes tumor progression in pancreatic cancer |
| Q40835603 | The c-myc oncogene in tumor progression. |
| Q39819269 | The canine transmissible venereal tumor: a unique result of tumor progression |
| Q47951488 | The cell-cell interaction between tumor-associated macrophages and small cell lung cancer cells is involved in tumor progression via STAT3 activation |
| Q41649289 | The cellular basis of tumor progression |
| Q41986400 | The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression |
| Q33914168 | The clinical significance of tumor progression: breast cancer as a model. |
| Q98288459 | The combination of Biochanin A and SB590885 potentiates the inhibition of tumour progression in hepatocellular carcinoma |
| Q40976672 | The community effect in FGF-1 mediated tumor progression of a rat bladder carcinoma does not involve a direct paracrine signaling |
| Q90970660 | The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression |
| Q95262020 | The contrasting roles of Dysferlin during tumor progression in renal cell carcinoma |
| Q37501853 | The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus |
| Q26863506 | The critical roles of COUP-TFII in tumor progression and metastasis |
| Q96692088 | The crosstalk between AXL and YAP promotes tumor progression through STAT3 activation in head and neck squamous cell carcinoma |
| Q40259858 | The crucial role of cyclooxygenase-2 in osteopontin-induced protein kinase C alpha/c-Src/IkappaB kinase alpha/beta-dependent prostate tumor progression and angiogenesis |
| Q89397464 | The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression |
| Q79916220 | The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy |
| Q34330439 | The diverse role of chemokines in tumor progression: prospects for intervention (Review). |
| Q55353236 | The downregulation of Rap1 GTPase-activating protein is associated with a poor prognosis in colorectal cancer and may impact on tumor progression. |
| Q92618504 | The downregulation of miR-519a predicts poor prognosis and contributes to tumor progression in gastric cancer |
| Q33891330 | The downregulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression |
| Q40351794 | The dual adverse effects of TGF-beta secretion on tumor progression. |
| Q36988432 | The dual effects of interleukin-18 in tumor progression. |
| Q42000888 | The dual role of mesenchymal stem cells in tumor progression. |
| Q40914088 | The early and intermediate precursor lesions of tumor progression in the melanocytic system: common acquired nevi and atypical (dysplastic) nevi |
| Q43276023 | The effect of LMWH (Nadroparin) on tumor progression |
| Q55476501 | The effect of extent of resection on time to tumor progression and survival in patients with glioblastoma multiforme of the cerebral hemisphere. |
| Q41846748 | The effect of one additional driver mutation on tumor progression. |
| Q36028192 | The effect of soluble E-selectin on tumor progression and metastasis. |
| Q46076373 | The effect of the microenvironment of head and neck cancers on tumor progression |
| Q38092641 | The effects of anesthetics on tumor progression |
| Q52442738 | The effects of iodinated glycerol, trichlorfon, and acetaminophen on tumor progression in a Fischer rat leukemia transplant model |
| Q91620819 | The effects of surface charge on the intra-tumor penetration of drug delivery vehicles with tumor progression |
| Q97093978 | The emerging role of EGFL6 in angiogenesis and tumor progression |
| Q104060700 | The emerging roles of exosomes in anti-cancer drug resistance and tumor progression: An insight towards tumor-microenvironment interaction |
| Q39671201 | The endocrinology and treatment of prostate tumor progression |
| Q38815324 | The endoplasmic reticulum stress/unfolded protein response in gliomagenesis, tumor progression and as a therapeutic target in glioblastoma. |
| Q34664564 | The enigma of ectopic expression of FGFR3 in multiple myeloma: a critical initiating event or just a target for mutational activation during tumor progression |
| Q29544441 | The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis |
| Q35227977 | The experimental study of tumor progression: a review. |
| Q36617433 | The expression of CCAAT/enhancer binding protein (C/EBP) in the human ovary in vivo: specific increase in C/EBPbeta during epithelial tumour progression |
| Q34071833 | The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study. |
| Q48649169 | The expression of rho proteins decreases with human brain tumor progression: potential tumor markers. |
| Q62858657 | The expression profile of integrin receptors and osteopontin in thyroid malignancies varies depending on the tumor progression rate and presence of BRAF V600E mutation |
| Q93016597 | The extracellular matrix in tumor progression and metastasis |
| Q37150091 | The extracellular matrix protein 1: its molecular interaction and implication in tumor progression |
| Q35701317 | The fibrinolytic system and matrix metalloproteinases in angiogenesis and tumor progression |
| Q37151504 | The four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription |
| Q90046717 | The fractal dimension of chromatin - a potential molecular marker for carcinogenesis, tumor progression and prognosis |
| Q36691376 | The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis |
| Q62817812 | The great escape: Is immune evasion required for tumor progression? |
| Q28369581 | The host environment promotes the constitutive activation of nuclear factor-kappaB and proinflammatory cytokine expression during metastatic tumor progression of murine squamous cell carcinoma |
| Q34420776 | The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression |
| Q37042949 | The human melanocyte system as a model for studies on tumor progression |
| Q34376363 | The hypoxia-inducible factor and tumor progression along the angiogenic pathway. |
| Q45906234 | The impact of cellular senescence and DNA damage on colorectal tumour progression. |
| Q37528193 | The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations |
| Q57752520 | The importance of melanoma inhibitory activity gene family in the tumor progression of oral cancer |
| Q71636696 | The incidence of chromogranin A defined endocrine cells decreases with tumour progression in gastric adenocarcinoma |
| Q36959353 | The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages |
| Q37704694 | The influence of glucocorticoid signaling on tumor progression |
| Q36375370 | The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors |
| Q42468467 | The initial steps of tumor progression in melanocytic lineage: a histochemical approach |
| Q44507138 | The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression |
| Q40354717 | The interplay between gastric cancer cell lines and PBMCs mediated by the CC chemokine RANTES plays an important role in tumor progression |
| Q90469294 | The interplay between slow-cycling, chemoresistant cancer cells and fibroblasts creates a proinflammatory niche for tumor progression |
| Q52651786 | The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. |
| Q40355313 | The intrinsic mitochondrial membrane potential of colonic carcinoma cells is linked to the probability of tumor progression |
| Q36347991 | The involvement of selectins and their ligands in tumor-progression |
| Q47971739 | The involvement of selectins in cell adhesion, tumor progression, and metastasis |
| Q84561259 | The keratin-14 expression in actinic keratosis and squamous cell carcinoma: is this a prognostic factor for tumor progression? |
| Q92642996 | The long non-coding RNA AK001796 contributes to poor prognosis and tumor progression in hepatocellular carcinoma |
| Q42376413 | The long non-coding RNA AK023948 enhances tumor progression in hepatocellular carcinoma |
| Q37696256 | The long noncoding RNA HOXA11 antisense induces tumor progression and stemness maintenance in cervical cancer |
| Q89682989 | The long noncoding RNA cancer susceptibility candidate 2 inhibits tumor progression in osteosarcoma |
| Q54356965 | The lymphangiogenic factor SOX 18: a key indicator to stage gastric tumor progression. |
| Q35016807 | The macrophage growth factor CSF-1 in mammary gland development and tumor progression |
| Q53343032 | The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis. |
| Q36738929 | The matricellular protein CYR61 interferes with normal pancreatic islets architecture and promotes pancreatic neuroendocrine tumor progression |
| Q34513388 | The mechanisms of angiogenesis in hepatocellular carcinoma: angiogenic switch during tumor progression |
| Q36131038 | The metastasis associated protein S100A4: role in tumour progression and metastasis |
| Q44286060 | The methylenetetrahydrofolate reductase (MTHFR) gene in colorectal cancer: role in tumor development and significance of allelic loss in tumor progression |
| Q99347561 | The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M2 receptor subtype |
| Q98177066 | The miR-1224-5p/TNS4/EGFR axis inhibits tumour progression in oesophageal squamous cell carcinoma |
| Q34316643 | The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression |
| Q37694682 | The microRNA miR-33a suppresses IL-6-induced tumor progression by binding Twist in gallbladder cancer |
| Q98730814 | The microRNA-424/503 cluster: A master regulator of tumorigenesis and tumor progression with paradoxical roles in cancer |
| Q82633614 | The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma |
| Q77799923 | The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin |
| Q40930917 | The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. |
| Q41505806 | The molecular biology of oral carcinogenesis: toward a tumor progression model |
| Q30997662 | The morphologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study |
| Q38165133 | The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all? |
| Q92600341 | The multifaceted contribution of α-ketoglutarate to tumor progression: An opportunity to exploit? |
| Q38234285 | The multifaceted regulation and functions of PKM2 in tumor progression |
| Q47836659 | The multifaceted role of periostin in priming the tumor microenvironments for tumor progression |
| Q36683524 | The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis |
| Q37880353 | The neuronal influence on tumor progression. |
| Q36343042 | The neuropilins and their role in tumorigenesis and tumor progression |
| Q28084891 | The new deal: a potential role for secreted vesicles in innate immunity and tumor progression |
| Q90465680 | The non-coding RNA OTUB1-isoform2 promotes ovarian tumour progression and predicts poor prognosis |
| Q38216862 | The non-reverse transcriptase activity of the human telomerase reverse transcriptase promotes tumor progression (review). |
| Q36781789 | The onset and extent of genomic instability in sporadic colorectal tumor progression |
| Q36918678 | The other side of MMPs: protective roles in tumor progression |
| Q47214718 | The overexpression of PXN promotes tumor progression and leads to radioresistance in cervical cancer |
| Q64069179 | The overexpression of Rab9 promotes tumor progression regulated by XBP1 in breast cancer |
| Q40098867 | The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. |
| Q39325284 | The p53 isoform, Δ133p53α, stimulates angiogenesis and tumour progression. |
| Q78030778 | The p53 paradox in the pathogenesis of tumor progression |
| Q37780433 | The perivascular niche microenvironment in brain tumor progression |
| Q38602808 | The phospholipid code: a key component of dying cell recognition, tumor progression and host-microbe interactions |
| Q37009435 | The plasma membrane transporter SLC5A8 suppresses tumour progression through depletion of survivin without involving its transport function |
| Q52558723 | The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance. |
| Q26825155 | The possible mechanisms of tumor progression via CSF-1/CSF-1R pathway activation |
| Q47571865 | The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression |
| Q64105592 | The potential risk of tumor progression after use of dehydrated human amnion/chorion membrane allograft in a positive margin resection model |
| Q38204343 | The potential role of HIF on tumour progression and dissemination. |
| Q45004021 | The potential role of hypoxia inducible factor 1alpha in tumor progression after hypoxia and chemotherapy in hepatocellular carcinoma |
| Q85194959 | The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer |
| Q91326341 | The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma |
| Q79810211 | The prevalence of the HPV 16 genome, integrated viral status and p53 genotype in cervical cancer population of north-eastern Hungary, the correlation with the established markers of tumour progression |
| Q30486489 | The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. |
| Q39687792 | The production of prostanoids in human cancers, and their implications for tumor progression |
| Q51650350 | The promoting role of a tumour-secreted chemorepellent in self-metastatic tumour progression. |
| Q39215671 | The proprotein convertase furin in tumour progression |
| Q28141150 | The proprotein convertases furin and PACE4 play a significant role in tumor progression |
| Q92060499 | The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression |
| Q41432777 | The rat Nb2 lymphoma: a novel model for tumor progression |
| Q46459585 | The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. |
| Q36338683 | The regulation of cell-cell adhesion during epithelial-mesenchymal transition, motility and tumor progression |
| Q89852291 | The regulation of nitric oxide in tumor progression and therapy |
| Q45005748 | The regulatory network of proneural glioma in tumor progression |
| Q35537397 | The relationship between gene expression of Forkhead box C2 and tumor progression in cervical carcinoma. |
| Q71524901 | The rise and fall of apoptosis during multistage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors |
| Q40531773 | The role of 80K/MARCKS, a specific substrate of protein kinase C, in cell growth and tumour progression |
| Q38740114 | The role of AKT isoforms in glioblastoma: AKT3 delays tumor progression. |
| Q28255886 | The role of EZH2 in tumour progression |
| Q47687077 | The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma |
| Q35782195 | The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy |
| Q38735665 | The role of FilGAP, a Rac-specific Rho-GTPase-activating protein, in tumor progression and behavior of astrocytomas |
| Q92623079 | The role of HOPX in normal tissues and tumor progression |
| Q39266433 | The role of adhesions between homologous cancer cells in tumor progression and targeted therapy. |
| Q41084428 | The role of alpha v-integrins in tumour progression and metastasis |
| Q37066225 | The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target |
| Q35577238 | The role of apoptosis in tumor progression and metastasis. |
| Q38216639 | The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance |
| Q30252204 | The role of canonical and non-canonical Hedgehog signaling in tumor progression in a mouse model of small cell lung cancer |
| Q81449751 | The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma |
| Q33990828 | The role of contortrostatin, a snake venom disintegrin, in the inhibition of tumor progression and prolongation of survival in a rodent glioma model |
| Q77774686 | The role of cytokines and chemokines on tumor progression: A review |
| Q38097628 | The role of endosomal signaling triggered by metastatic growth factors in tumor progression |
| Q37900435 | The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression |
| Q90918571 | The role of exosomal PD-L1 in tumor progression and immunotherapy |
| Q38680486 | The role of exosomes in tumor progression and metastasis (Review). |
| Q42161605 | The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression |
| Q89942007 | The role of hydrogen peroxide-inducible clone-5 in tumor progression |
| Q35980392 | The role of hypoxia-induced factors in tumor progression |
| Q38521016 | The role of individual inheritance in tumor progression and metastasis |
| Q38020728 | The role of inflammation and proteinases in tumor progression |
| Q38010997 | The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression |
| Q36597831 | The role of mesothelin in tumor progression and targeted therapy |
| Q93064585 | The role of microRNA-148a and downstream DLGAP1 on the molecular regulation and tumor progression on human glioblastoma |
| Q38983618 | The role of microRNA-196a in tumorigenesis, tumor progression, and prognosis |
| Q36516414 | The role of nitric oxide in tumour progression |
| Q28305027 | The role of osteopontin in tumor progression and metastasis in breast cancer |
| Q38963086 | The role of p300 in the tumor progression of oral squamous cell carcinoma |
| Q72776244 | The role of p53 in tumor progression |
| Q41192118 | The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model |
| Q37334300 | The role of podoplanin in tumor progression and metastasis. |
| Q68593650 | The role of polyamines as a marker of tumor progression and regression in experimental tumors |
| Q36652214 | The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression |
| Q28083838 | The role of splicing factors in deregulation of alternative splicing during oncogenesis and tumor progression |
| Q36589860 | The role of the VEGF-C/VEGFRs axis in tumor progression and therapy |
| Q40971229 | The role of the estrogen receptor in tumor progression |
| Q35681624 | The role of the guanine nucleotide exchange factor Tiam1 in cellular migration, invasion, adhesion and tumor progression |
| Q40964893 | The role of thrombospondin-1 in tumor progression and angiogenesis |
| Q34345537 | The role of thrombospondin-1 in tumor progression. |
| Q35951880 | The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression |
| Q39636385 | The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26. |
| Q37633551 | The role of tumor progression locus 2 protein kinase in glial inflammatory response |
| Q52583504 | The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. |
| Q37971780 | The role of tumor-associated macrophage in tumor progression |
| Q104283330 | The role of tumor-associated macrophages (TAMs) in tumor progression and relevant advance in targeted therapy |
| Q29614311 | The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies |
| Q33765559 | The role of tumour-derived iNOS in tumour progression and angiogenesis |
| Q28261890 | The roles of Galectin-3 in autoimmunity and tumor progression |
| Q92551863 | The secreted matrix protein mindin increases prostate tumor progression and tumor-bone crosstalk via ERK 1/2 regulation |
| Q37052649 | The selectin-selectin ligand axis in tumor progression |
| Q39027426 | The semaphorins and their receptors as modulators of tumor progression |
| Q37200576 | The semaphorins: versatile regulators of tumour progression and tumour angiogenesis |
| Q36679538 | The signaling mechanism of ROS in tumor progression |
| Q41126011 | The significance of heregulin in breast cancer tumor progression and drug resistance |
| Q46252699 | The significance of matrix metalloproteinases during early stages of tumor progression |
| Q55069698 | The single N-glycan deletion mutant of soluble ErbB3 protein attenuates heregulin β1-induced tumor progression by blocking of the HIF-1 and Nrf2 pathway. |
| Q40077593 | The spectrum of human lung cancer cells in culture: a potential model for studying molecular determinants of tumor progression and metastasis |
| Q34157516 | The splicing factor RBM4 controls apoptosis, proliferation, and migration to suppress tumor progression |
| Q43199707 | The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression |
| Q90800341 | The stress hormone norepinephrine promotes tumor progression through β2-adrenoreceptors in oral cancer |
| Q42462930 | The stromal reaction in basal cell carcinomas. A prerequisite for tumour progression and treatment strategy |
| Q40151542 | The study of homology between tumor progression genes and members of retroviridae as a tool to predict target-directed therapy failure. |
| Q28483778 | The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells |
| Q39728217 | The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells |
| Q38682206 | The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression. |
| Q90454478 | The transmembrane protein LRIG2 increases tumor progression in skin carcinogenesis |
| Q38627555 | The tumor microenvironment: the connective tissue/tumor cell/host organ system that modulates tumor progression |
| Q68021741 | The tumor progression-associated human melanoma antigen P3.58 mediates monocyte-lymphocyte interactions in vitro |
| Q41157516 | The tumour suppressor gene p53 as a regulator of proliferative life-span and tumour progression. |
| Q34786592 | The ubiquitin E3 ligase ITCH enhances breast tumor progression by inhibiting the Hippo tumor suppressor pathway |
| Q35911159 | The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer |
| Q36998634 | The uncertain role of unmodified mesenchymal stem cells in tumor progression: what master switch? |
| Q37661096 | The use of bevacizumab and trastuzumab beyond tumor progression: a new avenue in cancer treatment? |
| Q53303063 | The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy. |
| Q38764964 | The utility of hyperthermic intra-abdominal chemotherapy with gemcitabine for the inhibition of tumor progression in an experimental model of pancreatic peritoneal carcinomatosis, in relation to their behavior with pancreatic cancer stem cells CD133 |
| Q38480768 | The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence |
| Q101570079 | Therapeutic Potential of Tpl2 (Tumor Progression Locus 2) Inhibition on Diabetic Vasculopathy Through the Blockage of the Inflammasome Complex |
| Q89180454 | Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models |
| Q90344497 | Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma |
| Q83306322 | Therapy mediated by mitophagy abrogates tumor progression |
| Q35867131 | Therapy-induced tumour secretomes promote resistance and tumour progression |
| Q88990720 | Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression |
| Q30458838 | Thermally targeted delivery of a c-Myc inhibitory polypeptide inhibits tumor progression and extends survival in a rat glioma model |
| Q34734429 | Thiocoraline activates the Notch pathway in carcinoids and reduces tumor progression in vivo |
| Q53104606 | Three-Dimensional Measurement of Hepatocellular Carcinoma Ablation Zones and Margins for Predicting Local Tumor Progression. |
| Q93170954 | Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report |
| Q98170178 | Three-dimensional visualization of brain tumor progression based accurate segmentation via comparative holographic projection |
| Q37709136 | Thrombin inhibition and cisplatin block tumor progression in ovarian cancer by alleviating the immunosuppressive microenvironment |
| Q36843779 | Thrombin inhibition and cyclophosphamide synergistically block tumor progression and metastasis |
| Q46439216 | Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression |
| Q46424548 | Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression |
| Q47120215 | Thrombospondin-1 is a multifaceted player in tumor progression |
| Q91236249 | Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47 |
| Q57993344 | Thymic epithelial tumour progression in an SV40T transgenic mouse model |
| Q113756547 | Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival |
| Q111489586 | Thymoquinone Suppresses Cellular Proliferation, Inhibits VEGF Production and Obstructs Tumor Progression and Invasion in the Rat Model of DMH-Induced Colon Carcinogenesis |
| Q101134017 | Thymoquinone inhibits IL-7-induced tumor progression and metastatic invasion in prostate cancer cells by attenuating matrix metalloproteinase activity and Akt/NF-κB signaling |
| Q70830252 | Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays |
| Q52345778 | Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma. |
| Q37719981 | Tim-3 is upregulated in human colorectal carcinoma and associated with tumor progression |
| Q54591190 | Time to first tumor progression as a predictor of efficacy of continued treatment with trastuzumab beyond progression in human epidermal growth factor receptor 2-positive metastatic breast cancer. |
| Q43248615 | Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer |
| Q35582077 | Time-dependent effect of hypoxia on tumor progression and liver progenitor cell markers in primary liver tumors |
| Q33493417 | Timed somatic deletion of p53 in mice reveals age-associated differences in tumor progression |
| Q53476715 | Timing of SV40 oncogene activation by site-specific recombination determines subsequent tumor progression during murine lens development. |
| Q26772032 | Tissue Regeneration in the Chronically Inflamed Tumor Environment: Implications for Cell Fusion Driven Tumor Progression and Therapy Resistant Tumor Hybrid Cells |
| Q91723388 | Tissue amino acid profiles are characteristic of tumor type, malignant phenotype, and tumor progression in pancreatic tumors |
| Q79906656 | Tissue factor and PAR signaling in tumor progression |
| Q36490167 | Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies |
| Q33672303 | Tissue factor associates with survival and regulates tumour progression in osteosarcoma. |
| Q36396873 | Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy |
| Q37414584 | Tissue factor in tumour progression |
| Q37122001 | Tissue factor, angiogenesis and tumour progression |
| Q46094869 | Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy |
| Q71998308 | Tissue inhibitors of metalloproteinases: role in tumor progression |
| Q39945610 | Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation |
| Q36854347 | Tissue transglutaminase in tumour progression: friend or foe? |
| Q47119778 | Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression |
| Q51806878 | Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. |
| Q82045223 | Tissue-type plasminogen activator activity in morphologically normal tissues adjacent to gastrointestinal carcinomas is associated with the degree of tumor progression |
| Q80888770 | Titanocene modulation of cytokine imbalance induced by Ehrlich ascites tumour progression |
| Q90468281 | Toll like receptor 7 expressed by malignant cells promotes tumor progression and metastasis through the recruitment of myeloid derived suppressor cells |
| Q38014847 | Toll-Like Receptors (TLRs): The Role in Tumor Progression |
| Q84781787 | Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression |
| Q38196396 | Topographical changes in extracellular matrix: Activation of TLR4 signaling and solid tumor progression |
| Q54482053 | Toward the use of monoclonal antibodies in the analysis of tumor progression and cellular heterogeneity of human breast cancer. |
| Q46390923 | Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an Ikappa-B Kinase-beta-dependent pathway and is required for Tpl2 activation by external signals |
| Q52319522 | Tracking cellular and molecular changes in a species-specific manner during experimental tumor progression in vivo. |
| Q34107144 | Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression. |
| Q34636766 | Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma |
| Q45392132 | Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. |
| Q33799676 | Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression |
| Q40083471 | Transcriptional regulation of subtilisin-like proprotein convertase PACE4 by E2F: possible role of E2F-mediated upregulation of PACE4 in tumor progression |
| Q34997469 | Transcriptional repression of catalase in mouse skin tumor progression |
| Q91349807 | Transcriptome analysis of luminal breast cancer reveals a role for LOL in tumor progression and tamoxifen resistance |
| Q38799778 | Transcriptome and Proteome Analyses of TNFAIP8 Knockdown Cancer Cells Reveal New Insights into Molecular Determinants of Cell Survival and Tumor Progression |
| Q92127865 | Transcriptome profiling of gastric-type endocervical adenocarcinomas identifies key signaling pathways for tumor progression |
| Q42774674 | Transcriptomic analysis of a transgenic zebrafish hepatocellular carcinoma model reveals a prominent role of immune responses in tumour progression and regression |
| Q72120285 | Transformation and tumor progression are frequently associated with expression of the alpha 3/beta 1 heterodimer in solid tumors |
| Q36356124 | Transformation of human kidney proximal tubule cells by ras-containing retroviruses. Implications for tumor progression |
| Q38003168 | Transformation of non-tumor host cells during tumor progression: theories and evidence |
| Q40730133 | Transforming growth factor beta 1 dysregulation in a human oral carcinoma tumour progression model |
| Q40780554 | Transforming growth factor beta and fibroblast growth factor as promoters of tumor progression to malignancy |
| Q40801234 | Transforming growth factor beta and the cell surface in tumor progression |
| Q55478756 | Transforming growth factor beta as a potential tumor progression factor among hyperdiploid glioblastoma cultures: evidence for the role of platelet-derived growth factor. |
| Q73623100 | Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma |
| Q56797372 | Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression |
| Q38983785 | Transgelin overexpression in lung adenocarcinoma is associated with tumor progression |
| Q37107024 | Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression |
| Q36651930 | Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis |
| Q52087398 | Transgenic overexpression of a dominant negative mutant of FADD that, although counterselected during tumor progression, cooperates in L-myc-induced tumorigenesis. |
| Q48907429 | Transient early computed tomographic changes mimicking tumor progression after brain tumor irradiation. |
| Q33980750 | Transition of tumor-associated macrophages from MHC class II(hi) to MHC class II(low) mediates tumor progression in mice |
| Q37178036 | Transitions between lung cancer phenotypes--implications for tumor progression |
| Q91755959 | Transmembrane protein 64 modulates prostate tumor progression by regulating Wnt3a secretion |
| Q60045465 | Transmembrane protein GRINA modulates aerobic glycolysis and promotes tumor progression in gastric cancer |
| Q51716103 | Transposable elements and tumor progression. |
| Q41625143 | Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression |
| Q58562129 | Treatment-induced tumor cell apoptosis and secondary necrosis drive tumor progression in the residual tumor microenvironment through MerTK and IDO-1 |
| Q30627773 | Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities |
| Q39562830 | Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma |
| Q35944516 | Triggering of Toll-like Receptor-2 in Mouse Myelomonocytic Leukaemia Cells WEHI-3B Leads to the Suppression of Apoptosis and Promotes Tumor Progression in Vivo. |
| Q104496415 | Trim24 prompts tumor progression via inducing EMT in renal cell carcinoma |
| Q101564932 | Tripartite-motif family genes associated with cancer stem cells affect tumor progression and can assist in the clinical prognosis of kidney renal clear cell carcinoma |
| Q89220829 | Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity |
| Q36616576 | Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma |
| Q45892673 | Trks are novel oncogenes involved in the induction of neovascularization, tumor progression, and nodal metastasis in oral squamous cell carcinoma |
| Q48141924 | Trop-1 are conserved growth stimulatory molecules that mark early stages of tumor progression |
| Q46579442 | Trp53 inactivation in the tumor microenvironment promotes tumor progression by enhancing pro-inflammatory tumor stromal populations |
| Q43224742 | Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. |
| Q60045462 | Tspan8 and Tspan8/CD151 knockout mice unravel the contribution of tumor and host exosomes to tumor progression |
| Q64053653 | Tumor Cell “Slimming” Regulates Tumor Progression through PLCL1/UCP1‐Mediated Lipid Browning |
| Q57292427 | Tumor DNA-dependent protein kinase catalytic subunit expression is associated with hepatitis B surface antigen status and tumor progression in patients with hepatocellular carcinoma |
| Q94465290 | Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression |
| Q39328680 | Tumor Progression Following Petroclival Meningioma Subtotal Resection: A Volumetric Study. |
| Q40645815 | Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions |
| Q27318631 | Tumor Progression Locus 2 Promotes Induction of IFNλ, Interferon Stimulated Genes and Antigen-Specific CD8+ T Cell Responses and Protects against Influenza Virus |
| Q93646047 | Tumor Progression and Metastasis |
| Q50059028 | Tumor Progression is Mediated by Thymosin-ß4 through a TGFß/MRTF Signaling Axis. |
| Q91823089 | Tumor Progression of Breast Cancer during Hyperinsulinemic Obesity |
| Q48130708 | Tumor Progression of Non-Small Cell Lung Cancer Controlled by Albumin and Micellar Nanoparticles of Itraconazole, a Multitarget Angiogenesis Inhibitor |
| Q28818440 | Tumor Stiffening, a Key Determinant of Tumor Progression, is Reversed by Nanomaterial-Induced Photothermal Therapy |
| Q40472696 | Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. |
| Q34306107 | Tumor associated macrophages and neutrophils in tumor progression |
| Q39446327 | Tumor cell cross talk with tumor-associated leukocytes leads to induction of tumor exosomal fibronectin and promotes tumor progression |
| Q36821072 | Tumor cell-derived microparticles polarize M2 tumor-associated macrophages for tumor progression |
| Q38128106 | Tumor cell-mediated neovascularization and lymphangiogenesis contrive tumor progression and cancer metastasis |
| Q53470188 | Tumor cell-specific loss of p53 protein in a unique in vitro model of human breast tumor progression. |
| Q74088949 | Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment |
| Q57457783 | Tumor growth velocity: A modified tumor growth rate defining tumor progression during sorafenib treatment in patients with metastatic renal cell carcinoma |
| Q44218092 | Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression |
| Q36709699 | Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study |
| Q33353192 | Tumor metabolism as modulator of immune response and tumor progression |
| Q38194314 | Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression. |
| Q74523247 | Tumor progression |
| Q72659831 | Tumor progression accompanied by increase in proliferation rate in breast cancer: a preliminary report |
| Q39531055 | Tumor progression after preoperative portal vein embolization |
| Q41481799 | Tumor progression and angiogenesis: cathepsin B & Co. |
| Q41107789 | Tumor progression and cellular differentiation of pulmonary adenocarcinomas in SV40 large T antigen transgenic mice |
| Q90208509 | Tumor progression and chromatin landscape of lung cancer are regulated by the lineage factor GATA6 |
| Q40982989 | Tumor progression and expression of matrix metalloproteinase-2 (MMP-2) mRNA by human urinary bladder cancer cells. |
| Q40530762 | Tumor progression and homeostasis |
| Q72388324 | Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer |
| Q33846232 | Tumor progression and metastasis |
| Q44249630 | Tumor progression and metastasis |
| Q46771686 | Tumor progression and metastasis from genetic to microenvironmental determinants: a workshop of the tumor progression and metastasis NIH study section in honor of Dr. Martin L. Padarathsingh, May 31, 2006, Georgetown, Washington, DC. |
| Q41581595 | Tumor progression and metastasis in murine D2 hyperplastic alveolar nodule mammary tumor cell lines |
| Q38030506 | Tumor progression and metastasis: role of translational deregulation. |
| Q88646824 | Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab |
| Q36982110 | Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. |
| Q50962055 | Tumor progression and oxidant-antioxidant status. |
| Q53454079 | Tumor progression and oxidant-antioxidant status. |
| Q74201343 | Tumor progression and serum anti-HuD antibody concentration in patients with paraneoplastic neurological syndromes |
| Q44936264 | Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years |
| Q74502584 | Tumor progression and survival in patients with T1G3 bladder tumors: multicentric retrospective study comparing 94 patients treated during 17 years |
| Q73287976 | Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome |
| Q28087036 | Tumor progression and the different faces of the PERK kinase |
| Q48967298 | Tumor progression and transformation of low-grade glial tumors associated with pregnancy. |
| Q43955827 | Tumor progression as a factor of variability of diurnal rhythm of phosphorus metabolism in a tumor |
| Q37328830 | Tumor progression associated with erythropoiesis-stimulating agents |
| Q68749974 | Tumor progression by DNA flow cytometry in human colorectal cancer |
| Q82838302 | Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction |
| Q45287769 | Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma |
| Q61466188 | Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL |
| Q56901877 | Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites |
| Q50354240 | Tumor progression driven by pathways activating matrix metalloproteinases and their inhibitors. |
| Q51074507 | Tumor progression during preoperative chemotherapy predicts failure to complete 2-stage hepatectomy for colorectal liver metastases: results of an Italian multicenter analysis of 130 patients. |
| Q50205781 | Tumor progression effects on drug vector access to tumor-associated capillary bed. |
| Q41686370 | Tumor progression following transformation of murine monocytes by v-myc: acquisition of immortalization and tumorigenicity |
| Q54442651 | Tumor progression in Apc(1638N) mice with Exo1 and Fen1 deficiencies. |
| Q50913527 | Tumor progression in DICER1-mutated cystic nephroma-witnessing the genesis of anaplastic sarcoma of the kidney. |
| Q53518982 | Tumor progression in Sencar mouse skin as a function of initiator dose and promoter dose, duration, and type. |
| Q71639483 | Tumor progression in a giant cell type malignant fibrous histiocytoma of bone: clinical, radiologic, histologic, and cytogenetic evidence |
| Q40830251 | Tumor progression in chronic lympholeukemia |
| Q42809631 | Tumor progression in four mammary epithelial cell lines derived from the same patient |
| Q70458244 | Tumor progression in hepatocellular carcinoma may be mediated by p53 mutation |
| Q52016638 | Tumor progression in hepatocellular carcinoma: relationship with tumor stroma and parenchymal disease. |
| Q61900618 | Tumor progression in human malignant melanoma is associated with changes in α6/β1 laminin receptor |
| Q70331960 | Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes |
| Q37724095 | Tumor progression in malignant lymphomas |
| Q38605625 | Tumor progression in melanoma: the biology of epidermal melanocytes in vitro. |
| Q40254819 | Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants |
| Q40131234 | Tumor progression in murine leukemia virus-induced T-cell lymphomas: monitoring clonal selections with viral and cellular probes |
| Q42810190 | Tumor progression in nude mice and its representation in cell culture |
| Q70579446 | Tumor progression in ocular melanomas |
| Q38323111 | Tumor progression in patients receiving adjuvant whole-brain radiotherapy vs localized radiotherapy after surgical resection of brain metastases |
| Q70058025 | Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation |
| Q34414233 | Tumor progression in the LPB-Tag transgenic model of prostate cancer is altered by vitamin D receptor and serum testosterone status |
| Q69359592 | Tumor progression in the human melanocytic system |
| Q77620798 | Tumor progression in the intestine: smad about you |
| Q93065829 | Tumor progression in two-stage liver resections-is the shorter inter-stage period in associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) of benefit to the patient? |
| Q69453175 | Tumor progression in vitro: the paradoxical natural antibody and complement-selected phenotype |
| Q53519731 | Tumor progression in vitro: tumor-promoter-induced reversible decrease in natural immune susceptibility. |
| Q44218029 | Tumor progression in vivo: increased soybean agglutinin lectin binding, N-acetylgalactosamine-specific lectin expression, and liver metastasis potential |
| Q80309696 | Tumor progression in waiting time for radiotherapy in head and neck cancer |
| Q42502782 | Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling |
| Q39904256 | Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor-specific CD8+ T cells. |
| Q28143265 | Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfated glycoprotein 2) in human prostate cancer specimens |
| Q73482946 | Tumor progression is associated with a significant decrease in the expression of the endostatin precursor collagen XVIII in human hepatocellular carcinomas |
| Q53621248 | Tumor progression is associated with increasing CD11b+ cells and CCL2 in Lewis rat sarcoma. |
| Q34157182 | Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production. |
| Q98159127 | Tumor progression locus 2 (TPL2) in tumor-promoting Inflammation, Tumorigenesis and Tumor Immunity |
| Q34718730 | Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance |
| Q36163393 | Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation |
| Q34305887 | Tumor progression locus 2 (Tpl2) deficiency does not protect against obesity-induced metabolic disease |
| Q27021391 | Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer |
| Q34076041 | Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation |
| Q42559592 | Tumor progression locus 2 ablation suppressed hepatocellular carcinoma development by inhibiting hepatic inflammation and steatosis in mice |
| Q35187958 | Tumor progression locus 2 differentially regulates IFNγ and IL-17 production by effector CD4+ T cells in a T cell transfer model of colitis |
| Q49577574 | Tumor progression locus 2 in hepatocytes potentiates both liver and systemic metabolic disorders. |
| Q37626144 | Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells. |
| Q41672710 | Tumor progression locus 2-dependent oxidative burst drives phosphorylation of extracellular signal-regulated kinase during TLR3 and 9 signaling |
| Q85227673 | Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice |
| Q80405128 | Tumor progression locus-2 is a critical regulator of pancreatic and lung inflammation during acute pancreatitis |
| Q64993454 | Tumor progression mechanisms: Insights from the central immune regulation of tissue homeostasis. |
| Q36780366 | Tumor progression mediated by two cooperating DNA segments of human cytomegalovirus |
| Q47715761 | Tumor progression of culture-adapted human embryonic stem cells during long-term culture |
| Q41666413 | Tumor progression of murine epidermal cells after treatment in vitro with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid. |
| Q42856274 | Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor |
| Q33882555 | Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization |
| Q71727176 | Tumor progression studied by analysis of cellular features of serial ascitic ovarian carcinoma tumors |
| Q54662223 | Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers. |
| Q35941989 | Tumor progression to the metastatic state involves structural modifications in DNA markedly different from those associated with primary tumor formation |
| Q45166892 | Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? |
| Q36137255 | Tumor progression, biology, and host response in melanoma |
| Q33700535 | Tumor progression, early diagnosis and prognosis of melanoma |
| Q77589902 | Tumor progression, histologic grading and DNA-ploidy as predictive factors of lymphogenous metastasis in primary carcinoma of the Fallopian tube |
| Q26779980 | Tumor progression, metastasis, and modulators of epithelial-mesenchymal transition in endometrioid endometrial carcinoma: an update |
| Q30696948 | Tumor progression, micrometastasis, and genetic instability tracked with histochemical marker genes |
| Q54476622 | Tumor progression, oncogenes and the evolution of metastatic phenotypic diversity. |
| Q41716056 | Tumor progression- and metastasis-associated proteins identified using a model of locally recurrent rat mammary adenocarcinomas |
| Q36604037 | Tumor progression--targets for differential therapy |
| Q90319010 | Tumor progression-dependent angiogenesis in gastric cancer and its potential application |
| Q35894880 | Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma |
| Q35115829 | Tumor progression: Small GTPases and loss of cell-cell adhesion |
| Q38009554 | Tumor progression: chance and necessity in Darwinian and Lamarckian somatic (mutationless) evolution |
| Q34134459 | Tumor progression: defining the soil round the tumor seed |
| Q38005397 | Tumor progression: potential role of unstable genomic changes |
| Q35749722 | Tumor progression: the effects of thrombospondin-1 and -2. |
| Q52318550 | Tumor progression: the neuronal input. |
| Q36868736 | Tumor progression: the role of cadherins and integrins |
| Q53546893 | Tumor promotion and tumor progression. |
| Q92256619 | Tumor-Derived Exosomes Mediate the Instability of Cadherins and Promote Tumor Progression |
| Q37631412 | Tumor-Derived Tissue Factor Aberrantly Activates Complement and Facilitates Lung Tumor Progression via Recruitment of Myeloid-Derived Suppressor Cells |
| Q88238722 | Tumor-Induced Generation of Splenic Erythroblast-like Ter-Cells Promotes Tumor Progression |
| Q90473178 | Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response |
| Q93242957 | Tumor-Secreted Exosomal miR-222 Promotes Tumor Progression via Regulating P27 Expression and Re-Localization in Pancreatic Cancer |
| Q86016932 | Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma |
| Q115029994 | Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer |
| Q54457644 | Tumor-associated macrophages are involved in tumor progression in papillary renal cell carcinoma. |
| Q33718878 | Tumor-associated macrophages contribute to tumor progression in ovarian cancer. |
| Q90819649 | Tumor-associated macrophages: an accomplice in solid tumor progression |
| Q37408808 | Tumor-associated macrophages: effectors of angiogenesis and tumor progression. |
| Q39087629 | Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression |
| Q34221714 | Tumor-derived exosomes promote tumor progression and T-cell dysfunction through the regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma |
| Q37716749 | Tumor-derived exosomes: A message delivery system for tumor progression. |
| Q37109165 | Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression |
| Q38973960 | Tumor-derived transforming growth factor-β is critical for tumor progression and evasion from immune surveillance |
| Q53656759 | Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients. |
| Q35169807 | Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. |
| Q83519460 | Tumor-infiltrating CD4+ Th17 cells produce IL-17 in tumor microenvironment and promote tumor progression in human gastric cancer |
| Q36713394 | Tumor-infiltrating immune cells: triggers for tumor capsule disruption and tumor progression? |
| Q37707464 | Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. |
| Q55664946 | Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. |
| Q96233165 | Tumor-stroma biomechanical crosstalk: a perspective on the role of caveolin-1 in tumor progression |
| Q38072443 | Tumor-stromal interactions in breast tumor progression--significance of histological heterogeneity of tumor-stromal fibroblasts |
| Q40779534 | Tumoral Vitamin D Synthesis by CYP27B1 1-α-Hydroxylase Delays Mammary Tumor Progression in the PyMT-MMTV Mouse Model and Its Action Involves NF-κB Modulation |
| Q41815304 | Tumoral prostate shows different expression pattern of somatostatin receptor 2 (SSTR2) and phosphotyrosine phosphatase SHP-1 (PTPN6) according to tumor progression. |
| Q86758791 | Tumorigenesis and tumor progression related gene expression profiles in colorectal cancer |
| Q98618816 | Tumour Progression Stage-Dependent Secretion of YB-1 Stimulates Melanoma Cell Migration and Invasion |
| Q53253508 | Tumour Progression and Spontaneous Regression in the Lewis Rat Sarcoma Model. |
| Q61857365 | Tumour endothelial marker 8 (TEM-8) in human colon cancer and its association with tumour progression |
| Q53632433 | Tumour endothelial marker 8 (TEM-8) in human colon cancer and its association with tumour progression. |
| Q84067387 | Tumour immunology: TSLP drives human tumour progression |
| Q86328926 | Tumour prevention and tumour progression: a dual role for statins? |
| Q33830325 | Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem |
| Q38275346 | Tumour progression and cancer-induced pain: a role for protease-activated receptor-2? |
| Q38097250 | Tumour progression and liver regeneration--insights from animal models |
| Q26766468 | Tumour progression and metastasis |
| Q68061204 | Tumour progression and metastasis |
| Q53021758 | Tumour progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumours. |
| Q53926940 | Tumour progression and survival in patients with T1G3 bladder tumours. |
| Q73930822 | Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome |
| Q24683843 | Tumour progression and the nature of cancer |
| Q71330496 | Tumour progression in a patient with granulomatous mycosis fungoides |
| Q38516171 | Tumour progression in experimental oral carcinogenesis is associated with changes in EGF and TGF-beta receptor expression and altered responses to these growth factors |
| Q42389438 | Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites |
| Q30987268 | Tumour progression or pseudoprogression? A review of post-treatment radiological appearances of glioblastoma. |
| Q71330726 | Tumour progression: random mutations or an integrated survival response to cellular stress conserved from unicellular organisms? |
| Q98513350 | Tumour radiological appearance evaluated by enhanced CT correlates with tumour progression and survival in curable gallbladder cancer |
| Q58352361 | Tumour vascular endothelial growth factor (VEGF) mRNA in relation to serum VEGF protein levels and tumour progression in human renal cell carcinoma |
| Q36414978 | Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy |
| Q35835003 | Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression |
| Q28072763 | Tumour-derived exosomes as a signature of pancreatic cancer - liquid biopsies as indicators of tumour progression |
| Q29614307 | Tumour-educated macrophages promote tumour progression and metastasis |
| Q57788209 | Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression |
| Q53160884 | Tumourigenic characteristics of embryonal carcinoma cells as a model for studying tumour progression of human embryonic stem cells. |
| Q96021533 | Tunneling Nanotubes: The Fuel of Tumor Progression? |
| Q39555445 | Two-dimensional gel electrophoresis using immobilized pH gradient strips and FlamingoTM fluorescent gel stain identified non-nuclear proteins possibly related to malignant tumour progression |
| Q39707621 | Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression |
| Q51671353 | Tyrosine Phosphatase PTPRJ/DEP-1 Is an Essential Promoter of Vascular Permeability, Angiogenesis, and Tumor Progression. |
| Q55260426 | U.S.-Japan seminar on "genomic instability during carcinogenesis and tumor progression". |
| Q91251301 | UBE2S mediates tumor progression via SOX6/β-Catenin signaling in endometrial cancer |
| Q64058072 | UBN2 promotes tumor progression via the Ras/MAPK pathway and predicts poor prognosis in colorectal cancer |
| Q64059990 | UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway |
| Q92801974 | UNC13C Suppress Tumor Progression via Inhibiting EMT Pathway and Improves Survival in Oral Squamous Cell Carcinoma |
| Q38792263 | USO1 promotes tumor progression via activating Erk pathway in multiple myeloma cells |
| Q90590891 | USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma |
| Q38833245 | USP14 activation promotes tumor progression in hepatocellular carcinoma |
| Q33592884 | USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma |
| Q99632998 | UV-type specific alteration of miRNA expression and its association with tumor progression and metastasis in SCC cell lines |
| Q37743497 | UXT-AS1-induced alternative splicing of UXT is associated with tumor progression in colorectal cancer |
| Q38891828 | Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway. |
| Q96693561 | Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression |
| Q39175658 | Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer |
| Q91712683 | Ultrasound-targeted microbubble destruction-mediated miR-767 inhibition suppresses tumor progression of non-small cell lung cancer |
| Q86572349 | Uncovering microbes' role in tumor progression |
| Q98221333 | Uncovering the Exosomes Diversity: A Window of Opportunity for Tumor Progression Monitoring |
| Q38275699 | Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives |
| Q41218661 | Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma |
| Q37932053 | Unexpected tumor progression after conization for carcinoma in situ of the uterine cervix |
| Q50073383 | Unfolded Protein Response of the Endoplasmic Reticulum in Tumor Progression and Immunogenicity. |
| Q57464770 | Unique pattern of neutrophil migration and function during tumor progression |
| Q42365250 | Unique synergistic formulation of curcumin, epicatechin gallate and resveratrol, tricurin, suppresses HPV E6, eliminates HPV+ cancer cells, and inhibits tumor progression. |
| Q37042935 | Unknown Primary Tumors: An Example of Accelerated (Type 2) Tumor Progression |
| Q41314794 | Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression |
| Q104512018 | Unraveling the role of fibroblasts, FGF5 and FGFR2 in HER2-targeted therapies resistance and tumor progression |
| Q58025009 | Unregulated and Independent Expression of Collagenase and Transin Related to Tumor Progression |
| Q36250634 | Up-regulated CKS2 promotes tumor progression and predicts a poor prognosis in human colorectal cancer |
| Q33913172 | Up-regulation of CDK16 by multiple mechanisms in hepatocellular carcinoma promotes tumor progression |
| Q35145060 | Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer |
| Q44864789 | Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer |
| Q34639683 | Up-regulation of hepatoma-derived growth factor facilitates tumor progression in malignant melanoma [corrected] |
| Q50520368 | Up-regulation of long non-coding RNA PCAT-1 correlates with tumor progression and poor prognosis in gastric cancer. |
| Q88483788 | Up-regulation of long noncoding RNA M26317 correlates with tumor progression and poor prognosis in gastric cancer |
| Q38911896 | Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer |
| Q38353561 | Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. |
| Q92409331 | Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival |
| Q54096451 | Upregulated EBI3 Correlates with Poor Outcome and Tumor Progression in Breast Cancer. |
| Q39424966 | Upregulated IL-19 in breast cancer promotes tumor progression and affects clinical outcome |
| Q34727169 | Upregulated ankyrin repeat-rich membrane spanning protein contributes to tumour progression in cutaneous melanoma |
| Q54243283 | Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. |
| Q38763269 | Upregulated microRNA-301a in osteosarcoma promotes tumor progression by targeting CDC14A. |
| Q92738337 | Upregulated microRNA‑671‑3p promotes tumor progression by suppressing forkhead box P2 expression in non‑small‑cell lung cancer |
| Q112703758 | Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway |
| Q49425617 | Upregulation of ALDH1B1 promotes tumor progression in osteosarcoma. |
| Q38851065 | Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer |
| Q47299042 | Upregulation of B7-H4 promotes tumor progression of intrahepatic cholangiocarcinoma |
| Q102155255 | Upregulation of ERCC6L is associated with tumor progression and unfavorable prognosis in hepatocellular carcinoma |
| Q94601981 | Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma |
| Q39380910 | Upregulation of HOXA10 in gastric cancer with the intestinal mucin phenotype: reduction during tumor progression and favorable prognosis |
| Q88089387 | Upregulation of IL-11, an IL-6 Family Cytokine, Promotes Tumor Progression and Correlates with Poor Prognosis in Non-Small Cell Lung Cancer |
| Q52580098 | Upregulation of LncDQ is Associated with Poor Prognosis and Promotes Tumor Progression via Epigenetic Regulation of the EMT Pathway in HCC. |
| Q49536537 | Upregulation of LncRNA BCYRN1 promotes tumor progression and enhances EpCAM expression in gastric carcinoma. |
| Q35877252 | Upregulation of NETO2 expression correlates with tumor progression and poor prognosis in colorectal carcinoma |
| Q90403209 | Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma |
| Q47593557 | Upregulation of PAG1/Cbp contributes to adipose-derived mesenchymal stem cells promoted tumor progression and chemoresistance in breast cancer |
| Q82636716 | Upregulation of REG Ialpha accelerates tumor progression in pancreatic cancer with diabetes |
| Q49569472 | Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression. |
| Q37311518 | Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients' prognosis |
| Q54399674 | Upregulation of connexin 30 in intestinal phenotype gastric cancer and its reduction during tumor progression. |
| Q91329980 | Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma |
| Q41722299 | Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma |
| Q90898936 | Upregulation of long noncoding RNA ANRIL correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma |
| Q41593059 | Upregulation of long noncoding RNA HOXA-AS3 promotes tumor progression and predicts poor prognosis in glioma |
| Q42687941 | Upregulation of long noncoding RNA LOC440040 promotes tumor progression and predicts poor prognosis in patients with prostate cancer |
| Q37232335 | Upregulation of long noncoding RNA SPRY4-IT1 correlates with tumor progression and poor prognosis in cervical cancer |
| Q52968179 | Upregulation of miR-3658 in bladder cancer and tumor progression. |
| Q92895591 | Upregulation of miR-675-5p induced by lncRNA H19 was associated with tumor progression and development by targeting tumor suppressor p53 in non-small cell lung cancer |
| Q95937534 | Upregulation of miRNA‑301a‑3p promotes tumor progression in gastric cancer by suppressing NKRF and activating NF‑κB signaling |
| Q51747474 | Upregulation of microRNA-17-92 cluster associates with tumor progression and prognosis in osteosarcoma. |
| Q45882877 | Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer |
| Q35038714 | Upregulation of microRNA-23a/b promotes tumor progression and confers poor prognosis in patients with gastric cancer |
| Q39215878 | Upregulation of microRNA-372 associates with tumor progression and prognosis in hepatocellular carcinoma |
| Q64057597 | Upregulation of phosphoserine phosphatase contributes to tumor progression and predicts poor prognosis in non-small cell lung cancer patients |
| Q42483046 | Upregulation of the EP1 receptor for prostaglandin E2 promotes skin tumor progression |
| Q38754988 | Upregulation of the long non-coding RNA BANCR correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma |
| Q90837698 | Upregulation of the long non-coding RNA FOXD2-AS1 is correlated with tumor progression and metastasis in papillary thyroid cancer |
| Q60932030 | Upregulation of valosin-containing protein (VCP) is associated with poor prognosis and promotes tumor progression of orbital B-cell lymphoma |
| Q94482192 | Uptake of high-density lipoprotein by scavenger receptor class B type 1 is associated with prostate cancer proliferation and tumor progression in mice |
| Q44748846 | Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy |
| Q33675116 | Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression |
| Q37270057 | Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy |
| Q42119412 | Urokinase plasminogen activator secreted by cancer-associated fibroblasts induces tumor progression via PI3K/AKT and ERK signaling in esophageal squamous cell carcinoma. |
| Q35576777 | Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. |
| Q30498370 | Urokinase receptor is a key player in tumour progression |
| Q36576715 | Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease |
| Q35626234 | Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization |
| Q90513609 | Use of Serum Mesothelin as an Indicator of Tumor Progression in Routine Clinical Practice of Malignant Pleural Mesothelioma Treatment |
| Q38224984 | Use of ribozymes in validation of targets involved in tumor progression. |
| Q36463936 | Usefulness of carcinoembryonic antigen for monitoring tumor progression during palliative chemotherapy in metastatic colorectal cancer |
| Q81872547 | Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival |
| Q38985215 | Using [¹⁸F]FBAU for imaging brain tumor progression in an F98/tk-luc glioma-bearing rat model |
| Q39195755 | Utility of PET/CT After Cryoablation for Early Identification of Local Tumor Progression in Osseous Metastatic Disease |
| Q49014010 | Utility of computed tomography fusion imaging for the evaluation of the ablative margin of radiofrequency ablation for hepatocellular carcinoma and the correlation to local tumor progression. |
| Q38341587 | V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. |
| Q42059658 | V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a |
| Q38061176 | VEGF in tumor progression and targeted therapy |
| Q85494496 | VEGF inhibition beyond tumour progression |
| Q86144688 | VEGF-B expression in colorectal carcinomas and its relevance for tumor progression |
| Q91336478 | VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a β1 integrin/VEGFR autocrine loop |
| Q91283847 | VICKZ1 enhances tumor progression and metastasis in lung adenocarcinomas in mice |
| Q35001420 | Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inh |
| Q90632828 | Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression |
| Q90220331 | Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression |
| Q93355582 | Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma |
| Q45912062 | Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. |
| Q71525211 | Variability and discontinuity of the pathognomonic systemic effects caused by Walker 256 tumor progression in rats |
| Q33943198 | Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment |
| Q41594010 | Variant generation and selection: an in vitro model of tumor progression |
| Q38459826 | Vascular endothelial growth factor (VEGF) expression in oral tissues: possible relevance to angiogenesis, tumour progression and field cancerisation. |
| Q74060891 | Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression |
| Q36745878 | Vascular endothelial growth factor (VEGF) signaling in tumor progression |
| Q73016350 | Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression |
| Q77853450 | Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression |
| Q36676685 | Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages |
| Q41876374 | Vascular endothelial growth factor-A stimulates Snail expression in breast tumor cells: implications for tumor progression |
| Q38128665 | Vascular galectins: regulators of tumor progression and targets for cancer therapy. |
| Q53348098 | Vascular integration of endothelial progenitors during multistep tumor progression. |
| Q33246692 | Verification of predicted alternatively spliced Wnt genes reveals two new splice variants (CTNNB1 and LRP5) and altered Axin-1 expression during tumour progression |
| Q46106579 | Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma. |
| Q92110288 | Versican and Tumor-Associated Macrophages Promotes Tumor Progression and Metastasis in Canine and Murine Models of Breast Carcinoma |
| Q35569398 | Viable tumor tissue adherent to needle applicators after local ablation: a risk factor for local tumor progression |
| Q34448186 | Vicious cycle of TGF-β signaling in tumor progression and metastasis |
| Q41666144 | Viral Ha-ras mediated mammary tumor progression |
| Q33647013 | Vitamin D, intermediary metabolism and prostate cancer tumor progression |
| Q104500199 | Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer |
| Q58606781 | Volumetric 3D assessment of ablation zones after thermal ablation of colorectal liver metastases to improve prediction of local tumor progression |
| Q50223933 | WIP Drives Tumor Progression through YAP/TAZ-Dependent Autonomous Cell Growth. |
| Q91511168 | WNK1 promotes renal tumor progression by activating TRPC6-NFAT pathway |
| Q38695480 | WNT1-inducible signaling pathway protein-1 contributes to tumor progression and treatment failure in oral squamous cell carcinoma |
| Q102322107 | WNT4 secreted by tumor tissues promotes tumor progression in colorectal cancer by activation of the Wnt/β-catenin signalling pathway |
| Q92249815 | WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1 |
| Q58475219 | We-P14:484 Reduced mammary tumor progression in a transgenic mouse model fed an isoflavone-poor soy protein concentrate |
| Q54501671 | Well-differentiated pancreatic ductal adenocarcinomas measuring ≤ 1 cm exhibit early features of tumor progression: a report of five lesions and a comparative study with advanced lesions. |
| Q35837444 | Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression |
| Q34842686 | Wnt/β-catenin activation promotes prostate tumor progression in a mouse model |
| Q34827017 | Wnt1 overexpression promotes tumour progression in non-small cell lung cancer |
| Q39524651 | Wnt2 secreted by tumour fibroblasts promotes tumour progression in oesophageal cancer by activation of the Wnt/β-catenin signalling pathway. |
| Q54340040 | Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. |
| Q39207377 | Wnt3a mediated activation of Wnt/β-catenin signaling promotes tumor progression in glioblastoma |
| Q35071581 | Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression |
| Q61820352 | Wound-Induced Tumor Progression |
| Q38780744 | Y-box-binding protein 1 promotes tumor progression and inhibits cisplatin chemosensitivity in esophageal squamous cell carcinoma |
| Q38343224 | YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity |
| Q30635379 | YB-1 regulates stress granule formation and tumor progression by translationally activating G3BP1. |
| Q51115657 | YEATS Domain Containing 4 Promotes Gastric Cancer Cell Proliferation and Mediates Tumor Progression via Activating the Wnt/β-Catenin Signaling Pathway. |
| Q38574540 | YKL-40/CHI3L1 drives inflammation on the road of tumor progression |
| Q91154762 | Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation |
| Q39750949 | Yin Yang 1 overexpression in diffuse large B-cell lymphoma is associated with B-cell transformation and tumor progression |
| Q103022928 | ZNF703 promotes tumor progression in ovarian cancer by interacting with HE4 and epigenetically regulating PEA15 |
| Q110596788 | ZRANB1 enhances stem-cell-like features and accelerates tumor progression by regulating Sox9-mediated USP22/Wnt/β-catenin pathway in colorectal cancer |
| Q38419759 | Zebrafish as a platform to study tumor progression |
| Q34462187 | Zinc deficiency activates S100A8 inflammation in the absence of COX-2 and promotes murine oral-esophageal tumor progression |
| Q90108778 | Zinc-finger protein p52-ZER6 accelerates colorectal cancer cell proliferation and tumour progression through promoting p53 ubiquitination |
| Q53630218 | Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. |
| Q73179068 | [A case of multiple hepatocellular carcinoma complicated with N3 regional lymph node metastases preventing tumor progression by gradual introduction of lymph node excision and high-dose chemotherapy using percutaneous isolated hepatic perfusion] |
| Q85276819 | [A case of tumor progression after gamma knife radiosurgery for brain metastasis of thyroid papillary carcinoma in deep subcortical white matter] |
| Q79739914 | [AMPK in the cancer research field: tumor progression by ARK5] |
| Q83112475 | [ATAD3, a vital membrane-bound mitochondrial ATPase involved in tumor progression] |
| Q72211678 | [Accumulation of genetic alterations during human tumor progression] |
| Q53401566 | [Adaptive reactions of the cell as the staring point of tumor progression] |
| Q53303748 | [Angiogenesis and immune suppression: yin and yang of tumor progression?]. |
| Q73502797 | [Angiogenesis, lymphangiogenesis, and tumor progression] |
| Q53366590 | [Angiotensin converting enzyme: the antigenic properties of the domain, role in Alzheimer's disease and tumor progression]. |
| Q55470148 | [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors] |
| Q74010926 | [Barrett esophagus: epidemiology and natural history of tumor progression] |
| Q77362084 | [Bcl-2 expression in testicular cancer in relation to tumor progression] |
| Q80211801 | [Bcl-2 family proteins and mechanisms of the acceleration and inhibition of tumor progression in vivo] |
| Q68939361 | [Behavior of ABH surface antigens in superficial and invasive bladder neoplasma: inferences for the mechanism of tumor progression] |
| Q53567760 | [Biological aspects of the theory of tumor progression applied to clinical oncology] |
| Q69558387 | [Biological characteristics of tumor progression] |
| Q89873197 | [Cancer-associated fibroblasts and their significance in tumor progression] |
| Q93659127 | [Carcinoembryonic antigen: diagnosis and tumor progression in gastrointestinal tumors] |
| Q70324592 | [Changes in the actin cytoskeleton during transformation and tumor progression in liver epithelium in culture] |
| Q53517554 | [Changes in the growth characteristics of mouse and rat fibroblasts during tumor progression] |
| Q53511464 | [Colorectal carcinogenesis, tumor progression and chemoresistance] |
| Q73591736 | [Correlation between laminin and fibronectin on the basement membrane and tumor progression in early gastric cancer: an immunohistochemical study] |
| Q77755336 | [Correlation between proliferative processes and cell death in non-small cell lung cancer with glandular differentiation at different stages of tumor progression] |
| Q74626506 | [Correlation between the count of the various intraepithelial mononuclear leukocytes and tumor progression in the stomach] |
| Q91783366 | [Corrigendum] Pivotal roles of protein 4.1B/DAL‑1, a FERM‑domain containing protein, in tumor progression (Review) |
| Q91526516 | [Crohn's disease-associated colorectal carcinogenesis : TP53 mutations and copy number gains of chromosome arm 5p as (early) markers of tumor progression] |
| Q73461742 | [Cyclooxy genase-2 and tumor progression] |
| Q77419355 | [Disease-related gene and tumor progression] |
| Q72390612 | [Distribution of S-100 protein-positive dendritic cells inside the cancer nest and expression of HLA-DR antigen and blood group antigen on the cancer cell in transitional cell carcinoma of the urinary bladder--in relation to tumor progression and pr |
| Q82466881 | [Epidermotropic T cell lymphomas as models for tumor progression] |
| Q62351796 | [Epigenetic role of magnetic field exposure in tumor progression: fine-tuning experimental models] |
| Q69625020 | [Experimental approach to the investigation of tumor progression] |
| Q72075772 | [Expression and co-expression of cellular oncogenes in the course of tumor progression in neuroendocrine lung tumors] |
| Q50596181 | [Expression of nucleolar protein 14 and CD31 in pancreatic cancer mouse model and its correlation with tumor progression]. |
| Q77366182 | [Extracellular proteases of stromal origin: contribution to tumor progression and therapeutic perspectives] |
| Q70666820 | [Frequency of recurrences and tumor progression on superficial bladder carcinoma (author's transl)] |
| Q77163622 | [Gastrocolic tumor progression--a possibility or mere supposition?] |
| Q53510886 | [Genetic and epigenetic factors of cervical tumor progression]. |
| Q83180871 | [HIF-1 activation during tumor progression: implications and consequences] |
| Q87765244 | [Imitation of tumor progression by peripheral proliferation of lens epithelial cells - a diagnostic challenge] |
| Q90163241 | [Immunogenomic aspects of tumor progression] |
| Q77892677 | [Impact on tumor angiogenesis and tumor progression of expression of the 18 kd and 24 kd isoforms of FGF-2] |
| Q53433074 | [Inactivation of failsafe programs by Twist oncoproteins and tumor progression]. |
| Q85070008 | [Inflammation in tumor progression] |
| Q69250283 | [Ketotifen inhibits urticaria and tumor progression in neurofibromatosis] |
| Q94567114 | [Liquid biopsy as indication of tumour progression in lung cancer: a potential intervention in tertiary prevention] |
| Q71377165 | [Lymphomatoid papulosis--nodular lymphoma of the skin with slow tumor progression] |
| Q72813857 | [Malignant tumor progression and microenvironment] |
| Q53341454 | [Mechanisms of metastasis and molecular markers of malignant tumor progression. I. Colorectal cancer]. |
| Q95477514 | [Mesenchymal stem cells promote mouse breast tumor progression by inducing the suppressive function of myeloid-derived CD11b⁺ Gr1⁺ cells] |
| Q53607470 | [Metalloproteinases in tumor progression. Review]. |
| Q80990710 | [Molecular analysis of telomere length in follicular lymphomas. Its participation in tumor progression] |
| Q84757222 | [Molecular biological evaluation of prognostic parameters in GIST. Development of an integrative model of tumor progression] |
| Q79980027 | [Molecular mechanism of tumor progression. From Krompecher to the DNA microarray] |
| Q70329961 | [Morphological manifestations of tumor progression] |
| Q53412741 | [Multiple involvements of LRP-1 receptor in tumor progression]. |
| Q72079319 | [Palliative therapeutic control of tumor progression in patients with metastatic breast cancer] |
| Q73826261 | [Problems of tumor progression: doubts or hopes at the turn of the Millennium?] |
| Q84137850 | [RB, guardian of prostatic tumor progression] |
| Q101478874 | [Retracted] Suppression of YAP by DDP disrupts colon tumor progression |
| Q53466958 | [Role of intercellular interactions in tumor progression and metastasis] |
| Q82306634 | [Role of the epithelial-mesenchymal transition during tumor progression] |
| Q84958203 | [Role of the stress protein p8 in tumor progression and development of metastasis] |
| Q54530705 | [SIBLING proteins: molecular tools for tumor progression and angiogenesis]. |
| Q80534539 | [Serum levels of macrophage migration inhibitory factor and interleukin-8 in hepatocellular carcinoma patients: their correlations with tumor progression and prognosis] |
| Q71797554 | [Sialosyl-Le(a) and Sialosyl-Le(x) antigens in adhesion of cancer cells and tumor progression] |
| Q53401822 | [Signaling pathways regulating the expression of proteases during tumor progression] |
| Q76589202 | [TUMOR PROGRESSION IN 2 MAMMARY CARCINOMAS IN RATS INDUCED WITH ACETYLAMINOFLUORENE.] |
| Q72998826 | [The clinical value of mdm-2 (proto-oncogene) expression in testicular cancer, Correlation with tumor progression] |
| Q50243745 | [The complement system: a double edge sword in tumor progression]. |
| Q78373783 | [The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival] |
| Q88556326 | [The role of exosomal tetraspanins and proteases in tumor progression] |
| Q103050389 | [The role of three-dimensional chromatin structure changes in tumor progression] |
| Q95486023 | [The role of tyrosine phosphorylation of cancer stem cell marker CD133 in malignant tumor progression] |
| Q73027281 | [Tumor progression and angiogenesis] |
| Q80748708 | [Tumor progression and invasion-related genes for breast cancer] |
| Q74305454 | [Tumor progression and problems in the biology of lymphogranulomatosis]] |
| Q69615043 | [Tumor progression and some problems of lymphogranulomatosis pathogenesis] |
| Q53578996 | [Tumor progression and the body] |
| Q69476760 | [Tumor progression and tumor stem cell heterogeneity in relation to tumor radioresistance] |
| Q70999871 | [Tumor progression in chronic myeloleukosis] |
| Q53515825 | [Tumor progression in myeloma (a case of morphological and immunochemical transformation] |
| Q95515708 | [Tumor progression through membrane-bound mucin-mediated signaling] |
| Q95558433 | [Value of perineural invasion in prostatectomy specimen in the assessment on tumor progression and prognosis] |
| Q71226198 | [Variability and selection of clone populations of murine rhabdomyosarcoma in vivo. IV. Selection in the course of tumor progression] |
| Q81544989 | [mRNA expression of IGF-IIand HGF in relation to microvascular density, tumor progression and prognosis of gastric carcinoma] |
| Q79316610 | [mRNA expression of syndecan-1 and heparanase in relation to tumor progression and prognosis of gastric carcinoma] |
| Q45063959 | alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression |
| Q34357105 | alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer |
| Q54446332 | beta-Catenin nuclear accumulation in head and neck mucoepidermoid carcinoma: its role in cyclin D1 overexpression and tumor progression. |
| Q34100493 | beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression |
| Q37383437 | beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. |
| Q34667550 | c-FLIP is involved in tumor progression of peripheral T-cell lymphoma and targeted by histone deacetylase inhibitors |
| Q35804203 | c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression |
| Q112714319 | c-Myc-activated USP2-AS1 suppresses senescence and promotes tumor progression via stabilization of E2F1 mRNA |
| Q90628453 | c-Src Promotes Tumorigenesis and Tumor Progression by Activating PFKFB3 |
| Q91679358 | c-Src promotes tumor progression through downregulation of microRNA-129-1-3p |
| Q53491564 | c-myc over-expression in human primary ovarian tumours: its relevance to tumour progression |
| Q57201231 | cFLIP expression correlates with tumour progression and patient outcome in non-Hodgkin lymphomas of low grade of malignancy |
| Q112703939 | cGAS-STING signalings potentiate tumor progression via sustaining cancer stemness |
| Q98239453 | circ-NRIP1 Promotes Glycolysis and Tumor Progression by Regulating miR-186-5p/MYH9 Axis in Gastric Cancer |
| Q92578227 | circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer |
| Q92462857 | circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer |
| Q98289735 | circ_BICD2 acts as a ceRNA to promote tumor progression and Warburg effect in oral squamous cell carcinoma by sponging miR-107 to enhance HK2 |
| Q47284899 | eEF1A1 Overexpression Enhances Tumor Progression and Indicates Poor Prognosis in Hepatocellular Carcinoma |
| Q38253963 | eIF6 anti-association activity is required for ribosome biogenesis, translational control and tumor progression |
| Q39056231 | hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer |
| Q52714238 | hTERT promotes tumor progression by enhancing TSPAN13 expression in osteosarcoma cells. |
| Q41962611 | hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression |
| Q89390422 | l-asparaginase induces intrinsic mitochondrial-mediated apoptosis in human gastric adenocarcinoma cells and impedes tumor progression |
| Q28239424 | let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression |
| Q114062799 | lncRNA ACTA2-AS1 predicts malignancy and poor prognosis of triple-negative breast cancer and regulates tumor progression via modulating miR-532-5p |
| Q47993457 | lncRNA DANCR promotes tumor progression and cancer stemness features in osteosarcoma by upregulating AXL via miR-33a-5p inhibition |
| Q114038182 | lncRNA ELFN1-AS1 predicts poor prognosis and promotes tumor progression of non-small cell lung cancer by sponging miR-497 |
| Q55361710 | lncRNA Ftx promotes aerobic glycolysis and tumor progression through the PPARγ pathway in hepatocellular carcinoma. |
| Q99401417 | lncRNA PART1 and MIR17HG as ΔNp63α direct targets regulate tumor progression of cervical squamous cell carcinoma |
| Q88905968 | m6A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression |
| Q112641682 | m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer |
| Q35612865 | mLST8 Promotes mTOR-Mediated Tumor Progression |
| Q99214488 | mTOR-Dependent Role of Sestrin2 in Regulating Tumor Progression of Human Endometrial Cancer |
| Q39085730 | mTORC1/2 targeted by n-3 polyunsaturated fatty acids in the prevention of mammary tumorigenesis and tumor progression. |
| Q35187051 | miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans |
| Q55171126 | miR-107 promotes tumor progression by targeting the let-7 microRNA in mice and humans. |
| Q37402573 | miR-107 regulates tumor progression by targeting NF1 in gastric cancer |
| Q38804349 | miR-143 inhibits tumor progression by targeting FAM83F in esophageal squamous cell carcinoma |
| Q60050050 | miR-150-5p suppresses tumor progression by targeting VEGFA in colorectal cancer |
| Q43517148 | miR-155 is involved in tumor progression of mycosis fungoides |
| Q90867043 | miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma |
| Q39146500 | miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma |
| Q47713726 | miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer. |
| Q36244787 | miR-195 Inhibits Tumor Progression by Targeting RPS6KB1 in Human Prostate Cancer |
| Q88649911 | miR-196b is a prognostic factor of human laryngeal squamous cell carcinoma and promotes tumor progression by targeting SOCS2 |
| Q89636617 | miR-196b-5p-mediated downregulation of TSPAN12 and GATA6 promotes tumor progression in non-small cell lung cancer |
| Q90429370 | miR-19b serves as a prognostic biomarker of breast cancer and promotes tumor progression through PI3K/AKT signaling pathway |
| Q37565493 | miR-200b is a key regulator of tumor progression and metabolism targeting lactate dehydrogenase A in human malignant glioma |
| Q38835514 | miR-21 regulates tumor progression through the miR-21-PDCD4-Stat3 pathway in human salivary adenoid cystic carcinoma |
| Q97688858 | miR-22-3p Negatively Affects Tumor Progression in T-Cell Acute Lymphoblastic Leukemia |
| Q33952998 | miR-221/222 control luminal breast cancer tumor progression by regulating different targets. |
| Q35656084 | miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. |
| Q61813187 | miR-29c-3p regulates DNMT3B and LATS1 methylation to inhibit tumor progression in hepatocellular carcinoma |
| Q90030054 | miR-374a-5p promotes tumor progression by targeting ARRB1 in triple negative breast cancer |
| Q38724770 | miR-382 inhibits tumor progression by targeting SETD8 in non-small cell lung cancer |
| Q92843579 | miR-433 suppresses tumor progression via Smad2 in non-small cell lung cancer |
| Q92191418 | miR-4429 Inhibits Tumor Progression and Epithelial-Mesenchymal Transition Via Targeting CDK6 in Clear Cell Renal Cell Carcinoma |
| Q57132681 | miR-7 Suppresses Tumor Progression by Directly Targeting MAP3K9 in Pancreatic Cancer |
| Q38819843 | miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma |
| Q36083567 | miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis. |
| Q38717293 | miR-944 acts as a prognostic marker and promotes the tumor progression in endometrial cancer |
| Q37955986 | miR221/222 in cancer: their role in tumor progression and response to therapy |
| Q37295492 | miRNA profiling along tumour progression in ovarian carcinoma |
| Q34673760 | miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer |
| Q38784427 | miRNA-503 Promotes Tumor Progression and Is Associated with Early Recurrence and Poor Prognosis in Human Colorectal Cancer |
| Q39504671 | miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. |
| Q38617229 | miRNAs in melanoma: a defined role in tumor progression and metastasis |
| Q54089198 | miR‑188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma. |
| Q100508309 | microRNA-196a-5p inhibits testicular germ cell tumor progression via NR6A1/E-cadherin axis |
| Q87211066 | microRNA-21 and its emerging role in tumor progression in systemic malignancies |
| Q34993968 | microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. |
| Q35793647 | microRNA-217 inhibits tumor progression and metastasis by downregulating EZH2 and predicts favorable prognosis in gastric cancer. |
| Q38945884 | microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma. |
| Q84035862 | p12CDK2-AP1 is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma |
| Q63364741 | p16INK4a polymorphism: associations with tumour progression in patients with sporadic colorectal cancer |
| Q34721988 | p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase. |
| Q53467859 | p21ras independent down-regulation of ras-induced increases in natural antibody binding during tumor progression |
| Q64090546 | p27 transcriptionally coregulates cJun to drive programs of tumor progression |
| Q101125939 | p53 and ANXA4/NF‑κB p50 complexes regulate cell proliferation, apoptosis and tumor progression in ovarian clear cell carcinoma |
| Q41555733 | p53 and CD44 as clinical markers of tumour progression in colorectal carcinogenesis |
| Q36702494 | p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer |
| Q30665151 | p53 in surgically treated and pathologically staged cervical cancer: correlation with local tumor progression, but not with lymphatic spread |
| Q41750244 | p53 in tumor progression: life, death, and everything |
| Q80635744 | p53 is an indicator of tumor progression in early but not advanced gastric carcinomas |
| Q58091439 | p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression |
| Q41143945 | p53 performs an essential role in mediating the oncogenic stimulus triggered by loss of expression of neurofibromatosis type 2 during in vitro tumor progression |
| Q38553239 | p53 regulates cytoskeleton remodeling to suppress tumor progression |
| Q71170317 | p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma |
| Q64236737 | p53/Lactate dehydrogenase A axis negatively regulates aerobic glycolysis and tumor progression in breast cancer expressing wild-type p53 |
| Q47906170 | p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis. |
| Q53347345 | p57(kip2) expression is related to carcinogenesis and tumor progression in laryngeal tissues. |
| Q40610827 | p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. |
| Q42410139 | p85β increases phosphoinositide 3-kinase activity and accelerates tumor progression |
| Q36094306 | p85β phosphoinositide 3-kinase subunit regulates tumor progression |
| Q48432429 | pERK, pAkt and pBad: a possible role in cell proliferation and sustained cellular survival during tumorigenesis and tumor progression in ENU induced transplacental glioma rat model. |
| Q77715519 | ras and c-myc oncoproteins during tumor progression in the uterine cervix |
| Q37421359 | t10,c12-Conjugated linoleic acid stimulates mammary tumor progression in Her2/ErbB2 mice through activation of both proliferative and survival pathways |
| Q33645380 | v-Ha-ras oncogene insertion: a model for tumor progression of human small cell lung cancer |
| Q37413723 | {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. |
| Q39379827 | ΑB-crystallin in clear cell renal cell carcinoma: tumor progression and prognostic significance. |
| Q53640563 | α-SMA-Cre-mediated excision of PDK1 reveals an essential role of PDK1 in regulating morphology of cardiomyocyte and tumor progression in tissue microenvironment. |
| Q45187135 | αB-Crystallin and its emerging role in tumor progression and growth in systemic malignancies |
| Q36482872 | αB-Crystallin regulates expansion of CD11b⁺Gr-1⁺ immature myeloid cells during tumor progression. |
| Q38135169 | β-Adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy |
| Q39145972 | β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. |
| Q33758787 | β-lapachone suppresses tumour progression by inhibiting epithelial-to-mesenchymal transition in NQO1-positive breast cancers |
| Q35889538 | β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer |
| Q52352317 | β4-Integrin/PI3K Signaling Promotes Tumor Progression through the Galectin-3-N-Glycan Complex. |
| Q50076400 | γ-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway. |
| Q25326610 | Immune-Related Response Criteria | facet of | P1269 |
| Arabic (ar / Q13955) | تقدم الورم | wikipedia |
| Tumor progression | wikipedia |
Search more.